<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>MabThera, INN-rituximab</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-align:justify;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-align:justify;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-align:justify;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-align:justify;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.55pt;
	text-align:justify;
	text-indent:-70.55pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char Char Char Char Char1 Ch\,Comment Text Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char Char1 Char\,Comment Text Char2\,Comment Text Char2 Char Char\,Comment Text Char2 Char Char Char Char";
	mso-style-link:"Comment Text Char\,Comment Text Char Char Char Char Char Char1 Ch Char1\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char Char1\,Comment Text Char1 Char Char Char Char1 Char Char1\,Comment Text Char2 Char1\,Comment Text Char2 Char Char Char1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoPageNumber
	{font-family:"Arial",sans-serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:gray;
	font-weight:bold;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:6.0pt;
	margin-right:-1.4pt;
	margin-bottom:0in;
	margin-left:-1.85pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodyText22, li.BodyText22, div.BodyText22
	{mso-style-name:"Body Text 22";
	margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BodyText21, li.BodyText21, div.BodyText21
	{mso-style-name:"Body Text 21";
	margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TOCHeadings, li.TOCHeadings, div.TOCHeadings
	{mso-style-name:"TOC Headings";
	margin-top:19.85pt;
	margin-right:0in;
	margin-bottom:11.35pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.TextTi10, li.TextTi10, div.TextTi10
	{mso-style-name:"Text\:Ti10";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TextTi12, li.TextTi12, div.TextTi12
	{mso-style-name:"Text\:Ti12";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TextRef, li.TextRef, div.TextRef
	{mso-style-name:"Text\:Ref";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TextBull, li.TextBull, div.TextBull
	{mso-style-name:"Text\:Bull";
	mso-style-link:"Text\:Bull Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TextDash, li.TextDash, div.TextDash
	{mso-style-name:"Text\:Dash";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingIndent, li.HangingIndent, div.HangingIndent
	{mso-style-name:HangingIndent;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.TextTi12Char
	{mso-style-name:"Text\:Ti12 Char";}
p.HdTab1, li.HdTab1, div.HdTab1
	{mso-style-name:"Hd\:Tab\:1";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.TextTi10Char
	{mso-style-name:"Text\:Ti10 Char";}
p.SAS10, li.SAS10, div.SAS10
	{mso-style-name:"SAS\:10";
	margin:0in;
	line-height:9.5pt;
	font-size:10.0pt;
	font-family:"Courier New";
	letter-spacing:-.7pt;}
p.cdb-ListBulleted, li.cdb-ListBulleted, div.cdb-ListBulleted
	{mso-style-name:"cdb-List Bulleted";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Annex, li.Annex, div.Annex
	{mso-style-name:Annex;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Description, li.Description, div.Description
	{mso-style-name:Description;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.msoins0
	{mso-style-name:msoins;
	color:teal;
	text-decoration:underline;}
span.Initial
	{mso-style-name:Initial;
	font-family:"CG Times",serif;}
p.TableCellCenter, li.TableCellCenter, div.TableCellCenter
	{mso-style-name:"Table Cell Center";
	margin-top:2.5pt;
	margin-right:0in;
	margin-bottom:2.5pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.AnnexHeading, li.AnnexHeading, div.AnnexHeading
	{mso-style-name:"Annex Heading";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TableText10, li.TableText10, div.TableText10
	{mso-style-name:"TableText\:10";
	mso-style-link:"TableText\:10 Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TableText10Char
	{mso-style-name:"TableText\:10 Char";
	mso-style-link:"TableText\:10";}
span.TextBullChar
	{mso-style-name:"Text\:Bull Char";
	mso-style-link:"Text\:Bull";}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.5pt;
	margin-left:0in;
	line-height:15.0pt;
	font-size:11.0pt;
	font-family:"Minion",serif;}
span.ParagraphChar1
	{mso-style-name:"Paragraph Char1";
	mso-style-link:Paragraph;
	font-family:"Minion",serif;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Comment Text Char Char Char Char Char Char1 Ch Char1\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char Char1\,Comment Text Char1 Char Char Char Char1 Char Char1\,Comment Text Char2 Char1\,Comment Text Char2 Char Char Char1";
	mso-style-link:"Comment Text\,Comment Text Char Char Char Char Char Char1 Ch\,Comment Text Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char Char1 Char\,Comment Text Char2\,Comment Text Char2 Char Char\,Comment Text Char2 Char Char Char Char";}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShading-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.LUTOnormaltextChar
	{mso-style-name:"LUTO normal text Char";
	mso-style-link:"LUTO normal text";
	font-family:"Calibri",sans-serif;}
p.LUTOnormaltext, li.LUTOnormaltext, div.LUTOnormaltext
	{mso-style-name:"LUTO normal text";
	mso-style-link:"LUTO normal text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.55pt;
	line-height:110%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ColorfulList-Accent11, li.ColorfulList-Accent11, div.ColorfulList-Accent11
	{mso-style-name:"Colorful List - Accent 11";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.Korrektur, li.Korrektur, div.Korrektur
	{mso-style-name:Korrektur;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listeafsnit, li.Listeafsnit, div.Listeafsnit
	{mso-style-name:Listeafsnit;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListeafsnitCxSpFirst, li.ListeafsnitCxSpFirst, div.ListeafsnitCxSpFirst
	{mso-style-name:ListeafsnitCxSpFirst;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListeafsnitCxSpMiddle, li.ListeafsnitCxSpMiddle, div.ListeafsnitCxSpMiddle
	{mso-style-name:ListeafsnitCxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListeafsnitCxSpLast, li.ListeafsnitCxSpLast, div.ListeafsnitCxSpLast
	{mso-style-name:ListeafsnitCxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.HangingIndent0, li.HangingIndent0, div.HangingIndent0
	{mso-style-name:"Hanging Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1\,Comment Text Char Char Char Char Char Char1 Ch Char\,Comment Text Char Char1 Char\,Comment Text Char Char1 Char Char Char\,Comment Text Char1 Char Char Char Char1 Char Char\,Comment Text Char2 Char\,Comment Text Char2 Char Char Char";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	font-family:"Arial",sans-serif;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.m2716680816725646424gmail-msolistparagraph, li.m2716680816725646424gmail-msolistparagraph, div.m2716680816725646424gmail-msolistparagraph
	{mso-style-name:m_2716680816725646424gmail-msolistparagraph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.apple-style-span
	{mso-style-name:apple-style-span;}
p.Korrektur1, li.Korrektur1, div.Korrektur1
	{mso-style-name:Korrektur1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listeafsnit1, li.Listeafsnit1, div.Listeafsnit1
	{mso-style-name:Listeafsnit1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listeafsnit1CxSpFirst, li.Listeafsnit1CxSpFirst, div.Listeafsnit1CxSpFirst
	{mso-style-name:Listeafsnit1CxSpFirst;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listeafsnit1CxSpMiddle, li.Listeafsnit1CxSpMiddle, div.Listeafsnit1CxSpMiddle
	{mso-style-name:Listeafsnit1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listeafsnit1CxSpLast, li.Listeafsnit1CxSpLast, div.Listeafsnit1CxSpLast
	{mso-style-name:Listeafsnit1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TabFigFooter, li.TabFigFooter, div.TabFigFooter
	{mso-style-name:"TabFig Footer";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	text-indent:-.15in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.gmail-msocommenttext, li.gmail-msocommenttext, div.gmail-msocommenttext
	{mso-style-name:gmail-msocommenttext;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=Annex><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 100&nbsp;mg&nbsp;concentrate for
solution for infusion</span></p>

<p class=MsoNormal>MabThera 500&nbsp;mg concentrate for solution for infusion</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u>MabThera 100&nbsp;mg concentrate for solution for
infusion</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each mL contains 10&nbsp;mg of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 10&nbsp;mL vial contains 100&nbsp;mg
of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u>MabThera 500&nbsp;mg concentrate for solution for
infusion </u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>Each mL contains 10&nbsp;mg of rituximab. </p>

<p class=MsoNormal>Each 50&nbsp;mL vial contains 500&nbsp;mg of rituximab.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Rituximab is a genetically engineered
chimeric mouse/human monoclonal antibody representing a glycosylated immunoglobulin
with human IgG1 constant regions and murine light&#8209;chain and heavy&#8209;chain
variable region sequences. The antibody is produced by mammalian (Chinese
hamster ovary) cell suspension culture and purified by affinity chromatography
and ion exchange, including specific viral inactivation and removal procedures.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients with known effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 10&nbsp;mL vial contains 2.3&nbsp;mmol
(52.6&nbsp;mg) sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each 50&nbsp;mL vial contains 11.5&nbsp;mmol
(263.2&nbsp;mg) sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Clear, colourless liquid with pH of 6.2 
6.8 and osmolality of 324 - 396&nbsp;mOsmol/kg .</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera is
indicated in adults for the following indications:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Non&#8209;Hodgkins lymphoma (NHL)</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera is
indicated for the treatment of previously untreated adult patients with stage
III&#8209;IV follicular lymphoma in combination with chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera
maintenance therapy is indicated for the treatment of adult follicular lymphoma
patients responding to induction therapy.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera monotherapy is indicated for
treatment of adult patients with stage III&#8209;IV follicular lymphoma who are
chemoresistant or are in their second or subsequent relapse after chemotherapy.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera is
indicated for the treatment of adult patients with CD20 positive diffuse large
B&nbsp;cell non&#8209;Hodgkins lymphoma in combination with </span><span
lang=EN-GB>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)</span><span
lang=EN-GB> chemotherapy<span style='layout-grid-mode:line'>. </span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>MabThera in combination with chemotherapy is
indicated for the treatment of paediatric patients (aged &#8805; 6 months to
&lt; 18 years old) with previously untreated advanced stage CD20 positive
diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia
(mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='layout-grid-mode:line'>Chronic lymphocytic leukaemia (CLL)</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>MabThera in combination with chemotherapy is
indicated for the treatment of patients with previously untreated and </span><span
lang=EN-GB>relapsed/refractory CLL</span><span lang=EN-GB style='layout-grid-mode:
line'>. Only limited data are available on efficacy and safety for patients
previously treated with monoclonal antibodies including MabThera or patients
refractory to previous MabThera plus chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>See section
5.1 for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB style='layout-grid-mode:line'>Rheumatoid arthritis</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera in combination with methotrexate
is indicated for the treatment of adult patients with severe active rheumatoid
arthritis who have had an inadequate response or intolerance to other disease&#8209;modifying
anti&#8209;rheumatic drugs (DMARD) including one or more tumour necrosis factor
(TNF) inhibitor therapies.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera has been shown to reduce the rate
of progression of joint damage as measured by X&#8209;ray and to improve
physical function, when given in combination with methotrexate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB style='layout-grid-mode:line'>Granulomatosis with
polyangiitis and microscopic polyangiitis </span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera, in combination with
glucocorticoids, is indicated for the treatment of adult patients with severe,
active granulomatosis with polyangiitis (Wegeners) (GPA) and microscopic
polyangiitis (MPA).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>MabThera, in combination with glucocorticoids, is indicated
for the induction of remission in paediatric patients (aged &#8805; 2 to &lt;
18 years old) with severe, active GPA (Wegeners) and MPA.</p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pemphigus vulgaris</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera is
indicated for the treatment of patients with moderate to severe pemphigus
vulgaris (PV).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera should be administered under the
close supervision of an experienced </span><span lang=EN-GB>healthcare
professional</span><span lang=EN-GB>, and in an environment where full resuscitation
facilities are immediately available (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Premedication and prophylactic
medications</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Premedication consisting of an anti&#8209;pyretic
and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be
given before each administration of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adult patients with non&#8209;Hodgkins
lymphoma and CLL, premedication with glucocorticoids should be considered if
MabThera is not given in combination with glucocorticoid&#8209;containing
chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In paediatric patients with non Hodgkins
lymphoma, premedication with paracetamol and H1 antihistamine (=
diphenhydramine or equivalent) should be administered 30 to 60 minutes before
the start of the infusion of MabThera. In addition, prednisone should be given
as indicated in Table 1.</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Prophylaxis
with adequate hydration and administration of uricostatics starting 48 hours
prior to start of therapy is recommended for CLL patients to reduce the risk of
tumour lysis syndrome. For CLL patients whose lymphocyte counts are &gt; 25 x
10<sup>9</sup>/L it is recommended to administer prednisone/prednisolone
100&nbsp;mg intravenous shortly before infusion with MabThera to decrease the
rate and severity of acute infusion reactions and/or cytokine release syndrome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with rheumatoid arthritis, GPA</span><span
lang=EN-GB> or MPA</span><span lang=EN-GB> or pemphigus vulgaris, premedication
with 100&nbsp;mg intravenous methylprednisolone should be completed 30 minutes
prior to each infusion of MabThera to decrease the incidence and severity of
infusion related </span>reactions<span lang=EN-GB> (IRRs).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In adult patients with</span><span
lang=EN-GB> </span><span lang=EN-GB>GPA</span><span lang=EN-GB> or MPA</span><span
lang=EN-GB>,<span style='color:black'> methylprednisolone given intravenously
for 1 to 3 days at a dose of 1000&nbsp;mg per day is recommended prior to the
first infusion of MabThera (the last dose of methylprednisolone may be given on
the same day as the first infusion of MabThera). This should be followed by
oral prednisone 1&nbsp;mg/kg/day (not to exceed 80&nbsp;mg/day, and tapered as
rapidly as possible based on clinical need) during and after the 4 week
induction course of MabThera treatment. </span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pneumocystis jirovecii
pneumonia (PJP) prophylaxis is recommended for adult patients with GPA/MPA or
PV during and following MabThera treatment, as appropriate according to local
clinical practice guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><i><span style='font-size:11.0pt'>Paediatric population</span></i></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>In paediatric patients with
GPA or MPA, prior to the first MabThera IV infusion, methylprednisolone should
be given IV for three daily doses of 30</span><span lang=EN-GB>&nbsp;</span><span
style='font-size:11.0pt'>mg/kg/day (not to exceed 1 g/day) to treat severe
vasculitis symptoms. Up to three additional daily doses of 30</span><span
lang=EN-GB>&nbsp;</span><span style='font-size:11.0pt'>mg/kg IV
methylprednisolone can be given prior to the first MabThera infusion.</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>Following completion of IV
methylprednisolone administration, patients should receive oral prednisone 1</span><span
lang=EN-GB>&nbsp;</span><span style='font-size:11.0pt'>mg/kg/day (not to exceed
60</span><span lang=EN-GB>&nbsp;</span><span style='font-size:11.0pt'>mg/day)
and tapered as rapidly as possible per clinical need (see section 5.1).</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><u><span style='font-size:11.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal>Pneumocystis jirovecii pneumonia (PJP) prophylaxis is
recommended for paediatric patients with GPA or MPA during and following
MabThera treatment, as appropriate.</p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important to check the medicinal
product labels to ensure that the appropriate formulation (intravenous or
subcutaneous formulation) is being given to the patient, as prescribed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=FR>Non&#8209;Hodgkins lymphoma</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=FR>Follicular
non&#8209;Hodgkin's lymphoma</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Combination
therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended dose of MabThera in combination with chemotherapy for induction
treatment of previously untreated or relapsed/refractory patients with
follicular lymphoma is: 375&nbsp;mg/m<sup>2</sup> body surface area per cycle,
for up to 8 cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera should be administered on day 1 of
each chemotherapy cycle, after intravenous administration of the glucocorticoid
component of the chemotherapy if applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maintenance
therapy</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Previously untreated
follicular lymphoma</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera used as a
maintenance treatment for patients with previously untreated follicular
lymphoma who have responded to induction treatment is: </span><span lang=EN-GB>375&nbsp;mg/m<sup>2</sup>
body surface area once every 2 </span><span lang=EN-GB>months (starting 2
months after the last dose of induction therapy) until disease</span><span
lang=EN-GB> progression or for a maximum period of two years (12 infusions in
total).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Relapsed/refractory
follicular lymphoma</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera used as a
maintenance treatment for patients with relapsed/refractory follicular lymphoma
who have responded to induction treatment is: </span><span lang=EN-GB>375&nbsp;mg/m<sup>2</sup>
body surface area once every 3 months </span><span lang=EN-GB>(starting 3
months after the last dose of induction therapy) </span><span lang=EN-GB>until
disease progression or for a maximum period of two years (8 infusions in total).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Monotherapy</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Relapsed/refractory
follicular lymphoma</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera
monotherapy used as induction treatment for adult patients with stage III&#8209;IV
follicular lymphoma who are chemoresistant or are in their second or subsequent
relapse after chemotherapy is: 375&nbsp;mg/m<sup>2 </sup>body surface area,
administered as an intravenous infusion once weekly for four weeks. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For retreatment with MabThera monotherapy
for patients who have responded to previous treatment with MabThera monotherapy
for relapsed/refractory follicular lymphoma, the recommended dose is:
375&nbsp;mg/m<sup>2</sup> body surface area, administered as an intravenous
infusion once weekly for four weeks (see section 5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adult Diffuse large B&nbsp;cell non&#8209;Hodgkin's
lymphoma</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera should be used in combination with
CHOP chemotherapy. The recommended dosage is 375&nbsp;mg/m<sup>2</sup> body
surface area, administered on day 1 of each chemotherapy cycle for 8 cycles
after intravenous infusion of the glucocorticoid component of CHOP. Safety and
efficacy of <span style='layout-grid-mode:line'>MabThera have not been
established in combination with other chemotherapies in diffuse large B cell
non&#8209;Hodgkins lymphoma.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Dose
adjustments during treatment</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No dose
reductions of MabThera are recommended. When MabThera is given in combination
with chemotherapy, standard dose reductions for the chemotherapeutic medicinal
products should be applied.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='layout-grid-mode:line'>Chronic lymphocytic leukaemia</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosage of MabThera in
combination with chemotherapy </span><span lang=EN-GB>for previously untreated
and relapsed/refractory patients</span><span lang=EN-GB> is 375&nbsp;mg/m<sup>2</sup>
body surface area administered on day 0 of the first treatment cycle followed
by 500&nbsp;mg/m<sup>2 </sup>body surface area administered on day 1 of each
subsequent cycle for 6 cycles in total. The chemotherapy should be given after
MabThera infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='layout-grid-mode:line'>Rheumatoid arthritis</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
treated with MabThera must be given the patient alert card with each infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A course of MabThera consists of two
1000&nbsp;mg intravenous infusions. The recommended dosage of MabThera is
1000&nbsp;mg by intravenous infusion followed by a second 1000&nbsp;mg
intravenous infusion two weeks later.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The</span><span
lang=EN-GB style='font-size:8.0pt'> </span><span lang=EN-GB>need for further
courses should be evaluated 24 weeks following the previous course. Retreatment
should be given at that time if residual disease activity remains, otherwise
retreatment should be delayed until disease activity returns.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Available data suggest that clinical
response is usually achieved within 16 &#8209; 24 weeks of an initial treatment
course. Continued therapy should be carefully reconsidered in patients who show
no evidence of therapeutic benefit within this time period</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='layout-grid-mode:line'>Granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
treated with MabThera must be given the patient alert card with each infusion. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adult induction of remission</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The recommended dosage
of MabThera for induction of remission therapy in adult patients with GPA and MPA
is 375&nbsp;mg/m<sup>2</sup> body surface area, administered as an intravenous
infusion once weekly for 4 weeks (four infusions in total). </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adult maintenance treatment</span></i></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>Following induction of
remission with MabThera, maintenance treatment in adult patients with GPA and
MPA should be initiated no sooner than 16 weeks after the last MabThera
infusion.</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>Following induction of
remission with other standard of care immunosuppressants, MabThera maintenance
treatment should be initiated during the 4 week period that follows disease
remission. </span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span style='font-size:11.0pt'>MabThera should be
administered as two 500&nbsp;mg IV infusions separated by two weeks, followed
by a 500&nbsp;mg IV infusion every 6 months thereafter. Patients should receive
MabThera for at least 24 months after achievement of remission (absence of
clinical signs and symptoms). For patients who may be at higher risk for
relapse, physicians should consider a longer duration of MabThera maintenance
therapy, up to 5 years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Pemphigus vulgaris</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
treated with MabThera must be given the patient alert card with each infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-family:"Times",serif'>The recommended
dosage of MabThera for the treatment of pemphigus vulgaris is 1000&nbsp;mg administered
as an IV infusion followed two weeks later by a second 1000&nbsp;mg IV infusion
in combination with a tapering course of glucocorticoids.</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times",serif'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt;page-break-after:avoid'><i><span style='font-size:11.0pt;
font-family:"Times",serif'>Maintenance treatment</span></i></p>

<p class=MsoCommentText><span style='font-size:11.0pt;font-family:"Times",serif'>A
maintenance infusion of 500&nbsp;mg IV should be administered at months 12 and
18, and then every 6 months thereafter if needed, based on clinical evaluation.</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times",serif'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt;page-break-after:avoid'><i><span style='font-size:11.0pt;
font-family:"Times",serif'>Treatment of relapse</span></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times",serif'>In the event of relapse, patients may receive 1000&nbsp;mg IV.
The healthcare provider should also consider resuming or increasing the
patients glucocorticoid dose based on clinical evaluation. </span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times",serif'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt;font-family:"Times",serif'>Subsequent
infusions may be administered no sooner than 16 weeks following the previous
infusion.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Non-Hodgkins lymphoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In paediatric patients from &#8805; 6
months to &lt; 18 years of age with previously untreated, advanced stage CD20
positive DLBCL/BL/BAL/BLL, MabThera should be used in combination with systemic
Lymphome Malin B (LMB) chemotherapy (see Tables 1 and 2). The recommended
dosage of MabThera is 375mg/m2 BSA, administered as an IV infusion. No MabThera
dose adjustments, other than by BSA, are required.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of MabThera
paediatric patients &#8805; 6 months to &lt; 18 years of age has not been
established in indications other than previously untreated advanced stage CD20
positive DLBCL/BL/BAL/BLL. Only limited data are available for patients under 3
years of age. See section 5.1 for further information. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:107%'><span lang=EN-GB style='line-height:
107%'>MabThera should not be used in paediatric patients from birth to &lt; 6
months of age with CD20 positive diffuse large B-cell lymphoma (see section
5.1)</span></p>

<p class=MsoNormal style='line-height:107%'><span lang=EN-GB style='line-height:
107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1 Posology of MabThera administration
for Non-Hodgkins lymphoma paediatric patients</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=604
 style='border-collapse:collapse;border:none'>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Cycle</span></b></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Day of treatment</span></b></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Administration details</span></b></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Prephase (COP)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>No MabThera given</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 rowspan=2 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Induction course 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>(COPDAM1)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day -2</span></p>
  <p class=MsoNormal><span lang=EN-GB>(corresponding to day 6 of the prephase)</span></p>
  <p class=MsoNormal><span lang=EN-GB>1<sup>st</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>During the 1<sup>st</sup> induction
  course, prednisone is given as part of the chemotherapy course, and should be
  administered prior to MabThera.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>2<sup>nd</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>MabThera will be given 48 hours after
  thefirst infusion of MabThera.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 rowspan=2 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Induction course 2</span></p>
  <p class=MsoNormal><span lang=EN-GB>(COPDAM2)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day -2</span></p>
  <p class=MsoNormal><span lang=EN-GB>3<sup>rd</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>In the 2<sup>nd</sup> induction course,
  prednisone is not given at the time of MabThera administration.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>4<sup>th</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>MabThera will be given 48 hours after the
  third infusion of MabThera.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Consolidation course 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>(CYM/CYVE)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>5<sup>th</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Prednisone is not given at the time of
  MabThera administration.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Consolidation course 2</span></p>
  <p class=MsoNormal><span lang=EN-GB>(CYM/CYVE)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 1</span></p>
  <p class=MsoNormal><span lang=EN-GB>6<sup>th</sup> MabThera infusion</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Prednisone is not given at the time of MabThera
  administration.</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Maintenance course 1 (M1)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 25 to 28 of consolidation course 2
  (CYVE)</span></p>
  <p class=MsoNormal><span lang=EN-GB>No MabThera given</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>Starts when peripheral counts have
  recovered from consolidation course 2 (CYVE) with ANC&gt; 1.0 x 10<sup>9</sup>/l
  and platelets &gt; 100 x 10<sup>9</sup>/l </span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=129 valign=top style='width:96.45pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Maintenance course 2 (M2)</span></p>
  </td>
  <td width=165 valign=top style='width:123.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>Day 28 of maintenance course 1 (M1)</span></p>
  <p class=MsoNormal><span lang=EN-GB>No MabThera given</span></p>
  </td>
  <td width=310 valign=top style='width:232.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal><span lang=EN-GB>-</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=604 colspan=3 valign=top style='width:453.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
  lang=EN-GB style='font-size:9.0pt;line-height:107%'>ANC = Absolute Neutrophil
  Count; COP = Cyclophosphamide, Vincristine, Prednisone; COPDAM =
  Cyclophosphamide, Vincristine, Prednisolone, Doxorubicin, Methotrexate; CYM =
  CYtarabine (Aracytine, Ara-C), Methotrexate; CYVE = CYtarabine (Aracytine,
  Ara-C), VEposide (VP16) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;2 Treatment Plan for Non-Hodgkins
lymphoma paediatric patients: Concomitant Chemotherapy with MabThera </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=604
 style='border-collapse:collapse;border:none'>
 <tr style='height:23.55pt'>
  <td width=83 valign=top style='width:62.0pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Treatment
  Plan</span></b></p>
  </td>
  <td width=247 valign=top style='width:185.1pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Patient
  Staging</span></b></p>
  </td>
  <td width=275 valign=top style='width:205.95pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Administration
  details</span></b></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=83 valign=top style='width:62.0pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group B</span></p>
  </td>
  <td width=247 valign=top style='width:185.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Stage III
  with high LDH level (&gt; N x 2),</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Stage IV
  CNS negative</span></p>
  </td>
  <td width=275 valign=top style='width:205.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Prephase
  followed by 4 courses: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2
  induction courses (COPADM) with HDMTX 3g/m<sup>2 </sup>and 2 consolidation
  courses (CYM) </span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=83 rowspan=2 valign=top style='width:62.0pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group C</span></p>
  </td>
  <td width=247 valign=top style='width:185.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group C1:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>B- AL CNS
  negative, Stage IV &amp; BAL CNS positive and CSF negative</span></p>
  </td>
  <td width=275 rowspan=2 valign=top style='width:205.95pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Prephase
  followed by 6 courses: </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2
  induction courses (COPADM) with HDMTX 8g/m, 2 consolidation courses (CYVE)
  and 2 maintenance courses (M1 and M2) </span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=247 valign=top style='width:185.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Group C3:</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>BAL CSF
  positive, Stage IV CSF positive</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=604 colspan=3 valign=top style='width:453.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Consecutive
  courses should be given as soon as blood count recovery and patients
  condition allows except for the maintenance courses which are given at 28 day
  intervals</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=604 colspan=3 valign=top style='width:453.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt;line-height:107%'>BAL =
  Burkitt leukaemia (mature B-cell acute leukaemia); CSF = Cerebrospinal
  Fluid; CNS = Central Nervous System; HDMTX = High-dose Methotrexate; LDH =
  Lactic Acid Dehydrogenase</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TextTi12 style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>Granulomatosis with polyangiitis
(GPA) and microscopic polyangiitis (MPA)</span></u></p>

<p class=TextTi12 style='margin-bottom:0in'><i><u><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>Induction of remission</span></u></i></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt'>The
recommended dosage of MabThera for induction of remission therapy in paediatric
patients with severe, active GPA or MPA is 375&nbsp;mg/m<sup>2</sup> BSA,
administered as an IV infusion once weekly for 4&nbsp;weeks.</span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of MabThera in paediatric
patients (&#8805; 2 to &lt; 18 years of age) has not been established in
indications other than severe, active GPA or MPA.</span></p>

<p class=MsoNormal>MabThera should not be used in paediatric patients less than
2&nbsp;years of age with severe, active GPA or MPA as there is a possibility of
an inadequate immune response towards childhood vaccinations against common,
vaccine preventable childhood diseases (e.g. measles, mumps, rubella, and
poliomyelitis) (see section 5.1).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required in elderly
patients (aged &gt;65 years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The prepared
MabThera solution should be administered as an intravenous infusion through a
dedicated line. It should not be administered as an intravenous push or bolus.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be closely monitored for
the onset of cytokine release syndrome (see section 4.4). Patients who develop
evidence of severe reactions, especially severe dyspnoea, bronchospasm or
hypoxia should have the infusion interrupted immediately. Patients with non&#8209;Hodgkins
lymphoma should then be evaluated for evidence of tumour lysis syndrome
including appropriate laboratory tests and, for pulmonary infiltration, with a
chest X&#8209;ray. In all patients, the infusion should not be restarted until
complete resolution of all symptoms, and normalisation of laboratory values and
chest X&#8209;ray findings. At this time, the infusion can be initially resumed
at not more than one&#8209;half the previous rate. If the same severe adverse
reactions occur for a second time, the decision to stop the treatment should be
seriously considered on a case by case basis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mild or
moderate infusion&#8209;related reactions (IRR) (section 4.8) usually respond
to a reduction in the rate of infusion. The infusion rate may be increased upon
improvement of symptoms. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>First
infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended initial rate for infusion is 50&nbsp;mg/h; after the first 30
minutes, it can be escalated in 50&nbsp;mg/h increments every 30 minutes, to a
maximum of 400&nbsp;mg/h.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Subsequent
infusions </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>All indications</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subsequent doses of MabThera can be infused
at an initial rate of 100&nbsp;mg/h, and increased by 100&nbsp;mg/h increments
at 30 minute intervals, to a maximum of 400&nbsp;mg/h.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric patients  non-Hodgkins
lymphoma</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>First infusion </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended initial rate for infusion
is 0.5 mg/kg/h (maximum 50 mg/h); it can be escalated by 0.5 mg/kg/h every 30
minutes if there is no hypersensitivity or infusion-related reactions, to a
maximum of 400 mg/h.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subsequent infusions </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subsequent doses of MabThera can be infused
at an initial rate of 1 mg/kg/h (maximum 50 mg/h); it can be increased by 1
mg/kg/h every 30 minutes to a maximum of 400 mg/h.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rheumatoid
arthritis only </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Alternative subsequent,
faster, infusion schedule</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If patients
did not experience a serious infusion-related reaction with their first or
subsequent infusions of a dose of 1000&nbsp;mg MabThera administered over the
standard infusion&nbsp;schedule, a more rapid infusion can be administered for second
and subsequent infusions using the same concentration as in previous infusions
(4&nbsp;mg/mL in a 250&nbsp;mL volume). Initiate at a rate of 250&nbsp;mg/hour
for the first 30 minutes and then 600&nbsp;mg/hour for the next 90 minutes. If
the more rapid infusion is tolerated, this infusion schedule can be used when
administering subsequent infusions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who have clinically significant
cardiovascular disease, including arrhythmias, or previous serious infusion
reactions to any prior biologic therapy or to rituximab, should not be
administered the more rapid infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Contraindications for use in non&#8209;Hodgkins
lymphoma and chronic lymphocytic leukaemia</span></u><u><span lang=EN-GB> </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to murine proteins, or to any of the other excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Active, severe infections (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Patients in a severely immunocompromised state.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Contraindications for use in rheumatoid
arthritis, </span></u><u><span lang=EN-GB style='layout-grid-mode:line'>granulomatosis
with polyangiitis, microscopic polyangiitis</span></u><u><span lang=EN-GB> <span
style='layout-grid-mode:line'>and</span> pemphigus vulgaris</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to murine proteins, or to any of the other excipients listed in section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Active, severe infections (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Patients in a severely immunocompromised state.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe heart failure (New York Heart
Association Class IV) or severe, uncontrolled cardiac disease </span><span
lang=EN-GB>(see section 4.4 regarding other cardiovascular diseases)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Traceability </p>

<p class=MsoNormal><span lang=EN-GB>In order to improve traceability of
biological medicinal products, the tradename and batch number of the
administered product should be clearly recorded. </span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Progressive multifocal leukoencephalopathy</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients treated with MabThera for
rheumatoid arthritis, GPA<span style='layout-grid-mode:line'>, MPA</span> or
pemphigus vulgaris must be given the patient alert card with each infusion. The
alert card contains important safety information for patients regarding
potential increased risk of infections, including progressive multifocal
leukoencephalopathy (PML).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare cases of fatal PML have been
reported following use of MabThera. Patients must be monitored at regular
intervals for any new or worsening neurological symptoms or signs that may be
suggestive of PML. If PML is suspected, further dosing must be suspended until
PML has been excluded. The clinician should evaluate the patient to determine
if the symptoms are indicative of neurological dysfunction, and if so, whether
these symptoms are possibly suggestive of PML. Consultation with a Neurologist
should be considered as clinically indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any doubt exists, further evaluation,
including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing
for JC Viral DNA and repeat neurological assessments, should be considered. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The physician should be particularly alert to symptoms suggestive of
PML that the patient may not notice (e.g. cognitive, neurological or
psychiatric symptoms). </span><span lang=EN-GB>Patients should also be advised
to inform their partner or caregivers about their treatment, since they may
notice symptoms that the patient is not aware of.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If a patient develops PML, the dosing of
MabThera must be permanently discontinued. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following reconstitution of the immune
system in immunocompromised patients with PML, stabilisation or improved
outcome has been seen. It remains unknown if early detection of PML and
suspension of MabThera therapy may lead to similar stabilisation or improved
outcome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Non&#8209;Hodgkins lymphoma and chronic lymphocytic leukaemia</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Infusion-related reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is associated with infusion-related
reactions, which may be related to release of cytokines and/or other chemical
mediators. Cytokine release syndrome may be clinically indistinguishable from
acute hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This set of reactions which includes
syndrome of cytokine release, tumour lysis syndrome and anaphylactic and
hypersensitivity reactions are described below. They are not specifically
related to the route of administration of MabThera and can be observed with
both formulations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe infusion&#8209;related reactions
with fatal outcome have been reported during post&#8209;marketing use of the
MabThera intravenous formulation, with an onset ranging within 30 minutes to 2
hours after starting the first MabThera intravenous infusion. They were
characterised by pulmonary events and in some cases included rapid tumour lysis
and features of tumour lysis syndrome in addition to fever, chills, rigors,
hypotension, urticaria, angioedema and other symptoms (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe cytokine release syndrome is
characterised by severe dyspnoea, often accompanied by bronchospasm and
hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema. This
syndrome may be associated with some features of tumour lysis syndrome such as
hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal
failure, elevated lactate dehydrogenase (LDH) and may be associated with acute
respiratory failure and death. The acute respiratory failure may be accompanied
by events such as pulmonary interstitial infiltration or oedema, visible on a
chest X&#8209;ray. The syndrome frequently manifests itself within one or two
hours of initiating the first infusion. Patients with a history of pulmonary
insufficiency or those with pulmonary tumour infiltration may be at greater
risk of poor outcome and should be treated with increased caution. Patients who
develop severe cytokine release syndrome should have their infusion interrupted
immediately (see section 4.2) and should receive aggressive symptomatic
treatment. Since initial improvement of clinical symptoms may be followed by
deterioration, these patients should be closely monitored until tumour lysis
syndrome and pulmonary infiltration have been resolved or ruled out. Further
treatment of patients after complete resolution of signs and symptoms has rarely
resulted in repeated severe cytokine release syndrome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with a high tumour burden or with
a high number (&#8805;25 x 10<sup>9</sup>/L) of circulating malignant cells
such as patients with CLL, who may be at higher risk of especially severe
cytokine release syndrome, should be treated with extreme caution. These
patients should be very closely monitored throughout the first infusion.
Consideration should be given to the use of a reduced infusion rate for the
first infusion in these patients or a split dosing over two days during the
first cycle</span><span lang=EN-GB> and any subsequent cycles if the lymphocyte
count is still &gt;25 x 10<sup>9</sup>/L</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infusion-related adverse reactions of all
kinds have been observed in 77% of patients treated with MabThera (including
cytokine release syndrome accompanied by hypotension and bronchospasm in 10% of
patients) see section 4.8. These symptoms are usually reversible with
interruption of MabThera infusion and administration of an anti&#8209;pyretic,
an antihistaminic and occasionally oxygen, intravenous saline or
bronchodilators, and glucocorticoids if required. Please see cytokine release
syndrome above for severe reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anaphylactic and other hypersensitivity
reactions have been reported following the intravenous administration of
proteins to patients. In contrast to cytokine release syndrome, true
hypersensitivity reactions typically occur within minutes after starting
infusion. Medicinal products for the treatment of hypersensitivity reactions,
e.g. epinephrine (adrenaline), antihistamines and glucocorticoids, should be
available for immediate use in the event of an allergic reaction during
administration of MabThera. Clinical manifestations of anaphylaxis may appear
similar to clinical manifestations of the cytokine release syndrome (described
above). Reactions attributed to hypersensitivity have been reported less
frequently than those attributed to cytokine release.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additional reactions reported in some cases
were myocardial infarction, atrial fibrillation, pulmonary oedema and acute
reversible thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Since hypotension may occur during MabThera
administration, consideration should be given to withholding anti&#8209;hypertensive
medicines 12 hours prior to the MabThera infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cardiac
disorders</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Angina
pectoris, cardiac arrhythmias<b> </b>such as atrial flutter and fibrillation,
heart failure and/or myocardial infarction have occurred in patients treated
with MabThera. Therefore patients with a history of cardiac disease and/or
cardiotoxic chemotherapy should be monitored closely.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Haematological toxicities</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Although MabThera is not myelosuppressive
in monotherapy, caution should be exercised when considering treatment of
patients with neutrophils &lt;&nbsp;1.5 x 10<sup>9</sup>/L and/or platelet
counts &lt;&nbsp;75 x 10<sup>9</sup>/L as clinical experience in this
population is limited<i>. </i>MabThera has been used in 21 patients who
underwent autologous bone marrow transplantation and other risk groups with a
presumable reduced bone marrow function without inducing myelotoxicity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular full blood counts, including
neutrophil and platelet counts, should be performed during MabThera therapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Infections</span></i></p>

<p class=MsoNormal><a name="OLE_LINK1"></a><a name="OLE_LINK2"><span
lang=EN-GB>Serious infections, including fatalities, can occur during therapy
with MabThera</span></a><span lang=EN-GB> (see section 4.8).</span><b><i><span
lang=EN-GB style='font-family:"Times New Roman Bold"'> </span></i></b><span
lang=EN-GB>MabThera should not be administered to patients with an active,
severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see
section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Physicians should exercise caution when
considering the use of MabThera in patients with a history of recurring or
chronic infections or with underlying conditions which may further predispose
patients to serious infection (see section 4.8). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of hepatitis B reactivation have been
reported in subjects receiving MabThera including fulminant hepatitis with
fatal outcome. The majority of these subjects were also exposed to cytotoxic
chemotherapy. </span><span lang=EN-GB>Limited information from one study in
relapsed/refractory CLL patients suggests that MabThera treatment may also
worsen the outcome of primary hepatitis B infections.</span><span lang=EN-GB> </span><span
lang=EN-GB>Hepatitis B virus (HBV) screening should be performed in all
patients before initiation of treatment with MabThera. At minimum this should
include HBsAg&#8209;status and HBcAb&#8209;status. These can be complemented
with other appropriate markers as per local guidelines. Patients with active
hepatitis B disease should not be treated with MabThera. Patients with positive
hepatitis B serology (either HBsAg or HBcAb) should consult liver disease
experts before start of treatment and should be monitored and managed following
local medical standards to prevent hepatitis B reactivation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare cases of progressive multifocal
leukoencephalopathy (PML) have been reported during post&#8209;marketing use of
MabThera in NHL and CLL (see section 4.8). The majority of patients had
received MabThera in combination with chemotherapy or as part of a
hematopoietic stem cell transplant. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Immunisations</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety of immunisation with </span><span
lang=EN-GB>live viral vaccines, following MabThera therapy has not been studied
for NHL and CLL patients<i> </i>and vaccination with live virus vaccines is not
recommended. Patients treated with MabThera may receive non&#8209;live
vaccinations; however, with non&#8209;live vaccines response rates may be
reduced. In a non&#8209;randomised study, adult patients with relapsed low&#8209;grade
NHL who received MabThera monotherapy when compared to healthy untreated
controls had a lower rate of response to vaccination with tetanus recall antigen
(16% vs. 81%) and Keyhole Limpet Haemocyanin (KLH) neoantigen (4% vs. 76% when
assessed for &gt;2&#8209;fold increase in antibody titer). For CLL patients,
similar results are assumable considering similarities between both diseases
but that has not been investigated in clinical trials.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mean pre&#8209;therapeutic antibody</span><span
lang=EN-GB> titres against a panel of antigens (Streptococcus pneumoniae,
influenza A, mumps, rubella, varicella) were maint</span><span lang=EN-GB>ained
for at least 6 months after treatment with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Skin
reactions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe skin
reactions such as Toxic Epidermal Necrolysis (Lyells syndrome) and Stevens&#8209;Johnson
syndrome, some with fatal outcome, have been reported<i> </i>(see section 4.8).<i>
</i>In case of such an event, with a suspected relationship to MabThera,
treatment should be permanently discontinued. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Only limited
data are available for patients under 3 years of age. See section 5.1 for
further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Rheumatoid
arthritis,<i><span style='layout-grid-mode:line'> </span></i><span
style='layout-grid-mode:line'>granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA), and pemphigus vulgaris</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Methotrexate
(MTX) nave populations with rheumatoid arthritis</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The use of
MabThera is not recommended in MTX&#8209;nave patients since a favourable
benefit risk relationship has not been established.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Infusion-related reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is associated with infusion
related reactions (IRRs), which may be related to release of cytokines and/or
other chemical mediators. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe IRRs with fatal outcome have been
reported in rheumatoid arthritis patients in the post&#8209;marketing setting.
In rheumatoid arthritis most infusion&#8209;related events reported in clinical
trials were mild to moderate in severity. The most common symptoms were
allergic reactions like headache, pruritus, throat irritation, flushing, rash,
urticaria, hypertension, and pyrexia. In general, the proportion of patients
experiencing any infusion reaction was higher following the first infusion than
following the second infusion of any treatment course. The incidence of IRR
decreased with subsequent courses (see section 4.8). The reactions reported
were usually reversible with a reduction in rate, or interruption, of MabThera
infusion and administration of an anti&#8209;pyretic, an antihistamine, and,
occasionally, oxygen, intravenous saline or bronchodilators, and
glucocorticoids if required. Closely monitor patients with pre&#8209;existing
cardiac conditions and those who experienced prior cardiopulmonary adverse
reactions. Depending on the severity of the IRR and the required interventions,
temporarily or permanently discontinue MabThera. In most cases, the infusion
can be resumed at a 50% reduction in rate (e.g. from 100&nbsp;mg/h to
50&nbsp;mg/h) when symptoms have completely resolved.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Medicinal
products for the treatment of hypersensitivity reactions, e.g. epinephrine
(adrenaline), antihistamines and glucocorticoids, should be available for
immediate use in the event of an allergic reaction during administration of
MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no data on the safety of MabThera
in patients with moderate heart failure (NYHA class III) or severe,
uncontrolled cardiovascular disease. In patients treated with MabThera, the
occurrence of pre&#8209;existing ischemic cardiac conditions becoming
symptomatic, such as angina pectoris, has been observed, as well as atrial
fibrillation and flutter. Therefore, in patients with a known cardiac history,
and those who experienced prior cardiopulmonary adverse reactions, the risk of
cardiovascular complications resulting from infusion reactions should be
considered before treatment with MabThera and patients closely monitored during
administration. Since hypotension may occur during MabThera infusion,
consideration should be given to withholding anti&#8209;hypertensive
medications 12 hours prior to the MabThera infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IRRs in patients with GPA, MPA and
pemphigus vulgaris were consistent with those seen for rheumatoid arthritis
patients in clinical trials and in the post-marketing setting (see section 4.8)</span><i><span
lang=EN-GB>.</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK9"></a><a name="OLE_LINK10"><i><span
lang=EN-GB>Cardiac disorders</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>Angina pectoris, cardiac arrhythmias<b> </b>such
as atrial flutter and fibrillation, heart failure and/or myocardial infarction
have occurred in patients treated with MabThera. Therefore, patients with a
history of cardiac disease should be monitored closely (see Infusion-related
reactions, above).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="OLE_LINK3"></a><a name="OLE_LINK4"><i><span
lang=EN-GB>Infections</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>Based on the mechanism of action of
MabThera and the knowledge that B cells play an important role in maintaining
normal immune response, patients have an increased risk of infection following
MabThera therapy (see section 5.1). Serious infections, including fatalities,
can occur during therapy with MabThera</span><span lang=EN-GB> (see section
4.8).</span><b><i><span lang=EN-GB style='font-family:"Times New Roman Bold"'> </span></i></b><span
lang=EN-GB>MabThera should not be administered to patients with an active,
severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see
section 4.3) or severely immunocompromised patients (e.g. where levels of CD4
or CD8 are very low). Physicians should exercise caution when considering the
use of MabThera in patients with a history of recurring or chronic infections
or with underlying conditions which may further predispose patients to serious
infection, e.g. hypogammaglobulinaemia (see section 4.8). It is recommended
that immunoglobulin levels are determined prior to initiating treatment with
MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients reporting signs and symptoms of
infection following MabThera therapy should be promptly evaluated and treated
appropriately. Before giving a subsequent course of MabThera treatment, patients
should be re&#8209;evaluated for any potential risk for infections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare cases of fatal progressive multifocal
leukoencephalopathy (PML) have been reported following use of MabThera</span><span
lang=EN-GB> for the treatment of rheumatoid arthritis and autoimmune diseases
including Systemic Lupus Erythematosus (SLE) and vasculitis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Hepatitis B Infections</i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of hepatitis B reactivation,
including those with a fatal outcome, have been reported in rheumatoid arthritis,
GPA and MPA patients receiving MabThera.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hepatitis B virus (HBV) screening should be
performed in all patients before initiation of treatment with MabThera. At
minimum this should include HBsAg&#8209;status and HBcAb&#8209;status. These
can be complemented with other appropriate markers as per local guidelines.
Patients with active hepatitis B disease should not be treated with MabThera. Patients
with positive hepatitis B serology (either HBsAg or HBcAb) should consult liver
disease experts before start of treatment and should be monitored and managed
following local medical standards to prevent hepatitis B reactivation.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Late
neutropenia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Measure blood neutrophils prior to each
course of MabThera, and regularly up to 6&#8209;months after cessation of
treatment, and upon signs or symptoms of infection (see section 4.8). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Skin
reactions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe skin
reactions such as Toxic Epidermal Necrolysis (Lyells syndrome) and Stevens&#8209;Johnson
syndrome, some with fatal outcome, have been reported<i> </i>(see section 4.8).<i>
</i>In case of such an event with a suspected relationship to MabThera,
treatment should be permanently discontinued. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Immuni</span></i><span lang=EN-GB>s<i>ation</i></span></p>

<p class=MsoNormal><span lang=EN-GB>Physicians should review the patients
vaccination status and patients should, if possible, be brought up-to-date
with all immunisations in agreement with current immunisation guidelines prior
to initiating MabThera therapy. Vaccination should be completed at least 4
weeks prior to first administration of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety of immunisation with live viral
vaccines following MabThera therapy has not been studied. Therefore vaccination
with live virus vaccines is not recommended whilst on MabThera or whilst
peripherally B cell depleted. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients treated with MabThera may receive
non&#8209;live vaccinations; however, response rates to non&#8209;live vaccines
may be reduced. In a randomised trial, patients with rheumatoid arthritis
treated with MabThera and methotrexate had comparable response rates to tetanus
recall antigen (39% vs. 42%), reduced rates to pneumococcal polysaccharide
vaccine (43% vs. 82% to at least 2 pneumococcal antibody serotypes), and KLH
neoantigen (47% vs. 93%), when given 6 months after MabThera as compared to
patients only receiving methotrexate. Should non&#8209;live vaccinations be required
whilst receiving MabThera therapy, these should be completed at least 4 weeks
prior to commencing the next course of MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the overall experience of MabThera
repeat treatment over one year in rheumatoid arthritis, the proportions of
patients with positive antibody titres against S. pneumoniae, influenza, mumps,
rubella, varicella and tetanus toxoid were generally similar to the proportions
at baseline. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Concomitant/sequential use of other
DMARDs in rheumatoid arthritis</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The concomitant use of MabThera and anti&#8209;rheumatic
therapies other than those specified under the rheumatoid arthritis indication
and posology is not recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are limited data from clinical trials
to fully assess the safety of the sequential use of other DMARDs (including TNF
inhibitors and other biologics) following MabThera (see section 4.5). The
available data indicate that the rate of clinically relevant infection is
unchanged when such therapies are used in patients previously treated with
MabThera, however patients should be closely observed for signs of infection if
biologic agents and/or DMARDs are used following MabThera therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Malignancy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Immunomodulatory drugs may increase the
risk of malignancy. On the basis of limited experience with MabThera in
rheumatoid arthritis patients (see section 4.8) the present data do not seem to
suggest any increased risk of malignancy. However, the possible risk for the
development of solid tumours cannot be excluded at this time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients </span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains</span><span
lang=EN-GB> 2.3&nbsp;mmol (or 52.6&nbsp;mg) sodium per 10&nbsp;mL vial and
11.5&nbsp;mmol (or 263.2&nbsp;mg) sodium per 50&nbsp;mL vial, </span>equivalent
to 2.6% (for 10ml vial) and 13.2% (for 50ml vial) of the WHO recommended
maximum daily intake of 2 g sodium for an adult<span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Currently,
there are limited data on possible drug interactions with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In CLL patients, co&#8209;administration
with MabThera </span><span lang=EN-GB>did not appear to have an</span><span
lang=EN-GB> effect on the pharmacokinetics of fludarabine </span><span
lang=EN-GB>or</span><span lang=EN-GB> cyclophosphamide. In addition, there was
no apparent effect of fludarabine and cyclophosphamide on the pharmacokinetics
of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration with methotrexate
had no effect on the pharmacokinetics of MabThera in rheumatoid arthritis
patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with human anti&#8209;mouse
antibody (HAMA) or anti-drug antibody (ADA) titres may have allergic or
hypersensitivity reactions when treated with other diagnostic or therapeutic
monoclonal antibodies.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In patients with rheumatoid arthritis, 283 patients
received subsequent therapy with a biologic DMARD following MabThera. In these
patients the rate of clinically relevant infection while on MabThera was 6.01
per 100 patient years compared to 4.97 per 100 patient years following
treatment with the biologic DMARD. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Contraception in males and females</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Due to the
long retention time of rituximab in B&nbsp;cell depleted patients, women of
childbearing potential should use effective contraceptive methods during and
for 12 months following treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>IgG
immunoglobulins are known to cross the placental barrier.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>B cell levels in human neonates following
maternal exposure to MabThera have not been studied in clinical trials. There
are no adequate and well&#8209;controlled data from studies in pregnant women,
however transient B&#8209;cell depletion and lymphocytopenia have been reported
in some infants born to mothers exposed to MabThera during pregnancy. Similar
effects have been observed in animal studies (see section 5.3). For these
reasons MabThera should not be administered to pregnant women unless the
possible benefit outweighs the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Whether
rituximab is excreted in human milk is not known. However, because maternal IgG
is excreted in human milk, and rituximab was detectable in milk from lactating
monkeys, </span><span lang=EN-GB>women should not breastfeed while treated with
MabThera and for 12 months following MabThera treatment.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Animal
studies did not reveal deleterious effects of rituximab on reproductive organs.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No studies on the effects of MabThera on
the ability to drive and use machines have been performed, although the
pharmacological activity and adverse reactions reported to date suggest that
MabThera would have no or negligible influence on the ability to drive and use
machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Experience
from non&#8209;Hodgkins lymphoma and chronic lymphocytic leukaemia in adults</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Summary
of the safety profile</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall safety profile of MabThera in
non&#8209;Hodgkins lymphoma and CLL is based on data from patients from
clinical trials and from post&#8209;marketing surveillance. These patients were
treated either with MabThera monotherapy (as induction treatment or maintenance
treatment following induction treatment) or in combination with chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently observed adverse
reactions (ADRs) in patients receiving MabThera were IRRs which occurred in the
majority of patients during the first infusion. The incidence of infusion&#8209;related
symptoms decreases substantially with subsequent infusions and is less than 1%
after eight doses of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Infectious events (predominantly bacterial
and viral) occurred in approximately 30&#8209;55% of patients during clinical
trials in patients with NHL and in 30&#8209;50% of patients during clinical
trials in patients with CLL.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently reported or observed </span><u><span
lang=EN-GB>serious</span></u><span lang=EN-GB> adverse reactions were:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> IRRs
(including cytokine&#8209;release syndrome, tumour&#8209;lysis syndrome), see
section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infections,
see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Cardiovascular
events, see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other serious ADRs reported include
hepatitis B reactivation and PML (see section 4.4.). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
frequencies of ADRs reported with MabThera alone or in combination with
chemotherapy are summarised in Table 3. Frequencies are defined as very common
(</span><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>
1/10), common&nbsp;(</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;1/100 to &lt;&nbsp;1/10), uncommon&nbsp;(</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp; 1/1,000
to &lt; 1/100), rare (</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> 1/10,000 to &lt; 1/1000), very rare (&lt;&nbsp;1/10,000) and not
known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in the order of decreasing
seriousness.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ADRs identified only during post&#8209;marketing
surveillance, and for which a frequency could not be estimated, are listed
under not known.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;3 ADRs reported in clinical trials
or during postmarketing surveillance in patients with NHL and CLL disease
treated with MabThera monotherapy/maintenance or in combination with
chemotherapy </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="13%" style='width:13.24%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p align=center style='text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:8.5pt'>MedDRA</span></b></p>
   <p align=center style='text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:9.0pt'>System Organ Class</span></b></p>
   </td>
   <td width="14%" style='width:14.02%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Common</span></b></p>
   </td>
   <td width="16%" style='width:16.52%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Common</span></b></p>
   </td>
   <td width="16%" style='width:16.18%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Uncommon</span></b></p>
   </td>
   <td width="13%" style='width:13.32%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Rare</span></b></p>
   </td>
   <td width="15%" style='width:15.26%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Rare</span></b></p>
   </td>
   <td width="11%" style='width:11.44%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Infections and infestations</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>bacterial infections, viral infections, <sup>+</sup>bronchitis
  </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>sepsis, <sup>+</sup>pneumonia, <sup>+</sup>febrile
  infection, <sup>+</sup>herpes zoster, <sup>+</sup>respiratory tract
  infection, fungal infections, infections of unknown aetiology, <sup>+</sup>acute
  bronchitis, <sup>+</sup>sinusitis,</span><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'> h</span><span lang=EN-GB style='font-size:9.0pt'>epatitis
  B</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>1</span></sup><sup><span
  lang=EN-GB style='font-size:9.0pt'> </span></sup></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>serious viral infection<sup>2</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>Pneumocystis jirovecii</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>PML</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Blood and
  lymphatic system disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>neutropenia,
  leucopenia, <sup>+</sup>febrile neutropenia, <sup>+</sup>thrombocytopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>anaemia, </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>pancytopenia, <sup>+</sup>granulocytopenia</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>coagulation
  disorders, aplastic anaemia, haemolytic anaemia, lymphadenopathy</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>transient
  increase in serum IgM levels</span><sup><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'>3</span></sup></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>late neutropenia<sup>3</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Immune system
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion-related reactions<sup>4</sup>,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>angioedema</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hypersensitivity</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>anaphylaxis</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>tumour lysis syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cytokine release syndrome<sup>4</sup>, serum sickness</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion&#8209;related acute reversible thrombocytopenia<sup>4</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hyperglycaemia,
  weight decrease, peripheral oedema, face oedema, increased LDH, hypocalcaemia</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Psychiatric
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>depression,
  nervousness</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10><b><span lang=EN-GB style='font-size:9.0pt'>Nervous system
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>paraesthesia,
  hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>dysgeusia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>peripheral neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>facial nerve palsy<sup>5</sup></span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cranial neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>loss of other senses<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Eye disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lacrimation
  disorder, conjunctivitis</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe vision loss<sup>5</sup></span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Ear and
  labyrinth disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>tinnitus, ear pain</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>hearing loss<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Cardiac
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>myocardial infarction</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>, arrhythmia, <sup>+</sup>atrial
  fibrillation, tachycardia, <sup>+</sup>cardiac disorder</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>left ventricular failure, <sup>+</sup>supraventricular
  tachycardia, <sup>+</sup>ventricular tachycardia, <sup>+</sup>angina, <sup>+</sup>myocardial
  ischaemia, bradycardia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>severe cardiac disorders
  </span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4
  and 6</span></sup></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>heart failure</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Vascular
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertension, orthostatic hypotension, hypotension<sup>
  </sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>vasculitis (predominately cutaneous),</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>leukocytoclastic vasculitis</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Bronchospasm</span><sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>4</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>, respiratory disease, chest pain, dyspnoea,
  increased cough, rhinitis</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>asthma,
  bronchiolitis obliterans, lung disorder, hypoxia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>interstitial lung disease<sup>7</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>respiratory failure<sup>4</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lung infiltration</span><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'> </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>nausea<sup> </sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>vomiting, diarrhoea, abdominal pain, dysphagia,
  stomatitis, constipation, dyspepsia, anorexia, throat irritation</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>abdominal
  enlargement</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>gastro&#8209;intestinal perforation<sup>7</sup></span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10><b><span lang=EN-GB style='font-size:9.0pt'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:9.0pt'>pruritus, rash, <sup>+</sup>alopecia<sup>
  </sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:9.0pt'>urticaria,
  sweating, night sweats, <sup>+</sup>skin disorder</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe bullous skin reactions,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>Stevens&#8209;Johnson syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>toxic epidermal necrolysis (Lyells syndrome)<sup> 7</sup> </span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Musculoskeletal,
  connective tissue disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertonia, myalgia, arthralgia, back pain, neck
  pain, pain</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Renal and
  urinary disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>renal failure<sup>4</sup></span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>General disorders and administration site conditions</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>fever, chills, asthenia, headache<sup> </sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>tumour pain, flushing, malaise, cold syndrome, <sup>+</sup>fatigue,
  <sup>+</sup>shivering, </span></p>
  <p class=TextTi10 style='page-break-after:avoid'><sup><span lang=EN-GB
  style='font-size:9.0pt'>+</span></sup><span lang=EN-GB style='font-size:9.0pt'>multi&#8209;organ
  failure</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>4</span></sup></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>infusion site pain</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Investigations</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>decreased IgG levels</span></p>
  </td>
  <td width="16%" valign=top style='width:16.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.26%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.44%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:9.0pt'>For each term, the
  frequency count was based on reactions of all grades (from mild to severe),
  except for terms marked with &quot;+&quot; where the frequency count was
  based only on severe (&#8805; grade 3 NCI common toxicity criteria)
  reactions. &nbsp;Only the highest frequency observed in the trials is
  reported</span></p>
  <p class=TextTi10><sup><span lang=EN-GB style='font-size:9.0pt'>1</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes reactivation and primary
  infections; frequency based on R&#8209;FC regimen in relapsed/refractory CLL</span></p>
  <p class=TextTi10><sup><span lang=EN-GB style='font-size:9.0pt'>2</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infection below </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>3</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section haematologic adverse
  reactions below</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>4</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infusionrelated
  reactions below. Rarely fatal cases reported</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>5</span></sup><b><span lang=EN-GB
  style='font-size:9.0pt'> </span></b><span lang=EN-GB style='font-size:9.0pt'>signs
  and symptoms of cranial neuropathy. Occurred at various times up to several
  months after completion of MabThera therapy</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>6</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> observed mainly in patients with prior cardiac condition
  and/or cardiotoxic chemotherapy and were mostly associated with infusion&#8209;related
  reactions</span></p>
  <p class=TextTi10><sup><span lang=EN-GB style='font-size:9.0pt'>7</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes fatal cases</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following terms have been reported as
adverse events during clinical trials, however, were reported at a similar or
lower incidence in the MabThera arms compared to control arms: haematotoxicity,
neutropenic infection, urinary tract infection, sensory disturbance, pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Signs and symptoms suggestive of an
infusion&#8209;related reaction were reported in more than 50% of patients in
clinical trials, and were predominantly seen during the first infusion, usually
in the first one to two hours. These symptoms mainly comprised fever, chills
and rigors. Other symptoms included flushing, angioedema, bronchospasm,
vomiting, nausea, urticaria/rash, fatigue, headache, throat irritation,
rhinitis, pruritus, pain, tachycardia, hypertension, hypotension, dyspnoea,
dyspepsia, asthenia and features of tumour lysis syndrome. Severe infusion&#8209;related
reactions (such as bronchospasm, hypotension) occurred in up to 12% of the
cases. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additional reactions reported in some cases
were myocardial infarction, atrial fibrillation, pulmonary oedema</span><span
lang=EN-GB> and acute reversible thrombocytopenia</span><span lang=EN-GB>.
Exacerbations of pre&#8209;existing cardiac conditions such as angina pectoris
or congestive heart failure or </span><span lang=EN-GB style='layout-grid-mode:
line'>severe cardiac disorders (heart failure, myocardial infarction, </span><span
lang=EN-GB>atrial fibrillation</span><span lang=EN-GB style='layout-grid-mode:
line'>), </span><span lang=EN-GB>pulmonary oedema, multi&#8209;organ failure</span><span
lang=EN-GB style='layout-grid-mode:line'>, tumour lysis syndrome, cytokine
release syndrome, renal failure, and respiratory failure were reported </span><span
lang=EN-GB>at lower or unknown frequencies. The incidence of infusion&#8209;related
symptoms decreased substantially with subsequent infusions and is &lt;1% of
patients by the eighth cycle of MabThera (containing) treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Infections </span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera induces B&#8209;cell depletion in
about 70&#8209;80% of patients, but was associated with decreased serum
immunoglobulins only in a minority of patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Localised candida infections as well as
Herpes zoster were reported at a higher incidence in the MabThera&#8209;containing
arm of randomised studies. </span><span lang=EN-GB>Severe infections were
reported in about 4% of patients treated with MabThera monotherapy. </span><span
lang=EN-GB>Higher frequencies of infections overall, including grade 3 or 4
infections, were observed during MabThera maintenance treatment up to 2 years
when compared to observation. </span><span lang=EN-GB>There was no cumulative
toxicity in terms of infections reported over a 2&#8209;year treatment period</span><span
lang=EN-GB>. In addition, other serious viral infections either new,
reactivated or exacerbated, some of which were fatal, have been reported with
MabThera treatment. The majority of patients had received MabThera in
combination with chemotherapy or as part</span><span lang=EN-GB> of a
haematopoetic stem cell transplant. Examples of these serious viral infections
are infections caused by the h</span><span lang=EN-GB>erpes viruses
(Cytomegalovirus, Varicella Zoster Virus and Herpes Simplex Virus), JC virus
(progressive multifocal leukoencephalopathy (PML)) and hepatitis C virus. Cases
of fatal PML that occurred after disease progression and retreatment have also
been reported in clinical trials. C</span><span lang=EN-GB>ases of
hepatitis&nbsp;B reactivation, have been reported, the majority of which were
in patients receiving MabThera in combination with cytotoxic chemotherapy</span><span
lang=EN-GB>. In patients with </span><span lang=EN-GB>relapsed/refractory </span><span
lang=EN-GB>CLL, the </span><span lang=EN-GB>incidence of grade 3/4 hepatitis B
infection (reactivation and primary infection) was 2% in R&#8209;FC vs 0% FC.
Progression of Kaposis sarcoma has been observed in MabThera&#8209;exposed
patients with pre&#8209;existing Kaposis sarcoma. These cases occurred in non&#8209;approved
indications and the majority of patients were HIV positive.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Haematologic adverse reactions<b> </b></span></i></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials with MabThera
monotherapy given for 4 weeks, haematological abnormalities occurred in a
minority of patients and were usually mild and reversible. Severe (grade 3/4)
neutropenia was reported in 4.2%, anaemia in 1.1% and thrombocytopenia in 1.7%
of the patients. During<u> </u>MabThera maintenance treatment for up to 2
years, leucopenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade
3/4) were reported at a higher incidence when compared to observation. The
incidence of thrombocytopenia was low (&lt;1%, grade&nbsp;3/4) and was not
different between treatment arms. During the treatment course in studies with
MabThera in combination with chemotherapy, </span><span lang=EN-GB>grade&nbsp;3/4
leucopenia (R&#8209;CHOP 88% vs. CHOP 79%, R&#8209;FC 23% vs. FC 12%), neutropenia
(R&#8209;CVP 24% vs. CVP 14%; R&#8209;CHOP 97% vs. CHOP 88%, R&#8209;FC 30% vs.
FC 19% in previously untreated CLL), pancytopenia (R&#8209;FC 3% vs. FC 1% in
previously untreated CLL) were usually reported with higher frequencies when
compared to chemotherapy alone. However, the higher incidence of neutropenia in
patients treated with MabThera and chemotherapy was not associated with a
higher incidence of infections and infestations compared to patients treated
with chemotherapy alone. Studies in previously untreated and
relapsed/refractory CLL have established that in up to 25% of patients treated
with R&#8209;FC neutropenia was prolonged (defined as neutrophil count
remaining below 1x10<sup>9</sup>/L between day 24 and 42 after the last dose)
or occurred with a late onset (defined as neutrophil count below 1x10<sup>9</sup>/L
later than 42 days after last dose in patients with no previous prolonged
neutropenia or who recovered prior to day 42) following treatment with MabThera
plus FC.</span><span lang=EN-GB> There were no differences reported for the
incidence of anaemia.</span><span lang=EN-GB> </span><span lang=EN-GB>Some c</span><span
lang=EN-GB>ases of late </span><span lang=EN-GB>neutropenia occurring more than
four weeks after the last infusion of MabThera were reported. </span><span
lang=EN-GB>In the CLL first&#8209;line study, Binet stage C patients
experienced more adverse events in the R&#8209;FC arm compared to the FC arm (R&#8209;FC
83% vs. FC 71%)</span><span lang=EN-GB>. In the relapsed/refractory CLL study </span><span
lang=EN-GB>grade </span><span lang=EN-GB>3/4 </span><span lang=EN-GB>thrombocytopenia
was reported in 11% of patients in the R&#8209;FC group compared to 9% of
patients in the FC group.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In studies of MabThera in patients with
Waldenstroms macroglobulinaemia, transient increases in serum IgM levels have
been observed following treatment initiation, which may be associated with
hyperviscosity and related symptoms. The transient IgM increase usually
returned to at least baseline level within 4 months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cardiovascular adverse reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cardiovascular reactions during clinical
trials with MabThera monotherapy were reported in 18.8% of patients with the
most frequently reported events being hypotension and hypertension. Cases of
grade 3 or 4 arrhythmia (including ventricular and supraventricular
tachycardia) and angina pectoris during infusion were reported. </span><span
lang=EN-GB>During maintenance treatment, the incidence of grade&nbsp;3/4
cardiac disorders was comparable between patients treated with MabThera and
observation. Cardiac events were reported as serious adverse events (including
atrial fibrillation, myocardial infarction, left ventricular failure,
myocardial ischaemia) in 3% of patients treated with MabThera compared to
&lt;1% on observation. In studies evaluating MabThera in combination with
chemotherapy, the incidence of grade 3 and 4 cardiac arrhythmias, predominantly
supraventricular arrhythmias such as tachycardia and atrial
flutter/fibrillation, was higher in the R&#8209;CHOP group (14 patients, 6.9%)
as compared to the CHOP group (3 patients, 1.5%)</span><span lang=EN-GB>. All
of these arrhythmias either occurred in the context of a MabThera infusion or
were associated with predisposing conditions such as fever, infection, acute
myocardial infarction or pre&#8209;existing respiratory and cardiovascular
disease. No difference between the R&#8209;CHOP and CHOP group was observed in
the incidence of other grade 3 and 4 cardiac events including heart failure,
myocardial disease and manifestations of coronary artery disease</span><span
lang=EN-GB>. In CLL, the overall incidence of grade 3 or 4 cardiac disorders
was low both in the first&#8209;line study (4% R&#8209;FC, 3% FC) and in the
relapsed/refractory study (4% R&#8209;FC, 4% FC). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Respiratory system</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of interstitial lung disease, some
with fatal outcome have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Neurologic
disorders</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>During the treatment period (induction
treatment phase comprising of R&#8209;CHOP for at most eight cycles), four
patients (2%) treated with R&#8209;CHOP, all with cardiovascular risk factors,
experienced thromboembolic cerebrovascular accidents during the first treatment
cycle. There was no difference between the treatment groups in the incidence of
other thromboembolic events. In contrast, three patients (1.5%) had
cerebrovascular events in the CHOP group, all of which occurred during the follow&#8209;up
period. In CLL, the overall incidence of grade 3 or 4 nervous system disorders
was low </span><span lang=EN-GB>both in the first&#8209;line study </span><span
lang=EN-GB>(4% R&#8209;FC, 4% FC) </span><span lang=EN-GB>and in the
relapsed/refractory study (3% R&#8209;FC, 3% FC)</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cases of </span><span
lang=EN-GB>posterior reversible encephalopathy syndrome (PRES) / reversible
posterior leukoencephalopathy syndrome (RPLS)</span><span lang=EN-GB> have been
reported.</span><span lang=EN-GB> Signs and symptoms included visual
disturbance, headache, seizures and altered mental status, with or without
associated hypertension. A diagnosis of PRES/RPLS requires confirmation by
brain imaging. The reported cases had recognised risk factors for PRES/RPLS,
including the patients underlying disease, hypertension, immunosuppressive
therapy and/or chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gastrointestinal perforation in some cases
leading to death has been observed in patients receiving MabThera for treatment
of non&#8209;Hodgkin lymphoma. In the majority of these cases, MabThera was
administered with chemotherapy.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>IgG
levels</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the clinical trial evaluating MabThera
maintenance treatment in relapsed/refractory follicular lymphoma, median IgG
levels were below the lower limit of normal (LLN) (&lt;&nbsp;7 g/L) after
induction treatment in both the observation and the MabThera groups. In the
observation group, the median IgG level subsequently increased to above the
LLN, but remained constant in the MabThera group. The proportion of patients
with IgG levels below the LLN was about 60% in the MabThera group throughout
the 2 year treatment period, while it decreased in the observation group (36%
after 2&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A small number of spontaneous and
literature cases of </span><span lang=EN-GB>hypogammaglobulinaemia have been
observed in paediatric patients treated with MabThera, in some cases severe and
requiring long&#8209;term immunoglobulin substitution therapy. The consequences
of long term B cell depletion in paediatric patients are unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Toxic Epidermal Necrolysis (Lyell syndrome)
and Stevens&#8209;Johnson syndrome, some with fatal</span><span lang=EN-GB>
outcome, have been reported very rarely.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>Patient
subpopulations &#8209; MabThera monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Elderly (</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65 years): </span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of ADRs of all grades and
grade 3/4 ADR was similar in elderly patients compared to younger patients
(&lt;65 years). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bulky
disease </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>There was a
higher incidence of grade 3/4 ADRs in patients with bulky disease than in
patients without bulky disease (25.6% vs. 15.4%). The incidence of ADRs of any
grade was similar in these two groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Re&#8209;treatment</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
percentage of patients reporting ADRs upon re&#8209;treatment with further
courses of MabThera was similar to the percentage of patients reporting ADRs
upon initial exposure (any grade and grade 3/4 ADRs).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='layout-grid-mode:line'>Patient subpopulations &#8209; MabThera
combination therapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Elderly (</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65 years) </span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of grade</span><span
lang=EN-GB> 3/4 </span><span lang=EN-GB>blood and lymphatic adverse events was
higher in elderly patients compared to younger patients </span><span
lang=EN-GB>(&lt;65 years)</span><span lang=EN-GB>, with previously untreated or
relapsed/refractory CLL.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Experience from paediatric
DLBCL/BL/BAL/BLL</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Summary of safety profile</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>A multicenter, open-label randomized study
of Lymphome Malin B chemotherapy (LMB) with or without MabThera was conducted
in paediatric patients (aged &#8805; 6 months to &lt; 18 years old) with
previously untreated advanced stage CD20 positive DLBCL/BL/BAL/BLL. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A total of 309 paediatric patients received
MabThera and were included in the safety analysis population. Paediatric
patients randomized to the LMB chemotherapy arm with MabThera, or enrolled in
the single arm part of the study, were administered MabThera at a dose of
375mg/m2 BSA and received a total of six IV infusions of MabThera (two during
each of the two induction courses and one during each of the two consolidation
courses of the LMB scheme). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile of MabThera in
paediatric patients (aged &#8805; 6 months to &lt; 18 years </span>old<span
lang=EN-GB>) with previously untreated advanced stage CD20 positive
DLBCL/BL/BAL/BLL was generally consistent in type, nature and severity with the
known safety profile in adult NHL and CLL patients. Addition of MabThera to
chemotherapy did result in an increased risk of some events including
infections (including sepsis) compared to chemotherapy only. </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Experience
from rheumatoid arthritis </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Summary
of the safety profile</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The overall
safety profile of MabThera in rheumatoid arthritis is based on data from
patients from clinical trials and from post&#8209;marketing surveillance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile of MabThera in patients
with moderate to severe rheumatoid arthritis (RA) is summarised in the sections
below. In clinical trials more than 3100 patients </span><span lang=EN-GB>received
at least one treatment course and were followed for periods ranging from 6
months to over</span><span lang=EN-GB> 5 years; approximately 2400 patients
received two or more courses of treatment with over 1000 having received 5 or
more courses. The safety information collected during post marketing experience
reflects the expected adverse reaction profile as seen in clinical trials for
MabThera (see section 4.4). </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients received 2 x 1000&nbsp;mg of
MabThera separated by an interval of two weeks; in addition to methotrexate (10&#8209;25&nbsp;mg/week).
MabThera infusions were administered after an intravenous infusion of
100&nbsp;mg methylprednisolone; patients also received treatment with oral
prednisone for 15 days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse reactions
are listed in Table 4. Frequencies are defined as very common (&#8805;1/10),
common (&#8805;1/100 to &lt;1/10), uncommon (&#8805;1/1,000 to &lt;1/100), and
very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The most
frequent adverse reactions considered due to receipt of MabThera were IRRs. The
overall incidence of IRRs in clinical trials was 23% with the first infusion
and decreased with subsequent infusions. Serious IRRs were uncommon (0.5% of
patients) and were predominantly seen during the initial course. </span><span
lang=EN-GB style='layout-grid-mode:line'>In addition to adverse reactions seen
in RA clinical trials for MabThera, progressive multifocal leukoencephalopathy
(PML) (see section 4.4) and serum sickness&#8209;like reaction have been
reported during post marketing experience.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;4 Summary of adverse reactions
reported in clinical trials or during postmarketing surveillance occurring in
patients with rheumatoid arthritis receiving MabThera </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="105%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="19%" style='width:19.3%;border:solid windowtext 1.0pt;padding:
   0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>MedDRA</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>System Organ Class</span></b></p>
   </td>
   <td width="17%" style='width:17.82%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Common</span></b></p>
   </td>
   <td width="17%" style='width:17.84%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Common</span></b></p>
   </td>
   <td width="16%" valign=top style='width:16.32%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Uncommon</span></b></p>
   </td>
   <td width="13%" valign=top style='width:13.4%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Rare</span></b></p>
   </td>
   <td width="15%" valign=top style='width:15.32%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very rare</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Infections and infestations</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>upper respiratory tract infection, urinary tract
  infections</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:9.0pt'>b</span><span lang=PT-BR style='font-size:9.0pt'>ronchitis,
  sinusitis, gastroenteritis, tinea </span><span lang=PT-BR style='font-size:
  9.0pt'>pedis</span><span lang=ES style='font-size:9.0pt'>peds</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>PML, reactivation of hepatitis B</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>neutropenia<sup>1</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>late neutropenia<sup>2</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>serum sickness&#8209;like reaction</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Immune system disorders</span></b></p>
  </td>
  <td width="17%" rowspan=2 valign=top style='width:17.82%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
  style='font-size:9.0pt'>3</span></sup><span lang=EN-GB style='font-size:9.0pt'>infusion-related
  reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat
  irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal
  pain, peripheral oedema, erythema)</span></p>
  </td>
  <td width="17%" rowspan=2 valign=top style='width:17.84%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" rowspan=2 valign=top style='width:16.32%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
  style='font-size:9.0pt'>3</span></sup><span lang=EN-GB style='font-size:9.0pt'>infusion
  related reactions (generalized oedema, bronchospasm, wheezing, laryngeal
  oedema, angioneurotic oedema, generalized pruritus, anaphylaxis,
  anaphylactoid reaction)</span></p>
  </td>
  <td width="13%" rowspan=2 valign=top style='width:13.4%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" rowspan=2 valign=top style='width:15.32%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Hypercholesterolemia</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Psychiatric disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>depression,
  anxiety</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Nervous system
  disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>headache</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>paraesthesia,
  migraine, dizziness, sciatica</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Cardiac
  disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>angina pectoris,
  atrial fibrillation, heart failure, myocardial infarction</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>atrial flutter</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>dyspepsia,
  diarrhoea, gastro&#8209;oesophageal reflux, mouth ulceration, upper abdominal
  pain</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>alopecia</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-CH
  style='font-size:9.0pt'>toxic epidermal necrolysis (Lyells syndrome),
  Stevens&#8209;Johnson syndrome<sup>5</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Musculo
  skeletal disorders and connective tissue disorders</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>arthralgia /
  musculoskeletal pain, osteoarthritis, bursitis</span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" valign=top style='width:19.3%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Investigations</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>decreased IgM levels<sup>4</sup></span></p>
  </td>
  <td width="17%" valign=top style='width:17.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>decreased IgG
  levels<sup>4</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>1</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> Frequency category derived from
  laboratory values collected as part of routine laboratory monitoring in
  clinical trials</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>2</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> Frequency category derived from post&#8209;marketing
  data.</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>3 </span></sup><span
  lang=EN-GB style='font-size:9.0pt'>Reactions occurring during or within 24 hours
  of infusion. See also infusion&#8209;related reactions below. IRRs may occur
  as a result of hypersensitivity and/or to the mechanism of action.</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>4</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> Includes observations collected as part
  of routine laboratory monitoring.</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>5</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> Includes fatal cases</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Multiple
courses</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Multiple
courses of treatment are associated with a similar ADR profile to that observed
following first exposure. The rate of all ADRs following first MabThera
exposure was highest during the first 6 months and declined thereafter. This is
mostly accounted for by IRRs (most frequent during the first treatment course),
RA exacerbation and infections, all of which were more frequent in the first 6
months of treatment. </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infusion&#8209;related
reactions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The most
frequent ADRs following receipt of MabThera in clinical studies were IRRs
(refer to Table&nbsp;4). Among the 3189 patients treated with MabThera, 1135
(36%) experienced at least one IRR with 733/3189 (23%) of patients experiencing
an IRR following first infusion of the first exposure to MabThera. The
incidence of IRRs declined with subsequent infusions. In clinical trials fewer
than 1% (17/3189) of patients experienced a serious IRR. There were no CTC
Grade 4 IRRs and no deaths due to IRRs in the clinical trials. The proportion
of CTC Grade 3 events and of IRRs leading to withdrawal decreased by course and
were rare from course 3 onwards. Premedication with intravenous glucocorticoid
significantly reduced the incidence and severity of IRRs (see sections 4.2 and
4.4). Severe IRRs with fatal outcome have been reported in the post&#8209;marketing
setting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In a trial
designed to evaluate the safety of a more rapid MabThera infusion in patients
with rheumatoid arthritis, patients with moderate&#8209;to&#8209;severe active
RA who did not experience a serious IRR during or within 24 hours of their
first studied infusion were allowed to receive a 2&#8209;hour intravenous
infusion of MabThera. Patients with a history of a serious infusion reaction to
a biologic therapy for RA were excluded from entry. The incidence, types and
severity of IRRs were consistent with that observed historically. No serious
IRRs were observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infections</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The overall
rate of infection was approximately 94 per 100 patient years in MabThera treated
patients. The infections were predominately mild to moderate and consisted
mostly of upper respiratory tract infections and urinary tract infections. The
incidence of infections that were serious or required IV antibiotics was
approximately 4 per 100 patient years. The rate of serious infections did not
show any significant increase following multiple courses of MabThera. Lower
respiratory tract infections (including pneumonia) have been reported during
clinical trials, at a similar incidence in the MabThera arms compared to
control arms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of progressive multifocal
leukoencephalopathy with fatal outcome have been reported following use of
MabThera for the treatment of autoimmune diseases. This includes rheumatoid
arthritis and off&#8209;label autoimmune diseases, including Systemic Lupus
Erythematosus (SLE) and vasculitis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with non&#8209;Hodgkins
lymphoma receiving MabThera in combination with cytotoxic chemotherapy, cases
of hepatitis B reactivation have been reported (see non&#8209;Hodgkins lymphoma).
Reactivation of hepatitis B infection has also been very rarely reported in RA
patients receiving MabThera (see Section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cardiovascular adverse reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Serious cardiac reactions were reported at
a rate of </span><span lang=EN-GB>1.3 per 100 patient years in the MabThera
treated patients compared to 1.3 per 100 patient years in placebo treated
patients. The proportions of patients experiencing cardiac reactions (all or
serious) did not increase over multiple courses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Neurologic events</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of posterior reversible
encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy
syndrome (RPLS) have been reported. Signs and symptoms included visual
disturbance, headache, seizures and altered mental status, with or without associated
hypertension. A diagnosis of PRES/RPLS requires confirmation by brain imaging.
The reported cases had recognised risk factors for PRES/RPLS, including the
patients underlying disease, hypertension, immunosuppressive therapy and/or
chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Neutropenia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Events of neutropenia were observed with
MabThera treatment, the majority of which were transient and mild or moderate
in severity. Neutropenia can occur several months after the administration of
MabThera (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In placebo&#8209;controlled periods of
clinical trials, 0.94% (13/1382) of MabThera treated patients and 0.27% (2/731)
of placebo patients developed severe neutropenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Neutropenic events, including severe late
onset and persistent neutropenia, have been rarely reported in the post&#8209;marketing
setting, some of which were associated with fatal infections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Toxic Epidermal Necrolysis (Lyells
syndrome) and Stevens&#8209;Johnson syndrome, some with fatal</span><span
lang=EN-GB> outcome, have been reported very rarely.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Laboratory
abnormalities</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Hypogammaglobulinaemia
(IgG or IgM below the lower limit of normal) has been observed in RA patients
treated with MabThera. There was no increased rate in overall infections or
serious infections after the development of low IgG or IgM (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A small number of spontaneous and
literature cases of </span><span lang=EN-GB>hypogammaglobulinaemia have been
observed in paediatric patients treated with MabThera, in some cases severe and
requiring long&#8209;term immunoglobulin substitution therapy. The consequences
of long-term B cell depletion in paediatric patients are unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Experience
from granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adult induction of remission (GPA/MPA
Study 1) </span></i></p>

<p class=MsoNormal><span lang=EN-GB>In GPA/MPA Study 1, 99 adult patients were
treated for induction of remission of GPA and MPA with MabThera (375&nbsp;mg/m<sup>2</sup>,
once weekly for 4 weeks) and glucocorticoids (see section 5.1<i>).</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ADRs listed in Table 5 were all adverse
events which occurred at an incidence of <i>&#8805;</i> 5% in the MabThera
group and at a higher frequency than the comparator group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:53.85pt;text-indent:-53.85pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 5</span></b><b><span lang=EN-GB> </span></b><b><span
lang=EN-GB>Adverse reactions occurring at 6&#8209;months in &#8805; 5% of adult
patients receiving MabThera in GPA/MPA Study 1, and at a higher frequency than
the comparator group.</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>MedDRA
   System organ class</span></b></p>
   <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><b><span
   lang=EN-GB>Adverse reaction</span></b></p>
   </td>
   <td width=212 valign=top style='width:159.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Rituximab</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(n=99)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infections
  and infestations</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Urinary tract infection</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>7%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Bronchitis</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Herpes zoster</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Nasopharyngitis</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Blood
  and lymphatic<br>
  system disorder</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Thrombocytopenia</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Cytokine release
  syndrome</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Hyperkalaemia</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Nervous
  system disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Dizziness</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Tremor</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>10%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Hypertension</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Flushing</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Respiratory,
  thoracic and <br>
  mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Cough</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>12%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Dyspnoea</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Epistaxis</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Nasal congestion</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Gastrointestinal
  <br>
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Dyspepsia</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Constipation</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Skin
  and subcutaneous <br>
  tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>Acne</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Musculoskeletal
  and connective <br>
  tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Muscle spasms</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>18%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Arthralgia</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Back pain</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>10%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Muscle weakness</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Musculoskeletal
  pain</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Pain in
  extremities</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>5%</span></p>
  </td>
 </tr>
 <tr>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>General disorders and <br>
  administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Peripheral
  oedema</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>16%</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=510 colspan=2 valign=top style='width:382.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Investigations</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=298 valign=top style='width:223.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>Decreased
  haemoglobin</span></p>
  </td>
  <td width=212 valign=top style='width:159.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:14.0pt'><i><span lang=EN-GB>Adult maintenance
treatment (GPA/MPA Study 2)</span></i></p>

<p class=MsoNormal style='line-height:14.0pt'>In <span lang=EN-GB>GPA/MPA Study
2</span>, a total of 57 adult patients with severe, active GPA and MPA were
treated with MabThera for the maintenance of remission (see section <span
lang=EN-GB>5.1</span>).</p>

<p class=MsoNormal style='margin-left:53.85pt;text-indent:-53.85pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:53.85pt;text-indent:-53.85pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 6</span></b><b><span lang=EN-GB> </span></b><b><span
lang=EN-GB>Adverse reactions occurring in &#8805; 5% of adult patients
receiving MabThera in GPA/MPA Study 2, and at a higher frequency than the
comparator group</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
  14.0pt;page-break-after:avoid'><b>MedDRA System Organ Class</b><br>
  Adverse reaction</p>
  </td>
  <td width=261 style='width:195.4pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>Rituximab <br>
  (n=57)</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><b>Infections
  and infestations </b></p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Bronchitis</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>14%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Rhinitis</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>5%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=536 colspan=2 valign=top style='width:402.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-right:191.65pt;line-height:14.0pt;
  page-break-after:avoid'><b>Respiratory, thoracic and mediastinal disorders</b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Dyspnoea</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>9%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=536 colspan=2 valign=top style='width:402.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><b>Gastrointestinal
  disorders </b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Diarrhoea</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>7%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><b>General
  disorders and administration site conditions</b></p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Pyrexia</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>9%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Influenza-like illness</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>5%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt;page-break-after:
  avoid'>Oedema peripheral</p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>5%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><b>Injury,
  poisoning and procedural complications</b></p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=276 valign=top style='width:206.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='text-indent:21.3pt;line-height:14.0pt'>Infusion-related
  reactions<sup>1</sup></p>
  </td>
  <td width=261 style='width:195.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'>12%</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=536 colspan=2 valign=top style='width:402.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:14.0pt'><sup><span style='font-size:
  10.0pt'>1</span></sup><span style='font-size:10.0pt'>Details on infusion
  related reactions are provided in the description of selected adverse
  reactions section.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The overall safety profile was consistent with the
well-established safety profile for MabThera in approved autoimmune
indications, including GPA/MPA. Overall, 4% of patients in the MabThera arm
experienced adverse events leading to discontinuation. Most adverse events in
the MabThera arm were mild or moderate in intensity. No patients in the
MabThera arm had fatal adverse events.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The most commonly reported events considered as ADRs were
infusion-related reactions and infections. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:14.0pt'><i><span lang=EN-GB>Long-term
follow-up (GPA/MPA Study 3)</span></i></p>

<p class=MsoNormal>In a long-term observational safety&nbsp;study,&nbsp;97 GPA/MPA&nbsp;patients
received&nbsp;treatment&nbsp;with MabThera (mean of 8 infusions [range 1-28])&nbsp;for
up to&nbsp;4 years,&nbsp;according to their physicians standard practice and
discretion.&nbsp; The overall safety profile was consistent with the
well-established safety profile of MabThera in RA and GPA/MPA and no new adverse&nbsp;reactions&nbsp;were
reported.&nbsp;&nbsp; </p>

<p class=MsoNormal><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population</span></i><span
lang=EN-GB> </span></p>

<p class=MsoNormal>An open-label, single arm study was conducted in
25&nbsp;paediatric patients with severe, active GPA or MPA. The overall study
period consisted of a 6-month remission induction phase with a minimum 18-month
follow-up, up to 4.5 years overall. During the follow-up phase, MabThera was
given at the discretion of the investigator (17 out of 25 patients received
additional MabThera treatment). Concomitant treatment with other
immunosuppressive therapy was permitted (see section 5.1).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>ADRs were considered as adverse events that occurred at an
incidence of &#8805; 10%. These included: infections (17 patients [68%] in the
remission induction phase; 23 patients [92%] in the overall study period), IRRs
(15 patients [60%] in the remission induction phase; 17 patients [68%] in the
overall study period), and nausea (4 patients [16%] in the remission induction
phase; 5 patients [20%] in the overall study period). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>During the overall study period, the safety profile of
MabThera was consistent with that reported during the remission induction
phase.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The safety profile of MabThera in paediatric GPA or MPA
patients was consistent in type, nature and severity with the known safety
profile in adult patients in the approved autoimmune indications, including
adult GPA or MPA.&nbsp;&nbsp; </p>

<p class=MsoNormal><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=MsoNormal style='line-height:14.0pt'><i><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:14.0pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-22.45pt'><i><span lang=EN-GB>Infusion-related
reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In </span><span
lang=EN-GB>GPA/MPA Study 1 (adult induction of remission study)</span><span
lang=EN-GB style='color:black'>, </span><span lang=EN-GB>IRRs were defined as
any adverse event occurring within 24 hours of an infusion and considered to be
infusion&#8209;related by investigators in the safety population</span><span
lang=EN-GB>. Of the 99 patients treated with MabThera, 12 (12%) experienced at
least one IRR. </span><span lang=EN-GB>All IRRs were CTC Grade 1 or 2. The most
common IRRs included cytokine release syndrome, flushing, throat irritation,
and tremor. </span><span lang=EN-GB>MabThera was given in combination with
intravenous glucocorticoids which may reduce the incidence and severity of
these events.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In <span lang=EN-GB>GPA/MPA Study 2 (adult maintenance
study)</span>, 7/57 (12%) patients in the MabThera arm experienced at least one
infusion-related reaction. The incidence of IRR symptoms was highest during or
after the first infusion (9%) and decreased with subsequent infusions (&lt;4%).
All IRR symptoms were mild or moderate and most of them were reported from the
SOCs Respiratory, Thoracic and Mediastinal Disorders and Skin and Subcutaneous
Tissue disorders. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'>In the clinical trial in paediatric
patients with GPA or MPA, the reported IRRs were predominantly seen with the
first infusion (8 patients [32%]), and then decreased over time with the number
of MabThera infusions (20% with the second infusion, 12% with the third
infusion and 8% with the fourth infusion). The most common IRR symptoms
reported during the remission induction phase were: headache, rash, rhinorrhea
and pyrexia (8%, for each symptom). The observed symptoms of IRRs were similar
to those known in adult GPA or MPA patients treated with MabThera. The
majority of IRRs were Grade 1 and Grade 2, there were two non-serious Grade 3
IRRs, and no Grade 4 or 5 IRRs reported. One serious Grade 2 IRR (generalized
oedema which resolved with treatment) was reported in one patient (see section
4.4).</p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Infections </span></i></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>GPA/MPA Study 1</span><span
lang=EN-GB>, the overall rate of infection was approximately 237 per 100
patient years (95% CI 197 &#8209; 285) at the 6&#8209;month primary endpoint.
Infections were predominately mild to moderate and consisted mostly of upper
respiratory tract infections, herpes zoster and urinary tract infections. The
rate of serious infections was approximately 25 per 100 patient years. The most
frequently reported serious infection in the MabThera group was pneumonia at a
frequency of 4%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span lang=EN-GB style='font-size:11.0pt'>In GPA/MPA Study 2,
30/57 (53%) patients in the MabThera</span><span style='font-size:11.0pt'> arm experienced
infections. The incidence of all grade infections was similar between the arms.
</span><span style='font-size:11.0pt'>Infections were predominately mild to
moderate</span><span style='font-size:11.0pt'>. The most common infections in
the MabThera arm included upper respiratory tract infections, gastroenteritis,
urinary tract infections and herpes zoster. The incidence of serious infections
was similar in both arms (approximately 12%). The most commonly reported
serious infection in the MabThera group was mild or moderate bronchitis.</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>In the clinical trial in
paediatric patients with severe, active GPA and MPA, 91% of reported infections
were non-serious and 90% were mild to moderate. </span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>The most common infections
in the overall phase were: upper respiratory tract infections (URTIs) (48%),
influenza (24%), conjunctivitis (20%), nasopharyngitis (20%), lower respiratory
tract infections (16%), sinusitis (16%), viral URTIs (16%), ear infection
(12%), gastroenteritis (12%), pharyngitis (12%), urinary tract infection
(12%). Serious infections were reported in 7 patients (28%), and included:
influenza (2 patients [8%]) and lower respiratory tract infection (2 patients
[8%]) as the most frequently reported events.</span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Malignancies</span></i><span
lang=EN-GB><br>
In </span><span lang=EN-GB>GPA/MPA Study 1</span><span lang=EN-GB>, the
incidence of malignancy in MabThera treated patients in the GPA</span><span
lang=EN-GB> and MPA </span><span lang=EN-GB>clinical study was 2.00 per 100
patient years at the study common closing date (when the final patient had
completed the follow&#8209;up period).&nbsp; On the basis of standardised
incidence ratios, the incidence of malignancies appears to be similar to that
previously reported in patients with ANCA&#8209;associated vasculitis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the paediatric clinical trial, no
malignancies were reported with a follow-up period of up to 54 months.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cardiovascular adverse reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>GPA/MPA Study 1</span><span
lang=EN-GB>, </span><span lang=EN-GB>cardiac events occurred at a rate of
approximately 273 per 100 patient years (95% CI 149&#8209;470) at the 6&#8209;month
primary endpoint. The rate of serious cardiac events was 2.1 per 100 patient
years (95% CI 3 &#8209;15). The most frequently reported events were
tachycardia (4%) and atrial fibrillation (3%) (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Neurologic events</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of posterior reversible
encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy
syndrome (RPLS) have been reported in autoimmune conditions. Signs and symptoms
included visual disturbance, headache, seizures and altered mental status, with
or without associated hypertension. A diagnosis of PRES/RPLS requires
confirmation by brain imaging. The reported cases had recognised risk factors
for PRES/RPLS, including the patients underlying disease, hypertension,
immunosuppressive therapy and/or chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatitis&#8209;B reactivation</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A small number of cases of hepatitis&#8209;B
reactivation, some with fatal outcome, have been reported in granulomatosis
with polyangiitis and microscopic polyangiitis patients receiving MabThera in
the postmarketing setting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hypogammaglobulinaemia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Hypogammaglobulinaemia (IgA, IgG or IgM
below the lower limit of normal) has been observed in adult and pediatric GPA
and MPA patients treated with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>GPA/MPA Study 1</span><span
lang=EN-GB>, at 6 months</span><span lang=EN-GB>, in the</span><span
lang=EN-GB> MabThera group, 27%, 58% and 51% of patients with normal
immunoglobulin levels at baseline had low IgA, IgG and IgM levels, respectively,
compared to 25%, 50% and 46% in the cyclophosphamide group. </span><span
lang=EN-GB style='color:black'>The rate of overall infections and serious
infections was not increased after the development of low IgA, IgG or IgM.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In <span lang=EN-GB>GPA/MPA Study 2</span>, no clinically
meaningful differences between the two treatment arms or decreases in total
immunoglobulin, IgG, IgM or IgA levels were observed throughout the trial.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In the paediatric clinical trial, during
the overall study period, 3/25 (12%) patients reported an event of
hypogammaglobulinaemia, 18 patients (72%) had prolonged </span>(defined as Ig
levels below lower limit of normal for at least 4 months) <span lang=EN-GB>low
IgG levels (of whom 15 patients also had prolonged low IgM). Three patients
received treatment with intravenous immunoglobulin (IV-IG). Based on limited
data, no firm conclusions can be drawn regarding whether prolonged low IgG and
IgM led to an increased risk of serious infection in these patients. The
consequences of long term B cell depletion in paediatric patients are unknown.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid;vertical-align:
baseline'><i><span lang=EN-GB>Neutropenia</span></i></p>

<p class=MsoNormal style='vertical-align:baseline'><span lang=EN-GB>In </span><span
lang=EN-GB>GPA/MPA Study 1, 24% of patients in the MabThera group (single
course) and 23% of patients in the cyclophosphamide group developed CTC grade 3
or greater neutropenia. Neutropenia was not associated with an observed
increase in serious infection in MabThera&#8209;treated patients. </span><span
lang=EN-GB style='background:yellow'></span></p>

<p class=MsoNormal style='text-align:justify;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In <span lang=EN-GB>GPA/MPA Study 2</span>, the incidence of
all-grade neutropenia was 0% for MabThera-treated patients vs 5% for
azathioprine treated patients.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Toxic Epidermal Necrolysis (Lyells
syndrome) and Stevens&#8209;Johnson syndrome, some with fatal</span><span
lang=EN-GB> outcome, have been reported very rarely.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Experience
from pemphigus vulgaris</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><i><u><span style='font-size:11.0pt'>Summary of the safety
profile in PV Study 1 (Study ML22196) and PV Study 2 (Study WA29330)</span></u></i></p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>The safety
profile of MabThera in combination with short-term, low-dose glucocorticoids in
the treatment of patients with pemphigus vulgaris was studied in a Phase 3, randomised,
controlled, multicenter, open-label study in pemphigus patients that included
38&nbsp;pemphigus vulgaris (PV) patients randomised to the MabThera group (PV
Study 1). Patients randomised to the MabThera group received an initial
1000&nbsp;mg IV on Study Day 1 and a second 1000&nbsp;mg IV on Study Day 15. Maintenance
doses of 500&nbsp;mg IV were administered at months 12 and 18. Patients could receive
1000&nbsp;mg IV at the time of relapse <span lang=EN-GB>(see section 5.1)</span>.
</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>In PV Study 2,
a randomized, double-blind, double-dummy, active-comparator, multicenter study
evaluating the efficacy and safety of MabThera compared with mycophenolate
mofetil (MMF) in patients with moderate-to-severe PV requiring oral
corticosteroids, 67&nbsp;PV patients received treatment with MabThera (initial
1000&nbsp;mg IV on Study Day 1 and a second 1000&nbsp;mg IV on Study Day 15
repeated at Weeks 24 and 26) for up to 52 weeks (see section 5.1). </p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>The safety
profile of MabThera in PV was consistent with the established safety profile in
other approved autoimmune indications. </p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Tabulated
list of adverse reactions for PV Studies 1 and 2</span></u></i></p>

<p class=MsoNormal>Adverse reactions from PV Studies 1 and 2 are presented in
Table 7. In PV Study 1, ADRs were defined as adverse events which occurred at a
rate of &nbsp;<span style='font-family:Symbol'></span>&nbsp;5% among
MabThera-treated PV patients, with a &nbsp;<span style='font-family:Symbol'></span>&nbsp;2%
absolute difference in incidence between the MabThera-treated group and the
standard-dose prednisone group up to month 24. No patients were withdrawn due
to ADRs in Study 1. In PV Study 2, ADRs were defined as adverse events
occurring in &#8805;5% of patients in the MabThera arm and assessed as related.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 7</span></b><b><span lang=EN-GB> </span></b><b><span
lang=EN-GB>Adverse reactions in MabThera-treated pemphigus vulgaris patients in
PV Study 1 (up to Month 24) and PV Study 2 (up to Week 52)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:11.75pt'>
   <td width="38%" style='width:38.86%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:11.75pt'>
   <p align=center style='text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:8.5pt'>MedDRA System Organ Class</span></b></p>
   </td>
   <td width="29%" style='width:29.96%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.75pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:8.5pt'>Very Common</span></b></p>
   </td>
   <td width="31%" style='width:31.18%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.75pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:8.5pt'>Common</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:86.9pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:86.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Infections and infestations</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:86.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Upper respiratory tract infection</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:86.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Herpes virus infection</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Herpes zoster</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Oral herpes</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Conjunctivitis</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nasopharyngitis</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Oral candidiasis</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Urinary tract infection</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:36.6pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Neoplasms Benign, Malignant and Unspecified (incl
  cysts and polyps)</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Skin papilloma</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.8pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Psychiatric disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Persistent depressive disorder</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Major depression</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Irritability</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.8pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Nervous system disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Headache</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.4pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Cardiac disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Tachycardia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.4pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Abdominal pain upper</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:37.25pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Alopecia</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Pruritus</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Urticaria</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Skin disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:37.25pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Musculoskeletal, connective tissue and bone disorders</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Musculoskeletal pain</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Arthralgia</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Back pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:36.6pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>General disorders and administration site conditions</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Fatigue</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Asthenia</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Pyrexia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.8pt'>
  <td width="38%" valign=top style='width:38.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Injury, Poisoning and Procedural Complications</span></b></p>
  </td>
  <td width="29%" valign=top style='width:29.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Infusion-related reactions*</span></p>
  </td>
  <td width="31%" valign=top style='width:31.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:63.75pt'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:63.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.0pt'>*Infusion-related reactions for PV Study 1 included symptoms collected
  on the next scheduled visit after each infusion, and adverse events occurring
  on the day of or one day after the infusion.&nbsp; The most common
  infusion-related reaction symptoms/Preferred Terms for PV Study 1 included
  headaches, chills, high blood pressure, nausea, asthenia and pain.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></b></p>
  <p class=TextTi10 style='page-break-after:avoid'><span style='font-size:9.0pt'>The
  most common infusion-related reaction symptoms/Preferred Terms for PV Study 2
  were dyspnoea, erythema, hyperhidrosis, flushing/hot flush, hypotension/low
  blood pressure and rash/rash pruritic</span><span style='font-size:9.0pt'>.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:53.85pt;text-indent:-53.85pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><u><span style='font-family:"Times",serif;color:black'>Description
of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:12.0pt'><i>&nbsp;</i></p>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:12.0pt'><i>Infusion-related
reactions</i></p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>In PV Study 1,
infusion-related reactions were common (58%). Nearly all infusion-related
reactions were mild to moderate. The proportion of patients experiencing an
infusion- related reaction was 29% (11 patients), 40% (15 patients), 13% (5
patients), and 10% (4&nbsp;patients) following the first, second, third, and
fourth infusions, respectively. No patients were withdrawn from treatment due
to infusion-related reactions. Symptoms of infusion-related reactions were
similar in type and severity to those seen in RA and GPA/MPA patients.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>In PV Study 2,
IRRs occurred primarily at the first infusion and the frequency of IRRs
decreased with subsequent infusions: 17.9%, 4.5%, 3% and 3% of patients
experienced IRRs at the first, second, third, and fourth infusions,
respectively. In 11/15 patients who experienced at least one IRR, the IRRs
were Grade 1 or 2. In 4/15 patients, Grade &#8805;3 IRRs were reported and led
to discontinuation of MabThera treatment; three of the four patients
experienced serious (life-threatening) IRRs. Serious IRRs occurred at the
first (2&nbsp;patients) or second (1&nbsp;patient) infusion and resolved with
symptomatic treatment. </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Infections</i></p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt;page-break-after:
avoid'>In PV Study 1, 14 patients (37%) in the MabThera group experienced
treatment-related infections compared to 15 patients (42%) in the standard-dose
prednisone group. The most common infections in the MabThera group were herpes
simplex and zoster infections, bronchitis, urinary tract infection, fungal
infection and conjunctivitis. Three patients (8%) in the MabThera group experienced
a total of 5 serious infections (<i>Pneumocystis jirovecii</i> pneumonia,
infective thrombosis, intervertebral discitis, lung infection, <i>Staphylococcal</i>
sepsis) and one patient (3%) in the standard-dose prednisone group experienced
a serious infection (<i>Pneumocystis jirovecii</i> pneumonia). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>In PV Study 2,
42 patients (62.7%) in the MabThera arm experienced infections. The most
common infections in the MabThera group were upper respiratory tract infection,
nasopharyngitis, oral candidiasis and urinary tract infection. Six patients
(9%) in the MabThera arm experienced serious infections.</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'><i>Laboratory
abnormalities</i></p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>PV Study 2, in
the MabThera arm, transient decreases in lymphocyte count, driven by decreases
in the peripheral T-cell populations, as well as a transient decrease in
phosphorus level were very commonly observed post-infusion. These were
considered to be induced by IV methylprednisolone premedication infusion.</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:.05pt;line-height:12.0pt'>In PV Study 2,
low IgG levels were commonly observed and low IgM levels were very commonly
observed; however, there was no evidence of an increased risk of serious
infections after the development of low IgG or IgM.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via </span><span lang=EN-GB style='color:black;background:
#BFBFBF'>the national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:#BFBFBF'>Appendix V</span></a><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited experience with doses higher than
the approved dose of intravenous MabThera formulation is available from
clinical trials in humans. The highest intravenous dose of MabThera tested in
humans to date is 5000&nbsp;mg (2250&nbsp;mg/m<sup>2</sup>), tested in a dose
escalation study in patients with CLL. No additional safety signals were
identified.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who experience overdose should
have immediate interruption of their infusion and be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the postmarketing setting five cases of
MabThera overdose have been reported. Three cases had no reported adverse
event. The two adverse events that were reported were flu&#8209;like symptoms,
with a dose of 1.8&nbsp;g of rituximab and fatal respiratory failure, with a
dose of 2&nbsp;g of rituximab. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: antineoplastic agents, monoclonal antibodies<i>,</i> ATC code: L01X C02</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab binds specifically to the
transmembrane antigen, CD20, a non&#8209;glycosylated phosphoprotein, located
on pre&#8209;B and mature B lymphocytes. The antigen is expressed on </span><span
lang=EN-GB style='font-family:Symbol'>&gt;</span><span lang=EN-GB>95&nbsp;% of
all B&nbsp;cell non&#8209;Hodgkins lymphomas. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>CD20 is found
on both normal and malignant B&nbsp;cells, but not on haematopoietic stem
cells, pro&#8209;B&nbsp;cells, normal plasma cells or other normal tissue. This
antigen does not internalise upon antibody binding and is not shed from the
cell surface. CD20 does not circulate in the plasma as a free antigen and,
thus, does not compete for antibody binding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Fab domain of rituximab binds to the
CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector
functions to mediate B&nbsp;cell lysis. Possible mechanisms of effector&#8209;mediated
cell lysis include complement&#8209;dependent cytotoxicity (CDC) resulting from
C1q binding, and antibody&#8209;dependent cellular cytotoxicity (ADCC) mediated
by one or more of the Fc</span><span lang=EN-GB style='font-family:Symbol'>g</span><span
lang=EN-GB> receptors on the surface of granulocytes, macrophages and NK cells.
Rituximab binding to CD 20 antigen on B lymphocytes has also been demonstrated
to induce cell death via apoptosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Peripheral B&nbsp;cell counts declined
below normal following completion of the first dose of MabThera. In patients
treated for haematological malignancies, B cell recovery began within 6 months
of treatment and generally returned to normal levels within 12 months after
completion of therapy, although in some patients this may take longer </span><span
lang=EN-GB>(up to a median recovery time of 23 months post&#8209;induction
therapy)</span><span lang=EN-GB>. In rheumatoid arthritis patients, immediate
depletion of B cells in the peripheral blood was observed following two
infusions of 1000&nbsp;mg MabThera separated by a 14-day interval. Peripheral
blood B cell counts begin to increase from week 24 and evidence for
repopulation is observed in the majority of patients by week 40, whether
MabThera was administered as monotherapy or in combination with methotrexate.</span><span
lang=EN-GB> A small proportion of patients had prolonged peripheral B cell
depletion lasting 2 years or more after their last dose of MabThera. </span><span
lang=EN-GB>In patients with GPA or MPA, the number of peripheral blood B cells
decreased to &lt;10 cells/&#956;L after two weekly infusions of rituximab
375&nbsp;mg/m<sup>2</sup>, and remained at that level in most patients up to
the 6 month timepoint. The majority of patients (81%) showed signs of B cell
return, with counts &gt;10 cells/&#956;L by month 12, increasing to 87% of
patients by month 18.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Clinical experience in Non&#8209;Hodgkins lymphoma
and in chronic lymphocytic leukaemia</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Follicular
lymphoma</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Initial
treatment, weekly for 4 doses </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In the
pivotal trial, 166 patients with relapsed or chemoresistant low&#8209;grade or
follicular B&nbsp;cell NHL received 375&nbsp;mg/m<sup>2</sup> of MabThera as an
intravenous infusion once weekly for four weeks. The overall response rate
(ORR) in the intent&#8209;to&#8209;treat (ITT) population was 48&nbsp;% (CI<sub>95</sub>%
41% &#8209; 56%) with a 6% complete response (CR) and a 42&nbsp;% partial
response (PR) rate. The projected median time to progression (TTP) for
responding patients was 13.0 months. In a subgroup analysis, the ORR was higher
in patients with IWF B, C, and D histological subtypes as compared to IWF A
subtype (58&nbsp;% vs. 12%), higher in patients whose largest lesion was
&lt;&nbsp;5 cm vs. &gt; 7 cm in greatest diameter (53% vs. 38%), and higher in
patients with chemosensitive relapse as compared to chemoresistant (defined as
duration of response &lt;&nbsp;3 months) relapse (50% vs. 22%). ORR in patients
previously treated with autologous bone marrow transplant (ABMT) was 78% versus
43% in patients with no ABMT. Neither age, sex, lymphoma grade, initial
diagnosis, presence or absence of bulky disease, normal or high LDH nor
presence of extranodal disease had a statistically significant effect (Fishers
exact test) on response to MabThera. A statistically significant correlation
was noted between response rates and bone marrow involvement. 40% of patients
with bone marrow involvement responded compared to 59% of patients with no bone
marrow involvement (p=0.0186). This finding was not supported by a stepwise
logistic regression analysis in which the following factors were identified as
prognostic factors: histological type, bcl&#8209;2 positivity at baseline,
resistance to last chemotherapy and bulky disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Initial
treatment, weekly for 8 doses </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In a multi&#8209;centre,
single&#8209;arm trial, 37 patients with relapsed or chemoresistant, low grade
or follicular B&nbsp;cell NHL received 375&nbsp;mg/m<sup>2</sup> of MabThera as
intravenous infusion weekly for eight doses. The ORR was 57% (95% Confidence
interval (CI); 41%  73%; CR 14%, PR 43%) with a projected median TTP for
responding patients of 19.4 months (range 5.3 to 38.9 months).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Initial treatment, bulky disease, weekly
for 4 doses </span></p>

<p class=MsoNormal><span lang=EN-GB>In pooled data from three trials, 39
patients with relapsed or chemoresistant, bulky disease (single lesion&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;10 cm in
diameter), low grade or follicular B&nbsp;cell NHL received 375&nbsp;mg/m2 of
MabThera as intravenous infusion weekly for four doses. The ORR was 36&nbsp;%
(CI</span><sub><span lang=EN-GB>95</span></sub><span lang=EN-GB>% 21%  51%; CR
3%, PR 33%) with a median TTP for responding patients of 9.6&nbsp;months (range
4.5 to 26.8 months).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Re&#8209;treatment, weekly for 4 doses<b> </b></span></p>

<p class=MsoNormal><span lang=EN-GB>In a multi&#8209;centre, single&#8209;arm
trial, 58 patients with relapsed or chemoresistant low grade or follicular
B&nbsp;cell NHL, who had achieved an objective clinical response to a prior
course of MabThera, were re&#8209;treated with 375&nbsp;mg/m<sup>2</sup> of
MabThera as intravenous infusion weekly for four doses. Three of the patients
had received two courses of MabThera before enrolment and thus were given a
third course in the study. Two patients were re&#8209;treated twice in the
study. For the 60 re&#8209;treatments on study, the ORR was 38% (CI<sub>95</sub>%
26%  51%; 10% CR, 28% PR) with a projected median TTP for responding patients
of 17.8 months (range 5.4  26.6). This compares favourably with the TTP
achieved after the prior course of MabThera (12.4 months).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Initial treatment, in combination with
chemotherapy</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In an open&#8209;label randomised trial, a
total of 322 previously untreated patients with follicular lymphoma were
randomised to receive either CVP chemotherapy (cyclophosphamide 750&nbsp;mg/m<sup>2</sup>,
vincristine 1.4&nbsp;mg/m<sup>2</sup> up to a maximum of 2&nbsp;mg on day 1,
and prednisolone 40&nbsp;mg/m<sup>2</sup>/day on days 1&nbsp;&#8209;5) every 3
weeks for 8 cycles or MabThera 375&nbsp;mg/m<sup>2</sup> in combination with
CVP (R&#8209;CVP). MabThera was administered on the first day of each treatment
cycle. A total of&nbsp;321 patients (162 R&#8209;CVP, 159 CVP) received therapy
and were analysed for efficacy. The median follow-up of patients was 53 months.
R&#8209;CVP led to a significant benefit over CVP for the primary endpoint,
time to treatment failure (27 months vs. 6.6 months, p &lt;&nbsp;0.0001, log&#8209;rank
test). The proportion of patients with a tumour response (CR, CRu, PR) was significantly
higher (p&lt;&nbsp;0.0001 Chi&#8209;Square test) in the R&#8209;CVP group
(80.9%) than the CVP group (57.2%). Treatment with R&#8209;CVP significantly
prolonged the time to disease progression or death compared to CVP, 33.6 months
and 14.7 months, respectively (p&nbsp;&lt;&nbsp;0.0001, log&#8209;rank test).
The median duration of response was 37.7 months in the R&#8209;CVP group and
was 13.5 months in the CVP group (p &lt;&nbsp;0.0001, log&#8209;rank test). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The difference between the treatment groups
with respect to overall survival showed a significant clinical difference
(p=0.029, log&#8209;rank test stratified by centre): survival rates at 53
months were 80.9% for patients in the R&#8209;CVP group compared to 71.1% for
patient</span><span lang=EN-GB>s in the CVP group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from three other randomised trials
using MabThera in combination with chemotherapy regimen other than CVP (CHOP,
MCP, CHVP/Interferon&#8209;&#945;) have also demonstrated significant
improvements in response rates, time&#8209;dependent parameters as well as in
overall survival. Key results from all four studies are summarised in Table&nbsp;8.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;8 Summary of key results from four
phase III randomised studies evaluating the benefit of MabThera with different
chemotherapy regimens in follicular lymphoma</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>Study</span></b></p>
   </td>
   <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Treatment,</span></b></p>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>N</span></b></p>
   </td>
   <td width=67 style='width:50.0pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
   FU, </span></b></p>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>months</span></b></p>
   </td>
   <td width=76 style='width:56.7pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>ORR, %</span></b></p>
   </td>
   <td width=85 style='width:63.8pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>CR,<br>
   %</span></b></p>
   </td>
   <td width=127 style='width:94.9pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>Median TTF/PFS/ EFS, months</span></b></p>
   </td>
   <td width=72 style='width:53.95pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:11.0pt'>OS rates,<br>
   %</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>M39021</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>CVP, 159</span></p>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>R&#8209;CVP, 162</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>53</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>57</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>81</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>41</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median TTP:</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>14.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>33.6</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>P&lt;0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>53&#8209;months </span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>71.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>80.9</span></p>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>p=0.029</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>GLSG00</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>CHOP, 205<br>
  R&#8209;CHOP, 223</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>18</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>90<br>
  96</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>17<br>
  20</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median TTF: 2.6 years</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Not reached<br>
  p &lt; 0.001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>18&#8209;months</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>90<br>
  95<br>
  p = 0.016</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>OSHO</span></b><b><span lang=EN-GB
  style='font-size:10.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'>39</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>MCP, 96<br>
  R&#8209;MCP, 105</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>47</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>75<br>
  92</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>25 <br>
  50</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median PFS: 28.8</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Not reached<br>
  p &lt; 0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>48&#8209;months</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>74 <br>
  87 <br>
  p = 0.0096</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>FL2000</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=left style='text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>CHVP&#8209;IFN, 183<br>
  R&#8209;CHVP&#8209;IFN, 175</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>42</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>85 <br>
  94</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>49<br>
  76</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median EFS: 36 <br>
  Not reached</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>42&#8209;months</span></p>
  <p class=TextTi12 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>84 <br>
  91<br>
  p = 0.029</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>EFS  Event Free Survival</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>TTP  Time to progression
or death<br>
PFS  Progression&#8209;Free Survival<br>
TTF  Time to Treatment Failure<br>
OS rates  survival rates at the time of the analyses</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Maintenance
therapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Previously
untreated follicular lymphoma </span></p>

<p class=MsoNormal><span lang=EN-GB>In a prospective, open label, international,
multi&#8209;centre, phase III trial 1193 patients with previously untreated
advanced follicular lymphoma received induction therapy with R&#8209;CHOP
(n=881), R&#8209;CVP (n=268) or R&#8209;FCM (n=44), according to the
investigators choice. A total of 1078 patients responded to induction therapy,
of which 1018 were randomised to MabThera maintenance therapy (n=505) or
observation (n=513). The two treatment groups were well balanced with regards
to baseline characteristics and disease status. MabThera maintenance treatment
consisted of a single infusion of MabThera at 375 mg/m<sup>2</sup> body surface
area given every 2 months until disease progression or for a maximum period of
two years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
pre-specified primary analysis was conducted at a median observation time of 25
months from randomization, maintenance therapy with MabThera resulted in a
clinically relevant and statistically significant improvement in the primary
endpoint of investigator assessed progression&#8209;free survival (PFS) as
compared to observation in patients with previously untreated follicular
lymphoma (Table 9). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Significant benefit from maintenance
treatment with MabThera was also seen for the secondary endpoints event&#8209;free
survival (EFS), time to next anti&#8209;lymphoma treatment (TNLT) time to next
chemotherapy (TNCT) and overall response rate (ORR) in the primary analysis
(Table 9). </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Data from extended follow-up of patients in the study
(median follow-up 9 years) confirmed the long-term benefit of MabThera
maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table 9).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b>Table&nbsp;9 </b><b><span lang=EN-GB>Overview of efficacy
results for MabThera maintenance vs. observation at the protocol-defined
primary analysis and after 9 years median follow-up (final analysis)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=227 rowspan=2 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Primary analysis<br>
  (median FU: 25 months)</span></b></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Final analysis<br>
  (median FU: 9.0 years)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Observation<br>
  N=513</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>MabThera<br>
  N=505</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Observation<br>
  N=513</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>MabThera<br>
  N=505</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Primary efficacy</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Progression-free survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4.06
  years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>10.49
  years</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>log-rank p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hazard ratio (95% CI)</span></p>
  <p class=MsoNormal><span lang=EN-GB>risk reduction</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.50
  (0.39, 0.64)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>50%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.61
  (0.52, 0.73)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Secondary efficacy</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Overall survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>log-rank p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.7246</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.7948</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hazard ratio (95% CI)</span></p>
  <p class=MsoNormal><span lang=EN-GB>risk reduction</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.89
  (0.45, 1.74)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.04
  (0.77, 1.40)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>-6%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Event-free survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>38
  months</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4.04
  years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9.25
  years</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>log-rank p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hazard ratio (95% CI)</span></p>
  <p class=MsoNormal><span lang=EN-GB>risk reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.54
  (0.43, 0.69)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>46%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.64
  (0.54, 0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>TNLT (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6.11
  years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>log-rank p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0003</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hazard ratio (95% CI)</span></p>
  <p class=MsoNormal><span lang=EN-GB>risk reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.61
  (0.46, 0.80)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.66
  (0.55, 0.78)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>TNCT (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9.32
  years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>log-rank p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0011</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>hazard ratio (95% CI)</span></p>
  <p class=MsoNormal><span lang=EN-GB>risk reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.60
  (0.44, 0.82)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.71
  (0.59, 0.86)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>39%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Overall response rate*</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>55%</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>74%</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>61%</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>79%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>chi-squared test p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>odds ratio (95% CI)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.33
  (1.73, 3.15)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.43
  (1.84, 3.22)</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Complete response (CR/CRu) rate*</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>48%</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>67%</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>53%</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>67%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>chi-squared test p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>odds ratio (95% CI)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.21
  (1.65, 2.94)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.34
  (1.80, 3.03) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>* at end of
maintenance/observation; final analysis results based on median follow-up of 73
months. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>FU: follow-up; NR:
not reached at time of clinical cut off, TNCT: time to next chemotherapy
treatment; TNLT: time to next anti lymphoma treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera maintenance treatment provided
consistent benefit in all predefined subgroups tested: gender (male, female),
age (</span><span lang=EN-GB style='font-family:Symbol'>&lt;</span><span
lang=EN-GB style='font-family:Symbol'> </span><span lang=EN-GB>60 years, &gt;=
60 years), FLIPI score (&lt;=1, 2 or &gt;= 3), induction therapy (R&#8209;CHOP,
R&#8209;CVP or R&#8209;FCM) and regardless of the quality of response to
induction treatment (CR, CRu or PR). Exploratory analyses of the benefit of
maintenance treatment showed a less pronounced effect in elderly patients (&gt;
70&nbsp;years of age), however sample sizes were small.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Relapsed/Refractory
follicular lymphoma </span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In a prospective, open label,
international, multi&#8209;centre, phase III trial, 465 patients with
relapsed/refractory follicular lymphoma were randomised in a first step to
induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisolone; n=231) or MabThera plus CHOP (R&#8209;CHOP, n=234). The two
treatment groups were well balanced with regard to baseline characteristics and
disease status. A total of 334 patients achieving a complete or partial
remission following induction therapy were randomised in a second step to
MabThera maintenance therapy (n=167) or observation (n=167). MabThera
maintenance treatment consisted of a single infusion of MabThera at
375&nbsp;mg/m<sup>2</sup> body surface area given every 3 months until disease
progression or for a maximum period of two years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The final efficacy analysis included all
patients randomised to both parts of the study. After a median observation time
of 31 months for patients randomised to the induction phase, R&#8209;CHOP
significantly improved the outcome of patients with relapsed/refractory
follicular lymphoma when compared to CHOP (see Table&nbsp;10).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;10 Induction phase: overview of
efficacy results for CHOP vs. R&#8209;CHOP (31 months median observation time) </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=517
 style='margin-left:3.5pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=125 valign=top style='width:93.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=88 valign=top style='width:66.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>CHOP</span></b></p>
   </td>
   <td width=96 valign=top style='width:1.0in;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R</span></b><b><span
   lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
   lang=EN-GB style='font-size:11.0pt'>CHOP</span></b></p>
   </td>
   <td width=80 valign=top style='width:60.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>p</span></b><b><span
   lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
   lang=EN-GB style='font-size:11.0pt'>value</span></b></p>
   </td>
   <td width=128 valign=top style='width:96.0pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction<sup>1)</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Primary efficacy </span></b></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>ORR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>74&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>87&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0003</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Na</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>CR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>29&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0005</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Na</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>PR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.9449</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Na</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>1)</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Estimates were calculated by hazard ratios</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>2)</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Last tumour response as assessed by the
investigator. The primary statistical test for response was the trend test
of CR versus PR versus non&#8209;response (p &lt;&nbsp;0.0001) </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Abbreviations: NA,
not available; ORR: overall response rate; CR: complete response; PR: partial
response</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients randomised to the maintenance
phase of the trial, the median observation time was 28 months from maintenance
randomisation. Maintenance treatment with MabThera led to a clinically relevant
and statistically significant improvement in the primary endpoint, PFS, (time
from maintenance randomisation to relapse, disease progression or death) when
compared to observation alone (p&lt;&nbsp;0.0001 log&#8209;rank test). The
median PFS was 42.2 months in the MabThera maintenance arm compared to 14.3
months in the observation arm. Using a cox regression analysis, the risk of
experiencing progressive disease or death was reduced by 61% with MabThera
maintenance treatment when compared to observation (95% CI; 45%&#8209;72%).
Kaplan&#8209;Meier estimated progression&#8209;free rates at 12 months were 78%
in the MabThera maintenance group vs. 57&nbsp;% in the observation group. An
analysis of overall survival confirmed the significant benefit of MabThera
maintenance over observation (p=0.0039 log&#8209;rank test). MabThera maintenance
treatment reduced the risk of death by 56% (95% CI; 22%&#8209;75%). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;11 Maintenance phase: overview of
efficacy results MabThera vs. observation (28 months median observation time) </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=574
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=207 rowspan=2 valign=top style='width:155.4pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Efficacy Parameter</span></b></p>
   </td>
   <td width=273 colspan=3 valign=top style='width:204.4pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan</span></b><b><span
   lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
   lang=EN-GB style='font-size:11.0pt'>Meier Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=94 rowspan=2 valign=top style='width:70.85pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Observation</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N = 167)</span></b></p>
   </td>
   <td width=91 valign=top style='width:68.6pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>MabThera</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N=167)</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Log&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:19.85pt'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB
  style='font-size:11.0pt'>free survival (PFS)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14.3</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>42.2</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>61&nbsp;%</span></p>
  </td>
 </tr>
 <tr style='height:19.85pt'>
  <td width=207 valign=top style='width:155.4pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall survival </span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0039</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>56&nbsp;%</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Time to new lymphoma treatment</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>20.1</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>38.8</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>50&nbsp;%</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Disease</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB
  style='font-size:11.0pt'>free survival<sup>a</sup></span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16.5</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>53.7</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0003</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>67&nbsp;%</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Subgroup analysis</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=PT-BR
  style='font-size:11.0pt'>PFS</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR style='font-size:11.0pt'>CHOP</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR style='font-size:11.0pt'>R&#8209;CHOP</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR style='font-size:11.0pt'>CR</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR style='font-size:11.0pt'>PR</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><u><span lang=PT-BR
  style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=FR-CH
  style='font-size:11.0pt'>OS</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>CHOP</span></p>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>R&#8209;CHOP</span></p>
  <p class=TextTi10 style='page-break-after:avoid'><u><span lang=EN-GB
  style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>11.6</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.1</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14.3</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>14.3</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>37.5</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>51.9</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>52.8</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>37.8</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;&nbsp;0.0001</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0071</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0008</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;&nbsp;0.0001</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0348</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0482</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>71&nbsp;%</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46&nbsp;%</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>64&nbsp;%</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>54&nbsp;%</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>55&nbsp;%</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>56&nbsp;%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>NR: not reached; <sup>a</sup>:
only applicable to patients achieving a CR</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The benefit
of MabThera maintenance treatment was confirmed in all subgroups analysed,
regardless of induction regimen (CHOP or R&#8209;CHOP) or quality of response
to induction treatment (CR or PR) (Table&nbsp;11). MabThera maintenance
treatment significantly prolonged median PFS in patients responding to CHOP
induction therapy (median PFS 37.5 months vs. 11.6 months, p&lt;&nbsp;0.0001)
as well as in those responding to R&#8209;CHOP induction (median PFS 51.9 months
vs. 22.1 months, p=0.0071). Although subgroups were small, MabThera maintenance
treatment provided a significant benefit in terms of overall survival for both
patients responding to CHOP and patients responding to R&#8209;CHOP, although
longer follow&#8209;up is required to confirm this observation. </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><i><u><span lang=FR>Adult Diffuse large B&nbsp;cell non&#8209;Hodgkins
lymphoma</span></u></i></p>

<p class=MsoNormal><i><u><span lang=FR><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>In a randomised, open&#8209;label trial, a
total of 399&nbsp;previously untreated elderly patients (age 60 to 80 years)
with diffuse large B&nbsp;cell lymphoma received standard CHOP chemotherapy
(cyclophosphamide 750&nbsp;mg/m<sup>2</sup>, doxorubicin 50&nbsp;mg/m<sup>2</sup>,
vincristine 1.4&nbsp;mg/m<sup>2</sup> up to a maximum of 2&nbsp;mg on day 1,
and prednisolone 40&nbsp;mg/m<sup>2</sup>/day on days 1&#8209;5) every 3 weeks
for eight cycles, or MabThera 375&nbsp;mg/m<sup>2</sup> plus CHOP (R&#8209;CHOP).
MabThera was administered on the first day of the treatment cycle. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The final efficacy analysis included all
randomised patients (197 CHOP, 202 R&#8209;CHOP),<span style='layout-grid-mode:
line'> and had a median follow&#8209;up duration of approximately 31 months. </span>The
two treatment groups were well balanced in baseline disease characteristics and
disease status. <span style='layout-grid-mode:line'>The final analysis</span>
confirmed that R&#8209;CHOP treatment was associated with a clinically relevant
and statistically significant improvement in the duration of event&#8209;free
survival (the primary efficacy parameter; where events were death, relapse or
progression of lymphoma, or institution of a new anti&#8209;lymphoma treatment)
(p=0.0001). Kaplan Meier estimates of the median duration of event&#8209;free
survival were 35 months in the R&#8209;CHOP arm compared to 13 months in the
CHOP arm, representing a risk reduction of 41%. At 24 months, estimates for
overall survival were 68.2% in the R&#8209;CHOP arm compared to 57.4% in the
CHOP arm. A subsequent analysis of the duration of overall survival, carried
out with a median follow&#8209;up duration of 60 months, confirmed the benefit
of R&#8209;CHOP over CHOP treatment (p=0.0071), representing a risk reduction
of 32%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The analysis of all secondary parameters
(response rates, progression&#8209;free survival, disease&#8209;free survival,
duration of response) verified the treatment effect of R&#8209;CHOP compared to
CHOP. The complete response rate after cycle 8 was 76.2% in the R&#8209;CHOP
group and 62.4% in the CHOP group (p=0.0028). The risk of disease progression
was reduced by 46% and the risk of relapse by 51%.</span></p>

<p class=MsoNormal><span lang=EN-GB>In all patient subgroups (gender, age, age
adjusted IPI, Ann Arbor stage, ECOG, &#946;2 microglobulin, LDH, albumin, B
symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk
ratios for event&#8209;free survival and overall survival (R&#8209;CHOP
compared with CHOP) were less than 0.83 and 0.95 respectively. R&#8209;CHOP was
associated with improvements in outcome for both high&#8209; and low&#8209;risk
patients according to age adjusted IPI.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Clinical laboratory findings </span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Of 67 patients evaluated for human anti&#8209;mouse
antibody (<span style='text-transform:uppercase'>hama</span><span
style='text-transform:uppercase'>)</span>, no responses were noted. Of
356&nbsp;patients evaluated for anti-drug antibody (<span style='text-transform:
uppercase'>ADA)</span>, 1.1&nbsp;% (4 patients) were positive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Chronic lymphocytic leukaemia</span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>In two open&#8209;label randomised trials,
a total of 817 previously untreated patients and 552 patients with
relapsed/refractory CLL were randomised to receive either FC chemotherapy
(fludarabine 25&nbsp;mg/m<sup>2</sup>, cyclophosphamide 250&nbsp;mg/m<sup>2</sup>,
days 1&#8209;3) every 4 weeks for 6 cycles or MabThera in combination with FC
(R&#8209;FC). MabThera was administered at a dosage of 375&nbsp;mg/m<sup>2</sup>
during the first cycle one day prior to chemotherapy and at a dosage of
500&nbsp;mg/m<sup>2</sup> on day 1 of each subsequent treatment cycle. Patients
were excluded from the study in relapsed/refractory CLL if they had previously
been treated with monoclonal antibodies or if they were refractory (defined as
failure to achieve a partial remission for at least 6 months) to fludarabine or
any nucleoside analogue. A total of 810 patients (403 R&#8209;FC, 407 FC) for
the first&#8209;line study (Table&nbsp;12a and Table 12b) and 552 patients (276
R&#8209;FC, 276 FC) for the relapsed/refractory study (Table&nbsp;13) were
analysed for efficacy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the first&#8209;line study, after a
median observation time of 48.1&nbsp;months, the median PFS was 55&nbsp;months
in the R&#8209;FC group and 33&nbsp;months in the FC group
(p&nbsp;&lt;&nbsp;0.0001, log&#8209;rank test). The analysis of overall
survival showed a significant benefit of R&#8209;FC treatment over FC
chemotherapy alone (p&nbsp;=&nbsp;0.0319, log&#8209;rank test) (Table 12a).<b><i>
</i></b>The benefit in terms of PFS was consistently observed in most patient
subgroups analysed according to disease risk at baseline (i.e. Binet stages A&#8209;C)
(Table 12b).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;12a First&#8209;line treatment of
chronic lymphocytic leukaemia</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;page-break-after:avoid'><b><span
lang=EN-GB>Overview of efficacy results for MabThera plus FC vs. FC alone &#8209;
48.1 months median observation time</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=577
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:25.55pt'>
   <td width=208 rowspan=2 valign=top style='width:156.2pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Efficacy Parameter</span></b></p>
   </td>
   <td width=274 colspan=3 valign=top style='width:205.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan&#8209;Meier
   Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=95 rowspan=2 valign=top style='width:71.2pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='height:7.45pt'>
   <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:
   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N = 409)</span></b></p>
   </td>
   <td width=83 valign=top style='width:62.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R&#8209;FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N=408)</span></b></p>
   </td>
   <td width=95 valign=top style='width:71.1pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Log&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB
  style='font-size:11.0pt'>free survival (PFS)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>32.8</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>55.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>45%</span></p>
  </td>
 </tr>
 <tr style='height:13.35pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall survival </span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0319</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>27%</span></p>
  </td>
 </tr>
 <tr style='height:14.75pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Event free survival</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>51.8</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>44%</span></p>
  </td>
 </tr>
 <tr style='height:14.6pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Response rate
  (CR, nPR, or PR)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>72.6%</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>85.8%</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.85pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>CR rates</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>16.9%</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>36.0%</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001 </span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Duration of
  response*</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>36.2</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>57.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>44%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Disease free
  survival (DFS)**</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>48.9</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>60.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.0520</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>31%</span></p>
  </td>
 </tr>
 <tr style='height:15.5pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Time to new
  treatment</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>47.2</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>69.7</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>42%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Response rate and
CR rates analysed using Chi&#8209;squared Test. NR: not reached; n.a.: not
applicable</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>*: only applicable to patients achieving a
CR, nPR, PR</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>**: only applicable to patients achieving a
CR</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;12b First&#8209;line treatment of
chronic lymphocytic leukaemia</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;page-break-after:avoid'><b><span
lang=EN-GB>Hazard ratios of progression&#8209;free survival according to Binet
stage (ITT)  48.1 months median observation time</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=586
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:25.55pt'>
  <td width=227 rowspan=2 valign=top style='width:170.1pt;border:solid black 1.0pt;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span></b><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
  lang=EN-GB style='font-size:11.0pt'>free survival (PFS)</span></b></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=113 colspan=2 valign=top style='width:85.05pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Number of patients</span></b></p>
  </td>
  <td width=132 rowspan=2 valign=top style='width:99.25pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Hazard Ratio (95% CI)</span></b></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>p&#8209;value (Wald test,
  not adjusted)</span></b></p>
  </td>
 </tr>
 <tr style='height:7.45pt'>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R</span></b><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
  lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dotted windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 style='margin-left:1.7pt;text-align:justify;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Binet stage A</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.39 (0.15; 0.98)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0442</span></p>
  </td>
 </tr>
 <tr style='height:12.4pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dotted windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Binet stage B</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>259</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>263</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.52 (0.41; 0.66)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Binet stage C</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>126</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>126</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.68 (0.49; 0.95)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0224</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>CI: Confidence
Interval</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the relapsed/refractory study, the
median progression&#8209;free survival (primary endpoint)</span><span
lang=EN-GB> was 30.6 months </span><span lang=EN-GB>in the R&#8209;FC group and
20.6 months in the FC group (p=0.0002, log&#8209;rank test). The benefit in
terms of PFS was observed in almost all patient subgroups analysed according to
disease risk at baseline. A slight but not significant improvement in overall
survival was reported in the R&#8209;FC compared to the FC arm. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;13 Treatment of relapsed/refractory
chronic lymphocytic leukaemia &#8209; overview of efficacy results for MabThera
plus FC vs. FC alone (25.3 months median observation time)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=577
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:25.55pt'>
   <td width=208 rowspan=2 valign=top style='width:156.2pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Efficacy Parameter</span></b></p>
   </td>
   <td width=274 colspan=3 valign=top style='width:205.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan&#8209;Meier
   Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=95 rowspan=2 valign=top style='width:71.2pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='height:7.45pt'>
   <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:
   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N = 276)</span></b></p>
   </td>
   <td width=92 valign=top style='width:68.95pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R&#8209;FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N=276)</span></b></p>
   </td>
   <td width=86 valign=top style='width:64.15pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Log&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB
  style='font-size:11.0pt'>free survival (PFS)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>20.6</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>30.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0002</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>35%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.4pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall survival </span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>51.9</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.2874</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>17%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Event free survival</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>19.3</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>28.7</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0002</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36%</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Response rate (CR, nPR, or PR)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58.0%</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>69.9%</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0034</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:26.75pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>CR rates</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>13.0%</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.3%</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0007 </span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Duration of response </span><span lang=EN-GB>*</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>27.6</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>39.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0252</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Disease free survival (DFS)**</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>42.2</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>39.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.8842</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>6%</span></p>
  </td>
 </tr>
 <tr style='height:26.3pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Time to new CLL treatment</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>34.2</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0024</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>35%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:9.0pt'>Response rate
and CR rates analysed using Chi&#8209;squared Test.</span></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>*: only applicable to patients achieving a
CR, nPR, PR; NR: not reached n.a. not applicable </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>**: only applicable to patients achieving a
CR; </span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from other supportive studies using
MabThera in combination with other chemotherapy regimens (including CHOP, FCM,
PC, PCM, </span><span lang=EN-GB>bendamustine and cladribine</span><span
lang=EN-GB>) for the treatment of previously untreated and/or
relapsed/refractory CLL patients have also demonstrated high overall response
rates with </span><em><span lang=EN-GB style='font-style:normal'>benefit in
terms of</span></em><em><span lang=EN-GB> </span></em><span lang=EN-GB>PFS
rates, albeit with modestly higher toxicity (especially myelotoxicity). These
studies support the use of MabThera with any chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>Data in approximately 180 patients pre&#8209;treated
with MabThera have demonstrated clinical benefit (including CR) and are
supportive for MabThera re&#8209;treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>A multicenter, open-label, randomized study
of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide,
high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug
[methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in
combination with MabThera was conducted in paediatric patients with previously
untreated advanced stage CD20 positive DLBCL/BL/BAL/BLL. Advanced stage is
defined as Stage III with elevated LDH level (B-high), [LDH &gt; twice the
institutional upper limit of the adult normal values (&gt; Nx2)] or any stage
IV or BAL. Patients were randomized to receive either LMB chemotherapy or six
IV infusions of MabThera at a dose of 375mg/m<sup>2</sup> BSA in combination
with LMB chemotherapy (two during each of the two induction courses and one
during each of the two consolidation courses) as per the LMB scheme. A total of
328 randomized patients were included in the efficacy analyses, of which one
patient under 3 years of age received MabThera in combination with LMB
chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The two treatment arms, LMB (LMB
chemotherapy) and R-LMB (LMB chemotherapy with MabThera), were well balanced
with regards to baseline characteristics. Patients had a median age of 7 and 8
years in the LMB arm and R-LMB arm, respectively. Approximately half of
patients were in Group B (50.6% in the LMB arm and 49.4% in the R-LMB arm),
39.6% in Group C1 in both arms, and 9.8% and 11.0% were in Group C3 in the LMB
and R-LMB arms, respectively. Based on Murphy staging, most patients were
either BL stage III (45.7% in the LMB arm and 43.3% in the R-LMB arm) or BAL,
CNS negative (21.3% in the LMB arm and 24.4% in the R-LMB arm). Less than half
of the patients (45.1% in both arms) had bone marrow involvement, and most
patients (72.6% in the LMB arm and 73.2% in the R-LMB arm) had no CNS
involvement. The primary efficacy endpoint was EFS, where an event was defined
as occurrence of progressive disease, relapse, second malignancy, death from
any cause, or non-response as evidenced by detection of viable cells in residue
after the second CYVE course, whichever occurs first. The secondary efficacy
endpoints were OS and CR (complete remission). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At the pre-specified interim analysis with
approximately 1 year of median follow-up, clinically relevant improvement in
the primary endpoint of EFS was observed, with 1-year rate estimates of 94.2%
(95% CI, 88.5% - 97.2%) in the R-LMB arm vs. 81.5% (95% CI, 73.0% - 87.8%) in
the LMB arm, and adjusted Cox HR 0.33 (95% CI, 0.14  0.79). Upon IDMC
(independent data monitoring committee) recommendation based on this result,
the randomization was halted and patients in the LMB arm were allowed to cross
over to receive MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Primary efficacy analyses were performed in
328 randomized patients with a median follow-up of 3.1 years. The results are
described in Table 14.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 14: Overview of Primary Efficacy
Results (ITT population)</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=595
 style='border-collapse:collapse'>
 <tr style='height:23.55pt'>
  <td width=151 valign=top style='width:113.0pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Analysis</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>LMB</span></b></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>(N = 164)</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>R-LMB</span></b></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>(N=164)</span></b></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=151 rowspan=3 valign=top style='width:113.0pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>EFS</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>28 events</span></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>10 events</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=445 colspan=2 valign=top style='width:333.6pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>One-sided log-rank test p-value 0.0006</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=445 colspan=2 valign=top style='width:333.6pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>Adjusted Cox HR 0.32 (90% CI: 0.17, 0.58)</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=151 valign=top style='width:113.0pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>3-year EFS rates</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>82.3%</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>(95% CI: 75.7%, 87.5%)</span></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>93.9%</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>(95% CI: 89.1%, 96.7%)</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=151 rowspan=3 valign=top style='width:113.0pt;border-top:none;
  border-left:solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>OS</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>20 deaths</span></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>8 deaths</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=445 colspan=2 valign=top style='width:333.6pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>One-sided log-rank test p-value 0.0061</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=445 colspan=2 valign=top style='width:333.6pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>Adjusted Cox model HR 0.36 (95% CI: 0.16; 0.81)</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=151 valign=top style='width:113.0pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>3-year OS rates</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>87.3%</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>(95% CI: 81.2%, 91.6%)</span></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>95.1%</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>(95% CI: 90.5%, 97.5%)</span></p>
  </td>
 </tr>
 <tr style='height:23.55pt'>
  <td width=151 valign=top style='width:113.0pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>CR rate</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>93.6% (95% CI: 88.2%; 97.0%) </span></p>
  </td>
  <td width=222 valign=top style='width:166.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.55pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=EN-GB>94.0% (95% CI: 88.8%, 97.2%) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The primary efficacy analysis showed an EFS
benefit of MabThera addition to LMB chemotherapy over LMB chemotherapy alone,
with an EFS HR 0.32 (90% CI 0.17 - 0.58) from a Cox regression analysis
adjusting for national group, histology, and therapeutic group. While no major
differences in numbers of patients achieving CR was observed between the two
treatment groups, the benefit of MabThera addition to LMB chemotherapy was also
shown in the secondary endpoint of OS, with the OS HR of 0.36 (95% CI, 0.16 
0.81).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with MabThera in all subsets of
the paediatric population with follicular lymphoma and CLL, and in the
paediatric population from birth to &lt; 6 months of age in CD20 positive
diffuse large B-cell lymphoma. See Section 4.2 for information on paediatric
use.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Clinical experience in rheumatoid arthritis</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK5"></a><a
name="OLE_LINK6"><span lang=EN-GB>The efficacy and safety of MabThera in
alleviating the symptoms and signs of rheumatoid arthritis in patients with an
inadequate response to TNF&#8209;inhibitors was demonstrated in a pivotal
randomised, controlled, double&#8209;blind, multicenter trial (Trial 1). </span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Trial 1 evaluated 517 patients that had
experienced an inadequate response or intolerance to one or more TNF inhibitor
therapies. Eligible patients had active rheumatoid arthritis, diagnosed
according to the criteria of the American College of Rheumatology (ACR).
MabThera was administered as two IV infusions separated by an interval of 15
days. Patients received 2 x 1000 mg intravenous infusions of MabThera or
placebo in combination with MTX. All patients received concomitant 60 mg oral
prednisone on days 2&#8209;7 and 30 mg on days 8&#8209;14 following the first
infusion.</span><span lang=EN-GB> The primary endpoint was the proportion of
patients who achieved an ACR20 response at week 24. Patients were followed
beyond week 24 for long term endpoints, including radiographic assessment at 56
weeks and at 104 weeks. During this time, 81% of patients</span><span
lang=EN-GB>, from the original placebo group received</span><span lang=EN-GB>
MabThera between weeks 24 and 56, under an open label extension study protocol.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Trials of MabThera in patients with early
arthritis (patients without prior methotrexate treatment and patients with an
inadequate response to methotrexate, but not yet treated with TNF&#8209;alpha
inhibitors) have met their primary endpoints. MabThera is not indicated for
these patients, since the safety data about long&#8209;term MabThera treatment
are insufficient, in particular concerning the risk of development of
malignancies and PML.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Disease activity outcomes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera in combination with methotrexate
significantly increased the proportion of patients achieving at least a
20&nbsp;% improvement in ACR score compared with patients treated with
methotrexate alone (Table&nbsp;15). Across all development studies the
treatment benefit was similar in patients independent of age, gender, body
surface area, race, number of prior treatments or disease status.<b> </b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Clinically and statistically significant improvement
was also noted on all individual components of the ACR response (tender and
swollen joint counts, patient and physician global assessment, disability index
scores (HAQ), pain assessment and C&#8209;Reactive Proteins (mg/dL).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;15 Clinical response outcomes </span></b><b><span
lang=EN-GB>at primary endpoint in Trial 1(ITT population)</span></b><b><span
lang=EN-GB> </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:4.0pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Outcome</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo+MTX</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>MabThera+MTX</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(2 x 1000 mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Trial 1 </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N= 201</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>N= 298</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>ACR20</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>36
  (18%)</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>153
  (51%)<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>ACR50</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11
  (5%)</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>80
  (27%)<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>ACR70</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3
  (1%)</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>37
  (12%)<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>EULAR
  Response (Good/Moderate)</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>44
  (22%)</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>193
  (65%)<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=106 valign=top style='width:79.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Mean
  change in DAS</span></p>
  </td>
  <td width=126 valign=top style='width:94.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB>0.34</span></p>
  </td>
  <td width=139 valign=top style='width:104.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-family:"Cambria Math",serif'>&#8209;</span><span lang=EN-GB>1.83<sup>***</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Outcome at 24
weeks</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Significant
difference from placebo + MTX at the primary timepoint: ***p &#8804; 0.0001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients treated with MabThera in
combination with methotrexate had a significantly greater reduction in disease
activity score (DAS28) than patients treated with methotrexate alone (Table 15).
Similarly, a good to moderate European League Against Rheumatism (EULAR)
response was achieved by significantly more MabThera treated patients treated
with MabThera and methotrexate compared to patients treated with methotrexate
alone (Table&nbsp;15).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Radiographic
response</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Structural
joint damage was assessed radiographically and expressed as change in modified
Total Sharp Score (mTSS) and its components, the erosion score and joint space
narrowing score.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In Trial 1, conducted in patients with
inadequate response or intolerance to one or more TNF inhibitor therapies, receiving
MabThera in combination with methotrexate demonstrated significantly less
radiographic progression than patients originally receiving methotrexate alone
at 56 weeks. Of the patients originally receiving methotrexate alone, 81&nbsp;%
received MabThera either as rescue between weeks 16&#8209;24 or in the
extension trial, before week 56. A higher proportion of patients receiving the
original MabThera/MTX treatment also had no erosive progression over 56 weeks
(Table&nbsp;16).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;16 Radiographic outcomes at 1 year
(mITT population)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border:solid black 1.0pt;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Placebo+MTX</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>MabThera+MTX</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>2  1000 mg</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Trial 1</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(n = 184)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(n = 273)</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Mean change from baseline:</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='margin-left:28.35pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Modified total sharp score</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>2.30</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.01<sup>*</sup></span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='margin-left:28.35pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Erosion score</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.32</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.60<sup>*</sup></span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='margin-left:28.35pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Joint space narrowing score</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.98</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.41<sup>**</sup></span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Proportion of patients with no radiographic change</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>46%</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>53%, NS</span></p>
  </td>
 </tr>
 <tr>
  <td width=310 valign=top style='width:232.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Proportion of patients with no erosive change </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>52%</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>60%, NS</span></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>150 patients
originally randomised to placebo&nbsp;+&nbsp;MTX in Trial 1 received at least
one course of RTX + MTX by one year</span></p>

<p class=MsoNormal><span lang=IT style='font-size:9.0pt'>* p &lt;0.05, ** p
&lt; 0.001. Abbreviation: NS, non significant </span></p>

<p class=MsoNormal><i><span lang=IT>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Inhibition of the rate of progressive joint
damage was also observed long term. Radiographic analysis at 2 years in Trial 1
demonstrated significantly reduced progression of structural joint damage in
patients receiving MabThera in combination with </span><span
class=TextTi12Char><span lang=EN-GB>methotrexate</span></span><span lang=EN-GB>
compared to </span><span class=TextTi12Char><span lang=EN-GB>methotrexate</span></span><span
lang=EN-GB> alone as well as a significantly higher proportion of patients with
no progression of joint damage over the 2-year period.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Physical function and quality of life
outcomes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Significant reductions in disability index
(HAQ&#8209;DI) and fatigue (FACIT&#8209;Fatigue) scores were observed in
patients treated with MabThera compared to patients treated with methotrexate
alone. The proportions of MabThera treated patients showing a minimal
clinically important difference (MCID) in HAQ&#8209;DI (defined as an
individual total score decrease of &gt;0.22) was also higher than among
patients receiving methotrexate alone (Table 17).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Significant improvement in health-related
quality of life was also demonstrated with significant improvement in both the
physical health score (PHS) and mental health score (MHS) of the SF&#8209;36.
Further, a significantly higher proportion of patients achieved MCIDs for these
scores (Table 17).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;17 Physical
function and quality of life outcomes at week 24 in Trial 1</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:4.0pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Outcome</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Placebo+MTX</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>MabThera+MTX</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>(2 x 1000 mg)</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  change in HAQ</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>DI</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>n=201</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.1</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>n=298</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>0.4<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>% HAQ</span><span
  lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>DI MCID</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>20%</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>51%</span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  change in FACIT</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>T</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>0.5</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>9.1<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mean Change
  in SF</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>36 PHS</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>n=197</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.9</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>n=294</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.8<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>% SF</span><span
  lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>36 PHS MCID</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13%</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48%<sup>***</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Mean change
  in SF</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>36 MHS</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.3</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.7<sup>**</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=193 valign=top style='width:145.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>% SF</span><span
  lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>36 MHS MCID</span></p>
  </td>
  <td width=116 valign=top style='width:86.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>20%</span></p>
  </td>
  <td width=124 valign=top style='width:93.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>38%<sup>*</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:"TimesNewRomanPSMT",serif'>
Outcome at 24 weeks</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Significant
difference from placebo at the primary time point: * p &lt; 0.05, **p &lt;
0.001 ***p &#8804; 0.0001</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>MCID HAQ&#8209;DI
&#8805;0.22, MCID SF&#8209;36 PHS &gt;5.42, MCID SF&#8209;36 MHS &gt;6.33</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Efficacy
in autoantibody (RF and or anti&#8209;CCP) seropositive patients </span></i></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Patients
seropositive to Rheumatoid Factor (RF) and/or anti&#8209; Cyclic Citrullinated
Peptide (anti&#8209;CCP) who were treated with MabThera in combination with </span></em><em><span
lang=EN-GB style='font-style:normal'>methotrexate</span></em><em><span
lang=EN-GB style='font-style:normal'> showed an enhanced response compared to
patients negative to both.</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy outcomes in MabThera treated
patients were analysed based on autoantibody status prior to commencing
treatment. At Week 24, patients who were seropositive to RF and/or anti&#8209;CCP
at baseline had a significantly increased probability of achieving ACR20 and 50
responses compared to seronegative patients (p=0.0312 and p=0.0096) (Table 18).
These findings were replicated at Week 48, where autoantibody seropositivity
also significantly increased the probability of achieving ACR70. At week 48
seropositive patients were 2&#8209;3 times more likely to achieve ACR responses
compared to seronegative patients. Seropositive patients also had a
significantly greater decrease in DAS28&#8209;ESR compared to seronegative
patients (Figure 1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 18 Summary of efficacy by baseline
autoantibody status</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=561
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Week 24</span></b></p>
  </td>
  <td width=193 colspan=2 valign=top style='width:144.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Week 48</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Seropositive</span></b></p>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(n=514)</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Seronegative</span></b></p>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(n=106)</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Seropositive</span></b></p>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(n=506)</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Seronegative</span></b></p>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(n=101)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>ACR20 (%)</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>62.3*</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>50.9</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>71. 1*</span></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>51.5</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>ACR50 (%)</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>32.7*</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>19.8</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>44.9**</span></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22.8</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>ACR70 (%)</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>12.1</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>5.7</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>20.9*</span></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>6.9</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>EULAR response (%)</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>74.8*</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>62.9</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>84.3*</span></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>72.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Mean change DAS28</span><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>ESR</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>1.97**</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>1.50</span></p>
  </td>
  <td width=96 valign=top style='width:72.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>2.48***</span></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>1.72</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>Significance levels were defined as <i>* p&lt;0.05,
**p&lt;0.001, ***p&lt;0.0001.</i></span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure 1</span></b><b><span lang=EN-GB>: Change
from baseline of DAS28&#8209;ESR by baseline autoantibody status</span></b></p>

<p class=MsoNormal><img border=0 width=537 height=363 id="Picture 1"
src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image001.png"></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Long&#8209;term efficacy with multiple
course therapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with MabThera in combination with
</span><span class=TextTi12Char><span lang=EN-GB>methotrexate</span></span><span
lang=EN-GB> over multiple courses resulted in sustained improvements in the
clinical signs and symptoms of RA, as indicated by ACR, DAS28&#8209;ESR and
EULAR responses which was evident in all patient populations studied (Figure
2). Sustained improvement in physical function as indicated by the HAQ&#8209;DI
score and the proportion of patients achieving MCID for HAQ&#8209;DI were
observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure 2:  ACR responses for 4 treatment courses
(24 weeks after each course (within patient, within visit) in patients with an
inadequate response to TNF&#8209;inhibitors (n=146)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><img border=0 width=326
height=223 id="Object 2"
src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image002.png"></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Clinical laboratory findings</span></u></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>A total of 392/3095 (12.7%) patients with
rheumatoid arthritis tested positive for ADAin clinical studies following
therapy with MabThera. The emergence of ADAwas not associated with clinical
deterioration or with an increased risk of reactions to subsequent infusions in
the majority of patients. The presence of ADA may be associated with worsening
of infusion or allergic reactions after the second infusion of subsequent
courses. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with MabThera in all subsets of the paediatric population with autoimmune
arthritis. See Section 4.2 for information on paediatric use.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%;page-break-after:avoid'><u><span
lang=EN-GB style='line-height:115%'>Clinical experience in granulomatosis with
polyangiitis (GPA) and microscopic polyangiitis (MPA)</span></u></p>

<p class=MsoNormal style='line-height:115%;page-break-after:avoid'><u><span
lang=EN-GB style='line-height:115%'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adult induction of remission</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>In GPA/MPA Study 1, a total of 197 patients
aged 15 years or older with severe active GPA (75%) and MPA (24%) were enrolled
and treated in an active&#8209;comparator, randomised, double&#8209;blind,
multicenter, non&#8209;inferiority trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients were randomised in a 1:1 ratio to
receive either oral cyclophosphamide daily (2&nbsp;mg/kg/day) for 3&#8209;6
months or MabThera (375&nbsp;mg/m<sup>2</sup>) once weekly for 4 weeks. All
patients in the cyclophosphamide arm received azathioprine maintenance therapy
in during follow&#8209;up. Patients in both arms received 1000&nbsp;mg of pulse
intravenous (IV) methylprednisolone (or another equivalent&#8209;dose
glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1&nbsp;mg/kg/day,
not exceeding 80&nbsp;mg/day). Prednisone tapering was to be completed by 6
months from the start of trial treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary outcome measure was achievement
of complete remission at 6 months defined as a Birmingham Vasculitis Activity
Score for Wegeners granulomatosis (BVAS/WG) of 0, and off glucocorticoid
therapy. The prespecified non&#8209;inferiority margin for the treatment
difference was 20%. The trial demonstrated non&#8209;inferiority of MabThera to
cyclophosphamide for complete remission (CR) at 6 months (Table 19).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Efficacy was observed both for patients
with newly diagnosed disease and for patients with relapsing disease (Table 20).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><a name="_Ref272402327"><b><span lang=EN-GB style='font-family:"Minion",serif'>Table&nbsp;</span></b></a><b><span
lang=EN-GB style='font-family:"Minion",serif'>19</span></b><b><span lang=EN-GB
style='font-family:"Minion",serif'> Percentage of</span></b><b><span
lang=EN-GB style='font-family:"Minion",serif'> adult</span></b><b><span
lang=EN-GB style='font-family:"Minion",serif'> patients who achieved complete
remission at 6 months (Intent&#8209;to&#8209;treat&nbsp;population*) </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:28.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=110 valign=top style='width:82.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=141 valign=top style='width:105.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>MabThera <br>
  (n&nbsp;</span></b><b><span lang=EN-GB style='font-family:Symbol'>=</span></b><b><span
  lang=EN-GB>&nbsp;99)</span></b></p>
  </td>
  <td width=160 valign=top style='width:120.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Cyclophosphamide <br>
  (n&nbsp;</span></b><b><span lang=EN-GB style='font-family:Symbol'>=</span></b><b><span
  lang=EN-GB>&nbsp;98)</span></b></p>
  </td>
  <td width=167 valign=top style='width:125.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Treatment Difference</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(MabThera&#8209; Cyclophosphamide)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
 </tr>
 <tr>
  <td width=110 valign=top style='width:82.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rate</span></p>
  </td>
  <td width=141 valign=top style='width:105.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>63.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=160 valign=top style='width:120.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>53.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=167 valign=top style='width:125.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10.6%<br>
  </span><span lang=EN-GB>95.1%<sup>b</sup> CI<br>
  </span><span lang=EN-GB>(</span><span lang=EN-GB style='font-family:Symbol'>-</span><span
  lang=EN-GB>3.2%, 24.3%)<sup> a</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
 </tr>
 <tr>
  <td width=578 colspan=4 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB
  style='font-size:9.0pt;font-family:Symbol'>-</span><b><span lang=EN-GB
  style='font-size:9.0pt'> </span></b><span lang=EN-GB
  style='font-size:9.0pt'>CI = confidence interval.</span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=EN-GB
  style='font-size:9.0pt;font-family:Symbol'>-</span><b><span lang=EN-GB
  style='font-size:9.0pt'> </span></b><span lang=EN-GB
  style='font-size:9.0pt'>* Worst case imputation</span></p>
  <p class=MsoNormal style='margin-left:.15in;text-align:justify;text-indent:
  -.15in'><sup><span lang=EN-GB style='font-size:9.0pt'>a</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>  Non&#8209;inferiority was </span><span
  lang=EN-GB style='font-size:9.0pt'>demonstrated</span><span lang=EN-GB
  style='font-size:9.0pt'> since the lower bound (&nbsp;</span><span
  lang=EN-GB style='font-size:9.0pt;font-family:Symbol'>-</span><span
  lang=EN-GB style='font-size:9.0pt'>&nbsp;3.2%) was higher than the pre&#8209;determined
  non&#8209;inferiority margin (&nbsp;</span><span lang=EN-GB style='font-size:
  9.0pt;font-family:Symbol'>-</span><span lang=EN-GB style='font-size:9.0pt'>&nbsp;20%).</span></p>
  <p class=MsoNormal style='text-align:justify;line-height:14.0pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>b</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> The 95.1% confidence level reflects an additional
  0.001 alpha to account for an interim efficacy analysis.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table 20  Complete remission at 6&#8209;months by
disease status</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:26.7pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>MabThera</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Cyclophosphamide</span></b></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Difference (CI 95%)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>All
  patients</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=99</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=98</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Newly diagnosed</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=48</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=48</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Relapsing</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=51</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>n=50</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=581 colspan=4 valign=top style='width:435.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Complete
  remission </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>All
  Patients</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>63.6%</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>53.1%</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>10.6% (</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>3.2, 24.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Newly
  diagnosed</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>60.4%</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>64.6%</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>&#8722; 4.2% (&#8722; 23.6, 15.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Relapsing</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>66.7%</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>42.0%</span></p>
  </td>
  <td width=146 valign=top style='width:109.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>24.7% (5.8, 43.6)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Worst
case imputation is applied for patients with missing data</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Complete remission
at 12 and 18 months</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the MabThera group, 48% of patients
achieved CR at 12 months, and 39% of patients achieved CR at 18 months. In
patients treated with cyclophosphamide (followed by azathioprine for maintenance
of complete remission), 39% of patients achieved CR at 12 months, and 33% of
patients achieved CR at 18 months. From month 12 to month 18, 8 relapses were
observed in the MabThera group compared with four in the cyclophosphamide
group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Laboratory evaluations</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A total of 23/99 (23%) MabThera&#8209;treated
patients from the induction of remission trial tested positive for ADA by 18
months. None of the 99 MabThera&#8209;treated patients were ADA positive at
screening. There was no apparent trend or negative impact of the presence of
ADA on safety or efficacy in the induction of remission trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adult maintenance treatment </span></u></i></p>

<p class=MsoNormal style='text-align:justify;text-indent:.85pt;line-height:
12.0pt'>A total of 117 patients (88 with GPA, 24 with MPA, and 5 with
renal-limited ANCA-associated vasculitis) in disease remission were randomized
to receive azathioprine (59 patients) or MabThera (58 patients) in a
prospective, multi-center, controlled, open-label study. Included patients
were 21 to 75 years of age and had newly diagnosed or relapsing disease in
complete remission after combined treatment with glucocorticoids and pulse
cyclophosphamide. The majority of patients were ANCA-positive at diagnosis or
during the course of their disease; had histologically confirmed necrotizing
small-vessel vasculitis with a clinical phenotype of GPA or MPA, or renal
limited ANCA-associated vasculitis; or both.</p>

<p class=MsoNormal style='text-align:justify;text-indent:.85pt;line-height:
12.0pt'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-indent:.85pt;line-height:
12.0pt'>Remission-induction therapy included IV prednisone, administered as per
the investigators discretion, preceded in some patients by methylprednisolone
pulses, and pulse cyclophosphamide until remission was attained after 4 to 6
months. At that time, and within a maximum of 1 month after the last
cyclophosphamide pulse, patients were randomly assigned to receive either
MabThera (two 500&nbsp;mg IV infusions separated by two weeks (on Day 1 and Day
15) followed by 500&nbsp;mg IV every 6 months for 18 months) or azathioprine
(administered orally at a dose of 2&nbsp;mg/kg/day for 12 months, then
1.5&nbsp;mg/kg/day for 6 months, and finally 1 mg/kg/day for 4 months
(treatment discontinuation after these 22 months)). Prednisone treatment was
tapered and then kept at a low dose (approximately 5&nbsp;mg per day) for at
least 18 months after randomization. Prednisone dose tapering and the decision
to stop prednisone treatment after month 18 were left at the investigators
discretion. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>All patients were followed until month 28 (10 or 6 months,
respectively, after the last MabThera infusion or azathioprine dose). <i>Pneumocystis
jirovecii</i> pneumonia prophylaxis was required for all patients with CD4+
T-lymphocyte counts less than 250 per cubic millimeter.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary outcome measure was the rate of major relapse at
month 28. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:12.0pt'><i>Results</i></p>

<p class=MsoNormal>At month 28, major relapse (defined by the reappearance of
clinical and/or laboratory signs of vasculitis activity ([BVAS] &gt; 0) that
could lead to organ failure or damage or could be life threatening) occurred in
3 patients (5%) in the <u>MabThera</u> group and 17 patients (29%) in the
azathioprine group (p=0.0007). Minor relapses (not life threatening and not
involving major organ damage) occurred in seven patients in the MabThera group
(12%) and eight patients in the azathioprine group (14%). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:12.0pt'>The cumulative incidence rate
curves showed that time to first major relapse was longer in patients with
MabThera starting from month 2 and was maintained up to month 28 (Figure 3).</p>

<p class=MsoNormal style='line-height:12.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:12.0pt'><b>Figure 3:  Cumulative
incidence over time of first major relapse</b></p>

<p class=TextTi12 style='margin-bottom:0in;line-height:12.0pt'><span
style='position:relative;z-index:251660288'><span style='left:0px;position:
absolute;left:-8px;top:-7607px;width:44px;height:1px'><img width=44 height=1
src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image003.png"
alt="Percentage of Patients with First Major Relapse"></span></span><span
style='font-size:11.0pt'> </span><img border=0 width=576 height=310
id="Picture 4" src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image004.png"></p>

<p class=MsoNormal><span style='position:relative;z-index:251658240'><span
style='position:absolute;left:230px;top:-7920px;width:141px;height:1px'><img
width=141 height=1 src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image005.png"
alt="Survival Time (Months)"></span></span><span style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:8.0pt'>&nbsp;</span></p>

<br clear=ALL>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=604 colspan=16 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Number of
  Subjects with Major Relapse</span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:52.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Azathioprine</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>8</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>8</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=35 valign=top style='width:26.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>10</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>13</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>15</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>17</span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:52.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Rituximab</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=35 valign=top style='width:26.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>1</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=16 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Number of
  subjects at risk</span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:52.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Azathioprine</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>59</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>56</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>52</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>50</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>47</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>47</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>44</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>44</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>42</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>41</span></p>
  </td>
  <td width=35 valign=top style='width:26.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>40</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>39</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>36</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>34</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:52.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>Rituximab</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>58</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>56</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>56</span></p>
  </td>
  <td width=36 valign=top style='width:26.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>56</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>55</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=36 valign=top style='width:26.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=35 valign=top style='width:26.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=37 valign=top style='width:27.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>52</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>50</span></p>
  </td>
  <td width=35 valign=top style='width:25.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoFootnoteText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:white'>Note: </span><span
lang=EN-GB style='font-size:8.0pt'>Patients were censored at month 28 if they
had no event. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Laboratory
evaluations</span></i></p>

<p class=MsoNormal><span style='color:black;background:white'>A total of 6/34
(18%) of MabThera treated patients from the maintenance therapy clinical trial
developed ADA. There was no apparent trend or negative impact of the presence
of ADA on safety or efficacy in the maintenance therapy clinical trial. </span></p>

<p class=MsoNormal><span style='color:black;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='layout-grid-mode:line'>Granulomatosis with polyangiitis (GPA) and
microscopic polyangiitis (MPA)</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='layout-grid-mode:line'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'>Study WA25615 (PePRS) was a
multicenter, open-label, single-arm, uncontrolled study in 25 paediatric
patients (&#8805; 2 to &lt; 18 years old) with severe, active GPA or MPA. The
median age of patients in the study was: 14 years (range: 6-17 years) and the
majority of patients (20/25 [80%]) were female. A total of 19 patients (76%)
had GPA and 6 patients (24%) had MPA at baseline. Eighteen patients (72%) had
newly diagnosed disease upon study entry (13 patients with GPA and 5 patients
with MPA) and 7 patients had relapsing disease (6 patients with GPA and 1
patient with MPA).</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The study design consisted of
an initial 6-month remission induction phase, with a minimum 18-month follow-up,
up to a maximum of 54 months (4.5 years) overall. Patients were to receive a minimum
of 3 doses of IV methylprednisolone (30&nbsp;mg/kg/day, not exceeding
1&nbsp;g/day) prior to the first MabThera IV infusion. If clinically indicated,
additional daily doses (up to three), of IV methylprednisolone could be given.
The remission induction regimen consisted of four once weekly IV infusions of
MabThera at a dose of 375&nbsp;mg/m2 BSA, on study days 1, 8, 15 and 22 in
combination with oral prednisolone or prednisone at 1 mg/kg/day (max
60&nbsp;mg/day) tapered to 0.2&nbsp;mg/kg/day minimum (max 10&nbsp;mg/day) by Month
6. After the remission induction phase, patients could, at the discretion of
the investigator, receive subsequent MabThera infusions on or after Month 6 to
maintain PVAS remission and control disease activity (including progressive
disease or flare) or to achieve first remission.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>All 25 patients completed all
four once weekly IV infusions for the 6-month remission induction phase. A
total of 24 out of 25 patients completed at least 18 months of follow-up. </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The objectives of this study
were to evaluate safety, PK parameters, and efficacy of MabThera in paediatric
GPA and MPA patients (&#8805; 2 to &lt; 18 years old). The efficacy objectives
of the study were exploratory and principally assessed using the Pediatric
Vasculitis Activity Score (PVAS) (Table 21).</p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>Cumulative Glucocorticoid dose (IV and Oral) by Month 6:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'>Twenty-four out of 25
patients (96%) in Study WA25615 achieved oral glucocorticoid taper to 0.2
mg/kg/day (or less than or equal to 10 mg/day, whichever was lower) at or by
Month 6 during the protocol-defined oral steroid taper.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>A decrease in median overall
oral glucocorticoid use was observed from Week 1 (median = 45 mg prednisone
equivalent dose [IQR: 35  60]) to Month 6 (median = 7.5 mg [IQR: 4-10]), which
was subsequently maintained at Month 12 (median = 5 mg [IQR: 2-10]) and M<s>m</s>onth
18 (median =5 mg [IQR: 1-5]). </p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal><i>Follow-Up Treatment</i></p>

<p class=MsoNormal>During the Overall Study Period, patients received between 4
and 28 infusions of MabThera (up to 4.5 yrs [53.8 months]). Patients received
up to 375 mg/m<sup>2</sup> x 4 of MabThera, approximately every 6 months at the
discretion of the investigator. In total, 17 out of 25 patients (68%) received
additional rituximab treatment at or post Month 6 until the Common Close Out,
14 out of these 17 patients received additional rituximab treatment between Month
6 and Month 18.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid'><b>Table 21:
Study WA25615 (PePRS) - PVAS Remission at Month 1, 2, 4, 6, 12 and 18 </b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:44.05pt'>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.05pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Study visit</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:44.05pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Number of Responders in PVAS Remission<sup>*</sup> (response rate [%])</p>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>n=25</p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:44.05pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>95% CI<sup>&#945;</sup></p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 1</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>0</p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>0.0%, 13.7%</p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 2</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>1 (4.0%)</p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>0.1%, 20.4%</p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 4</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>5 (20.0%)</p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>6.8%, 40.7%</p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 6</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>13 (52.0%)</p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>31.3%, 72.2%</p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 12</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>18 (72.0%) </p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>50.6%, 87.9%</p>
  </td>
 </tr>
 <tr>
  <td width=139 valign=top style='width:1.45in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>Month 18</p>
  </td>
  <td width=300 valign=top style='width:225.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>18 (72.0%) </p>
  </td>
  <td width=129 valign=top style='width:96.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:12.0pt;page-break-after:
  avoid'>50.6%, 87.9%</p>
  </td>
 </tr>
 <tr>
  <td width=568 colspan=3 valign=top style='width:426.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:12.0pt'><sup><span style='font-size:
  9.0pt;color:black;background:white'>*</span></sup><span style='font-size:
  9.0pt;color:black;background:white'> PVAS of 0 and achieved glucocorticoid
  taper to 0.2 mg/kg/day (or 10 mg/day, whichever is lower) at theassessment
  time-point.</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><sup><span
  style='font-size:9.0pt;color:black;background:white'>&#945;</span></sup><span
  style='font-size:9.0pt;color:black;background:white'>the efficacy results are
  exploratory and no formal statistical testing was performed for these
  endpoints</span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  style='font-size:9.0pt;color:black;background:white'>MabThera, treatment (375
  mg/m<sup>2</sup> x 4 infusions) up to Month 6 was identical for all patients.
  Follow-up treatment post Month 6 was at the discretion of the investigator.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>Laboratory evaluations</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A</span>
total of 4/25 patients (16%) developed ADA during the overall study period.
Limited data shows there was no trend observed in the adverse reactions
reported in ADA positive patients.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>There was no apparent trend
or negative impact of the presence of ADA on safety or efficacy in the
paediatric GPA and MPA clinical trials.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The European Medicines Agency
has waived the obligation to submit the results of studies with MabThera in
paediatric population &lt;&nbsp;2&nbsp;years of age in severe, active GPA or
MPA. See section 4.2 for information on paediatric use.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:115%;page-break-after:avoid'><u><span
lang=EN-GB style='line-height:115%'>Clinical experience in pemphigus vulgaris</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><br>
</span></u>PV Study 1 (Study ML22196)</p>

<p class=MsoNormal>The efficacy and safety of MabThera in combination with
short-term, low-dose glucocorticoid (prednisone) therapy were evaluated in
newly diagnosed patients with moderate to severe pemphigus (74 pemphigus
vulgaris [PV] and 16 pemphigus foliaceus [PF]) in this randomised, open-label,
controlled, multicenter study. Patients were between 19 and 79 years of age and
had not received prior therapies for pemphigus. In the PV population, 5 (13%)
patients in the MabThera group and 3 (8%) patients in the standard prednisone
group had moderate disease and 33 (87%) patients in the MabThera group and 33
(92%) patients in the standard-dose prednisone group had severe disease
according to disease severity defined by Harmans criteria.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients were stratified by baseline disease severity
(moderate or severe) and randomised 1:1 to receive either MabThera and low-dose
prednisone or standard-dose prednisone. Patients randomised to the MabThera
group received an initial intravenous infusion of 1000&nbsp;mg MabThera on
Study Day 1 in combination with 0.5&nbsp;mg/kg/day oral prednisone tapered off
over 3 months if they had moderate disease or 1&nbsp;mg/kg/day oral prednisone
tapered off over 6&nbsp;months if they had severe disease, and a second
intravenous infusion of 1000&nbsp;mg on Study Day 15. Maintenance infusions of
MabThera 500&nbsp;mg were administered at months 12 and 18. Patients randomised
to the standard-dose prednisone group received an initial 1&nbsp;mg/kg/day oral
prednisone tapered off over 12&nbsp;months if they had moderate disease or
1.5&nbsp;mg/kg/day oral prednisone tapered off over 18&nbsp;months if they had
severe disease. Patients in the MabThera group who relapsed could receive an
additional infusion of MabThera 1000&nbsp;mg in combination with reintroduced
or escalated prednisone dose. Maintenance and relapse infusions were
administered no sooner than 16 weeks following the previous infusion. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary objective for the study was complete remission
(complete epithelialisation and absence of new and/or established lesions) at
month 24 without the use of prednisone therapy for two months or more (CRoff
for <span style='font-family:Symbol'></span>2 months). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:115%;page-break-after:avoid'><i><span
style='line-height:115%'>PV Study 1 Results</span></i></p>

<p class=MsoNormal>The study showed statistically significant results of
MabThera and low-dose prednisone over standard-dose prednisone in achieving
CRoff <span style='font-family:Symbol'></span> 2 months at month&nbsp;24 in PV
patients (see Table 22). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=TableTitle style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:57.55pt;text-indent:-57.55pt'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Table 22 Percentage of PV patients who
achieved complete remission off corticosteroid therapy for two months or more
at month 24 (Intent-to-Treat Population - PV)</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.54%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="23%" valign=top style='width:23.88%;border:solid windowtext 1.0pt;
  border-right:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="20%" valign=top style='width:20.82%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>Rituximab
  +</p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>Prednisone</p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>N=38</p>
  </td>
  <td width="16%" valign=top style='width:16.42%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>Prednisone</p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>N=36</p>
  </td>
  <td width="18%" valign=top style='width:18.68%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>p-value<sup>
  a</sup></p>
  </td>
  <td width="20%" style='width:20.18%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>95%
  CI<sup>b</sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="23%" valign=top style='width:23.88%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>Number
  of responders (response rate [%])</p>
  </td>
  <td width="20%" valign=top style='width:20.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>34
  (89.5%)</p>
  </td>
  <td width="16%" valign=top style='width:16.42%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>10
  (27.8%)</p>
  </td>
  <td width="18%" valign=top style='width:18.68%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>&lt;0.0001</p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;page-break-after:avoid'>61.7%
  (38.4, 76.5)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="79%" colspan=4 valign=top style='width:79.82%;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=Paragraph style='margin-bottom:0in;text-align:justify;line-height:
  normal'><sup><span style='font-family:"Times New Roman",serif'>a</span></sup><span
  style='font-family:"Times New Roman",serif'>p-value is from Fishers exact
  test with mid-p correction</span></p>
  <p class=Paragraph style='margin-bottom:0in;text-align:justify;line-height:
  normal'><sup>b</sup> 95% confidence interval is corrected Newcombe interval<span
  style='font-size:8.0pt'> </span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=Paragraph style='margin-bottom:0in;text-align:justify;line-height:
  normal'><sup><span style='font-family:"Times New Roman",serif'>&nbsp;</span></sup></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The number of rituximab plus low-dose prednisone patients
off prednisone therapy or on minimal therapy (prednisone dose of 10 mg or less
per day) compared to standard-dose prednisone patients over the 24-month
treatment period shows a steroid-sparing effect of MabThera (Figure 4). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure 4:  Number of patients who were off or on
minimal corticosteroid (&#8804;10mg/day) therapy over time</span></b></p>

<p class=MsoNormal style='margin-bottom:8.5pt'><img border=0 width=573
height=278 id="Picture 5"
src="MABTHERA-EN-VIB181-220221-Clean-CD_files/image006.jpg"></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Post-hoc retrospective laboratory
evaluation</span></i></p>

<p class=MsoNormal>A total of 19/34 (56%) patients with PV, who were treated
with MabThera, tested positive for ADA antibodies by 18 months. The clinical
relevance of ADA formation in MabThera&#8209;treated PV patients is unclear.<span
style='color:black;background:white'> </span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='color:black;background:white'>&nbsp;</span></p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left;
line-height:12.0pt'><span style='font-size:11.0pt'>PV Study 2 (Study <span
style='color:#222222;background:white'>WA29330</span>)</span></p>

<p class=MsoNormal>In a randomized, double-blind, double-dummy,
active-comparator, multicenter study, the efficacy and safety of MabThera
compared with mycophenolate mofetil (MMF) were evaluated in patients with
moderate-to-severe PV receiving 60&#8209;120&nbsp;mg/day oral prednisone or
equivalent (1.0-1.5&nbsp;mg/kg/day) at study entry and tapered to reach a dose
of 60 or 80 mg/day by Day 1. Patients had a confirmed diagnosis of PV within
the previous 24&nbsp;months and evidence of moderate-to-severe disease (defined
as a total Pemphigus Disease Area Index, PDAI, activity score of <span
style='font-size:10.0pt;font-family:Symbol'></span>&nbsp;15). </p>

<p class=MsoNormal></p>

<p class=MsoNormal>One hundred and thirty-five patients were randomized to
treatment with MabThera 1000&nbsp;mg administered on Day 1, Day 15, Week 24 and
Week 26 or oral MMF 2&nbsp;g/day for 52&nbsp;weeks in combination with 60 or
80&nbsp;mg oral prednisone with the aim of tapering to 0&nbsp;mg/day prednisone
by Week 24. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary efficacy objective for this study was to
evaluate at week 52, the efficacy of MabThera compared with MMF in achieving
sustained complete remission defined as achieving healing of lesions with no
new active lesions (i.e., PDAI activity score of 0) while on 0&nbsp;mg/day
prednisone or equivalent, and maintaining this response for at least
16&nbsp;consecutive weeks, during the 52&#8209;week treatment period. </p>

<p class=MsoNormal><span style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%;page-break-after:avoid'><i><span
style='line-height:115%'>PV Study 2 Results</span></i></p>

<p class=MsoNormal>The study demonstrated the superiority of MabThera over MMF
in combination with a tapering course of oral corticosteroids in achieving
CRoff corticosteroid <span style='font-size:10.0pt;font-family:Symbol'></span>
16 weeks at Week 52 in PV patients (Table 23).The majority of patients in the mITT
population were newly diagnosed (74%) and 26% of patients had established
disease (duration of illness <span style='font-size:10.0pt;font-family:Symbol'></span>&nbsp;6
months and received prior treatment for PV). </p>

<p class=MsoNormal><span style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.0pt;text-indent:-56.0pt;page-break-after:
avoid'><b>Table 23  Percentage of PV Patients Who Achieved Sustained
Complete Remission Off Corticosteroid Therapy for 16 Weeks or More at Week 52
(Modified Intent-to-Treat Population)</b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=192 valign=top style='width:143.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>MabThera<br>
  (N=62)</p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>MMF<br>
  (N=63)</p>
  </td>
  <td width=174 valign=top style='width:130.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Difference (95% CI)</p>
  </td>
  <td width=53 valign=top style='width:39.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>p-value</p>
  </td>
 </tr>
 <tr>
  <td width=192 valign=top style='width:143.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Number of responders (response
  rate [%])</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'>Newly
  diagnosed patients</p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'>Patients
  with established disease</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>25 (40.3%)</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>19 (39.6%)<span
  style='font-size:8.0pt;font-family:CourierNew'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>6 (42.9%)</p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>6 (9.5%)</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>4 (9.1%) </p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>2 (10.5%)</p>
  </td>
  <td width=174 valign=top style='width:130.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>30.80% (14.70%, 45.15%)</p>
  </td>
  <td width=53 valign=top style='width:39.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&lt;0.0001</p>
  </td>
 </tr>
 <tr>
  <td width=581 colspan=5 valign=top style='width:6.05in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>MMF = Mycophenolate
  mofetil. CI = Confidence Interval. </p>
  <p class=MsoNormal style='page-break-after:avoid'>Newly diagnosed patients = duration
  of illness &lt; 6 months or no prior treatment for PV. </p>
  <p class=MsoNormal style='page-break-after:avoid'>Patients with established
  disease = duration of illness <span style='font-size:10.0pt;font-family:Symbol'></span>&nbsp;6
  months and received prior treatment for PV. </p>
  <p class=MsoNormal style='page-break-after:avoid'>Cochran-Mantel-Haenszel
  test is used for p-value. </p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The analysis of all secondary parameters (including
</span>cumulative oral corticosteroid dose, the total number of disease flares,
and change in health-related quality of life, as measured by the Dermatology
Life Quality Index<span lang=EN-GB>) verified the statistically significant
results of MabThera compared to MMF. Testing of secondary endpoints were
controlled for multiplicity. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Glucocorticoid exposure</i></p>

<p class=MsoNormal>The cumulative oral corticosteroid dose was significantly
lower in patients treated with MabThera. The median (min, max) cumulative
prednisone dose at Week 52 was 2775&nbsp;mg (450, 22180) in the MabThera group
compared to 4005&nbsp;mg (900, 19920) in the MMF group (p=0.0005). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Disease flare</i></p>

<p class=MsoNormal>The total number of disease flares was significantly lower
in patients treated with MabThera compared to MMF (6 vs. 44, p&lt;0.0001) and
there were fewer patients who had at least one disease flare (8.1% vs. 41.3%).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Laboratory evaluations</i></p>

<p class=MsoNormal style='page-break-after:avoid'>By week 52, a total of 20/63
(31.7%) (19 treatment-induced and 1 treatment-enhanced) MabThera -treated PV
patients tested positive for ADA. There was no apparent negative impact of the
presence of ADA on safety or efficacy in PV Study 2.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adult Non&#8209;Hodgkins
lymphoma</span></u></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>Based on a population pharmacokinetic
analysis in 298 NHL patients who received single or multiple infusions of
MabThera as a single agent or in combination with CHOP therapy (applied
MabThera doses ranged from 100 to 500&nbsp;mg/m<sup>2</sup>), the typical
population estimates of nonspecific clearance (CL<sub>1</sub>), specific
clearance (CL<sub>2</sub>) likely contributed by B cells or tumour burden, and
central compartment volume of distribution (V<sub>1</sub>) were 0.14 L/day,
0.59 L/day, and 2.7 L, respectively. The estimated median terminal elimination
half&#8209;life of MabThera was 22 days (range, 6.1 to 52 days). Baseline CD19&#8209;positive
cell counts and size of measurable tumour lesions contributed to some of the
variability in CL<sub>2</sub> of MabThera in data from 161 patients given
375&nbsp;mg/m<sup>2</sup> as an intravenous infusion for 4 weekly doses.
Patients with higher CD19&#8209;positive cell counts or tumour lesions had a
higher CL<sub>2</sub>. However, a large component of inter&#8209;individual
variability remained for CL<sub>2</sub> after correction for CD19&#8209;positive
cell counts and tumour lesion size. V<sub>1</sub> varied by body surface area
(BSA) and CHOP therapy. This variability in V<sub>1</sub> (27.1% and 19.0%)
contributed by the range in BSA (1.53 to 2.32&nbsp;m<sup>2</sup>) and
concurrent CHOP therapy, respectively, were relatively small. Age, gender and
WHO performance status had no effect on the pharmacokinetics of MabThera. This
analysis suggests that dose adjustment of MabThera with any of the tested
covariates is not expected to result in a meaningful reduction in its
pharmacokinetic variability.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera, administered as an intravenous
infusion at a dose of 375&nbsp;mg/m<sup>2</sup> at weekly intervals for 4 doses
to 203 patients with NHL naive to MabThera, yielded a mean C<sub>max</sub>
following the fourth infusion of 486&nbsp;g/mL (range, 77.5 to
996.6&nbsp;g/mL). Rituximab was detectable in the serum of patients 3  6
months after completion of last treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Upon administration of MabThera at a dose
of 375&nbsp;mg/m<sup>2</sup> as an intravenous infusion at weekly intervals for
8 doses to 37 patients with NHL, the mean C<sub>max</sub> increased with each
successive infusion, spanning from a mean of 243&nbsp;g/mL (range, 16 
582&nbsp;g/mL) after the first infusion to 550&nbsp;g/mL (range, 171 
1177&nbsp;g/mL) after the eighth infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic profile of MabThera
when administered as 6 infusions of 375&nbsp;mg/m<sup>2</sup> in combination
with 6 cycles of CHOP chemotherapy was similar to that seen with MabThera
alone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric DLBCL/BL/BAL/BLL </span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In </span><span lang=EN-GB>the clinical
trial studying paediatric DLBCL/BL/BAL/BLL, the PK was studied in a subset of
35 patients aged 3 years and older. The PK was comparable between the two age
groups (</span><span lang=EN-GB style='font-family:Symbol'>&#8805;</span><span
lang=EN-GB>3 to </span><span lang=EN-GB style='font-family:Symbol'>&lt;</span><span
lang=EN-GB>12 years vs. </span><span lang=EN-GB style='font-family:Symbol'>&#8805;</span><span
lang=EN-GB>12 to &lt;18 years). After two MabThera IV infusions of
375&nbsp;mg/m<sup>2</sup> in each of the two induction cycles (cycle 1 and 2)
followed by one MabThera IV infusion of 375&nbsp;mg/m<sup>2</sup> in each of
the consolidation cycles (cycle 3 and 4) the maximum concentration was highest
after the fourth infusion (cycle 2) with a geometric mean of 347&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>g/mL followed by
lower geometric mean maximum concentrations thereafter (Cycle&nbsp;4: 247&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>g/mL). With this
dose regimen, trough levels were sustained (geometric means: 41.8&nbsp;g/mL
(pre-dose Cycle&nbsp;2; after 1 cycle), 67.7&nbsp;g/mL (pre-dose Cycle&nbsp;3,
after 2&nbsp;cycles) and 58.5&nbsp;g/mL (pre-dose Cycle&nbsp;4, after 3
cycles)). The median elimination half-life in paediatric patients aged 3 years
and older was 26&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The PK characteristics of MabThera in
paediatric patients with DLBCL/BL/BAL/BLL were similar to what has been
observed in adult NHL patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No PK data
are available in the &#8805; 6 months to &lt; 3 years age group, however,
population PK prediction<a name="_2s8eyo1"></a> supports comparable systemic
exposure (AUC, Ctrough) in this age group compared to &#8805; 3 years (Table 24).
Smaller baseline tumor size is related to higher exposure due to lower time
dependent clearance, however, systemic exposures impacted by different tumor
sizes remain in the range of exposure that was efficacious and had an
acceptable safety profile.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><a name="_17dp8vu"></a><b><span
lang=EN-GB>Table 24: Predicted PK Parameters following the Rituximab Dosing
Regimen in Paediatric DLBCL/BL/BAL/BLL</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=604
 style='border-collapse:collapse;border:none'>
 <tr style='height:24.55pt'>
  <td width=135 style='width:101.4pt;border:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Age group</span></b></p>
  </td>
  <td width=156 style='width:117.3pt;border:solid black 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt;height:24.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#8805; 6 mo to &lt; 3 years</span></b></p>
  </td>
  <td width=156 style='width:117.3pt;border:solid black 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt;height:24.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#8805; 3 to &lt; 12 years</span></b></p>
  </td>
  <td width=156 style='width:117.35pt;border:solid black 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:24.55pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#8805; 12 to &lt; 18 years</span></b></p>
  </td>
 </tr>
 <tr style='height:19.85pt'>
  <td width=135 style='width:101.4pt;border:solid black 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=MsoNormal><span lang=EN-GB>C<sub>trough </sub>(g/mL)</span></p>
  </td>
  <td width=156 style='width:117.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>47.5
  (0.01-179)</span></p>
  </td>
  <td width=156 style='width:117.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>51.4
  (0.00-182)</span></p>
  </td>
  <td width=156 style='width:117.35pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>44.1
  (0.00-149)</span></p>
  </td>
 </tr>
 <tr style='height:31.2pt'>
  <td width=135 style='width:101.4pt;border:solid black 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt;height:31.2pt'>
  <p class=MsoNormal><span lang=EN-GB>AUC<sub>1-4 cycles</sub> (g*day/mL)</span></p>
  </td>
  <td width=156 style='width:117.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:31.2pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>13501
  (278-31070)</span></p>
  </td>
  <td width=156 style='width:117.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:31.2pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11609
  (135-31157)</span></p>
  </td>
  <td width=156 style='width:117.35pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:31.2pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11467
  (110-27066)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='font-size:9.0pt'>Results are presented as median (min  max); C<sub>trough</sub>
is pre-dose Cycle 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Chronic lymphocytic leukaemia</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>MabThera was administered as an intravenous
infusion at a </span><span lang=EN-GB>first&#8209;cycle </span><span
lang=EN-GB>dose of 375&nbsp;mg/m<sup>2</sup> </span><span lang=EN-GB>increased
to 500&nbsp;</span><span lang=EN-GB>mg/m<sup>2</sup> </span><span lang=EN-GB>each
cycle</span><span lang=EN-GB> for </span><span lang=EN-GB>5</span><span
lang=EN-GB> doses in combination with fludarabine and cyclophosphamide </span><span
lang=EN-GB>in</span><span lang=EN-GB> </span><span lang=EN-GB>CL</span><span
lang=EN-GB>L patients. The mean C<sub>max</sub> </span><span lang=EN-GB>(N=15)</span><span
lang=EN-GB> </span><span lang=EN-GB>was</span><span lang=EN-GB> </span><span
lang=EN-GB>408</span><span lang=EN-GB>&nbsp;g/mL (range, </span><span
lang=EN-GB>9</span><span lang=EN-GB>7  7</span><span lang=EN-GB>64</span><span
lang=EN-GB>&nbsp;g/mL) after the </span><span lang=EN-GB>fifth</span><span
lang=EN-GB> </span><span lang=EN-GB>500&nbsp;mg/</span><span lang=EN-GB>m<sup>2</sup></span><span
lang=EN-GB> </span><span lang=EN-GB>infusion and the mean terminal half&#8209;life
was 32 days (range, 14  62 days).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Rheumatoid
arthritis </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Following two intravenous infusions of
MabThera at a dose of 1000&nbsp;mg, two weeks apart, the mean terminal half&#8209;life
was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23
L/day (range, 0.091 to 0.67 L/day), and mean steady&#8209;state distribution
volume was 4.6 l (range, 1.7 to 7.51&nbsp;L). Population pharmacokinetic
analysis of the same data gave similar mean values for systemic clearance and
half&#8209;life, 0.26 L/day and 20.4 days, respectively. Population
pharmacokinetic analysis revealed that BSA and gender were the most significant
covariates to explain inter&#8209;individual variability in pharmacokinetic
parameters. After adjusting for BSA, male subjects had a larger volume of
distribution and a faster clearance than female subjects. The gender&#8209;
related pharmacokinetic differences are not considered to be clinically
relevant and dose adjustment is not required. No pharmacokinetic data are
available in patients with hepatic or renal impairment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of rituximab were assessed
following two intravenous (IV) doses of 500 mg and&nbsp;1000&nbsp;mg on Days 1
and 15 in four studies. In all these studies, rituximab pharmacokinetics were
dose proportional over the limited dose&nbsp;range studied. Mean C<sub>max</sub>
for serum rituximab following first infusion ranged from 157 to 171 </span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL for 2 x 500
mg dose and ranged from 298 to 341 </span><span lang=EN-GB style='font-family:
Symbol'>m</span><span lang=EN-GB>g/mL for 2 x 1000 mg dose. Following second
infusion, mean C<sub>max</sub> ranged&nbsp;from 183 to 198 </span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL for the
2&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span>&nbsp;500&nbsp;mg
dose and&nbsp;ranged from 355 to 404&nbsp;<span lang=EN-GB style='font-family:
Symbol'>m</span><span lang=EN-GB>g/mL for the 2&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;1000&nbsp;mg dose.
Mean terminal elimination half&#8209;life ranged from 15 to 16 days for the 2 x
500 mg dose group and 17 to 21&nbsp;days for the&nbsp;2&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;1000&nbsp;mg
dose group. Mean C<sub>max</sub> was 16 to 19% higher following second infusion
compared to the first infusion for both doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of rituximab were
assessed following two IV doses of 500 mg and&nbsp;1000 mg upon re&#8209;treatment
in the second course. Mean C<sub>max</sub> for serum rituximab following first
infusion was 170 to 175 </span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/mL for 2 x 500 mg dose and 317 to 370 </span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL for 2 x 1000 mg dose.
C<sub>max</sub> following second infusion, was 207 </span><span lang=EN-GB
style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL for the 2 x 500 mg
dose and ranged from 377 to 386 </span><span lang=EN-GB style='font-family:
Symbol'>m</span><span lang=EN-GB>g/mL for the 2 x 1000 mg dose. Mean terminal
elimination half&#8209;life after the second infusion, following the second
course, was 19 days for 2 x 500 mg dose and ranged from 21 to&nbsp;22 days for
the 2 x 1000 mg dose. PK&nbsp;parameters for rituximab were comparable over the
two treatment courses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic (PK) parameters in the
anti&#8209;TNF inadequate responder population, following the same dosage regimen
(2 x 1000&nbsp;mg, IV, 2 weeks apart), were similar with a mean maximum serum
concentration of 369&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/mL and a mean terminal half&#8209;life of 19.2 days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Granulomatosis
with polyangiitis (GPA) and microscopic polyangiitis (MPA)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Adult
Population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Based on the population pharmacokinetic
analysis of data in 97 patients with granulomatosis with polyangiitis and
microscopic polyangiitis who received 375 mg/m<sup>2</sup> MabThera once weekly
for four doses, the estimated median terminal elimination half&#8209;life was
23 days (range, 9 to 49 days). Rituximab mean clearance and volume of
distribution were 0.313 L/day (range, 0.116 to 0.726 L/day) and 4.50 L (range
2.25 to 7.39 L) respectively. </span>Maximum concentration during the first 180
days (C<sub>max</sub>), minimum concentration at Day 180 (C180) and Cumulative
area under the curve over 180 days (AUC180) were (median [range]) 372.6
(252.3-533.5) g/mL, 2.1 (0-29.3) g/mL and 10302 (3653-21874)g/mL*days,
respectively. <span lang=EN-GB>The PK parameters of rituximab in adult GPA and
MPA patients appear similar to what has been observed in rheumatoid arthritis
patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
Population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Based on the
population pharmacokinetic analysis of 25 children </span><span lang=EN-GB>(6-17
years old) </span><span lang=EN-GB>with GPA and MPA who received 375 mg/m<sup>2</sup>
MabThera once weekly for four doses, the estimated median terminal elimination
half&#8209;life was 22 days (range, 11 to 42 days). Rituximab mean clearance
and volume of distribution were 0.221 L/day (range, 0. 0996 to 0.381 L/day) and
2.27 L (range 1.43 to 3.17 L) respectively. </span>Maximum concentration during
the first 180 days (C<sub>max</sub>), minimum concentration at Day 180 (C180)
and Cumulative area under the curve over 180 days (AUC180) were (median
[range]) 382.8 (270.6-513.6) g/mL, 0.9 (0-17.7) g/mL and 9787 (4838-20446)
g/mL*day, respectively.<span lang=EN-GB>The PK parameters of rituximab in
paediatric patients with GPA or MPA were similar to those in adults with GPA or
MPA, once taking into account the BSA effect on clearance and volume of
distribution parameters.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pemphigus vulgaris</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The PK parameters in adult PV patients
receiving MabThera 1000&nbsp;mg at Days 1, 15, 168, and 182 are summarized in
Table 25.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 25</span></b><b><span lang=EN-GB> Population
PK in adult PV patients from PV Study 2 </span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=546
 style='width:409.25pt;border-collapse:collapse;border:none'>
 <tr style='height:22.0pt'>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Parameter</span></p>
  </td>
  <td width=349 colspan=2 valign=top style='width:262.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Infusion
  Cycle</span></p>
  </td>
 </tr>
 <tr style='height:48.6pt'>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1st
  cycle of 1000 mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Day
  1 and Day 15</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>N=67</span></p>
  </td>
  <td width=151 valign=top style='width:113.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2nd
  cycle of 1000 mg Day 168 and Day 182</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>N=67</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Terminal
  Half-life (days)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Median</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(Range)</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>21.0</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(9.3-36.2)</span></p>
  </td>
  <td width=151 valign=top style='width:113.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>26.5</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(16.4-42.8)</span></p>
  </td>
 </tr>
 <tr style='height:21.85pt'>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Clearance
  (L/day)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Mean</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(Range)</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>391</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(159-1510)</span></p>
  </td>
  <td width=151 valign=top style='width:113.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.85pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>247</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(128-454)</span></p>
  </td>
 </tr>
 <tr style='height:31.75pt'>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Central
  Volume of Distribution (L)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Mean</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(Range)</span></p>
  </td>
  <td width=198 valign=top style='width:148.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3.52</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(2.48-5.22)</span></p>
  </td>
  <td width=151 valign=top style='width:113.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:12.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>3.52</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(2.48-5.22)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Following
the first two rituximab administrations (at day 1 and 15, corresponding to
cycle 1), the PK parameters of rituximab in patients with PV were similar to
those in patients with GPA/MPA and patients with RA. Following the last two administrations
(at day 168 and 182, corresponding to cycle 2), rituximab clearance decreased
while the central volume of distribution remained unchanged.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rituximab
has shown to be highly specific to the CD20 antigen on B&nbsp;cells. Toxicity
studies in cynomolgus monkeys have shown no other effect than the expected
pharmacological depletion of B&nbsp;cells in peripheral blood and in lymphoid
tissue. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Developmental toxicity studies have been
performed in cynomolgus monkeys at doses up to 100&nbsp;mg/kg (treatment on
gestation days 20&#8209;50) and have revealed no evidence of toxicity to the
foetus due to rituximab. However, dose&#8209;dependent pharmacologic depletion
of B&nbsp;cells in the lymphoid organs of the foetuses was observed</span><span
lang=EN-GB>, which persisted post natally and was accompanied by a decrease in
IgG level in the newborn animals affected. B cell counts returned to normal in
these animals within 6 months of birth and did not compromise the reaction to
immunisation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Standard tests to investigate mutagenicity
have not been carried out, since such tests are not relevant for this molecule.
</span><span lang=EN-GB>No long&#8209;term animal studies have been performed
to establish the carcinogenic potential of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>Specific studies to determine the effects
of rituximab on fertility have not been performed. In general toxicity studies
in cynomolgus monkeys no deleterious effects on reproductive organs in males or
females were observed. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sodium
citrate</span> (E331)</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Polysorbate
80</span> (E433)</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sodium
chloride</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sodium
hydroxide (for pH adjustment) (E524)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hydrochloric
acid (for pH adjustment) (E507)</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No incompatibilities
between MabThera and polyvinyl chloride or polyethylene bags or infusion sets
have been observed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>36 months</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Diluted medicinal product</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>After aseptic dilution in sodium
chloride solution</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>The prepared
infusion solution of MabThera in 0.9% sodium chloride solution is physically
and chemically stable for 30 days at 2&nbsp;C&nbsp;&#8209;&nbsp;8&nbsp;C plus
an additional 24 hours at &#8804; 30&nbsp;C. </span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>After aseptic dilution in D-glucose
solution</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>The prepared
infusion solution of MabThera in 5% D-glucose solution is physically and
chemically stable for 24&nbsp;hours at 2 C - 8 C plus an additional 12 hours
at room temperature.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, the
prepared infusion solution should be used immediately. If not used immediately,
in&#8209;use storage times and conditions prior to use are the responsibility
of the user and would normally not be longer than 24 hours at 2&nbsp;C 
8&nbsp;C, unless dilution has taken place in controlled and validated aseptic
conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C 
8&nbsp;C). Keep the container in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>For storage
conditions after dilution of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>MabThera 100 mg concentrate for solution
for infusion</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Clear Type I glass vials with butyl rubber
stopper containing 100&nbsp;mg of rituximab in 10&nbsp;mL. Pack of 2 vials.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>MabThera 500 mg concentrate for solution
for infusion </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Clear Type I glass vials with butyl rubber
stopper containing 500 mg of rituximab in 50 mL. Pack of 1 vial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6 Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is provided in sterile, preservative&#8209;free,
non&#8209;pyrogenic, single use vials.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Use sterile needle and syringe to prepare
MabThera. Aseptically withdraw the necessary amount of MabThera, and dilute to
a calculated concentration of 1&nbsp;to 4&nbsp;mg/mL rituximab into an infusion
bag containing sterile, pyrogen&#8209;free </span><span lang=EN-GB>sodium
chloride 9&nbsp;mg/mL (0.9%) solution for injection</span><span lang=EN-GB> or
5% D&#8209;Glucose in water. For mixing the solution, gently invert the bag in
order to avoid foaming. Care must be taken to ensure the sterility of prepared
solutions. Since the medicinal product does not contain any anti&#8209;microbial
preservative or bacteriostatic agents, aseptic technique must be observed.
Parenteral medicinal products should be inspected visually for particulate
matter and discolouration prior to administration. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>MabThera 100 mg concentrate for solution
for infusion</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/98/067/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>MabThera 500 mg concentrate for solution
for infusion </span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/98/067/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>Date of first
authorisation: </span><span lang=EN-GB>2 June 1998 </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:"TimesNewRoman,Italic",serif'>Date of latest renewal:</span><span
lang=EN-GB> 2 June 2008</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:"TimesNewRoman,Italic",serif'>Detailed information on this
medicinal product is available on the website of the European Medicines Agency
(EMA) http://www.ema.europa.eu/</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:"TimesNewRoman,Italic",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400&nbsp;mg solution for
subcutaneous injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Each mL contains 120&nbsp;mg of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contain<b>s</b> 1400&nbsp;mg/11.7
mL rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab is a genetically engineered
chimeric mouse/human monoclonal antibody representing a glycosylated
immunoglobulin with human IgG1 constant regions and murine light&#8209;chain
and heavy&#8209;chain variable region sequences. The antibody is produced by
mammalian (Chinese hamster ovary) cell suspension culture and purified by
affinity chromatography and ion exchange, including specific viral inactivation
and removal procedures. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Solution for injection</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Clear to
opalescent, colourless to yellowish liquid with pH of 5.2  5.8 and osmolality
of 300 - 400 mOsmol/kg.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is indicated in adults for </span><span
lang=EN-GB>Non&#8209;Hodgkins lymphoma (NHL)</span><span lang=EN-GB>: </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera is
indicated for the treatment of previously untreated patients with stage III&#8209;IV
follicular lymphoma in combination with chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera
maintenance therapy is indicated for the treatment of follicular lymphoma
patients responding to induction therapy.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera is
indicated for the treatment of patients with CD20 positive diffuse large
B&nbsp;cell non&#8209;Hodgkins lymphoma in combination with </span><span
lang=EN-GB>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)</span><span
lang=EN-GB> chemotherapy<span style='layout-grid-mode:line'>. </span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera </span><span lang=EN-GB>should be
administered under the close supervision of an experienced </span><span
lang=EN-GB>healthcare professional</span><span lang=EN-GB>, and in an
environment where full resuscitation facilities are immediately available (see
section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Premedication consisting of an anti&#8209;pyretic
and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be
given before each administration of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Premedication with glucocorticoids should
be considered if MabThera is not given in combination with glucocorticoid&#8209;containing
chemotherapy.<b> </b></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera</span><span
lang=EN-GB> </span><span lang=EN-GB>subcutaneous formulation used for </span><span
lang=EN-GB>adult</span><span lang=EN-GB> patients is a subcutaneous injection
at a fixed dose of 1400&nbsp;mg irrespective of the patients body surface
area. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Before
starting MabThera subcutaneous injections, a</span><span lang=EN-GB>ll patients
must always receive beforehand, a full dose of MabThera by </span><span
lang=EN-GB>intravenous infusion, using MabThera intravenous formulation (see
section 4.4).</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If patients
were not able to receive one full MabThera intravenous infusion dose prior to
the switch, they should continue the subsequent cycles with MabThera
intravenous formulation until a full intravenous dose is successfully
administered. </span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore, the switch to MabThera
subcutaneous formulation can only occur at the second or subsequent cycles of
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important to check the medicinal
product labels to ensure that the appropriate formulation (intravenous or
subcutaneous formulation) and strength is being given to the patient, as
prescribed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera </span><span
lang=EN-GB>subcutaneous formulation </span><span lang=EN-GB>is not intended for
intravenous administration and should be given via subcutaneous injection only.
The 1400 mg strength is intended for subcutaneous use in </span><span
lang=EN-GB style='layout-grid-mode:line'>non Hodgkin lymphoma</span><span
lang=EN-GB> (NHL) only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Follicular non&#8209;Hodgkin's lymphoma</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Combination therapy</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera in
combination with chemotherapy for induction treatment of previously untreated
or relapsed/ refractory patients with follicular lymphoma is: </span><span
lang=EN-GB>first cycle with MabThera </span><span lang=EN-GB>intravenous
formulation</span><span lang=EN-GB> </span><span lang=EN-GB>375&nbsp;mg/m<sup>2</sup>
body surface area, </span><span lang=EN-GB>followed by subsequent cycles with
MabThera subcutaneous formulation injected at a fixed dose of 1400&nbsp;mg per
cycle </span><span lang=EN-GB>for up to 8cycles.</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>MabThera should
be administered on day 1 of each chemotherapy cycle, after administration of
the glucocorticoid component of the chemotherapy if applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Maintenance therapy</span></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB> Previously untreated follicular lymphoma</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>The recommended
dose of MabThera </span><span lang=EN-GB>subcutaneous formulation </span><span
lang=EN-GB>used as a maintenance treatment for patients with previously
untreated follicular lymphoma who have responded to induction treatment is: </span></p>

<p class=MsoNormal><span lang=EN-GB>1400&nbsp;mg once </span><span lang=EN-GB>every
2 </span><span lang=EN-GB>months (starting 2 months after the last dose of
induction therapy) until disease</span><span lang=EN-GB> progression or for a
maximum period of two years (12 administrations in total)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB> Relapsed/refractory follicular lymphoma</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>The recommended
dose of MabThera </span><span lang=EN-GB>subcutaneous formulation </span><span
lang=EN-GB>used as a maintenance treatment for patients with
relapsed/refractory follicular lymphoma who have responded to induction
treatment is:</span></p>

<p class=MsoNormal><span lang=EN-GB>1400&nbsp;mg </span><span lang=EN-GB>once
every 3 months </span><span lang=EN-GB>(starting 3 months after the last dose
of induction therapy)</span><span lang=EN-GB> until disease progression or for
a maximum period of two years (8 administrations in total). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Diffuse large B&nbsp;cell non&#8209;Hodgkin's
lymphoma</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>MabThera should
be used in combination with CHOP chemotherapy. The recommended dose is: </span><span
lang=EN-GB>first cycle, MabThera </span><span lang=EN-GB>intravenous
formulation:</span><span lang=EN-GB> </span><span lang=EN-GB>375&nbsp;mg/m<sup>2</sup>
body surface area, </span><span lang=EN-GB>followed by</span><span lang=EN-GB> </span><span
lang=EN-GB>subsequent cycles with MabThera subcutaneous formulation injected at
a fixed dose of 1400&nbsp;mg per cycle. In total: </span><span lang=EN-GB>8
cycles.</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>MabThera is
administered on day 1 of each chemotherapy cycle after intravenous infusion of
the glucocorticoid component of CHOP.</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Safety and efficacy of <span
style='layout-grid-mode:line'>MabThera have not been established in combination
with other chemotherapies in diffuse large B cell non&#8209;Hodgkins lymphoma.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><u><span lang=EN-GB>Dose
adjustments during treatment</span></u></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>No dose reductions of MabThera are recommended. When MabThera is
given in combination with</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>chemotherapy, standard dose reductions for the chemotherapeutic
medicinal products should be</span></p>

<p class=MsoNormal><span lang=EN-GB>applied (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of MabThera in
children below 18 years has not been established. No data are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required in elderly
patients (aged &gt;65 years). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Subcutaneous injections:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400 mg </span><span lang=EN-GB>subcutaneous
formulation </span><span lang=EN-GB>should be administered as subcutaneous
injection only, </span><span lang=EN-GB>over approximately 5 minutes. </span><span
lang=EN-GB>The hypodermic injection needle must only be attached to the syringe
immediately prior to administration to avoid potential needle clogging.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera subcutaneous formulation should be
injected subcutaneously into the abdominal wall and never into areas where the
skin is red, bruised, tender, hard or areas where there are moles or scars.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:#222222'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>No
data are available on performing the injection in other sites of the body,
therefore injections should be restricted to the abdominal wall.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the treatment course with MabThera </span><span
lang=EN-GB>subcutaneous formulation</span><span lang=EN-GB>, other medicinal
products for subcutaneous administration should preferably be given at
different sites.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If an injection
is interrupted it can be resumed at the same site or another location may be
used, if appropriate.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Intravenous
infusion administration:</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>The Summary of Product Characteristics
(SmPC) of MabThera100&nbsp;mg and 500&nbsp;mg concentrate for solution for
infusion should be referred to for information on dosing instructions and
method of administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to </span><span lang=EN-GB>murine proteins, hyaluronidase or to any of the
other excipients listed in section 6</span><span lang=EN-GB>.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Active, severe infections (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Patients in a severely immunocompromised state.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve traceability of
biological medicinal products,&nbsp;the tradename&nbsp;and batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
information provided in the section 4.4 pertains to the use of MabThera
subcutaneous formulation in the approved indications <i>Treatment of non-Hodgkins
lymphoma (strength 1400 mg) and Treatment of Chronic Lymphocytic Leukaemia </i>(strength
1600 mg). For information related to the other indications, please refer to the
SmPC of MabThera intravenous formulation. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The use of MabThera subcutaneous
formulation as monotherapy in patients with stage III&#8209;IV follicular
lymphoma who are chemoresistant or are in their second or subsequent relapse
after chemotherapy cannot be recommended as the safety of the once weekly subcutaneous</span><span
lang=EN-GB> </span><span lang=EN-GB>administration has not been established.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Progressive multifocal leukoencephalopathy</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Use of MabThera may be associated with an
increased risk of progressive multifocal leukoencephalopathy (PML). Patients
must be monitored at regular intervals for any new or worsening neurological
symptoms or signs that may be suggestive of PML. If PML is suspected, further
dosing must be suspended until PML has been excluded. The clinician should
evaluate the patient to determine if the symptoms are indicative of
neurological dysfunction, and if so, whether these symptoms are possibly
suggestive of PML. Consultation with a neurologist should be considered as
clinically indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any doubt exists, further evaluation,
including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing
for JC Viral DNA and repeat neurological assessments, should be considered. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The physician should be particularly alert to symptoms suggestive of
PML that the patient may not notice (e.g. cognitive, neurological or
psychiatric symptoms). </span><span lang=EN-GB>Patients should also be advised
to inform their partner or caregivers about their treatment, since they may
notice symptoms that the patient is not aware of.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If a patient develops PML, the dosing of
MabThera must be permanently discontinued. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following reconstitution of the immune
system in immunocompromised patients with PML, stabilisation or improved
outcome has been seen. It remains unknown if early detection of PML and
suspension of MabThera therapy may lead to similar stabilisation or improved
outcome.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Infusion/Administration&#8209;related
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is associated with
infusion/administration&#8209;related reactions, which may be related to
release of cytokines and/or other chemical mediators. Cytokine release syndrome
may be clinically indistinguishable from acute hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This set of reactions which includes
syndrome of cytokine release, tumor lysis syndrome and anaphylactic and
hypersensitivity reactions are described below. They are not specifically
related to the route of administration of MabThera and can be observed with
both formulations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe infusion&#8209;related reactions
with fatal outcome have been reported during post&#8209;marketing use of the
MabThera intravenous formulation, with an onset ranging within 30 minutes to 2
hours after starting the first MabThera intravenous infusion. They were
characterized by pulmonary events and in some cases included rapid tumour lysis
and features of tumour lysis syndrome in addition to fever, chills, rigors,
hypotension, urticaria, angioedema and other symptoms (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe cytokine release syndrome is
characterised by severe dyspnea, often accompanied by bronchospasm and hypoxia,
in addition to fever, chills, rigors, urticaria, and angioedema. This syndrome
may be associated with some features of tumour lysis syndrome such as
hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal
failure, elevated lactate dehydrogenase (LDH) and may be associated with acute
respiratory failure and death. The acute respiratory failure may be accompanied
by events such as pulmonary interstitial infiltration or oedema, visible on a
chest X&#8209;ray. The syndrome frequently manifests itself within one or two hours
of initiating the first infusion. Patients with a history of pulmonary
insufficiency or those with pulmonary tumour infiltration may be at greater
risk of poor outcome and should be treated with increased caution. Patients who
develop severe cytokine release syndrome should have their infusion interrupted
immediately (see section 4.2) and should receive aggressive symptomatic
treatment. Since initial improvement of clinical symptoms may be followed by
deterioration, these patients should be closely monitored until tumour lysis
syndrome and pulmonary infiltration have been resolved or ruled out. Further
treatment of patients after complete resolution of signs and symptoms has
rarely resulted in repeated severe cytokine release syndrome. </span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
with a high tumour burden or with a high number (&#8805;25 x 10<sup>9</sup>/L)
of circulating malignant cells, who may be at higher risk of especially severe
cytokine release syndrome, should be treated with extreme caution. These
patients should be very closely monitored throughout the first infusion.
Consideration should be given to the use of a reduced infusion rate for the
first infusion in these patients or a split dosing over two days during the
first cycle</span><span lang=EN-GB> and any subsequent cycles if the lymphocyte
count is still &gt;25 x 10<sup>9</sup>/L</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anaphylactic and other hypersensitivity
reactions have been reported following the intravenous administration of
proteins to patients. In contrast to cytokine release syndrome, true
hypersensitivity reactions typically occur within minutes after starting
infusion. Medicinal products for the treatment of hypersensitivity reactions,
e.g., epinephrine (adrenaline), antihistamines and glucocorticoids, should be
available for immediate use in the event of an allergic reaction during
administration of MabThera. Clinical manifestations of anaphylaxis may appear
similar to clinical manifestations of the cytokine release syndrome (described
above). Reactions attributed to hypersensitivity have been reported less
frequently than those attributed to cytokine release.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additional reactions reported in some cases
were myocardial infarction, atrial fibrillation, pulmonary oedema and acute
reversible thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Since
hypotension may occur during MabThera administration, consideration should be
given to withholding anti&#8209;hypertensive medicines 12 hours prior to giving
MabThera.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion
related adverse reactions of all kinds have been observed in 77% of patients
treated with MabThera intravenous formulation (including cytokine release
syndrome accompanied by hypotension and bronchospasm in 10&nbsp;% of patients)
see section 4.8. These symptoms are usually reversible with interruption of
MabThera infusion and administration of an anti&#8209;pyretic, an
antihistaminic, and, occasionally, oxygen, intravenous saline or bronchodilators,
and glucocorticoids if required. Please see cytokine release syndrome above for
severe reactions.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration related reactions have been observed
in up to 50% of patients treated with MabThera subcutaneous formulation in
clinical trials. The reactions occurring within 24 hours of the subcutaneous
injection consisted primarily of erythema pruritus, rash and injections site
reactions such as pain, swelling and redness and were generally of mild or
moderate (grade 1 or 2) and transient nature (see section 4.8).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Local cutaneous reactions were very common
in patients receiving MabThera subcutaneous in clinical trials. Symptoms
included pain, swelling, induration, haemorrhage, erythema, pruritus and rash
(see section 4.8). Some local cutaneous reactions occurred more than 24 hours
after the </span><span lang=EN-GB>MabThera subcutaneous </span><span
lang=EN-GB>administration. The majority of local cutaneous reactions seen
following administration of MabThera subcutaneous formulation was mild or
moderate and resolved without any specific treatment</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:#222222;background:white'>Before starting MabThera subcutaneous
injections, all patients must always receive beforehand, a full dose of
MabThera by intravenous infusion, using MabThera intravenous formulation. The
highest risk of experiencing an administration related reaction is generally
observed at cycle one. Beginning the therapy with MabThera intravenous infusion
would allow a better handling of the administration reactions by slowing or
stopping the intravenous infusion.&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If patients were not able to receive one
full MabThera intravenous infusion dose prior to the switch, they should
continue the subsequent cycles with MabThera intravenous formulation until a
full intravenous dose is successfully administered. Therefore, the switch to
MabThera subcutaneous formulation can only occur at the second or subsequent
cycles of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with the intravenous formulation,
MabThera </span><span lang=EN-GB>subcutaneous formulation </span><span
lang=EN-GB>should be administered in an environment where full resuscitation
facilities are immediately available and under the close supervision of an
experienced healthcare professional. Premedication consisting of an
analgesic/antipyretic and an antihistamine should always be administered before
each dose of MabThera </span><span lang=EN-GB>subcutaneous formulation</span><span
lang=EN-GB>. Premedication with glucocorticoids should also be considered.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:#222222;background:white'>Patients
should be observed for at least 15 minutes following MabThera subcutaneous
administration.&nbsp;A longer period may be appropriate in&nbsp;patients with
an increased risk of hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:#222222'>Patients should be
instructed to contact their treating physician immediately if symptoms that are
suggestive of severe hypersensitivity or cytokine release syndrome occur at any
time after medicinal product administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Cardiac disorders</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Angina pectoris, cardiac arrhythmias<b> </b>such
as atrial flutter and fibrillation, heart failure and/or myocardial infarction
have occurred in patients treated with MabThera. Therefore patients with a
history of cardiac disease and/or cardiotoxic chemotherapy should be monitored
closely.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Haematological toxicities</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Although MabThera is not myelosuppressive
in monotherapy, caution should be exercised when considering treatment of
patients with neutrophils &lt;&nbsp;1.5 x 10<sup>9</sup>/L and/or platelet
counts &lt;&nbsp;75 x 10<sup>9</sup>/L as clinical experience in this
population is limited<i>. </i>The MabThera intravenous formulation has been
used in 21 patients who underwent autologous bone marrow transplantation and
other risk groups with a presumable reduced bone marrow function without
inducing myelotoxicity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular full blood counts, including
neutrophil and platelet counts, should be performed during MabThera therapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Serious infections, including fatalities,
can occur during therapy with MabThera</span><span lang=EN-GB> (see section
4.8).</span><b><i><span lang=EN-GB style='font-family:"Times New Roman Bold"'> </span></i></b><span
lang=EN-GB>MabThera should not be administered to patients with an active,
severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see
section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Physicians should exercise caution when
considering the use of MabThera in patients with a history of recurring or
chronic infections or with underlying conditions which may further predispose
patients to serious infection (see section 4.8). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of hepatitis B reactivation have been
reported in patients receiving the MabThera intravenous formulation including
fulminant hepatitis with fatal outcome. The majority of these patients were
also exposed to cytotoxic chemotherapy</span><span lang=EN-GB>.</span><span
lang=EN-GB> </span><span lang=EN-GB>Hepatitis B virus (HBV) screening should be
performed in all patients before initiation of treatment with MabThera. At
minimum this should include HBsAg&#8209;status and HBcAb&#8209;status. These
can be complemented with other appropriate markers as per local guidelines.
Patients with active hepatitis B disease should not be treated with MabThera.
Patients with positive hepatitis B serology (either HBsAg or HBcAb) should
consult liver disease experts before start of treatment and should be monitored
and managed following local medical standards to prevent hepatitis B
reactivation.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare cases of PML have been reported
during post&#8209;marketing use of </span><span lang=EN-GB>the MabThera
intravenous formulation</span><span lang=EN-GB> in NHL (see section 4.8). The
majority of patients had received rituximab in combination with chemotherapy or
as part of a hematopoietic stem cell transplant. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immunisation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety of immunisation with </span><span
lang=EN-GB>live viral vaccines, following MabThera therapy has not been studied
for NHL patients<i> </i>and vaccination with live virus vaccines is not
recommended. Patients treated with MabThera may receive non&#8209;live
vaccinations; however, with non&#8209;live vaccines response rates may be
reduced. In a non&#8209;randomized study, patients with relapsed low&#8209;grade
NHL who received </span><span lang=EN-GB>the MabThera intravenous formulation
as </span><span lang=EN-GB>monotherapy when compared to healthy untreated
controls had a lower rate of response to vaccination with tetanus recall
antigen (16% vs. 81%) and Keyhole Limpet Haemocyanin (KLH) neoantigen (4% vs.
69% when assessed for &gt;2&#8209;fold increase in antibody titer). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mean pre&#8209;therapeutic antibody titers
against a panel of antigens (Streptococcus pneumoniae, influenza A, mumps,
rubella and varicella) were maintained for at least 6 months after treatment
with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Skin
reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe skin
reactions such as Toxic Epidermal Necrolysis (Lyells Syndrome) and Stevens &#8209;
Johnson syndrome, some with fatal outcome, have been reported<i> </i>(see
section 4.8).<i> </i>In case of such an event, with suspected relationship to
MabThera, treatment should be permanently discontinued.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Currently,
there are limited data on possible drug interactions with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co&#8209;administration with MabThera </span><span
lang=EN-GB>did not appear to have an</span><span lang=EN-GB> effect on the
pharmacokinetics of fludarabine </span><span lang=EN-GB>or</span><span
lang=EN-GB> cyclophosphamide. In addition, there was no apparent effect of
fludarabine and cyclophosphamide on the pharmacokinetics of </span><span
lang=EN-GB>MabThera</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with human anti&#8209;mouse
antibody (HAMA) or anti-drug antibody (ADA) titres may have allergic or
hypersensitivity reactions when treated with other diagnostic or therapeutic
monoclonal antibodies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></b></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Contraception in males and females</span></u></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Due to the long retention time of rituximab
in B cell depleted patients, women of childbearing potential must employ
effective contraceptive methods during and for 12 months after treatment with
MabThera.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>IgG immunoglobulins are known to cross the
placental barrier.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>B&#8209;cell levels in human neonates
following maternal exposure to MabThera have not been studied in clinical
trials. There are no adequate and well&#8209;controlled data from studies in
pregnant women, however transient B&#8209;cell depletion and lymphocytopenia
have been reported in some infants born to mothers exposed to MabThera during
pregnancy. Similar effects have been observed in animal studies (see section
5.3).For these reasons MabThera should not be administered to pregnant women
unless the possible benefit outweighs the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Whether rituximab is excreted in human milk
is not known. However, because maternal IgG is excreted in human milk, and
rituximab was detectable in milk from lactating monkeys, </span><span
lang=EN-GB>women should not breastfeed while treated with MabThera and for 12
months following MabThera treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Animal studies did not reveal deleterious
effects of rituximab or recombinant human hyaluronidase (rHuPH20) on
reproductive organs.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No studies on the effects of MabThera on
the ability to drive and use machines have been performed, although the
pharmacological activity and adverse reactions reported to date suggest that
MabThera would have no or negligible influence on the ability to drive and use
machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
information provided in this section pertains to the use of MabThera in
oncology. </span></p>

<p class=MsoNormal><span lang=EN-GB>For information related to the autoimmune
indications, please refer to the SmPC of MabThera intravenous formulation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the development programme, the
safety profile of MabThera subcutaneous formulation was comparable to that of
the intravenous formulation with the exception of local cutaneous reactions. </span></p>

<p class=MsoNormal><span lang=EN-GB>Local cutaneous reactions, including </span><span
lang=EN-GB>injection site reactions</span><span lang=EN-GB> were very common in
patients receiving MabThera </span><span lang=EN-GB>subcutaneous formulation</span><span
lang=EN-GB>. In the phase 3 SABRINA trial (BO22334), local cutaneous reaction
were reported in up to 20% of patients receiving subcutaneous MabThera. The
most common local cutaneous reactions in the Mabthera subcutaneous arm were
injection erythema (13%), injection pain (7%) and injection site oedema (4%).Events
seen following subcutaneous administration were mild or moderate, apart from
one patient who reported a local cutaneous reaction of Grade 3 intensity
(injection site rash) following the first MabThera subcutaneous administration
(Cycle 2). </span><span lang=EN-GB>Local cutaneous reactions of any grade in
the MabThera subcutaneous arm were most common during the first subcutaneous
cycle (Cycle 2), followed by the second, and the incidence decreased with
subsequent injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adverse reactions reported in
MabThera subcutaneous formulation usage</span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The risk of acute administration&#8209;related
reactions associated with the subcutaneous formulation of MabThera was assessed
in two open&#8209;label trials involving patients with follicular lymphoma
during induction and maintenance (SABRINA/BO22334) and during maintenance only
(SparkThera/BP22333). </span><span lang=EN-GB>In</span><span lang=EN-GB>SABRINA</span><span
lang=EN-GB>, severe administration&#8209;related reactions (grade&#8805;3) were
reported in two patients (2%) following administration of MabThera </span><span
lang=EN-GB>subcutaneous formulation. These events were Grade 3 injection site
rash and dry mouth. </span><span lang=EN-GB>In</span><span lang=EN-GB>SparkThera</span><span
lang=EN-GB>, no severe administration&#8209;related reactions were reported.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adverse reactions reported in
MabThera intravenous formulation usage</span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Experience from non&#8209;Hodgkins
lymphoma and chronic lymphocytic leukaemia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall safety profile of MabThera in
non&#8209;Hodgkins lymphoma and CLL is based on data from patients from
clinical trials and from post&#8209;marketing surveillance. These patients were
treated either with MabThera monotherapy (as induction treatment or maintenance
treatment following induction treatment) or in combination with chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently observed adverse
reactions (ADRs) in patients receiving MabThera were infusion&#8209;related
reactions which occurred in the majority of patients during the first infusion.
The incidence of infusion&#8209;related symptoms decreases substantially with
subsequent infusions and is less than 1&nbsp;% after eight doses of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>Infectious events (predominantly bacterial
and viral) occurred in approximately 30&#8209;55&nbsp;% of patients during
clinical trials in patients with NHL and in 30&#8209;50&nbsp;% of patients
during clinical trial in patients with CLL.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequent reported or observed
serious adverse reactions were:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infusion&#8209;related
reactions (including cytokine&#8209;release syndrome, tumour&#8209;lysis
syndrome), see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infections,
see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Cardiovascular
disorders, see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other serious ADRs reported include
hepatitis B reactivation and PML (see section 4.4.).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The frequencies of ADRs reported with
MabThera alone or in combination with chemotherapy are summarised in Table 1.
Frequencies are defined as very common (</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> 1/10), common &nbsp;(</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;1/100 to
&lt;&nbsp;1/10), uncommon &nbsp;(</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>&nbsp; 1/1,000 to &lt; 1/100), rare (</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> 1/10,000 to
&lt; 1/1000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated
from the available data). Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ADRs identified only during post&#8209;marketing
surveillance, and for which a frequency could not be estimated, are listed
under not known.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1 ADRs reported in clinical trials
or during postmarketing surveillance in patients with NHL and CLL disease
treated with MabThera monotherapy/maintenance or in combination with
chemotherapy </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="13%" style='width:13.78%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>MedDRA System Organ Class</span></b></p>
   </td>
   <td width="14%" style='width:14.7%;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Common</span></b></p>
   </td>
   <td width="15%" style='width:15.52%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Common</span></b></p>
   </td>
   <td width="14%" style='width:14.68%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Uncommon</span></b></p>
   </td>
   <td width="11%" style='width:11.12%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Rare</span></b></p>
   </td>
   <td width="14%" style='width:14.66%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Rare</span></b></p>
   </td>
   <td width="15%" style='width:15.56%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Infections and
  infestations</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>bacterial
  infections, viral infections, <sup>+</sup>bronchitis </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>sepsis, <sup>+</sup>pneumonia,
  <sup>+</sup>febrile infection, <sup>+</sup>herpes zoster, <sup>+</sup>respiratory
  tract infection, fungal infections, infections of unknown aetiology, <sup>+</sup>acute
  bronchitis, <sup>+</sup>sinusitis,</span><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'> h</span><span lang=EN-GB style='font-size:9.0pt'>epatitis
  B</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>1</span></sup><sup><span
  lang=EN-GB style='font-size:9.0pt'> </span></sup></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>serious viral infection<sup>2</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Blood and
  lymphatic system disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>neutropenia,
  leucopenia, <sup>+</sup>febrile neutropenia, <sup>+</sup>thrombocytopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>anaemia, </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>pancytopenia, <sup>+</sup>granulocytopenia</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>coagulation
  disorders, aplastic anaemia, haemolytic anaemia, lymphadenopathy</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>transient
  increase in serum IgM levels</span><sup><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'>3</span></sup></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>late neutropenia<sup>3</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Immune system
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion related reactions<sup>4</sup>,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>angioedema</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hypersensitivity</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>anaphylaxis</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>tumour lysis syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cytokine release syndrome<sup>4</sup>, serum sickness</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion&#8209;related acute reversible thrombocytopenia&nbsp;<sup>4</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hyperglycaemia,
  weight decrease, peripheral oedema, face oedema, increased LDH, hypocalcaemia</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Psychiatric
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>depression,
  nervousness,</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Nervous system
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>paraesthesia,
  hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>dysgeusia</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>peripheral neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>facial nerve palsy<sup>5</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cranial neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>loss of other senses<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Eye disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lacrimation
  disorder, conjunctivitis</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe vision loss<sup>5</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Ear and
  labyrinth disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>tinnitus, ear
  pain</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>hearing loss<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Cardiac
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>myocardial infarction</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>, arrhythmia, <sup>+</sup>atrial
  fibrillation, tachycardia, <sup>+</sup>cardiac disorder</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>left ventricular failure, <sup>+</sup>supraventricular
  tachycardia, <sup>+</sup>ventricular tachycardia, <sup>+</sup>angina, <sup>+</sup>myocardial
  ischaemia, bradycardia</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>severe cardiac
  disorders </span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>4 and 6</span></sup></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>heart failure</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Vascular
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertension, orthostatic hypotension, hypotension<sup>
  </sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>vasculitis (predominately cutaneous),</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>leukocytoclastic vasculitis</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Bronchospasm</span><sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>4</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>, respiratory disease, chest pain, dyspnoea,
  increased cough, rhinitis</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>asthma,
  bronchiolitis obliterans, lung disorder, hypoxia</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>interstitial lung disease<sup>7</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>respiratory failure<sup>4</sup>,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lung infiltration</span><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>, </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>nausea<sup> </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>vomiting<sup> </sup>, diarrhoea, abdominal pain,
  dysphagia, stomatitis, constipation, dyspepsia, anorexia, throat irritation</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>abdominal
  enlargement</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>gastro&#8209;intestinal perforation<sup>7</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>pruritis, rash, <sup>+</sup>alopecia<sup>
  </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>urticaria,
  sweating, night sweats, <sup>+</sup>skin disorder</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe bullous skin reactions,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>Stevens&#8209;Johnson Syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>toxic epidermal necrolysis (Lyells Syndrome)<sup> 7</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Musculoskeletal, connective tissue disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertonia, myalgia, arthralgia, back pain, neck
  pain, pain</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Renal and urinary disorders</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>renal failure<sup>4</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>General
  disorders and administration site conditions</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>fever<sup> </sup>,
  chills, asthenia, headache<sup> </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>tumour pain, flushing, malaise, cold syndrome, <sup>+</sup>fatigue,
  <sup>+</sup>shivering, </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
  style='font-size:9.0pt'>+</span></sup><span lang=EN-GB style='font-size:9.0pt'>multi&#8209;organ
  failure</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>4</span></sup></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>infusion site
  pain</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="13%" valign=top style='width:13.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Investigations</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>decreased IgG levels</span></p>
  </td>
  <td width="15%" valign=top style='width:15.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="99%" colspan=7 valign=top style='width:99.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>For each term,
  the frequency count was based on reactions of all grades (from mild to
  severe), except for terms marked with &quot;+&quot; where the frequency count
  was based only on severe (&#8805; grade 3 NCI common toxicity criteria)
  reactions. &nbsp;Only the highest frequency observed in the trials is
  reported</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>1</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes reactivation and primary
  infections; frequency based on R&#8209;FC regimen in relapsed/refractory CLL</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>2</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infection below </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>3</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section haematologic adverse
  reactions below</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>4</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infusion&#8209;related
  reactions below. Rarely fatal cases reported</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>5</span></sup><b><span lang=EN-GB
  style='font-size:9.0pt'> </span></b><span lang=EN-GB style='font-size:9.0pt'>signs
  and symptoms of cranial neuropathy. Occurred at various times up to several
  months after completion of MabThera therapy</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>6</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> observed mainly in patients with prior cardiac
  condition and/or cardiotoxic chemotherapy and were mostly associated with
  infusion&#8209;related reactions</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>7</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes fatal cases</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following terms have been reported as
adverse events during clinical trials, however, were reported at a similar or
lower incidence in the MabThera&#8209;arms compared to control arms:
haematotoxicity, neutropenic infection, urinary tract infection, sensory
disturbance, pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Signs and symptoms suggestive of an infusion&#8209;related
reaction were reported in more than 50&nbsp;% of patients in clinical trials
involving MabThera intravenous formulation, and were predominantly seen during
the first infusion, usually in the first one to two hours. These symptoms
mainly comprised fever, chills and rigors. Other symptoms included flushing,
angioedema, bronchospasm, vomiting, nausea, urticaria/rash, fatigue, headache,
throat irritation, rhinitis, pruritus, pain, tachycardia, hypertension,
hypotension, dyspnoea, dyspepsia, asthenia and features of tumour lysis
syndrome. Severe infusion&#8209;related reactions (such as bronchospasm,
hypotension) occurred in up to 12&nbsp;% of the cases. Additional reactions
reported in some cases were myocardial infarction, atrial fibrillation,
pulmonary oedema</span><span lang=EN-GB> and acute reversible thrombocytopenia</span><span
lang=EN-GB>. Exacerbations of pre&#8209;existing cardiac conditions such as
angina pectoris or congestive heart failure or <span style='layout-grid-mode:
line'>severe cardiac disorders (heart failure, myocardial infarction, </span>atrial
fibrillation<span style='layout-grid-mode:line'>), </span>pulmonary oedema,
multi&#8209;organ failure<span style='layout-grid-mode:line'>, tumour lysis
syndrome, cytokine release syndrome, renal failure, and respiratory failure
were reported </span>at lower or unknown frequencies. The incidence of infusion&#8209;related
symptoms decreased substantially with subsequent intravenous infusions and is &lt;1%
of patients by the eighth cycle of MabThera (containing) treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Infections </span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera induces B&#8209;cell depletion in
about 70&#8209;80% of patients, but was associated with decreased serum
immunoglobulins only in a minority of patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Localized
candida infections as well as Herpes zoster were reported at a higher incidence
in the MabThera&#8209;containing arm of randomized studies. </span><span
lang=EN-GB>Severe infections were reported in about 4% of patients treated with
MabThera monotherapy. </span><span lang=EN-GB>Higher frequencies of infections
overall, including grade 3 or 4 infections, were observed during MabThera
maintenance treatment up to 2 years when compared to observation. </span><span
lang=EN-GB>There was no cumulative toxicity in terms of infections reported
over a 2&#8209;year treatment period</span><span lang=EN-GB>. In addition,
other serious viral infections either new, reactivated or exacerbated, some of
which were fatal, have been reported with MabThera treatment. The majority of
patients had received MabThera in combination with chemotherapy or as part of a
hematopoietic stem cell transplant. Examples of these serious viral infections
are infections caused by the herpes viruses (Cytomegalovirus, Varicella Zoster
Virus and Herpes Simplex Virus), JC virus (PML) and hepatitis C virus. Cases of
fatal PML that occurred after disease progression and retreatment have also
been reported in clinical trials. C</span><span lang=EN-GB>ases of
hepatitis&nbsp;B reactivation, have been reported, the majority of which were
in patients receiving MabThera in combination with cytotoxic chemotherapy</span><span
lang=EN-GB>. </span><span lang=EN-GB>Progression of Kaposis sarcoma has been
observed in MabThera&#8209;exposed patients with pre&#8209;existing Kaposis
sarcoma. These cases occurred in non&#8209;approved indications and the
majority of patients were HIV positive.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Haematologic
adverse reactions<b> </b></span></i></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials with MabThera
monotherapy given for 4 weeks, haematological abnormalities occurred in a
minority of patients and were usually mild and reversible. Severe (grade&nbsp;3/4)
neutropenia was reported in 4.2%, anaemia in 1.1% and thrombocytopenia in 1.7%
of the patients. During<u> </u>MabThera maintenance treatment for up to 2
years, leucopoenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade
3/4) were reported at a higher incidence when compared to observation. The
incidence of thrombocytopenia was low (&lt;1&nbsp;%, grade&nbsp;3/4) and was
not different between treatment arms. During the treatment course in studies
with MabThera in combination with chemotherapy, </span><span lang=EN-GB>grade&nbsp;3/4
leucopoenia (R&#8209;CHOP 88% vs. CHOP 79%), neutropenia (R&#8209;CVP 24% vs.
CVP 14%; R&#8209;CHOP 97% vs. CHOP 88%), were usually reported with higher
frequencies when compared to chemotherapy alone. However, the higher incidence
of neutropenia in patients treated with MabThera and chemotherapy was not
associated with a higher incidence of infections and infestations compared to
patients treated with chemotherapy alone. </span><span lang=EN-GB>There were no
differences reported for the incidence of anaemia.</span><span lang=EN-GB> </span><span
lang=EN-GB>Some c</span><span lang=EN-GB>ases of late </span><span lang=EN-GB>neutropenia
occurring more than four weeks after the last infusion of MabThera were
reported. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>In studies of MabThera in patients with Waldenstroms
macroglobulinaemia, transient increases in serum IgM levels have been observed
following treatment initiation, which may be associated with hyperviscosity and
related symptoms. The transient IgM increase usually returned to at least
baseline level within 4 months</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cardiovascular adverse reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cardiovascular reactions during clinical
trials with MabThera monotherapy were reported in 18.8% of patients with the
most frequently reported events being hypotension and hypertension. Cases of
grade 3 or 4 arrhythmia (including ventricular and supraventricular
tachycardia) and angina pectoris during infusion were reported. </span><span
lang=EN-GB>During maintenance treatment, the incidence of grade&nbsp;3/4
cardiac disorders was comparable between patients treated with MabThera and
observation. Cardiac events were reported as serious adverse events (including
atrial fibrillation, myocardial infarction, left ventricular failure,
myocardial ischemia) in 3% of patients treated with MabThera compared to &lt;1%
on observation. In studies evaluating MabThera in combination with chemotherapy,
</span><span lang=EN-GB>the incidence of grade 3 and 4 cardiac arrhythmias,
predominantly supraventricular arrhythmias such as tachycardia and atrial
flutter/fibrillation, was higher in the R&#8209;CHOP group (14 patients, 6.9%)
as compared to the CHOP group (3 patients, 1.5%). All of these arrhythmias
either occurred in the context of a MabThera infusion or were associated with
predisposing conditions such as fever, infection, acute myocardial infarction
or pre&#8209;existing respiratory and cardiovascular disease. No difference
between the R&#8209;CHOP and CHOP group was observed in the incidence of other
grade 3 and 4 cardiac events including heart failure, myocardial disease and
manifestations of coronary artery disease</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Respiratory
system</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cases of
interstitial lung disease, some with fatal outcome have been reported.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Neurologic
disorders</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>During the
treatment period <b>(</b></span><span lang=EN-GB>induction treatment phase
comprising of R&#8209;CHOP for at most eight cycles)</span><span lang=EN-GB>,
four patients (2&nbsp;%) treated with R&#8209;CHOP, all with cardiovascular
risk factors, experienced thromboembolic cerebrovascular accidents during the
first treatment cycle. There was no difference between the treatment groups in
the incidence of other thromboembolic events. In contrast, three patients
(1.5%) had cerebrovascular events in the CHOP group, all of which occurred
during the follow&#8209;up period. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cases of </span><span
lang=EN-GB>posterior reversible encephalopathy syndrome (PRES) / reversible
posterior leukoencephalopathy syndrome (RPLS)</span><span lang=EN-GB> have been
reported.</span><span lang=EN-GB> Signs and symptoms included visual
disturbance, headache, seizures and altered mental status, with or without
associated hypertension. A diagnosis of PRES/RPLS requires confirmation by
brain imaging. The reported cases had recognized risk factors for PRES/RPLS,
including the patients underlying disease, hypertension, immunosuppressive
therapy and/or chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gastrointestinal perforation in some cases
leading to death has been observed in patients receiving MabThera for treatment
of Non&#8209;Hodgkins lymphoma (NHL). In the majority of these cases, MabThera
was administered with chemotherapy. </span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>IgG
levels</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the clinical trial evaluating MabThera
maintenance treatment in relapsed/refractory follicular lymphoma, median IgG
levels were below the lower limit of normal (LLN) (&lt;&nbsp;7 g/L) after
induction treatment in both the observation and the MabThera groups. In the
observation group, the median IgG level subsequently increased to above the
LLN, but remained constant in the MabThera group. The proportion of patients
with IgG levels below the LLN was about 60% in the MabThera group throughout
the 2 year treatment period, while it decreased in the observation group (36%
after 2&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Toxic Epidermal Necrolysis (Lyell Syndrome)
and Stevens&#8209;Johnson syndrome, some with fatal outcome, have been reported
very rarely.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>Patient
subpopulations &#8209; MabThera monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Elderly (</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65 years): </span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of ADRs of all grades and
grade 3 /4 ADR was similar in elderly patients compared to younger patients
(&lt;65 years). </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bulky
disease:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>There was a
higher incidence of grade 3/4 ADRs in patients with bulky disease than in
patients without bulky disease (25.6&nbsp;% vs. 15.4&nbsp;%). The incidence of
ADRs of any grade was similar in these two groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Re&#8209;treatment:</span></p>

<p class=MsoNormal><span lang=EN-GB>The percentage of patients reporting ADRs
upon re&#8209;treatment with further courses of MabThera was similar to the
percentage of patients reporting ADRs upon initial exposure (any grade and
grade 3/4 ADRs).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB
style='color:blue'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Limited experience
with doses higher than the approved dose of intravenous MabThera formulation is
available from clinical trials in humans. The highest intravenous dose of
MabThera tested in humans to date is 5000&nbsp;mg (2250&nbsp;mg/m<sup>2</sup>),
tested in a dose escalation study in patients with CLL. No additional safety
signals were identified.</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who experience overdose should
have immediate interruption of their infusion and be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Three<b><i> </i></b>patients in the
MabThera subcutaneous formulation trial SABRINA (BO22334) were<b><i> </i></b>inadvertently
administered subcutaneous formulation through the intravenous route up to a
maximum rituximab dose of 2780 mg with no untoward effect.<u><span
style='color:red'> </span></u></span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who experience overdose or
medication error should be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the post&#8209;marketing setting five
cases of MabThera overdose have been reported. Three cases had no reported
adverse event. The two adverse events that were reported were flu&#8209;like
symptoms, with a dose of 1.8&nbsp;g of rituximab and fatal respiratory failure,
with a dose of 2&nbsp;g of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: antineoplastic agents<i>,</i> monoclonal antibodies, ATC code: L01X C02</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera subcutaneous formulation contains
recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the
dispersion and absorption of co&#8209;administered substances when administered
subcutaneously.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab binds specifically to the
transmembrane antigen, CD20, a non&#8209;glycosylated phosphoprotein, located
on pre&#8209;B and mature B lymphocytes. The antigen is expressed on </span><span
lang=EN-GB style='font-family:Symbol'>&gt;</span><span lang=EN-GB>95&nbsp;% of
all B&nbsp;cell non&#8209;Hodgkins lymphomas. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>CD20 is found on both normal and malignant
B&nbsp;cells, but not on haematopoietic stem cells, pro&#8209;B&nbsp;cells,
normal plasma cells or other normal tissue. This antigen does not internalise
upon antibody binding and is not shed from the cell surface. CD20 does not
circulate in the plasma as a free antigen and, thus, does not compete for
antibody binding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Fab domain of rituximab binds to the
CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector
functions to mediate B&nbsp;cell lysis. Possible mechanisms of effector&#8209;mediated
cell lysis include complement&#8209;dependent cytotoxicity (CDC) resulting from
C1q binding, and antibody&#8209;dependent cellular cytotoxicity (ADCC) mediated
by one or more of the Fc</span><span lang=EN-GB style='font-family:Symbol'>g</span><span
lang=EN-GB> receptors on the surface of granulocytes, macrophages and NK cells.
Rituximab binding to CD 20 antigen on B lymphocytes has also been demonstrated
to induce cell death via apoptosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Peripheral B&nbsp;cell counts declined
below normal following completion of the first dose of MabThera. In patients
treated for hematological malignancies, B cell recovery began within 6 months
of treatment and generally returned to normal levels within 12 months after
completion of therapy, although in some patients this may take longer </span><span
lang=EN-GB>(up to a median recovery time of 23 months post&#8209;induction
therapy)</span><span lang=EN-GB>. In rheumatoid arthritis patients, immediate
depletion of B cells in the peripheral blood was observed following two
infusions of 1000&nbsp;mg MabThera separated by a 14 day interval. Peripheral
blood B cell counts begin to increase from week 24 and evidence for
repopulation is observed in the majority of patients by week 40, whether
MabThera was administered as monotherapy or in combination with methotrexate.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
experience of MabThera subcutaneous formulation in Non&#8209;Hodgkins lymphoma</span></u></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The clinical
experience of MabThera subcutaneous formulation in Non&#8209;Hodgkins lymphoma
</span><span lang=EN-GB>is based on data from a phase III clinical trial
(SABRINA BO22334) in patients with follicular lymphoma (FL) and a phase Ib dose&#8209;finding/dose&#8209;confirmation
trial (SparkThera BP22333) in patients with FL. Results from trial BP22333 are
presented in section 5.2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Trial BO22334 (SABRINA)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A two&#8209;stage phase III, international,
multi&#8209;centre, randomised, controlled, open&#8209;label trial was
conducted in patients with previously untreated follicular lymphoma, to
investigate the non&#8209;inferiority of the pharmacokinetic profile, together
with efficacy and safety of </span><span lang=EN-GB>MabThera subcutaneous
formulation</span><span lang=EN-GB> in combination with CHOP or CVP versus </span><span
lang=EN-GB>MabThera intravenous formulation </span><span lang=EN-GB>in
combination with CHOP or CVP. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The objective of the first stage was to
establish the rituximab </span><span lang=EN-GB>subcutaneous </span><span
lang=EN-GB>dose that resulted in comparable </span><span lang=EN-GB>MabThera
subcutaneous formulation </span><span lang=EN-GB>serum C<sub>trough</sub>
levels compared with </span><span lang=EN-GB>MabThera intravenous formulation</span><span
lang=EN-GB>, when given as part of induction treatment every 3 weeks (see
section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>Stage 1 enrolled previously untreated
patients (n=127) CD20&#8209;positive, Follicular Lymphoma (FL) Grade 1, 2 or
3a.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The objective of stage 2 was to provide
additional efficacy and safety data for subcutaneous rituximab compared with
rituximab </span>intravenous<span lang=EN-GB> using the 1400 mg subcutaneous
dose established in stage 1. Previously untreated patients with CD20&#8209;positive,
Follicular Lymphoma Grade 1, 2 or 3a (n=283) were enrolled in the stage 2.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:aqua'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall trial design was identical
among both stages and patients were randomized into the following two treatment
groups:</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:aqua'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>MabThera subcutaneous formulation (n= 205): first cycle MabThera
intravenous formulation plus 7 cycles of MabThera subcutaneous formulation in
combination with up to 8 cycles of CHOP or CVP chemotherapy administered every
3 weeks.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:.15pt;text-autospace:
none'><span lang=EN-GB>MabThera intravenous formulation was used at the
standard dose of 375&nbsp;mg/m<sup>2</sup> body surface area.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:.15pt;text-autospace:
none'><span lang=EN-GB>MabThera subcutaneous formulation was given at a fixed
dose of 1400&nbsp;mg.</span></p>

<p class=MsoNormal style='text-indent:28.35pt;text-autospace:none'><span
lang=EN-GB>Patients achieving at least partial response (PR) were entered on
the MabThera subcutaneous  formulation maintenance therapy once every 8 weeks
for 24 months.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-10.5pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>MabThera intravenous formulation (n= 205): 8 cycles of MabThera
intravenous formulation in combination with up to 8 cycles of CHOP or CVP
chemotherapy administered every 3 weeks. </span></p>

<p class=MsoNormal style='margin-left:28.05pt;text-autospace:none'><span
lang=EN-GB>MabThera intravenous formulation was used at the standard dose of
375&nbsp;mg/m<sup>2</sup>.</span></p>

<p class=MsoNormal style='margin-left:28.05pt;text-autospace:none'><span
lang=EN-GB>Patients achieving at least PR were entered on MabThera intravenous
formulation maintenance therapy once every 8 weeks for 24 months.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:aqua'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><a name="_Ref382318091">Key
efficacy results for the pooled analysis of 410 patients in SABRINA stages 1
and 2 are shown in table 2.</a></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Table&nbsp;2 Efficacy
results for SABRINA (BO22334) (Intent to Treat Population)</b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='height:17.0pt'>
  <td width=272 colspan=2 rowspan=2 valign=top style='width:204.2pt;border:
  solid black 1.0pt;background:white;padding:.05in 7.8pt .05in 7.8pt;
  height:17.0pt'><a name="_Ref380743996"></a>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>&nbsp;</b></p>
  </td>
  <td width=327 colspan=2 style='width:245.5pt;border:solid black 1.0pt;
  border-left:none;background:white;padding:.05in 7.8pt .05in 7.8pt;height:
  17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Pooled Stages 1 &amp; 2</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>N = 410</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=153 style='width:114.75pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Rituximab intravenous formulation</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>(n = 205)</span></b></p>
  </td>
  <td width=174 style='width:130.75pt;border:solid black 1.0pt;border-left:
  none;background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Rituximab subcutaneous formulation</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>(n = 205)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE-CH
  style='color:black'>ORR<sup> a</sup></span></b></p>
  </td>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>Point estimate</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>84.9% (n = 174)</span></b></p>
  </td>
  <td width=174 valign=top style='width:130.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>84.4% (n = 173)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>95% CI</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>[79.2%, 89.5%]</span></b></p>
  </td>
  <td width=174 valign=top style='width:130.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>[78.7%, 89.1%]</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE-CH
  style='color:black'>CRR</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>Point estimate</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>31.7% (n = 65)</span></b></p>
  </td>
  <td width=174 valign=top style='width:130.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>32.2% (n = 66)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>95% CI</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>[25.4%, 38.6%]</span></b></p>
  </td>
  <td width=174 valign=top style='width:130.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>[25.9%, 39.1%]</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='color:black'>PFS<sup>b</sup></span></b></p>
  </td>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE-CH
  style='color:black'>Proportion with PFS event</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>34.6% (n = 71 )</span></b></p>
  </td>
  <td width=174 valign=top style='width:130.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='color:black'>31.7% ( n = 65)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=219 valign=top style='width:164.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Hazard ratio (95% CI)</span></b></p>
  </td>
  <td width=327 colspan=2 valign=top style='width:245.5pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>0.90 [0.64%, 1.26%]</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>ORR  Overall Response Rate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>CRR  Complete Response Rate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>PFS  Progression-Free Survival (proportion with event,
disease progression/relapse or death from any cause)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><sup><span lang=EN-GB
style='font-size:9.0pt'>a</span></sup></b><b><span lang=EN-GB style='font-size:
9.0pt'> </span></b><span lang=EN-GB style='font-size:9.0pt'> at end of
Induction</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><sup><span lang=EN-GB
style='font-size:9.0pt'>b</span></sup></b><span lang=EN-GB style='font-size:
9.0pt'>  at time of final analysis (median follow-up 58 months) </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Exploratory analyses showed response rates
among BSA, chemotherapy and gender subgroups were not notably different from
the ITT population.</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><i><span
lang=EN-GB>Immunogenicity</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Data from the development programme of
MabThera subcutaneous formulation indicate that the formation of anti&#8209;rituximab
antibodies after subcutaneous administration is comparable with that observed
after intravenous administration. In the SABRINA trial (BO22334) the incidence
of treatment&#8209;induced/enhanced anti&#8209;rituximab antibodies was low and
similar in the intravenous and subcutaneous groups (1.9% vs. 2%,
respectively). The incidence of treatment&#8209;induced/enhanced anti&#8209;rHuPH20
antibodies was 8% in the intravenous group compared with 15% in the
subcutaneous group, and none of the patients who tested positive for anti&#8209;rHuPH20
antibodies tested positive for neutralizing antibodies. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The overall
proportion of patients found to have anti&#8209;rHuPH20 antibodies remained
generally constant over the follow&#8209;up period in both cohorts. The
clinical relevance of the development of anti-rituximab antibodies or anti&#8209;rHuPH20
antibodies after treatment with MabThera subcutaneous formulation is not known.</span></p>

<p class=MsoNormal><span lang=EN-GB>There was no apparent impact of the
presence of anti&#8209;rituximab or anti&#8209;rHuPH20 antibodies on safety or
efficacy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical experience of MabThera
concentrate for solution for infusion in Non&#8209;Hodgkins lymphoma </span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Follicular lymphoma</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Initial treatment in combination with
chemotherapy</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In an open&#8209;label
randomised trial, a total of 322 previously untreated patients with follicular
lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide
750&nbsp;mg/m<sup>2</sup>, vincristine 1.4&nbsp;mg/m<sup>2</sup> up to a
maximum of 2&nbsp;mg on day 1, and prednisolone 40&nbsp;mg/m<sup>2</sup>/day on
days 1&nbsp;&#8209;5) every 3 weeks for 8 cycles or MabThera 375&nbsp;mg/m<sup>2</sup>
in combination with CVP (R&#8209;CVP). MabThera was administered on the first
day of each treatment cycle. A total of&nbsp;321 patients (162 R&#8209;CVP, 159
CVP) received therapy and were analysed for efficacy. The median follow up of
patients was 53 months. R&#8209;CVP led to a significant benefit over CVP for
the primary endpoint, time to treatment failure (27 months vs. 6.6 months, p
&lt;&nbsp;0.0001, log&#8209;rank test). The proportion of patients with a
tumour response (CR, CRu, PR) was significantly higher (p&lt;&nbsp;0.0001 Chi&#8209;Square
test) in the R&#8209;CVP group (80.9&nbsp;%) than the CVP group (57.2&nbsp;%). </span><span
lang=EN-GB>Treatment with R&#8209;CVP significantly prolonged the time to
disease progression or death compared to CVP, 33.6 months and 14.7 months,
respectively </span><span lang=EN-GB>(p &lt;&nbsp;0.0001, log&#8209;rank test)</span><span
lang=EN-GB>. </span><span lang=EN-GB>The median duration of response was 37.7
months in the R&#8209;CVP group and was 13.5 months in the CVP group (p
&lt;&nbsp;0.0001, log&#8209;rank test). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The difference between the treatment groups
with respect to overall survival showed a significant clinical difference
(p=0.029, log&#8209;rank test stratified by center): survival rates at 53
months were 80.9&nbsp;% for patients in the R&#8209;CVP group compared to
71.1&nbsp;% for patients in the CVP group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from three other randomized trials
using MabThera in combination with chemotherapy regimen other than CVP (CHOP, MCP,
CHVP/Interferon&#8209;&#945;) have also demonstrated significant improvements
in response rates, time&#8209;dependent parameters as well as in overall
survival. Key results from all four trials are summarized in table&nbsp;3. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;3 Summary of key results from four phase
III randomized trials evaluating the benefit of MabThera with different
chemotherapy regimens in follicular lymphoma</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>Trial</span></b></p>
   </td>
   <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Treatment,</span></b></p>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>N</span></b></p>
   </td>
   <td width=67 style='width:50.0pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
   FU, </span></b></p>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>months</span></b></p>
   </td>
   <td width=76 style='width:56.7pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>ORR, %</span></b></p>
   </td>
   <td width=85 style='width:63.8pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>CR,<br>
   %</span></b></p>
   </td>
   <td width=127 style='width:94.9pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>Median TTF/PFS/ EFS mo</span></b></p>
   </td>
   <td width=72 style='width:53.95pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
   avoid'><b><span lang=EN-GB>OS rates,<br>
   %</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>M39021</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>CVP, 159</span></p>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>R&#8209;CVP, 162</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>53</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>57</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>81</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>41</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median TTP:</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>14.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>33.6</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>P&lt;0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>53&#8209;months </span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>71.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>80.9</span></p>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>p=0.029</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>GLSG00</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>CHOP, 205<br>
  R&#8209;CHOP, 223</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>18</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>90<br>
  96</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>17<br>
  20</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median TTF: 2.6 years</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>Not reached<br>
  p &lt; 0.001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>18&#8209;months</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>90<br>
  95<br>
  p = 0.016</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>OSHO</span></b><b><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'>39</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>MCP, 96<br>
  R&#8209;MCP, 105</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>47</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>75<br>
  92</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>25 <br>
  50</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median PFS: 28.8</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>Not reached<br>
  p &lt; 0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>48&#8209;months</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>74 <br>
  87 <br>
  p = 0.0096</span></p>
  </td>
 </tr>
 <tr>
  <td width=88 style='width:66.3pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>FL2000</span></b></p>
  </td>
  <td width=88 style='width:66.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>CHVP&#8209;IFN, 183<br>
  R&#8209;CHVP&#8209;IFN, 175</span></p>
  </td>
  <td width=67 style='width:50.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>42</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>85 <br>
  94</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>49<br>
  76</span></p>
  </td>
  <td width=127 style='width:94.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Median EFS: 36 <br>
  Not reached</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>p &lt; 0.0001</span></p>
  </td>
  <td width=72 style='width:53.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>42&#8209;months</span></p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>84 <br>
  91<br>
  p = 0.029</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>EFS  Event Free Survival</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>TTP  Time to progression or death<br>
PFS  Progression&#8209;Free Survival<br>
TTF  Time to Treatment Failure<br>
OS rates  survival rates at the time of the analyses</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maintenance
therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Previously
untreated follicular lymphoma </span></i></p>

<p class=MsoNormal><span lang=EN-GB>In a prospective, open label,
international, multi&#8209;center, phase III trial 1193 patients with previously
untreated advanced follicular lymphoma received induction therapy with R&#8209;CHOP
(n=881), R&#8209;CVP (n=268) or R&#8209;FCM (n=44), according to the
investigators choice. A total of 1078 patients responded to induction therapy,
of which 1018 were randomized to MabThera maintenance therapy (n=505) or
observation (n=513). The two treatment groups were well balanced with regards
to baseline characteristics and disease status. MabThera maintenance treatment
consisted of a single infusion of MabThera at 375 mg/m2 body surface area given
every 2 months until disease progression or for a maximum period of two years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
pre-specified primary analysis was conducted at a median observation time of 25
months from randomization, maintenance therapy with MabThera resulted in a
clinically relevant and statistically significant improvement in the primary
endpoint of investigator assessed progression&#8209;free survival (PFS) as
compared to observation in patients with previously untreated follicular
lymphoma (Table 4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Significant benefit from maintenance
treatment with MabThera was also seen for the secondary endpoints event&#8209;free
survival (EFS), time to next anti&#8209;lymphoma treatment (TNLT) time to next
chemotherapy (TNCT) and overall response rate (ORR) in the primary analysis (Table
4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Data from extended follow-up of patients in the study
(median follow-up 9 years) confirmed the long-term benefit of MabThera
maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table 4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;4 Overview of efficacy results for
MabThera maintenance vs. observation at the protocol-defined primary analysis
and after 9 years median follow-up (final analysis)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=227 rowspan=2 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Primary analysis<br>
  (median FU: 25 months)</span></b></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Final analysis<br>
  (median FU: 9.0 years)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Observation<br>
  N=513</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>MabThera<br>
  N=505</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Observation<br>
  N=513</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>MabThera<br>
  N=505</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Primary
  efficacy</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Progression-free
  survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.06 years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10.49 years</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>log-rank p
  value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hazard
  ratio (95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>risk
  reduction</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.50 (0.39, 0.64)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.61 (0.52, 0.73)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Secondary
  efficacy</span></b></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall
  survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>log-rank p
  value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.7246</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.7948</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hazard
  ratio (95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>risk
  reduction</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.89 (0.45, 1.74)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.04 (0.77, 1.40)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>-6%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Event-free
  survival (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>38 months</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.04 years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.25 years</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>log-rank p
  value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hazard
  ratio (95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>risk
  reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.54 (0.43, 0.69)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>46%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.64 (0.54, 0.76)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>TNLT
  (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.11 years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>log-rank p
  value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0003</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hazard
  ratio (95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>risk
  reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.61 (0.46, 0.80)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.66 (0.55, 0.78)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>TNCT
  (median)</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.32 years</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NR</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>log-rank p
  value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0011</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hazard
  ratio (95% CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>risk
  reduction </span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.60 (0.44, 0.82)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>40%</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.71 (0.59, 0.86)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall
  response rate*</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>55%</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>74%</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61%</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>79%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>chi-squared
  test p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>odds ratio
  (95% CI)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.33 (1.73, 3.15)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.43 (1.84, 3.22)</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Complete
  response (CR/CRu) rate*</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48%</span></p>
  </td>
  <td width=98 valign=top style='width:73.45pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>67%</span></p>
  </td>
  <td width=98 valign=top style='width:73.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>53%</span></p>
  </td>
  <td width=98 valign=top style='width:73.3pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>67%</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>chi-squared
  test p value</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>odds ratio
  (95% CI)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.21 (1.65, 2.94)</span></p>
  </td>
  <td width=196 colspan=2 valign=top style='width:146.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.34 (1.80, 3.03) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>* at end of maintenance/observation; final analysis
results based on median follow-up of 73 months. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>FU: follow-up; NR: not reached at time of clinical cut
off, TNCT: time to next chemotherapy treatment; TNLT: time to next anti
lymphoma treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera maintenance treatment provided
consistent benefit in all predefined subgroups tested: gender (male, female),
age (&lt; 60 years, &gt;= 60 years), FLIPI score (&lt;=1, 2 or &gt;= 3),
induction therapy (R&#8209;CHOP, R&#8209;CVP or R&#8209;FCM) and regardless of
the quality of response to induction treatment (CR/CRu or PR). Exploratory
analyses of the benefit of maintenance treatment showed a less pronounced
effect in elderly patients (&gt; 70&nbsp;years of age), however sample sizes
were small.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Relapsed/Refractory
follicular lymphoma </span></i></p>

<p class=MsoNormal><span lang=EN-GB>In a prospective, open label,
international, multi&#8209;centre, phase III trial, 465 patients with
relapsed/refractory follicular lymphoma were randomised in a first step to
induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisolone; n=231) or MabThera plus CHOP (R&#8209;CHOP, n=234). The two
treatment groups were well balanced with regard to baseline characteristics and
disease status. A total of 334 patients achieving a complete or partial
remission following induction therapy were randomised in a second step to
MabThera maintenance therapy (n=167) or observation (n=167). MabThera
maintenance treatment consisted of a single infusion of MabThera at
375&nbsp;mg/m<sup>2</sup> body surface area given every 3 months until disease
progression or for a maximum period of two years. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The final efficacy analysis included all
patients randomized to both parts of the trial. After a median observation time
of 31 months for patients randomised to the induction phase, R&#8209;CHOP
significantly improved the outcome of patients with relapsed/refractory
follicular lymphoma when compared to CHOP (see Table&nbsp;5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;5 Induction phase: overview of
efficacy results for CHOP vs. R&#8209;CHOP (31 months median observation time) </span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=517
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=125 valign=top style='width:93.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=88 valign=top style='width:66.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>CHOP</span></b></p>
   </td>
   <td width=96 valign=top style='width:1.0in;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>R</span></b><b><span lang=EN-GB style='font-family:
   "Cambria Math",serif'>&#8209;</span></b><b><span lang=EN-GB>CHOP</span></b></p>
   </td>
   <td width=80 valign=top style='width:60.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>p</span></b><b><span lang=EN-GB style='font-family:
   "Cambria Math",serif'>&#8209;</span></b><b><span lang=EN-GB>value</span></b></p>
   </td>
   <td width=128 valign=top style='width:96.0pt;border-top:solid black 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Risk Reduction<sup>1)</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Primary
  efficacy </span></b></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>ORR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>74&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>87&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0003</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Na</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>CR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0005</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Na</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>PR<sup>2)</sup></span></p>
  </td>
  <td width=88 valign=top style='width:66.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>58&nbsp;%</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>58&nbsp;%</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.9449</span></p>
  </td>
  <td width=128 valign=top style='width:96.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Na</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
style='font-size:9.0pt'>1)</span></sup><span lang=EN-GB style='font-size:9.0pt'>
Estimates were calculated by hazard ratios</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>2)</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Last tumour response as assessed by the
investigator. The primary statistical test for response was the trend test
of CR versus PR versus non&#8209;response (p &lt;&nbsp;0.0001) </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Abbreviations: NA,
not available; ORR: overall response rate; CR: complete response; PR: partial
response</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients randomized to the maintenance
phase of the trial, the median observation time was 28 months from maintenance
randomisation. Maintenance treatment with MabThera led to a clinically relevant
and statistically significant improvement in the primary endpoint, PFS, (time
from maintenance randomisation to relapse, disease progression or death) when
compared to observation alone (p&lt;&nbsp;0.0001 log&#8209;rank test).The
median PFS was 42.2 months in the MabThera maintenance arm compared to 14.3
months in the observation arm. Using a cox regression analysis, the risk of
experiencing progressive disease or death was reduced by 61&nbsp;% with
MabThera maintenance treatment when compared to observation (95&nbsp;% CI;
45&nbsp;%&#8209;72&nbsp;%). Kaplan&#8209;Meier estimated progression&#8209;free
rates at 12 months were 78&nbsp;% in the MabThera maintenance group vs.
57&nbsp;% in the observation group. An analysis of overall survival confirmed
the significant benefit of MabThera maintenance over observation (p=0.0039 log&#8209;rank
test). MabThera maintenance treatment reduced the risk of death by 56&nbsp;%
(95&nbsp;% CI; 22&nbsp;%&#8209;75&nbsp;%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;6 Maintenance phase: overview of
efficacy results MabThera vs. observation (28 months median observation time) </span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=574
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=207 rowspan=2 valign=top style='width:155.4pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Efficacy Parameter</span></b></p>
   </td>
   <td width=273 colspan=3 valign=top style='width:204.4pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Kaplan&#8209;Meier Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=94 rowspan=2 valign=top style='width:70.85pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Observation</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(N = 167)</span></b></p>
   </td>
   <td width=91 valign=top style='width:68.6pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>MabThera</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(N=167)</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Log&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Progression</span><span
  lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>free survival (PFS)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>14.3</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>42.2</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&lt;&nbsp;0.0001</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>61&nbsp;%</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall survival
  </span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0039</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>56&nbsp;%</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Time to
  new lymphoma treatment</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>20.1</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>38.8</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&lt;&nbsp;0.0001</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>50&nbsp;%</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Disease</span><span
  lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
  lang=EN-GB>free survival<sup>a</sup></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>16.5</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>53.7</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0003</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>67&nbsp;%</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Subgroup
  analysis</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR>PFS</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR>CHOP</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR>R&#8209;CHOP</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR>CR</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=PT-BR>PR</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=PT-BR><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=PT-BR><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT-BR>OS</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>CHOP</span></p>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>R&#8209;CHOP</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>11.6</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>22.1</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>14.3</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>14.3</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  </td>
  <td width=91 valign=top style='width:68.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>37.5</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>51.9</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>52.8</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>37.8</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>NR</span></i></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&lt;&nbsp;0.0001</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0071</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0008</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&lt;&nbsp;0.0001</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0348</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>0.0482</span></i></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>71&nbsp;%</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>46&nbsp;%</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>64&nbsp;%</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>54&nbsp;%</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>55&nbsp;%</span></i></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><i><span lang=EN-GB>56&nbsp;%</span></i></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>NR: not reached; <sup>a</sup>:
only applicable to patients achieving a CR</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The benefit of MabThera maintenance
treatment was confirmed in all subgroups analysed, regardless of induction
regimen (CHOP or R&#8209;CHOP) or quality of response to induction treatment
(CR or PR) (table&nbsp;6). MabThera maintenance treatment significantly
prolonged median PFS in patients responding to CHOP induction therapy (median
PFS 37.5 months vs. 11.6 months, p&lt;&nbsp;0.0001) as well as in those
responding to R&#8209;CHOP induction (median PFS 51.9 months vs. 22.1 months,
p=0.0071). Although subgroups were small, MabThera maintenance treatment
provided a significant benefit in terms of overall survival for both patients
responding to CHOP and patients responding to R&#8209;CHOP, although longer
follow&#8209;up is required to confirm this observation. </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=FR>Diffuse large
B&nbsp;cell non&#8209;Hodgkins lymphoma</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=FR><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In a
randomised, open&#8209;label trial, a total of 399&nbsp;previously untreated
elderly patients (age 60 to 80 years) with diffuse large B&nbsp;cell lymphoma
received standard CHOP chemotherapy (cyclophosphamide 750&nbsp;mg/m<sup>2</sup>,
doxorubicin 50&nbsp;mg/m<sup>2</sup>, vincristine 1.4&nbsp;mg/m<sup>2</sup> up
to a maximum of 2&nbsp;mg on day 1, and prednisolone 40&nbsp;mg/m<sup>2</sup>/day
on days 1&#8209;5) every 3 weeks for eight cycles, or MabThera 375&nbsp;mg/m<sup>2</sup>
plus CHOP (R&#8209;CHOP). MabThera was administered on the first day of the
treatment cycle. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The final efficacy analysis included all
randomised patients (197 CHOP, 202 R&#8209;CHOP),<span style='layout-grid-mode:
line'> and had a median follow&#8209;up duration of approximately 31 months. </span>The
two treatment groups were well balanced in baseline disease characteristics and
disease status. <span style='layout-grid-mode:line'>The final analysis</span>
confirmed that R&#8209;CHOP treatment was associated with a clinically relevant
and statistically significant improvement in the duration of event&#8209;free
survival (the primary efficacy parameter; where events were death, relapse or
progression of lymphoma, or institution of a new anti&#8209;lymphoma treatment)
(p = 0.0001). Kaplan Meier estimates of the median duration of event&#8209;free
survival were 35 months in the R&#8209;CHOP arm compared to 13 months in the
CHOP arm, representing a risk reduction of 41&nbsp;%. At 24 months, estimates
for overall survival were 68.2&nbsp;% in the R&#8209;CHOP arm compared to
57.4&nbsp;% in the CHOP arm. A subsequent analysis of the duration of overall
survival, carried out with a median follow&#8209;up duration of 60 months,
confirmed the benefit of R&#8209;CHOP over CHOP treatment (p=0.0071),
representing a risk reduction of 32&nbsp;%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The analysis of all secondary parameters
(response rates, progression&#8209;free survival, disease&#8209;free survival,
duration of response) verified the treatment effect of R&#8209;CHOP compared to
CHOP. The complete response rate after cycle 8 was 76.2&nbsp;% in the R&#8209;CHOP
group and 62.4&nbsp;% in the CHOP group (p=0.0028). The risk of disease
progression was reduced by 46&nbsp;% and the risk of relapse by 51&nbsp;%.</span></p>

<p class=MsoNormal><span lang=EN-GB>In all patients subgroups (gender, age, age
adjusted IPI, Ann Arbor stage, ECOG, &#946;2 microglobulin, LDH, albumin, B
symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk
ratios for event&#8209;free survival and overall survival (R&#8209;CHOP
compared with CHOP) were less than 0.83 and 0.95 respectively. R&#8209;CHOP was
associated with improvements in outcome for both high&#8209; and low&#8209;risk
patients according to age adjusted IPI.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical laboratory findings </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Of 67 patients evaluated for <span
style='text-transform:uppercase'>hama</span>, no responses were noted. Of
356&nbsp;patients evaluated for <span style='text-transform:uppercase'>ADA</span>,
1.1&nbsp;% (4 patients) were positive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with rituximab in all subsets
of the paediatric population with follicular lymphoma. See Section 4.2 for
information on paediatric use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab pharmacokinetics following single
dose administration of MabThera subcutaneous 375&nbsp;mg/m<sup>2</sup>, 625 mg/
m<sup>2</sup> and 800 mg/ m<sup>2</sup> were compared with MabThera intravenous
375 mg/ m<sup>2</sup> in FL patients. Following subcutaneous administration,
the absorption of rituximab is slow, reaching maximal concentrations about 3
days after administration. Based on popPK analysis an absolute bioavailability
of 71% was estimated. Rituximab exposure increased dose proportional over the
375&nbsp;mg/m<sup>2</sup> to 800 mg/m<sup>2</sup> subcutaneous dose range.
Pharmacokinetic parameters such as clearance, distribution volume, and
elimination half&#8209;life were comparable for both formulations.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Trial BP22333 (SparkThera)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A two&#8209;stage phase Ib trial to
investigate the pharmacokinetics, safety and tolerability of MabThera
subcutaneous formulation in patients with </span><span lang=EN-GB>follicular
lymphoma (FL)</span><span lang=EN-GB> as part of maintenance treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>In stage&nbsp;2, MabThera subcutaneous
formulation at a fixed dose of 1400&nbsp;mg was administered as subcutaneous
injection during maintenance treatment, after at least one cycle of </span><span
lang=EN-GB>MabThera intravenous formulation to</span><span lang=EN-GB> FL
patients who had previously responded to </span><span lang=EN-GB>MabThera
intravenous formulation</span><span lang=EN-GB> in induction.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The comparison of predicted median C<sub>max</sub>
data for MabThera subcutaneous formulation and </span><span lang=EN-GB>intravenous
formulation</span><span lang=EN-GB style='font-size:10.0pt'> </span><span
lang=EN-GB>are summarized in Table 7</span><span lang=EN-GB style='font-size:
10.0pt'>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 7:
Trial BP22333 (SparkThera): Absorption &#8209; Pharmacokinetic parameters of</span></b><b><span
lang=EN-GB> MabThera SC compared to MabThera IV</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='background:white;border-collapse:collapse;border:none'>
 <tr style='height:22.7pt'>
  <td width=168 valign=top style='width:125.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=100 valign=top style='width:75.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>MabThera </span><span lang=EN-GB style='color:black'>subcutaneous</span></p>
  </td>
  <td width=108 valign=top style='width:80.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>MabThera </span><span lang=EN-GB style='color:black'>intravenous</span></p>
  </td>
 </tr>
 <tr style='height:22.7pt'>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Predicted median C<sub>max</sub> (q2m) g/m</span><span
  lang=EN-GB style='color:black'>L</span></p>
  </td>
  <td width=100 valign=top style='width:75.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>201</span></p>
  </td>
  <td width=108 valign=top style='width:80.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>209</span></p>
  </td>
 </tr>
 <tr style='height:22.7pt'>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Predicted median C<sub>max</sub> (q3m) g/m</span><span
  lang=EN-GB style='color:black'>L</span></p>
  </td>
  <td width=100 valign=top style='width:75.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>189&nbsp;</span></p>
  </td>
  <td width=108 valign=top style='width:80.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>184</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The median T<sub>max</sub>
in the MabThera subcutaneous formulation was approximately 3 days as compared
to the T<sub>max</sub> occuring at or close to the end of the infusion for the </span><span
lang=EN-GB>intravenous formulation</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Trial BO22334 (SABRINA)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera subcutaneous formulation at a
fixed dose of 1400&nbsp;mg was administered for 6 cycles subcutaneously during
induction at 3&#8209;weekly intervals, following the first cycle of MabThera</span><span
lang=EN-GB> intravenous formulation</span><span lang=EN-GB>, in previously
untreated FL patients in combination with chemotherapy. The serum rituximab C<sub>max</sub>
at cycle&nbsp;7 was similar between the two treatment arms, with geometric mean
(CV%) values of 250.63 (19.01)&nbsp;&#956;g/mL and 236.82
(29.41)&nbsp;&#956;g/mL for the </span><span lang=EN-GB>intravenous </span><span
lang=EN-GB>and the subcutaneous formulations respectively, with the resulting
geometric mean ratio (C<sub>max,&nbsp;SC</sub>/C<sub>max,&nbsp;IV</sub>) of
0.941 (90%&nbsp;CI: 0.872, 1.015). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution/Elimination</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Geometric mean </span><span lang=EN-GB
style='font-size:10.0pt'>C<sub>trough</sub></span><span lang=EN-GB> and
geometric mean AUC</span><span lang=EN-GB style='color:#222222'>&#964;</span><span
lang=EN-GB> from the BP22333 and BO22334 trials are summarized in Table 8.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 8:
Distribution/Elimination &#8209; Pharmacokinetic parameters of MabThera
subcutaneous</span></b><b><span lang=EN-GB> compared to MabThera intravenous</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='background:white;border-collapse:collapse;border:none'>
 <tr style='height:17.0pt'>
  <td width=516 colspan=5 style='width:386.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Trial
  BP22333 (SparkThera)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean C<sub>trough</sub> (q2m) g/m</span><span
  lang=EN-GB style='color:black'>L</span><span lang=EN-GB style='color:black'> </span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean C<sub>trough</sub> (q3m) g/m</span><span
  lang=EN-GB style='color:black'>L</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean AUC</span><span lang=EN-GB
  style='color:#222222'>&#964;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sub><span lang=EN-GB
  style='color:black'>cycle 2 (q2m)</span></sub></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>g.day/m</span><span lang=EN-GB style='color:black'>L</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean AUC</span><span lang=EN-GB
  style='color:#222222'>&#964;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sub><span lang=EN-GB
  style='color:black'>cycle 2 (q3m)</span></sub></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>g.day/m</span><span lang=EN-GB style='color:black'>L</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>MabThera subcutaneous formulation</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>32.2</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>12.1</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>5430</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>5320</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>MabThera intravenous formulation</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>25.9&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>10.9&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>4012</span></p>
  </td>
  <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>3947</span></p>
  </td>
 </tr>
 <tr style='height:19.85pt'>
  <td width=516 colspan=5 style='width:386.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Trial BO22334 (SABRINA)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>C<sub>trough</sub> values at pre</span><span lang=EN-GB
  style='font-family:"Cambria Math",serif;color:black'>&#8209;</span><span
  lang=EN-GB style='color:black'>dose cycle 8</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>g/mL</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Geometric mean</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>AUC values at cycle 7</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>g.day/m</span><span lang=EN-GB style='color:black'>L</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>MabThera subcutaneous
  formulation</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>134.6&nbsp;</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>3778&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>MabThera intravenous
  formulation</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>83.1&nbsp;</span></p>
  </td>
  <td width=206 colspan=2 valign=top style='width:2.15in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>2734&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a population pharmacokinetic analysis in
403<b> </b>follicular lymphoma patients who received subcutaneous and/or
intravenous MabThera, single or multiple infusions of MabThera as a single
agent or in combination with chemotherapy, the population estimates of
nonspecific clearance (CL<sub>1</sub>), initial specific clearance (CL<sub>2</sub>)
likely contributed by B&nbsp;cells or tumour burden, and central compartment
volume of distribution (V<sub>1</sub>) were 0.194&nbsp;L/day, 0.535&nbsp;L/day,
and 4.37&nbsp;L/day, respectively. </span><span lang=EN-GB>The estimated median
terminal elimination half&#8209;life of MabThera subcutaneous formulation was
29.7&nbsp;days (range, 9.9 to 91.2&nbsp;days).The analysis data set contained
6003 quantifiable samples from 403 patients administered SC and/or IV rituximab
in trials BP22333 (3736 samples from 277 patients) and BO22334 (2267 samples
from126 patients). Twenty nine (0.48%) post&#8209;dose observations (all from
trial BP22333) were below the quantification limit. There were no missing
covariate values except baseline B&#8209;cell count. Baseline tumour load was
available only in trial BO22334.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>In
clinical trial BO22334, an effect was observed between body size&nbsp;and
exposure ratios reported in cycle 7, between rituximab subcutaneous formulation
1400 mg q3w and rituximab intravenous formulation 375 mg/m2&nbsp;q3w with C<sub>trough</sub>&nbsp;ratios
of 2.29, 1.31, and 1.41 in patients with low, medium and high BSA,
respectively&nbsp;(low BSA </span><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol;color:black;background:white'></span><span lang=EN-GB
style='color:black'>&nbsp;1.70&nbsp;m<sup>2</sup>; 1.70&nbsp;m<sup>2</sup>&nbsp;&lt;
medium&nbsp;BSA&nbsp;&lt;&nbsp;1.90&nbsp;m<sup>2</sup>; high BSA </span><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol;color:black;background:
white'></span><span lang=EN-GB style='color:black'>&nbsp;1.90&nbsp;m<sup>2</sup>).&nbsp;The
corresponding AUC&#964;&nbsp;ratios were 1.66, 1.17 and 1.32.</span></p>

<p class=MsoNormal><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>There
was no evidence of clinically relevant dependencies of rituximab
pharmacokinetics on age and sex.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anti&#8209;rituximab antibodies were
detected in only 13 patients and did not result in any clinically relevant
increase in steady&#8209;state clearance.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab has shown to be highly specific
to the CD20 antigen on B&nbsp;cells. Toxicity studies in cynomolgus monkeys
have shown no other effect than the expected pharmacological depletion of
B&nbsp;cells in peripheral blood and in lymphoid tissue. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Developmental toxicity studies have been
performed in cynomolgus monkeys at doses up to 100&nbsp;mg/kg (treatment on gestation
days 20&#8209;50) and have revealed no evidence of toxicity to the foetus due
to rituximab. However, dose&#8209;dependent pharmacologic depletion of
B&nbsp;cells in the lymphoid organs of the foetuses was observed</span><span
lang=EN-GB>, which persisted post natally and was accompanied by a decrease in
IgG level in the newborn animals affected. B cell counts returned to normal in
these animals within 6 months of birth and did not compromise the reaction to
immunization.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Standard tests to investigate mutagenicity
have not been carried out, since such tests are not relevant for this molecule.
</span><span lang=EN-GB>No long&#8209;term animal studies have been performed
to establish the carcinogenic potential of rituximab.<s> </s></span></p>

<p class=MsoNormal><span lang=EN-GB>Specific studies to determine the effects
of rituximab or rHuPH20 on fertility have not been performed. In general
toxicity studies in cynomolgus monkeys no deleterious effects on reproductive
organs in males or females were observed. Additionally, no effects on semen
quality were shown for rHuPH20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In embryofetal developmental studies in
mice, rHuPH20 caused reduced fetal weight and loss of implantations at systemic
exposures sufficiently in excess of human therapeutic exposure.</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no evidence of dysmorphogenesis
(i.e. teratogenesis) resulting from systemic exposure to rHuPH20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.7pt;text-indent:-.7pt;page-break-after:
avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Recombinant
human hyaluronidase (rHuPH20)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DA>L&#8209;histidine</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DA>L&#8209;histidine
hydrochloride monohydrate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>,</span><span lang=EN-GB
style='font-family:Symbol'>a</span><span lang=EN-GB>&#8209;trehalose dihydrate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>L&#8209;methionine</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 80 (E433)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Water for
injections</span><span lang=EN-GB style='color:green'> </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No incompatibilities between MabThera
subcutaneous formulation and polypropylene or polycarbonate syringe material or
stainless steel transfer and injection needles and polyethylene Luer cone
stoppers have been observed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30 months</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>After
first opening</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Once transferred from the vial into the syringe,
the solution of MabThera subcutaneous formulation is physically and chemically
stable for 48 hours at 2&nbsp;C&nbsp;&#8209;&nbsp;8&nbsp;C and subsequently
for 8 hours at </span><span lang=EN-GB>30C in diffuse daylight<span
style='layout-grid-mode:line'>.</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>F</span><span lang=EN-GB style='color:black'>rom
a microbiological point of view, the product should be used immediately. If not
used immediately, </span><span lang=EN-GB>preparation should take place in
controlled and validated aseptic conditions. I</span><span lang=EN-GB
style='color:black'>n&#8209;use storage times and conditions prior to use are
the responsibility of the user.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C 
8&nbsp;C). Keep the container in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>For storage
conditions after first opening see section 6.3.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Colourless type I glass vial with butyl
rubber stopper with aluminium over seal and a pink plastic flip&#8209;off disk,
containing 1400&nbsp;mg/11.7 mL of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each carton contains one vial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6 Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is provided in sterile,
preservative&#8209;free, non&#8209;pyrogenic, single use vials. Use sterile
needle and syringe to prepare MabThera. A peel&#8209;off sticker is included on
the vials which specifies the strength, route of administration and indication.
This sticker should be removed from the vial and stuck onto the syringe prior
to use. </span><span lang=EN-GB>The following points should be strictly
adhered to regarding the use and disposal of syringes and other medicinal
sharps: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Needles and syringes should never be reused</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Place all used needles and syringes into a sharps container
(puncture</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
lang=EN-GB>proof disposable container). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>EU/1/98/067/003</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 2 June 1998</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 2 June 2008</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency (EMA) </span><a href="http://www.ema.europa.eu/"><span
lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>http://www.ema.europa.eu/</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600&nbsp;mg solution for subcutaneous
injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Each mL contains 120&nbsp;mg of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contain<b>s</b> 1600&nbsp;mg/ 13.4
mL rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab is a genetically engineered
chimeric mouse/human monoclonal antibody representing a glycosylated
immunoglobulin with human IgG1 constant regions and murine light&#8209;chain
and heavy&#8209;chain variable region sequences. The antibody is produced by
mammalian (Chinese hamster ovary) cell suspension culture and purified by
affinity chromatography and ion exchange, including specific viral inactivation
and removal procedures.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Solution for injection</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Clear to
opalescent, colourless to yellowish liquid with pH of 5.2  5.8 and osmolality
of 300 - 400 mOsmol/kg.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera is
indicated in adults in combination with chemotherapy for the treatment of
patients with previously untreated and relapsed/refractory chronic lymphocytic
leukaemia (CLL). Only limited data are available on efficacy and safety for
patients previously treated with monoclonal antibodies including MabThera or
patients refractory to previous MabThera plus chemotherapy.</span></p>

<p class=MsoNormal style='background:white;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white;text-autospace:none'><span
lang=EN-GB style='color:black'>See section 5.1 for further information. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera </span><span lang=EN-GB>should be
administered under the close supervision of an experienced </span><span
lang=EN-GB>healthcare professional</span><span lang=EN-GB>, and in an
environment where full resuscitation facilities are immediately available (see
section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Premedication consisting of an anti&#8209;pyretic
and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be
given before each administration of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Premedication with glucocorticoids should
be considered if MabThera is not given in combination with glucocorticoid&#8209;containing
chemotherapy<span style='color:black;background:white'>&#8209;</span>.<b> </b></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of MabThera</span><span
lang=EN-GB> </span><span lang=EN-GB>su</span><span lang=EN-GB>bcutaneous
formulation used for adult patients is a subcutaneous injection at a fixed dose
of 1600&nbsp;mg irrespective of the patients body surface area. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Before starting MabThera subcutaneous
injections, a</span><span lang=EN-GB>ll patients must always receive
beforehand, a full dose of MabThera by </span><span lang=EN-GB>intravenous
infusion, using MabThera intravenous formulation (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If patients were not able to receive one
full MabThera intravenous infusion dose prior to the switch, they should
continue the subsequent cycles with MabThera intravenous formulation until a
full intravenous dose is successfully administered. </span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore, the switch to MabThera
subcutaneous formulation can only occur at the second or subsequent cycles of
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is important to check the medicinal
product labels to ensure that the appropriate formulation (intravenous or
subcutaneous formulation) </span><span lang=EN-GB>and strength</span><span
lang=EN-GB> is being given to the patient, as prescribed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera </span><span
lang=EN-GB>subcutaneous formulation </span><span lang=EN-GB>is not intended for
intravenous administration and should be given via subcutaneous injection only.
The 1600 mg strength is intended for subcutaneous use in CLL only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:white'>Prophylaxis with adequate hydration and
administration of uricostatics starting 48 hours prior to start of therapy is
recommended for CLL patients to reduce the risk of tumour lysis syndrome. For
CLL patients whose lymphocyte counts are &gt; 25 x 10<sup>9</sup>/L it is
recommended to administer prednisone/prednisolone 100&nbsp;mg intravenous
shortly before administration with MabThera to decrease the rate and severity
of acute infusion reactions and/or cytokine release syndrome.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>The recommended dosage of MabThera in combination with
chemotherapy </span><span lang=EN-GB style='color:black;background:white'>for
previously untreated and relapsed/refractory patients</span><span lang=EN-GB
style='color:black;background:white'> is: MabThera intravenous formulation 375&nbsp;mg/m<sup>2</sup>
body surface area administered on day 0 of the first cycle of treatment
followed by MabThera subcutaneous formulation injected at a fixed dose of 1600
mg per cycle, on day 1 of each subsequent cycle (in total: 6 cycles).</span><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>The chemotherapy should be given after MabThera administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><u><span lang=EN-GB>Dose
adjustments during treatment</span></u></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>No dose reductions of MabThera are recommended. When MabThera is
given in combination with</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>chemotherapy, standard dose reductions for the chemotherapeutic
medicinal products should be</span></p>

<p class=MsoNormal><span lang=EN-GB>applied (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of MabThera in
children below 18 years has not been established. No data are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required in elderly
patients (aged &gt;65 years). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Subcutaneous injections</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600 mg </span><span lang=EN-GB>subcutaneous
formulation </span><span lang=EN-GB>should be administered as subcutaneous
injection only, </span><span lang=EN-GB>over approximately 7 minutes. </span><span
lang=EN-GB>The hypodermic injection needle must only be attached to the syringe
immediately prior to administration to avoid potential needle clogging.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera subcutaneous formulation should be
injected subcutaneously into the abdominal wall and never into areas where the
skin is red, bruised, tender, hard or areas where there are moles or scars.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:#222222'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>No
data are available on performing the injection in other sites of the body,
therefore injections should be restricted to the abdominal wall.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the treatment course with MabThera </span><span
lang=EN-GB>subcutaneous formulation</span><span lang=EN-GB>, other medicinal
products for subcutaneous administration should preferably be given at
different sites.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If an injection
is interrupted it can be resumed at the same site or another location may be
used, if appropriate.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Intravenous
infusion administration</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>The Summary of Product Characteristics
(SmPC) of MabThera 100&nbsp;mg and 500&nbsp;mg concentrate for solution for
infusion should be referred to for information on dosing instructions and
method of administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to </span><span lang=EN-GB>murine proteins, hyaluronidase or to any of the other
excipients listed in section 6</span><span lang=EN-GB>.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Active, severe infections (see section
4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Patients in a severely immunocompromised state.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Treacibility</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve traceability of
biological medicinal products,&nbsp;the tradename&nbsp;and batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The information provided in the section 4.4
pertains to the use of MabThera subcutaneous formulation in the approved
indications <i>Treatment of non-Hodgkins lymphoma </i>(strength 1400 mg) and<i>
Treatment of CLL </i>(strength 1600 mg). For information related to the other
indications, please refer to the SmPC of MabThera intravenous formulation. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><u><span lang=EN-GB>Progressive multifocal leukoencephalopathy</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Use of MabThera may be associated with an
increased risk of progressive multifocal leukoencephalopathy (PML). Patients
must be monitored at regular intervals for any new or worsening neurological
symptoms or signs that may be suggestive of PML. If PML is suspected, further
dosing must be suspended until PML has been excluded. The clinician should
evaluate the patient to determine if the symptoms are indicative of
neurological dysfunction, and if so, whether these symptoms are possibly
suggestive of PML. Consultation with a neurologist should be considered as
clinically indicated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any doubt exists, further evaluation,
including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing
for JC Viral DNA and repeat neurological assessments, should be considered. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>The physician should be particularly alert to symptoms suggestive of
PML that the patient may not notice (e.g. cognitive, neurological or
psychiatric symptoms). </span><span lang=EN-GB>Patients should also be advised
to inform their partner or caregivers about their treatment, since they may
notice symptoms that the patient is not aware of.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If a patient develops PML, the dosing of
MabThera must be permanently discontinued. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following reconstitution of the immune
system in immunocompromised patients with PML, stabilisation or improved
outcome has been seen. It remains unknown if early detection of PML and
suspension of MabThera therapy may lead to similar stabilisation or improved
outcome.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infusion/Administration&#8209;related
reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MabThera is associated
with infusion/administration&#8209;related reactions, which may be related to
release of cytokines and/or other chemical mediators. Cytokine release syndrome
may be clinically indistinguishable from acute hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This set of reactions which includes
syndrome of cytokine release, tumor lysis syndrome and anaphylactic and
hypersensitivity reactions are described below. They are not specifically
related to the route of administration of MabThera and can be observed with
both formulations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe infusion&#8209;related reactions
with fatal outcome have been reported during post&#8209;marketing use of the
MabThera intravenous formulation, with an onset ranging within 30 minutes to 2
hours after starting the first MabThera intravenous infusion. They were
characterized by pulmonary events and in some cases included rapid tumour lysis
and features of tumour lysis syndrome in addition to fever, chills, rigors,
hypotension, urticaria, angioedema and other symptoms (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe cytokine release syndrome is
characterised by severe dyspnea, often accompanied by bronchospasm and hypoxia,
in addition to fever, chills, rigors, urticaria, and angioedema. This syndrome
may be associated with some features of tumour lysis syndrome such as
hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal
failure, elevated lactate dehydrogenase (LDH) and may be associated with acute
respiratory failure and death. The acute respiratory failure may be accompanied
by events such as pulmonary interstitial infiltration or oedema, visible on a
chest X&#8209;ray. The syndrome frequently manifests itself within one or two
hours of initiating the first infusion. Patients with a history of pulmonary
insufficiency or those with pulmonary tumour infiltration may be at greater
risk of poor outcome and should be treated with increased caution. Patients who
develop severe cytokine release syndrome should have their infusion interrupted
immediately (see section 4.2) and should receive aggressive symptomatic
treatment. Since initial improvement of clinical symptoms may be followed by
deterioration, these patients should be closely monitored until tumour lysis
syndrome and pulmonary infiltration have been resolved or ruled out. Further
treatment of patients after complete resolution of signs and symptoms has
rarely resulted in repeated severe cytokine release syndrome. </span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
with a high tumour burden or with a high number (&#8805;25 x 10<sup>9</sup>/L)
of circulating malignant cells, such as patients with CLL who may be at higher
risk of especially severe cytokine release syndrome, should be treated with
extreme caution. These patients should be very closely monitored throughout the
first infusion. Consideration should be given to the use of a reduced infusion
rate for the first infusion in these patients or a split dosing over two days
during the first cycle</span><span lang=EN-GB> and any subsequent cycles if the
lymphocyte count is still &gt;25 x 10<sup>9</sup>/L</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Anaphylactic and other hypersensitivity
reactions have been reported following the intravenous administration of
proteins to patients. In contrast to cytokine release syndrome, true
hypersensitivity reactions typically occur within minutes after starting
infusion. Medicinal products for the treatment of hypersensitivity reactions,
e.g., epinephrine (adrenaline), antihistamines and glucocorticoids, should be
available for immediate use in the event of an allergic reaction during
administration of MabThera. Clinical manifestations of anaphylaxis may appear
similar to clinical manifestations of the cytokine release syndrome (described
above). Reactions attributed to hypersensitivity have been reported less
frequently than those attributed to cytokine release.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additional reactions reported in some cases
were myocardial infarction, atrial fibrillation, pulmonary oedema and acute
reversible thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Since
hypotension may occur during MabThera administration, consideration should be
given to withholding anti&#8209;hypertensive medicines 12 hours prior to giving
MabThera.</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion
related adverse reactions of all kinds have been observed in 77% of patients
treated with MabThera intravenous formulation (including cytokine release
syndrome accompanied by hypotension and bronchospasm in 10&nbsp;% of patients)
see section 4.8. These symptoms are usually reversible with interruption of
MabThera infusion and administration of an anti&#8209;pyretic, an
antihistaminic, and, occasionally, oxygen, intravenous saline or
bronchodilators, and glucocorticoids if required. Please see cytokine release
syndrome above for severe reactions.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration related reactions have been
observed in up to 50% of patients treated with <span style='color:black;
background:white'>MabThera</span> subcutaneous formulation in clinical trials.
The reactions occurring within 24 hours of the subcutaneous injection consisted
primarily of erythema pruritus, rash and injections site reactions such as
pain, swelling and redness and were generally of mild or moderate (grade 1 or
2) and transient <span style='color:black;background:white'>nature (see section
4.8).</span></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Local
cutaneous reactions were very common in patients receiving MabThera
subcutaneous in clinical trials. Symptoms included pain, swelling, induration,
haemorrhage, erythema, pruritus and rash (see section 4.8). Some local
cutaneous reactions occurred more than 24 hours after the </span><span
lang=EN-GB>MabThera subcutaneous </span><span lang=EN-GB>administration. The
majority of local cutaneous reactions seen following administration of MabThera
subcutaneous formulation was mild or moderate and resolved without any specific
treatment</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:#222222;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black;background:white'>Before starting MabThera subcutaneous
injections, all patients must always receive beforehand, a full dose of
MabThera by intravenous infusion, using MabThera intravenous formulation. The
highest risk of experiencing an administration related reaction is generally
observed at cycle one. Beginning the therapy with MabThera intravenous infusion
would allow a better handling of the administration reactions by slowing or
stopping the intravenous infusion.&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If patients were not able to receive one
full MabThera intravenous infusion dose prior to the switch, they should
continue the subsequent cycles with MabThera intravenous formulation until a
full intravenous dose is successfully administered. Therefore, the switch to
MabThera subcutaneous formulation can only occur at the second or subsequent
cycles of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with the intravenous formulation,
MabThera </span><span lang=EN-GB>subcutaneous formulation </span><span
lang=EN-GB>should be administered in an environment where full resuscitation
facilities are immediately available and under the close supervision of an
experienced healthcare professional. Premedication consisting of an
analgesic/antipyretic and an antihistamine should always be administered before
each dose of MabThera </span><span lang=EN-GB>subcutaneous formulation</span><span
lang=EN-GB>. Premedication with glucocorticoids should also be considered.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:#222222;background:white'>Patients
should be observed for at least 15 minutes following MabThera subcutaneous
administration.&nbsp;A longer period may be appropriate in&nbsp;patients with
an increased risk of hypersensitivity reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:#222222'>Patients should be
instructed to contact their treating physician immediately if symptoms that are
suggestive of severe hypersensitivity or cytokine release syndrome occur at any
time after medicinal product administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Cardiac disorders</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Angina pectoris, cardiac arrhythmias<b> </b>such
as atrial flutter and fibrillation, heart failure and/or myocardial infarction
have occurred in patients treated with MabThera. Therefore patients with a
history of cardiac disease and/or cardiotoxic chemotherapy should be monitored
closely.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Haematological
toxicities</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Although
MabThera is not myelosuppressive in monotherapy, caution should be exercised
when considering treatment of patients with neutrophils &lt;&nbsp;1.5 x 10<sup>9</sup>/L
and/or platelet counts &lt;&nbsp;75 x 10<sup>9</sup>/L as clinical experience
in this population is limited<i>. </i>The MabThera intravenous formulation has
been used in 21 patients who underwent autologous bone marrow transplantation
and other risk groups with a presumable reduced bone marrow function without
inducing myelotoxicity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Regular full blood counts, including
neutrophil and platelet counts, should be performed during MabThera therapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Infections</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Serious infections, including fatalities,
can occur during therapy with MabThera</span><span lang=EN-GB> (see section
4.8).</span><b><i><span lang=EN-GB style='font-family:"Times New Roman Bold"'> </span></i></b><span
lang=EN-GB>MabThera should not be administered to patients with an active,
severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see
section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Physicians should exercise caution when
considering the use of MabThera in patients with a history of recurring or
chronic infections or with underlying conditions which may further predispose
patients to serious infection (see section 4.8). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of hepatitis B reactivation have been
reported in patients receiving the MabThera intravenous formulation including
fulminant hepatitis with fatal outcome. The majority of these patients were
also exposed to cytotoxic chemotherapy</span><span lang=EN-GB style='color:
black;background:white'>.</span><span lang=EN-GB style='color:black;background:
white'> </span><span lang=EN-GB style='color:black;background:white'>Limited
information from one study in relapsed/refractory CLL patients suggests that
MabThera treatment may also worsen the outcome of primary hepatitis B
infections.</span><span lang=EN-GB style='color:black;background:white'> </span><span
lang=EN-GB>Hepatitis B virus (HBV) screening should be performed in all
patients before initiation of treatment with MabThera. At minimum this should
include HBsAg&#8209;status and HBcAb&#8209;status. These can be complemented
with other appropriate markers as per local guidelines. Patients with active
hepatitis B disease should not be treated with MabThera. Patients with positive
hepatitis B serology (either HBsAg or HBcAb) should consult liver disease
experts before start of treatment and should be monitored and managed following
local medical standards to prevent hepatitis B reactivation.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare cases of PML have been reported
during post&#8209;marketing use of </span><span lang=EN-GB>the MabThera
intravenous formulation</span><span lang=EN-GB> in <span style='color:black;
background:white'>CLL</span> (see section 4.8). The majority of patients had
received rituximab in combination with chemotherapy or as part of a
hematopoietic stem cell transplant. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immunisation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The safety <span style='color:black;
background:white'>of immunisation with </span></span><span lang=EN-GB
style='color:black;background:white'>live viral vaccines, following MabThera
therapy has not been studied for NHL and CLL </span><span lang=EN-GB>patients<i>
</i>and vaccination with live virus vaccines is not recommended. Patients
treated with MabThera may receive non&#8209;live vaccinations; however, with
non&#8209;live vaccines response rates may be reduced. In a non&#8209;randomized
study, patients with relapsed low&#8209;grade NHL who received </span><span
lang=EN-GB>the MabThera intravenous formulation as </span><span lang=EN-GB>monotherapy
when compared to healthy untreated controls had a lower rate of response to
vaccination with tetanus recall antigen (16% vs. 81%) and Keyhole Limpet
Haemocyanin (KLH) neoantigen (4% vs. 69% when assessed for &gt;2&#8209;fold
increase in antibody titer). <span style='color:black;background:white'>For CLL
patients similar results are assumable considering similarities between both
diseases, but this has not been investigated in clinical trials.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mean pre&#8209;therapeutic antibody titers
against a panel of antigens (Streptococcus pneumoniae, influenza A, mumps,
rubella and varicella) were maintained for at least 6 months after treatment
with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Skin
reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Severe skin
reactions such as Toxic Epidermal Necrolysis (Lyells Syndrome) and Stevens &#8209;
Johnson syndrome, some with fatal outcome, have been reported<i> </i>(see
section 4.8).<i> </i>In case of such an event, with suspected relationship to
MabThera, treatment should be permanently discontinued.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Currently,
there are limited data on possible drug interactions with MabThera. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:white'>In CLL
patients, co</span><span lang=EN-GB>&#8209;administration with MabThera </span><span
lang=EN-GB>did not appear to have an</span><span lang=EN-GB> effect on the
pharmacokinetics of fludarabine </span><span lang=EN-GB>or</span><span
lang=EN-GB> cyclophosphamide. In addition, there was no apparent effect of
fludarabine and cyclophosphamide on the pharmacokinetics of </span><span
lang=EN-GB>MabThera</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with human anti&#8209;mouse
antibody (HAMA) or anti-drug antibody (ADA) titres may have allergic or
hypersensitivity reactions when treated with other diagnostic or therapeutic
monoclonal antibodies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></b></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Contraception in males and females</span></u></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>Due to the long retention time of rituximab
in B cell depleted patients, women of childbearing potential must employ
effective contraceptive methods during and for 12 months after treatment with
MabThera.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>IgG immunoglobulins are known to cross the
placental barrier.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>B&#8209;cell levels in human neonates
following maternal exposure to MabThera have not been studied in clinical
trials. There are no adequate and well&#8209;controlled data from studies in
pregnant women, however transient B&#8209;cell depletion and lymphocytopenia
have been reported in some infants born to mothers exposed to MabThera during
pregnancy. Similar effects have been observed in animal studies (see section
5.3).For these reasons MabThera should not be administered to pregnant women
unless the possible benefit outweighs the potential risk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Whether rituximab is excreted in human milk
is not known. However, because maternal IgG is excreted in human milk, and
rituximab was detectable in milk from lactating monkeys, </span><span
lang=EN-GB>women should not breastfeed while treated with MabThera and for 12
months following MabThera treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Animal studies did not reveal deleterious
effects of rituximab or recombinant human hyaluronidase (rHuPH20) on
reproductive organs.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No studies on the effects of MabThera on
the ability to drive and use machines have been performed, although the
pharmacological activity and adverse reactions reported to date suggest that
MabThera would have no or negligible influence on the ability to drive and use
machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
information provided in this section pertains to the use of MabThera in
oncology. </span></p>

<p class=MsoNormal><span lang=EN-GB>For information related to the autoimmune
indications, please refer to the SmPC of MabThera intravenous formulation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Summary of the safety profile </span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the development programme, the
safety profile of MabThera </span><span lang=EN-GB>subcutaneous formulation</span><span
lang=EN-GB> was comparable to that of the intravenous formulation with the
exception of local cutaneous reactions. </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Local
</span><span lang=EN-GB style='color:black'>cutaneous reactions including </span><span
lang=EN-GB style='color:black'>injection site reactions were very common in
patients receiving MabThera </span><span lang=EN-GB style='color:black'>subcutaneous
formulation.</span><span lang=EN-GB style='color:black'> In the NHL phase 3 trial
SABRINA (BO22334), local cutaneous reactions were reported in up to 20% of
patients receiving subcutaneous MabThera. The most common local cutaneous
reactions in the MabThera subcutaneous arm were injection site erythema (13%),
injection site pain (7%), and injection site oedema (4%). Events seen following
subcutaneous administration were mild or moderate, apart from one patient who
reported a local cutaneous reaction of Grade 3 intensity (injection site rash)
following the first MabThera subcutaneous administration (Cycle 2). Local
cutaneous reactions of any grade in the MabThera subcutaneous arm were most
common during the first subcutaneous cycle (Cycle 2), followed by the second,
and the incidence decreased with subsequent injections</span><span lang=EN-GB
style='color:black'>. </span><span style='color:black;background:white'>Similar
events were observed in the CLL SAWYER trial (BO25341) and were reported in up
to 42% of patients in the MabThera subcutaneous</span><span style='color:black;
background:white'> arm. Most common </span><span style='color:black;background:
white'>local cutaneous reactions were</span><span style='color:black;
background:white'> </span><span style='color:black;background:white'>injection
site erythema (26%), injection site pain (16%), and injection site swelling
(5%)</span><span style='color:black;background:white'>. T</span><span
lang=EN-GB style='color:black;background:white'>wo patients in SAWYER trial who
experienced Grade 3 local cutaneous reactions (injection site erythema,
injection site pain and injection site swelling).</span><span lang=EN-GB
style='color:black'> </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adverse reactions reported in
MabThera subcutaneous formulation usage</span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The risk of acute administration&#8209;related
reactions associated with the subcutaneous formulation of MabThera was assessed
in &#8209;<span style='color:black;background:white'>three clinical trials:
SparkThera and SABRINA (the two trials in NHL) and SAWYER the CLL trial</span>.
</span></p>

<p class=MsoNormal><span lang=EN-GB>In trial SABRINA, severe administration&#8209;related
reactions (grade&#8805;3) were reported in two patients (2%) following
administration of MabThera </span><span lang=EN-GB>subcutaneous formulation </span><span
lang=EN-GB>.</span><span lang=EN-GB> These events were Grade 3 injection site
rash and dry mouth.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>In trial SparkThera, no severe
administration&#8209;related reactions were reported.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>In SAWYER (BO25341), severe administration&#8209;related
reactions (Grade &#8805;3) were reported in four patients (5%) following
MabThera subcutaneous administration. These events were Grade 4
thrombocytopenia and Grade 3 anxiety, injection&#8209;site erythema and
urticaria.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Adverse reactions reported in
MabThera intravenous formulation usage</span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Experience from non&#8209;Hodgkins
lymphoma and chronic lymphocytic leukaemia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The overall safety profile of MabThera in
non&#8209;Hodgkins lymphoma and CLL is based on data from patients from
clinical trials and from post&#8209;marketing surveillance. These patients were
treated either with MabThera monotherapy (as induction treatment or maintenance
treatment following induction treatment) or in combination with chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently observed adverse
reactions (ADRs) in patients receiving MabThera were infusion&#8209;related
reactions which occurred in the majority of patients during the first infusion.
The incidence of infusion&#8209;related symptoms decreases substantially with
subsequent infusions and is less than 1&nbsp;% after eight doses of MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>Infectious events (predominantly bacterial
and viral) occurred in approximately 30&#8209;55&nbsp;% of patients during
clinical trials in patients with NHL and in 30&#8209;50&nbsp;% of patients
during clinical trial in patients with CLL.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The most
frequent reported or observed serious adverse reactions were:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infusion&#8209;related
reactions (including cytokine&#8209;release syndrome, tumour&#8209;lysis
syndrome), see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infections,
see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Cardiovascular
disorders, see section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other serious ADRs reported include
hepatitis B reactivation and PML (see section 4.4.).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The frequencies of ADRs reported with
MabThera alone or in combination with chemotherapy are summarised in Table 1.
Frequencies are defined as very common (</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> 1/10), common &nbsp;(</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;1/100 to
&lt;&nbsp;1/10), uncommon &nbsp;(</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>&nbsp; 1/1,000 to &lt; 1/100), rare (</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> 1/10,000 to
&lt; 1/1000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated
from the available data). Within each frequency grouping, undesirable effects
are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The ADRs identified only during post&#8209;marketing
surveillance, and for which a frequency could not be estimated, are listed
under not known.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1 ADRs reported in clinical trials
or during postmarketing surveillance in patients with NHL and CLL disease
treated with MabThera monotherapy/maintenance or in combination with
chemotherapy </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="14%" style='width:14.62%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>MedDRA System Organ Class</span></b></p>
   </td>
   <td width="12%" style='width:12.56%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Common</span></b></p>
   </td>
   <td width="15%" style='width:15.88%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Common</span></b></p>
   </td>
   <td width="13%" style='width:13.48%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Uncommon</span></b></p>
   </td>
   <td width="13%" style='width:13.48%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Rare</span></b></p>
   </td>
   <td width="13%" style='width:13.5%;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Very Rare</span></b></p>
   </td>
   <td width="16%" style='width:16.46%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:9.0pt'>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Infections and
  infestations</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>bacterial
  infections, viral infections, <sup>+</sup>bronchitis </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>sepsis, <sup>+</sup>pneumonia,
  <sup>+</sup>febrile infection, <sup>+</sup>herpes zoster, <sup>+</sup>respiratory
  tract infection, fungal infections, infections of unknown aetiology, <sup>+</sup>acute
  bronchitis, <sup>+</sup>sinusitis,</span><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'> h</span><span lang=EN-GB style='font-size:9.0pt'>epatitis
  B</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>1</span></sup><sup><span
  lang=EN-GB style='font-size:9.0pt'> </span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>serious viral infection<sup>2</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Blood and
  lymphatic system disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>neutropenia,
  leucopenia, <sup>+</sup>febrile neutropenia, <sup>+</sup>thrombocytopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>anaemia, </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>pancytopenia, <sup>+</sup>granulocytopenia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>coagulation
  disorders, aplastic anaemia, haemolytic anaemia, lymphadenopathy</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>transient
  increase in serum IgM levels</span><sup><span lang=EN-GB style='font-size:
  9.0pt;layout-grid-mode:line'>3</span></sup></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>late neutropenia<sup>3</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Immune system
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion related reactions<sup>4</sup>,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>angioedema</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hypersensitivity</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>anaphylaxis</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>tumour lysis syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cytokine release syndrome<sup>4</sup>, serum sickness</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>infusion&#8209;related acute reversible thrombocytopenia&nbsp;<sup>4</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>hyperglycaemia,
  weight decrease, peripheral oedema, face oedema, increased LDH, hypocalcaemia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Psychiatric
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>depression,
  nervousness,</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Nervous system
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>paraesthesia,
  hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>dysgeusia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>peripheral neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>facial nerve palsy<sup>5</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>cranial neuropathy,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>loss of other senses<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Eye disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lacrimation
  disorder, conjunctivitis</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe vision loss<sup>5</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Ear and
  labyrinth disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>tinnitus, ear
  pain</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>hearing loss<sup>5</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Cardiac
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>myocardial infarction</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>, arrhythmia, <sup>+</sup>atrial
  fibrillation, tachycardia, <sup>+</sup>cardiac disorder</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>+</span></sup><span
  lang=EN-GB style='font-size:9.0pt'>left ventricular failure, <sup>+</sup>supraventricular
  tachycardia, <sup>+</sup>ventricular tachycardia, <sup>+</sup>angina, <sup>+</sup>myocardial
  ischaemia, bradycardia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>severe cardiac
  disorders </span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>4 and 6</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>heart failure</span><sup><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>4 and 6</span></sup></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Vascular
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertension, orthostatic hypotension, hypotension<sup>
  </sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>vasculitis (predominately cutaneous),</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>leukocytoclastic vasculitis</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Bronchospasm</span><sup><span lang=EN-GB
  style='font-size:9.0pt;layout-grid-mode:line'>4</span></sup><span lang=EN-GB
  style='font-size:9.0pt'>, respiratory disease, chest pain, dyspnoea, increased
  cough, rhinitis</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>asthma,
  bronchiolitis obliterans, lung disorder, hypoxia</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>interstitial lung disease<sup>7</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>respiratory failure<sup>4</sup>,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>lung infiltration</span><span
  lang=EN-GB style='font-size:9.0pt;layout-grid-mode:line'>, </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>nausea<sup> </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>vomiting<sup> </sup>, diarrhoea, abdominal pain,
  dysphagia, stomatitis, constipation, dyspepsia, anorexia, throat irritation</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>abdominal
  enlargement</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>gastro&#8209;intestinal perforation<sup>7</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>pruritis, rash, <sup>+</sup>alopecia<sup>
  </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>urticaria,
  sweating, night sweats, <sup>+</sup>skin disorder</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>severe bullous skin reactions,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>Stevens&#8209;Johnson Syndrome,</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>toxic epidermal necrolysis (Lyells Syndrome)<sup> 7</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Musculoskeletal,
  connective tissue disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>hypertonia, myalgia, arthralgia, back pain, neck
  pain, pain</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>Renal and
  urinary disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>renal failure<sup>4</sup></span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:9.0pt'>General
  disorders and administration site conditions</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>fever<sup> </sup>,
  chills, asthenia, headache<sup> </sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>tumour pain, flushing, malaise, cold syndrome, <sup>+</sup>fatigue,
  <sup>+</sup>shivering, </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB
  style='font-size:9.0pt'>+</span></sup><span lang=EN-GB style='font-size:9.0pt'>multi&#8209;organ
  failure</span><sup><span lang=EN-GB style='font-size:9.0pt;layout-grid-mode:
  line'>4</span></sup></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>infusion site
  pain</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:9.0pt'>Investigations</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>decreased IgG levels</span></p>
  </td>
  <td width="15%" valign=top style='width:15.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.48%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>For each term,
  the frequency count was based on reactions of all grades (from mild to
  severe), except for terms marked with &quot;+&quot; where the frequency count
  was based only on severe (&#8805; grade 3 NCI common toxicity criteria)
  reactions. &nbsp;Only the highest frequency observed in the trials is
  reported</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>1</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes reactivation and primary
  infections; frequency based on R&#8209;FC regimen in relapsed/refractory CLL</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>2</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infection below </span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>3</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section haematologic adverse
  reactions below</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>4</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> see also section infusion&#8209;related
  reactions below. Rarely fatal cases reported</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>5</span></sup><b><span lang=EN-GB
  style='font-size:9.0pt'> </span></b><span lang=EN-GB style='font-size:9.0pt'>signs
  and symptoms of cranial neuropathy. Occurred at various times up to several months
  after completion of MabThera therapy</span></p>
  <p class=MsoNormal style='margin-left:6.5pt;text-indent:-6.5pt'><sup><span
  lang=EN-GB style='font-size:9.0pt'>6</span></sup><span lang=EN-GB
  style='font-size:9.0pt'> observed mainly in patients with prior cardiac
  condition and/or cardiotoxic chemotherapy and were mostly associated with
  infusion&#8209;related reactions</span></p>
  <p class=MsoNormal><sup><span lang=EN-GB style='font-size:9.0pt'>7</span></sup><span
  lang=EN-GB style='font-size:9.0pt'> includes fatal cases</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following terms have been reported as
adverse events during clinical trials, however, were reported at a similar or
lower incidence in the MabThera&#8209;arms compared to control arms:
haematotoxicity, neutropenic infection, urinary tract infection, sensory
disturbance, pyrexia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Signs and symptoms suggestive of an
infusion&#8209;related reaction were reported in more than 50&nbsp;% of
patients in clinical trials involving MabThera intravenous formulation, and
were predominantly seen during the first infusion, usually in the first one to
two hours. These symptoms mainly comprised fever, chills and rigors. Other
symptoms included flushing, angioedema, bronchospasm, vomiting, nausea,
urticaria/rash, fatigue, headache, throat irritation, rhinitis, pruritus, pain,
tachycardia, hypertension, hypotension, dyspnoea, dyspepsia, asthenia and
features of tumour lysis syndrome. Severe infusion&#8209;related reactions
(such as bronchospasm, hypotension) occurred in up to 12&nbsp;% of the cases.
Additional reactions reported in some cases were myocardial infarction, atrial
fibrillation, pulmonary oedema</span><span lang=EN-GB> and acute reversible
thrombocytopenia</span><span lang=EN-GB>. Exacerbations of pre&#8209;existing
cardiac conditions such as angina pectoris or congestive heart failure or <span
style='layout-grid-mode:line'>severe cardiac disorders (heart failure,
myocardial infarction, </span>atrial fibrillation<span style='layout-grid-mode:
line'>), </span>pulmonary oedema, multi&#8209;organ failure<span
style='layout-grid-mode:line'>, tumour lysis syndrome, cytokine release
syndrome, renal failure, and respiratory failure were reported </span>at lower
or unknown frequencies. The incidence of infusion&#8209;related symptoms
decreased substantially with subsequent intravenous infusions and is &lt;1% of
patients by the eighth cycle of MabThera (containing) treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Infections </span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera induces B&#8209;cell depletion in
about 70&#8209;80% of patients, but was associated with decreased serum
immunoglobulins only in a minority of patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Localized candida infections as well as
Herpes zoster were reported at a higher incidence in the MabThera&#8209;containing
arm of randomized studies. </span><span lang=EN-GB>Severe infections were
reported in about 4% of patients treated with MabThera monotherapy. </span><span
lang=EN-GB>Higher frequencies of infections overall, including grade 3 or 4
infections, were observed during MabThera maintenance treatment up to 2 years
when compared to observation. </span><span lang=EN-GB>There was no cumulative
toxicity in terms of infections reported over a 2&#8209;year treatment period</span><span
lang=EN-GB>. In addition, other serious viral infections either new,
reactivated or exacerbated, some of which were fatal, have been reported with
MabThera treatment. The majority of patients had received MabThera in
combination with chemotherapy or as part of a hematopoietic stem cell
transplant. Examples of these serious viral infections are infections caused by
the herpes viruses (Cytomegalovirus, Varicella Zoster Virus and Herpes Simplex
Virus), JC virus (PML) and hepatitis C virus. Cases of fatal PML that occurred
after disease progression and retreatment have also been reported in clinical
trials. C</span><span lang=EN-GB>ases of hepatitis&nbsp;B reactivation, have
been reported, the majority of which were in patients receiving MabThera in
combination with cytotoxic chemotherapy</span><span lang=EN-GB>. In patients
with relapsed/refractory CLL, the incidence of grade 3/4 hepatitis B infection
(reactivation and primary infection) was 2% in R&#8209;FC vs 0% in FC. </span><span
lang=EN-GB>Progression of Kaposis sarcoma has been observed in MabThera&#8209;exposed
patients with pre&#8209;existing Kaposis sarcoma. These cases occurred in non&#8209;approved
indications and the majority of patients were HIV positive.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Haematologic
adverse reactions<b> </b></span></i></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>In
clinical trials with MabThera monotherapy given for 4 weeks, haematological
abnormalities occurred in a minority of patients and were usually mild and
reversible. Severe (grade&nbsp;3/4) neutropenia was reported in 4.2%, anaemia
in 1.1% and thrombocytopenia in 1.7% of the patients. During<u> </u>MabThera
maintenance treatment for up to 2 years, leucopoenia (5% vs. 2%, grade 3/4) and
neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when
compared to observation. The incidence of thrombocytopenia was low
(&lt;1&nbsp;%, grade&nbsp;3/4) and was not different between treatment arms.
During the treatment course in studies with MabThera in combination with chemotherapy,
</span><span lang=EN-GB style='color:black'>grade&nbsp;3/4 leucopoenia (R&#8209;CHOP
88% vs. CHOP 79%, R&#8209;FC 23% vs. FC 12%), </span><span lang=EN-GB
style='color:black'>grade&nbsp;3/4 </span><span lang=EN-GB style='color:black'>neutropenia
(R&#8209;CVP 24% vs. CVP 14%; R&#8209;CHOP 97% vs. CHOP 88%, R&#8209;FC 30% vs.
FC 19% in previously untreated CLL), </span><span lang=EN-GB style='color:black'>grade&nbsp;3/4
</span><span lang=EN-GB style='color:black'>pancytopenia (R&#8209;FC 3% vs. FC
1% in previously untreated CLL) were usually reported with higher frequencies
when compared to chemotherapy alone. However, the higher incidence of
neutropenia in patients treated with MabThera and chemotherapy was not
associated with a higher incidence of infections and infestations compared to
patients treated with chemotherapy alone<span style='background:white'>.
Studies with MabThera intravenous formulation in previously untreated and
relapsed/refractory CLL have established that in up to 25% of patients treated with
R&#8209;FC neutropenia was prolonged (defined as neutrophil count remaining
below 1x10<sup>9</sup>/L between day 24 and 42 after the last dose) or occurred
with a late onset (defined as neutrophil count below 1x10<sup>9</sup>/L later
than 42 days after last dose in patients with no previous prolonged neutropenia
or who recovered prior to day 42) following treatment with MabThera plus FC.</span></span><span
lang=EN-GB style='color:black'>There were no differences reported for the
incidence of anaemia.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='color:black'>Some c</span><span lang=EN-GB style='color:black'>ases
of late </span><span lang=EN-GB style='color:black'>neutropenia occurring more
than four weeks after the last infusion of MabThera were reported. </span><span
lang=EN-GB style='color:black;background:white'>In the CLL first&#8209;line
study, Binet stage C patients experienced more adverse events in the R&#8209;FC
arm compared to the FC arm (R&#8209;FC 83% vs. FC 71%)</span><span lang=EN-GB
style='color:black;background:white'>. In the relapsed/refractory CLL study </span><span
lang=EN-GB style='color:black;background:white'>grade </span><span lang=EN-GB
style='color:black;background:white'>3/4 </span><span lang=EN-GB
style='color:black;background:white'>thrombocytopenia was reported in 11% of
patients in the R&#8209;FC group compared to 9% of patients in the FC group.</span><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>In studies of MabThera in patients with Waldenstroms
macroglobulinaemia, transient increases in serum IgM levels have been observed
following treatment initiation, which may be associated with hyperviscosity and
related symptoms. The transient IgM increase usually returned to at least
baseline level within 4 months</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Cardiovascular adverse reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cardiovascular reactions during clinical
trials with MabThera monotherapy were reported in 18.8% of patients with the
most frequently reported events being hypotension and hypertension. Cases of
grade 3 or 4 arrhythmia (including ventricular and supraventricular
tachycardia) and angina pectoris during infusion were reported. </span><span
lang=EN-GB>During maintenance treatment, the incidence of grade&nbsp;3/4
cardiac disorders was comparable between patients treated with MabThera and
observation. Cardiac events were reported as serious adverse events (including
atrial fibrillation, myocardial infarction, left ventricular failure,
myocardial ischemia) in 3% of patients treated with MabThera compared to &lt;1%
on observation. In studies evaluating MabThera in combination with
chemotherapy, </span><span lang=EN-GB>the incidence of grade 3 and 4 cardiac
arrhythmias, predominantly supraventricular arrhythmias such as tachycardia and
atrial flutter/fibrillation, was higher in the R&#8209;CHOP group (14 patients,
6.9%) as compared to the CHOP group (3 patients, 1.5%). All of these
arrhythmias either occurred in the context of a MabThera infusion or were
associated with predisposing conditions such as fever, infection, acute
myocardial infarction or pre&#8209;existing respiratory and cardiovascular disease.
No difference between the R&#8209;CHOP and CHOP group was observed in the
incidence of other grade 3 and 4 cardiac events including heart failure,
myocardial disease and manifestations of coronary artery disease</span><span
lang=EN-GB>. In CLL, the overall incidence of grade 3 or 4 cardiac disorders
was low both in the first&#8209;line study (4% R&#8209;FC, 3% FC) and in the
relapsed/refractory study (4% R&#8209;FC, 4% FC).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Respiratory system</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Cases of interstitial lung disease, some
with fatal outcome have been reported.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Neurologic
disorders</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>During the
treatment period <b>(</b></span><span lang=EN-GB>induction treatment phase
comprising of R&#8209;CHOP for at most eight cycles)</span><span lang=EN-GB>,
four patients (2&nbsp;%) treated with R&#8209;CHOP, all with cardiovascular
risk factors, experienced thromboembolic cerebrovascular accidents during the
first treatment cycle. There was no difference between the treatment groups in
the incidence of other thromboembolic events. In contrast, three patients
(1.5%) had cerebrovascular events in the CHOP group, all of which occurred
during the follow&#8209;up period. In CLL, the overall incidence of grade 3 or
4 nervous system disorders was low </span><span lang=EN-GB>both in the first&#8209;line
study </span><span lang=EN-GB>(4% R&#8209;FC, 4% FC) </span><span lang=EN-GB>and
in the relapsed/refractory study (3% R&#8209;FC, 3% FC)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cases of </span><span
lang=EN-GB>posterior reversible encephalopathy syndrome (PRES) / reversible
posterior leukoencephalopathy syndrome (RPLS)</span><span lang=EN-GB> have been
reported.</span><span lang=EN-GB> Signs and symptoms included visual
disturbance, headache, seizures and altered mental status, with or without
associated hypertension. A diagnosis of PRES/RPLS requires confirmation by
brain imaging. The reported cases had recognized risk factors for PRES/RPLS,
including the patients underlying disease, hypertension, immunosuppressive
therapy and/or chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Gastrointestinal
disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Gastrointestinal perforation in some cases
leading to death has been observed in patients receiving MabThera for treatment
of Non&#8209;Hodgkins lymphoma (NHL). In the majority of these cases, MabThera
was administered with chemotherapy. </span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>IgG
levels</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the clinical trial evaluating MabThera
maintenance treatment in relapsed/refractory follicular lymphoma, median IgG
levels were below the lower limit of normal (LLN) (&lt;&nbsp;7 g/L) after
induction treatment in both the observation and the MabThera groups. In the
observation group, the median IgG level subsequently increased to above the
LLN, but remained constant in the MabThera group. The proportion of patients
with IgG levels below the LLN was about 60% in the MabThera group throughout
the 2 year treatment period, while it decreased in the observation group (36%
after 2&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Toxic Epidermal Necrolysis (Lyell Syndrome)
and Stevens&#8209;Johnson syndrome, some with fatal outcome, have been reported
very rarely.</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='layout-grid-mode:line'>Patient
subpopulations &#8209; MabThera monotherapy</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Elderly (</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65 years): </span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of ADRs of all grades and
grade 3 /4 ADR was similar in elderly patients compared to younger patients
(&lt;65 years). </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Bulky
disease:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>There was a
higher incidence of grade 3/4 ADRs in patients with bulky disease than in
patients without bulky disease (25.6&nbsp;% vs. 15.4&nbsp;%). The incidence of
ADRs of any grade was similar in these two groups.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Re&#8209;treatment:</span></p>

<p class=MsoNormal><span lang=EN-GB>The percentage of patients reporting ADRs
upon re&#8209;treatment with further courses of MabThera was similar to the
percentage of patients reporting ADRs upon initial exposure (any grade and
grade 3/4 ADRs).</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='layout-grid-mode:line'>Patient subpopulations &#8209; MabThera
combination therapy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Elderly (</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65 years) </span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of grade</span><span
lang=EN-GB> 3/4 </span><span lang=EN-GB>blood and lymphatic adverse events was
higher in elderly patients<span style='color:black;background:#00B050'> </span>compared
to younger patients </span><span lang=EN-GB>(&lt;65 years)</span><span
lang=EN-GB>, with previously untreated or relapsed/refractory CLL.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='color:black;background:#BFBFBF'>the national
reporting system listed in </span></span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:#BFBFBF'>Appendix V</span></a><a
name="_Hlt531783513"></a><a name="_Hlt531783512"></a><span lang=EN-GB
style='color:blue'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited experience with doses higher than
the approved dose of intravenous MabThera formulation is available from
clinical trials in humans. The highest intravenous dose of MabThera tested in
humans to date is 5000&nbsp;mg (2250&nbsp;mg/m<sup>2</sup>), tested in a dose
escalation study in patients with CLL. No additional safety signals were
identified.</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who experience overdose should
have immediate interruption of their infusion and be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Three patients in the MabThera
subcutaneous NHL formulation trial SABRINA (BO22334) were inadvertently adminstered
subcutaneous formulation through the intravenous route </span><span
lang=EN-GB>up to a maximum rituximab dose of 2780 mg </span><span lang=EN-GB>with
no untoward effect.<u><span style='color:red'> </span></u></span></p>

<p class=MsoNormal><span lang=EN-GB>Patients who experience overdose or
medication error with MabThera should be closely monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the post&#8209;marketing setting five
cases of MabThera overdose have been reported. Three cases had no reported
adverse event. The two adverse events that were reported were flu&#8209;like
symptoms, with a dose of 1.8&nbsp;g of rituximab and fatal respiratory failure,
with a dose of 2&nbsp;g of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: antineoplastic agents<i>,</i> monoclonal antibodies, ATC code: L01X C02</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera subcutaneous formulation contains
recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the
dispersion and absorption of co&#8209;administered substances when administered
subcutaneously.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab binds specifically to the
transmembrane antigen, CD20, a non&#8209;glycosylated phosphoprotein, located
on pre&#8209;B and mature B lymphocytes. The antigen is expressed on </span><span
lang=EN-GB style='font-family:Symbol'>&gt;</span><span lang=EN-GB>95&nbsp;% of
all B&nbsp;cell non&#8209;Hodgkins lymphomas. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>CD20 is found on both normal and malignant
B&nbsp;cells, but not on haematopoietic stem cells, pro&#8209;B&nbsp;cells,
normal plasma cells or other normal tissue. This antigen does not internalise
upon antibody binding and is not shed from the cell surface. CD20 does not
circulate in the plasma as a free antigen and, thus, does not compete for
antibody binding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Fab domain of rituximab binds to the
CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector
functions to mediate B&nbsp;cell lysis. Possible mechanisms of effector&#8209;mediated
cell lysis include complement&#8209;dependent cytotoxicity (CDC) resulting from
C1q binding, and antibody&#8209;dependent cellular cytotoxicity (ADCC) mediated
by one or more of the Fc</span><span lang=EN-GB style='font-family:Symbol'>g</span><span
lang=EN-GB> receptors on the surface of granulocytes, macrophages and NK cells.
Rituximab binding to CD 20 antigen on B lymphocytes has also been demonstrated
to induce cell death via apoptosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Peripheral B&nbsp;cell counts declined
below normal following completion of the first dose of MabThera. In patients
treated for hematological malignancies, B cell recovery began within 6 months
of treatment and generally returned to normal levels within 12 months after
completion of therapy, although in some patients this may take longer </span><span
lang=EN-GB>(up to a median recovery time of 23 months post&#8209;induction
therapy)</span><span lang=EN-GB>. In rheumatoid arthritis patients, immediate
depletion of B cells in the peripheral blood was observed following two
infusions of 1000&nbsp;mg MabThera separated by a 14 day interval. Peripheral
blood B cell counts begin to increase from week 24 and evidence for
repopulation is observed in the majority of patients by week 40, whether
MabThera was administered as monotherapy or in combination with methotrexate.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
experience of MabThera subcutaneous formulation in chronic lymphocytic leukaemia</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>A two&#8209;part phase Ib, multicenter, randomized, open&#8209;label,
parallel&#8209;group trial (SAWYER BO25341) was conducted in patients with
previously untreated CLL, to investigate the non&#8209;inferiority of the
pharmacokinetic profile, together with efficacy and safety of MabThera
subcutaneous formulation in combination with chemotherapy.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The objective of the Part 1 was to select a MabThera
subcutaneous formulation dose that resulted in comparable MabThera serum C<sub>trough</sub>
levels compared with MabThera intravenous formulation. A total of 64 patients
with CLL were enrolled at any point prior to cycle 5 during their treatment
with MabThera intravenous formulation in combination with chemotherapy. The
dose of 1600 mg of MabThera subcutaneous formulation was selected for the Part
2 of the study.</p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The objective of the Part 2
was to establish the non&#8209;inferiority in observed C<sub>trough</sub>
levels between the selected MabThera subcutaneous dose and the reference
MabThera intravenous dose.</p>

<p class=MsoNormal style='page-break-after:avoid'>A total of 176 patients with
CLL were randomized into the following two treatment groups:</p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> MabThera subcutaneous (n= 88); 1<sup>st</sup>
cycle of MabThera intravenous 375 mg/m<sup>2</sup> in combination with
chemotherapy plus subsequent cycles (2&#8209;6) of MabThera subcutaneous 1600mg
in combination with chemotherapy.</p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> MabThera intravenous (n= 88); 1<sup>st</sup>
cycle of MabThera intravenous 375 mg/m<sup>2</sup><sup> </sup>in combination
with chemotherapy followed by up to 5 cycles of MabThera intravenous 500 mg/m<sup>2
</sup>in combination with chemotherapy.</p>

<p class=MsoNormal style='text-autospace:none'>The response rates for the analysis
of 176 patients in SAWYER Part 2 are shown in Table 2.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal><b>Table&nbsp;2 Efficacy results for SAWYER (BO25341)
(Intent to Treat Population)</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:17.0pt'>
  <td width=313 colspan=2 rowspan=2 valign=top style='width:234.6pt;border:
  solid black 1.0pt;background:white;padding:.05in 7.8pt .05in 7.8pt;
  height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
  <td width=293 colspan=2 style='width:219.75pt;border:solid black 1.0pt;
  border-left:none;background:white;padding:.05in 7.8pt .05in 7.8pt;height:
  17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Part</span></b><b><span style='color:black'> 2</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>N = 176</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=142 style='width:106.35pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Rituximab intravenous formulation</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>(n = 88</span></b><b><span style='color:black'>)</span></b></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Rituximab subcutaneous formulation</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>(n = 88</span></b><b><span style='color:black'>)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal><b><span lang=DE-CH style='color:black'>ORR<sup>a</sup></span></b></p>
  </td>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=DE-CH style='color:black'>Point estimate </span></b></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>80.7</span></b><b><span style='color:black'>% (n = 7</span><span
  style='color:black'>1</span></b><b><span style='color:black'>)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>8</span><span style='color:black'>5.2</span></b><b><span
  style='color:black'>% (n = 7</span><span style='color:black'>5</span></b><b><span
  style='color:black'>)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>95% CI</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>[7</span><span style='color:black'>0.</span></b><b><span
  style='color:black'>9%, 8</span><span style='color:black'>8</span></b><b><span
  style='color:black'>.</span><span style='color:black'>3</span></b><b><span
  style='color:black'>%]</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>[7</span><span style='color:black'>6.1%, </span></b><b><span
  style='color:black'>91</span><span style='color:black'>.9</span></b><b><span
  style='color:black'>%]</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal><b><span style='color:black'>CRR<sup>a</sup></span></b></p>
  </td>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Point estimate </span></b></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>31.8</span></b><b><span style='color:black'>% (n = </span><span
  style='color:black'>28</span></b><b><span style='color:black'>)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>27</span></b><b><span style='color:black'>.</span><span
  style='color:black'>3</span></b><b><span style='color:black'>% (n = </span><span
  style='color:black'>24</span></b><b><span style='color:black'>)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>95% CI</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>[2</span><span style='color:black'>2.3%, 42.6</span></b><b><span
  style='color:black'>%]</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>[</span><span style='color:black'>18.3</span></b><b><span
  style='color:black'>%, 3</span><span style='color:black'>7.8</span></b><b><span
  style='color:black'>%]</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=53 rowspan=2 style='width:40.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal><b>PFS<sup>b</sup></b></p>
  </td>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Proportion with PFS event</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>42.0% (n = 37</span></b><b><span style='color:black'>)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>34.1% (n = 30</span></b><b><span style='color:black'>)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=259 valign=top style='width:194.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>95% CI</span></b></p>
  </td>
  <td width=293 colspan=2 valign=top style='width:219.75pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in 7.8pt .05in 7.8pt;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>0.76 [0.47%, 1.23%]</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>ORR  Overall
Response Rate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>CRR  Complete
Response Rate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>PFS  Progression-Free
Survival (proportion with event, disease progression/relapse or death from any
cause)</span></p>

<p class=MsoNormal><b><sup><span lang=EN-GB style='font-size:9.0pt'>a</span></sup></b><b><span
lang=EN-GB style='font-size:9.0pt'> </span></b><span lang=EN-GB
style='font-size:9.0pt'> at 3 month follow-up visit (Part 2)</span></p>

<p class=MsoNormal><b><sup><span lang=EN-GB style='font-size:9.0pt'>b</span></sup></b><span
lang=EN-GB style='font-size:9.0pt'>  at time of final analysis (median
follow-up 53 months) </span></p>

<p class=MsoNormal style='text-align:justify'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Overall the results confirm
that MabThera subcutaneous formulation 1600 mg has a comparable benefit/risk
profile to that of MabThera intravenous formulation 500 mg/m<sup>2</sup>.</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify'><i><u><span lang=EN-GB>Immunogenicity</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Data from the development programme of
MabThera subcutaneous formulation indicate that the formation of anti&#8209;rituximab
antibodies after subcutaneous administration is comparable with that observed
after intravenous administration<span style='color:black;background:white'>. </span></span><span
style='color:black;background:white'>In SAWYER trial (BO25341) the incidence of
treatment&#8209;induced/enhanced anti&#8209;rituximab antibodies was similar in
the two treatment arms; 15% intravenous vs. 12% subcutaneous. The incidence of
treatment&#8209;induced/enhanced anti&#8209;rHuPH20 antibodies, only measured
in patients in the subcutaneous arm was 12%. None of the patients who tested
positive for anti&#8209;rHuPH20 antibodies tested positive for neutralizing
antibodies</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>The clinical relevance of the development of <span
style='background:white'>anti&#8209;rituximab or</span> anti&#8209;rHuPH20
antibodies after treatment with MabThera subcutaneous formulation is not known.
</span><span style='color:black'>There was no impact of the presence of anti&#8209;rituximab
or anti&#8209;rHuPH20 antibodies on safety, efficacy or PK of MabThera.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
experience of MabThera concentrate for solution for infusion in CLL</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In two open&#8209;label randomised trials,
a total of 817 previously untreated patients and 552 patients with relapsed/refractory
CLL were randomised to receive either FC chemotherapy (fludarabine 25&nbsp;mg/m<sup>2</sup>,
cyclophosphamide 250&nbsp;mg/m<sup>2</sup>, days 1&#8209;3) every 4 weeks for 6
cycles or MabThera in combination with FC (R&#8209;FC). MabThera was
administered at a dosage of 375&nbsp;mg/m<sup>2</sup> during the first cycle
one day prior to chemotherapy and at a dosage of 500&nbsp;mg/m<sup>2</sup> on
day 1 of each subsequent treatment cycle. Patients were excluded from the study
in relapsed/refractory CLL if they had previously been treated with monoclonal
antibodies or if they were refractory (defined as failure to achieve a partial
remission for at least 6 months) to fludarabine or any nucleoside analogue. A
total of 810 patients (403 R&#8209;FC, 407 FC) for the first&#8209;line study
(Table&nbsp;2a and Table 2b) and 552 patients (276 R&#8209;FC, 276 FC) for the
relapsed/refractory study (Table&nbsp;3) were analysed for efficacy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the first&#8209;line study, after a
median observation time of 48.1&nbsp;months, the median PFS was 55&nbsp;months
in the R&#8209;FC group and 33&nbsp;months in the FC group
(p&nbsp;&lt;&nbsp;0.0001, log&#8209;rank test). The analysis of overall
survival showed a significant benefit of R&#8209;FC treatment over FC
chemotherapy alone (p&nbsp;=&nbsp;0.0319, log&#8209;rank test) (Table 2a).<b><i>
</i></b>The benefit in terms of PFS was consistently observed in most patient
subgroups analysed according to disease risk at baseline (i.e. Binet stages A&#8209;C)
(Table 2b).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><a name="_Ref200176478"><b><span lang=EN-GB>Table&nbsp;</span></b></a><b><span
lang=EN-GB>2a First&#8209;&#8209;line treatment of chronic lymphocytic
leukaemia</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;page-break-after:avoid'><b><span
lang=EN-GB>Overview of efficacy results for MabThera plus FC vs. FC alone &#8209;
48.1 months median observation time</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=577
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:25.55pt'>
   <td width=208 rowspan=2 valign=top style='width:156.2pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Efficacy Parameter</span></b></p>
   </td>
   <td width=274 colspan=3 valign=top style='width:205.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan&#8209;Meier
   Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=95 rowspan=2 valign=top style='width:71.2pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='height:7.45pt'>
   <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:
   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N = 409)</span></b></p>
   </td>
   <td width=83 valign=top style='width:62.0pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R&#8209;FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N=408)</span></b></p>
   </td>
   <td width=95 valign=top style='width:71.1pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Log&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;&#8209;&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>free survival (PFS)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>32.8</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>55.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>45%</span></p>
  </td>
 </tr>
 <tr style='height:13.35pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall survival </span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0319</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.35pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>27%</span></p>
  </td>
 </tr>
 <tr style='height:14.75pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Event free survival</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>31.3</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>51.8</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.75pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>44%</span></p>
  </td>
 </tr>
 <tr style='height:14.6pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Response rate
  (CR, nPR, or PR)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>72.6%</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>85.8%</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.6pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.85pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>CR rates</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>16.9%</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>36.0%</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001 </span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.85pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Duration of
  response*</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>36.2</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>57.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>44%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Disease free
  survival (DFS)**</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>48.9</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>60.3</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.0520</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>31%</span></p>
  </td>
 </tr>
 <tr style='height:15.5pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10><span lang=EN-GB style='font-size:11.0pt'>Time to new
  treatment</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>47.2</span></p>
  </td>
  <td width=83 valign=top style='width:62.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>69.7</span></p>
  </td>
  <td width=95 valign=top style='width:71.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=TextTi10 align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>42%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>Response rate and
CR rates analysed using Chi&#8209;squared Test. NR: not reached; n.a.: not
applicable</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>*: only applicable to patients achieving a
CR, nPR, PR</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>**: only applicable to patients achieving a
CR</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;2b First&#8209;line treatment of
chronic lymphocytic leukaemia</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;page-break-after:avoid'><b><span
lang=EN-GB>Hazard ratios of progression&#8209;free survival according to Binet
stage (ITT)  48.1 months median observation time</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=586
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:25.55pt'>
  <td width=227 rowspan=2 valign=top style='width:170.1pt;border:solid black 1.0pt;
  border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span></b><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;</span></b><b><span
  lang=EN-GB style='font-size:11.0pt'>free survival (PFS)</span></b></p>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=113 colspan=2 valign=top style='width:85.05pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Number of patients</span></b></p>
  </td>
  <td width=132 rowspan=2 valign=top style='width:99.25pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Hazard Ratio (95% CI)</span></b></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.05pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>p&#8209;value (Wald test,
  not adjusted)</span></b></p>
  </td>
 </tr>
 <tr style='height:7.45pt'>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>R</span></b><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;&#8209;</span></b><b><span
  lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dotted windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 style='margin-left:1.7pt;text-align:justify;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Binet stage A</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>22</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>18</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.39 (0.15; 0.98)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0442</span></p>
  </td>
 </tr>
 <tr style='height:12.4pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dotted windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Binet stage B</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>259</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>263</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.52 (0.41; 0.66)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Binet stage C</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>126</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>126</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.68 (0.49; 0.95)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0224</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>CI: Confidence
Interval</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the relapsed/refractory study, the
median progression&#8209;free survival (primary endpoint)</span><span
lang=EN-GB> was 30.6 months </span><span lang=EN-GB>in the R&#8209;FC group and
20.6 months in the FC group (p=0.0002, log&#8209;&#8209;rank test). The benefit
in terms of PFS was observed in almost all patient subgroups analysed according
to disease risk at baseline. A slight but not significant improvement in
overall survival was reported in the R&#8209;FC compared to the FC arm. </span></p>

<p class=MsoNormal>No PK/clinical data are available in patients with a
refractory or relapsing disease.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b>Table&nbsp;3 Treatment of relapsed/refractory chronic
lymphocytic leukaemia &#8209;overview of</b><b><span lang=EN-GB> efficacy
results for MabThera plus FC vs. FC alone (25.3 months median observation time)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=577
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:25.55pt'>
   <td width=208 rowspan=2 valign=top style='width:156.2pt;border:solid black 1.0pt;
   border-left:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Efficacy Parameter</span></b></p>
   </td>
   <td width=274 colspan=3 valign=top style='width:205.5pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Kaplan&#8209;&#8209;Meier Estimate of <br>
   Median Time to Event (Months)</span></b></p>
   </td>
   <td width=95 rowspan=2 valign=top style='width:71.2pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.55pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Risk Reduction</span></b></p>
   </td>
  </tr>
  <tr style='height:7.45pt'>
   <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:
   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>FC</span></b></p>
   <p class=TextTi10 align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt'>(N = 276)</span></b></p>
   </td>
   <td width=92 valign=top style='width:68.95pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>R&#8209;&#8209;FC</span></b></p>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>(N=276)</span></b></p>
   </td>
   <td width=86 valign=top style='width:64.15pt;border:solid black 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Log&#8209;&#8209;Rank <br>
   p value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Progression</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Cambria Math",serif'>&#8209;&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>free survival (PFS)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>20.6</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>30.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0002</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>35%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.4pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Overall survival </span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>51.9</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.2874</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.4pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>17%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Event free survival</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>19.3</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>28.7</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0002</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>36%</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Response rate (CR, nPR, or PR)</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>58.0%</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>69.9%</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0034</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:26.75pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>CR rates</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>13.0%</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>24.3%</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0007 </span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>n.a.</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Duration of response </span><span lang=EN-GB>*</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>27.6</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>39.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0252</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>31%</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Disease free survival (DFS)**</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>42.2</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>39.6</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.8842</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Cambria Math",serif'>&#8209;&#8209;</span><span
  lang=EN-GB style='font-size:11.0pt'>6%</span></p>
  </td>
 </tr>
 <tr style='height:26.3pt'>
  <td width=208 valign=top style='width:156.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Time to new CLL treatment</span></p>
  </td>
  <td width=97 valign=top style='width:72.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>34.2</span></p>
  </td>
  <td width=92 valign=top style='width:68.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>NR</span></p>
  </td>
  <td width=86 valign=top style='width:64.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0.0024</span></p>
  </td>
  <td width=95 valign=top style='width:71.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.3pt'>
  <p class=TextTi10 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>35%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><i><span lang=EN-GB style='font-size:9.0pt'>Response rate
and CR rates analysed using Chi&#8209;&#8209;squared Test.</span></i></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>*: only applicable to patients achieving a
CR, nPR, PR; NR: not reached n.a. not applicable </span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt'>**: only applicable to patients achieving a
CR; </span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Results from other supportive studies using
MabThera in combination with other chemotherapy regimens (including CHOP, FCM,
PC, PCM, </span><span lang=EN-GB>bendamustine and cladribine</span><span
lang=EN-GB>) for the treatment of previously untreated and/or
relapsed/refractory CLL patients have also demonstrated high overall response
rates with </span><em><span lang=EN-GB style='font-style:normal'>benefit in
terms of</span></em><em><span lang=EN-GB> </span></em><span lang=EN-GB>PFS
rates, albeit with modestly higher toxicity (especially myelotoxicity). These
studies support the use of MabThera with any chemotherapy.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Data in
approximately 180 patients pre&#8209;&#8209;treated with MabThera have
demonstrated clinical benefit (including CR) and are supportive for MabThera re&#8209;&#8209;treatment.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with rituximab in all subsets
of the paediatric population with CLL. See Section 4.2 for information on
paediatric use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>MabThera </span>at a fixed dose of 1600 mg
was administered for 5 cycles subcutaneously at 4&#8209;weekly intervals,
following the first cycle of <span lang=EN-GB>MabThera intravenous formulation</span>,
in previously untreated CLL patients in combination with chemotherapy (fludarabine
and cyclophosphamide (FC). The serum <span lang=EN-GB>MabThera </span>C<sub>max</sub>
at Cycle&nbsp;6 was lower in the subcutaneous arm than the intravenous, with
geometric mean (CV%) values of 202 (36.1) &#956;g/mL and 280 (24.6) &#956;g/mL
with the resulting geometric mean ratio (C<sub>max,&nbsp;SC</sub>/C<sub>max,&nbsp;IV</sub>)
of 0.719 (90%&nbsp;CI: 0.653, 0.792). <span lang=EN-GB>The geometric mean t<sub>max</sub>
in the</span><span lang=EN-GB> MabThera subcutaneous group</span><span
lang=EN-GB> was approximately 3 days as compared to the t<sub>max</sub>
occuring at or close to the end of the infusion for the</span><span lang=EN-GB>
MabThera intravenous group. </span>The geometric mean C<sub>trough</sub> (CV%)
values at Cycle 5 (pre&#8209;dose Cycle 6) were higher among the MabThera
subcutaneous group than the MabThera intravenous group; 97.5 <span
style='font-family:Symbol'>m</span>g/mL (42.6) versus 61.5 <span
style='font-family:Symbol'>m</span>g/mL (63.9) respectively with a resulting
adjusted geometric mean ratio [90% CI] of 1.53 [1.27&#8209;1.85]. Similarly,
the geometric mean AUC (CV%) values at Cycle 6 were higher among the <span
lang=EN-GB>subcutaneous</span> group than the <span lang=EN-GB>intravenous</span>
group; 4088 <span lang=EN-GB>g</span><span style='font-family:Symbol'></span>day<span
lang=EN-GB>/mL</span> (34.2) versus 3630 <span lang=EN-GB>g</span><span
style='font-family:Symbol'></span>day<span lang=EN-GB>/mL</span> (32.8)
respectively) with a resulting adjusted geometric mean ratio [90% CI] of 1.10
[0.98&#8209;1.24].</p>

<p class=MsoNormal><span lang=EN-GB>Based on popPK analysis of study BO25341
(SAWYER) </span><span lang=EN-GB>an absolute</span><span lang=EN-GB>
bioavailability of 68.4% was estimated.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution/Elimination</span></u></p>

<p class=MsoNormal><u><span style='background:yellow'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span style='color:black;background:white'>The estimated
half&#8209;life of Mabthera subcutaneous formulation of 1600 mg is 30 days, the
estimated clearance is 0.22 L/day and the volume of distribution of the central
compartment is 4.65 L.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u>Special populations</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>As typical for monoclonal antibodies, rituximab PK
parameters depended on body size measures. All clearance and volume parameters
increased with BSA. In addition, central volume was slightly (9%) lower in
females compared to males. Absorption parameters of subcutaneous formulation,
<span style='color:black'>decreased with increasing BMI. </span>Conditional
simulations that summarized the impact of all body size dependencies on
rituximab exposure demonstrated that, while fixed subcutaneous dosing leads to
larger differences in exposure (C<sub>trough</sub> and AUC<sub>&#964;</sub>)
between subjects with low and high body sizes compared to body&#8209;weight&#8209;adjusted
intravenous dosing, it allows to maintain C<sub>trough</sub> and AUC<sub>&#964;</sub>
values for all body&#8209;size groups at the levels not lower than levels
attained by intravenous dosing, thus achieving at least the same target
saturation as for intravenousdosing. For subjects weighing <span
style='font-size:5.5pt'>&nbsp;</span><span style='font-family:Symbol'>&gt;</span><span
style='font-size:5.5pt'>&nbsp;</span>90&nbsp;kg, C<sub>trough</sub> values were
the same for the intravenous and subcutaneous regimens. For subjects weighing
60&#8209;90&nbsp;kg and <span style='font-size:5.5pt'>&nbsp;</span><span
style='font-family:Symbol'>&lt;</span><span style='font-size:5.5pt'>&nbsp;</span>60&nbsp;kg,
average C<sub>trough</sub> values following intravenous dosing were
approximately 16% and 34% lower compared to the subcutaneous regimen,
respectively. Similarly, for subjects in the high BSA tritile, C<sub>trough</sub>
values were the same for the intravenous and subcutaneous regimens. For
subjects in the middle and low BSA tritiles, average C<sub>trough</sub> values
following intravenous dosing were approximately 12% and 26% lower compared to
the subcutaneous regimen.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In addition to dependence on body size, time&#8209;dependent
clearance was higher in subjects with higher baseline tumour size, which is
consistent with target&#8209;mediated elimination. Higher time&#8209;dependenet
clearance in subjects with higher disease burden would lead to lower initial
exposure and longer time needed to achieve the same exposure as in subjects
with lower burden of the disease.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rituximab has shown to be highly specific
to the CD20 antigen on B&nbsp;cells. Toxicity studies in cynomolgus monkeys
have shown no other effect than the expected pharmacological depletion of
B&nbsp;cells in peripheral blood and in lymphoid tissue. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Developmental toxicity studies have been
performed in cynomolgus monkeys at doses up to 100&nbsp;mg/kg (treatment on
gestation days 20&#8209;50) and have revealed no evidence of toxicity to the
foetus due to rituximab. However, dose&#8209;dependent pharmacologic depletion
of B&nbsp;cells in the lymphoid organs of the foetuses was observed</span><span
lang=EN-GB>, which persisted post natally and was accompanied by a decrease in
IgG level in the newborn animals affected. B cell counts returned to normal in
these animals within 6 months of birth and did not compromise the reaction to
immunization.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Standard tests to investigate mutagenicity
have not been carried out, since such tests are not relevant for this molecule.
</span><span lang=EN-GB>No long&#8209;term animal studies have been performed
to establish the carcinogenic potential of rituximab.<s> </s></span></p>

<p class=MsoNormal><span lang=EN-GB>Specific studies to determine the effects
of rituximab or rHuPH20 on fertility have not been performed. In general
toxicity studies in cynomolgus monkeys no deleterious effects on reproductive
organs in males or females were observed. Additionally, no effects on semen
quality were shown for rHuPH20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In embryofetal developmental studies in
mice, rHuPH20 caused reduced fetal weight and loss of implantations at systemic
exposures sufficiently in excess of human therapeutic exposure.</span></p>

<p class=MsoNormal><span lang=EN-GB>There is no evidence of dysmorphogenesis
(i.e. teratogenesis) resulting from systemic exposure to rHuPH20.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.7pt;text-indent:-.7pt'><b><span
lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Recombinant human hyaluronidase (rHuPH20)</span></p>

<p class=MsoNormal><span lang=DA>L&#8209;histidine</span></p>

<p class=MsoNormal><span lang=DA>L&#8209;histidine hydrochloride monohydrate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>,</span><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>&#8209;trehalose dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;methionine</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 80 (E433)</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span><span
lang=EN-GB style='color:green'> </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No incompatibilities between MabThera
subcutaneous formulation and polypropylene or polycarbonate syringe material or
stainless steel transfer and injection needles and polyethylene Luer cone
stoppers have been observed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30 months</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>After
first opening</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Once transferred from the vial into the syringe,
the solution of MabThera subcutaneous formulation is physically and chemically
stable for 48 hours at 2&nbsp;C&nbsp;&#8209;&nbsp;8&nbsp;C and subsequently
for 8 hours at </span><span lang=EN-GB>30C in diffuse daylight<span
style='layout-grid-mode:line'>.</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>F</span><span lang=EN-GB style='color:black'>rom
a microbiological point of view, the product should be used immediately. If not
used immediately, </span><span lang=EN-GB>preparation should take place in
controlled and validated aseptic conditions. I</span><span lang=EN-GB
style='color:black'>n&#8209;use storage times and conditions prior to use are
the responsibility of the user.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C  8&nbsp;C). Keep the container in the outer carton in
order to protect from light.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>For storage conditions after first opening see
section 6.3.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Colourless type I glass vial with butyl
rubber stopper with aluminium over seal and a blue plastic flip&#8209;off disk,
containing 1600&nbsp;mg/13.4 mL of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each carton contains one vial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.6 Special precautions for disposal and other
handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>MabThera is
provided in sterile, preservative&#8209;free, non&#8209;pyrogenic, single use
vials. Use sterile needle and syringe to prepare MabThera. A peel&#8209;off
sticker is included on the vials which specifies the strength, route of
administration and indication. This sticker should be removed from the vial and
stuck onto the syringe prior to use. </span><span lang=EN-GB>The following
points should be strictly adhered to regarding the use and disposal of syringes
and other medicinal sharps: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Needles and syringes should never be reused</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Place all used needles and syringes into a Sharps container
(puncture</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8209;</span><span
lang=EN-GB>proof disposable container). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>EU/1/98/067/004</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 2 June 1998</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 2 June 2008</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency (EMA) </span><a href="http://www.ema.europa.eu/"><span
lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>http://www.ema.europa.eu/</span></a></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:"TimesNewRoman,Italic",serif'>&nbsp;</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:blue'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'><b>ANNEX II</b></p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>A. MANUFACTURERS
OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH
RELEASE</b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-align:justify;text-indent:
-35.4pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>B. CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>C. OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-35.4pt'><b>D. CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</b></p>

<p class=MsoNormal align=center style='margin-left:85.05pt;text-align:center;
text-indent:-35.4pt'><b>&nbsp;</b></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>A. MANUFACTURERS OF THE BIOLOGICAL
ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Names and addresses of the manufacturers
of the biological active substance</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Genentech Inc.</span></p>

<p class=MsoNormal><span lang=EN-GB>1000 New Horizons Way</span></p>

<p class=MsoNormal><span lang=EN-GB>Vacaville, CA 95688</span></p>

<p class=MsoNormal><span lang=EN-GB>USA</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Genentech, Inc.</span></p>

<p class=MsoNormal><span lang=EN-GB>1 Antibody Way</span></p>

<p class=MsoNormal><span lang=EN-GB>Oceanside, CA 92056 5802</span></p>

<p class=MsoNormal><span lang=EN-GB>USA</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Samsung BioLogics</span></p>

<p class=MsoNormal>300, Songdo Bio Way (Daero)<br>
Yeonsu-gu, Incheon 21987, </p>

<p class=MsoNormal>Korea </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>Roche Pharma</span><span lang=DE> </span><span
lang=DE>AG</span></p>

<p class=MsoNormal><span lang=DE>Emil&#8209;Barell&#8209;Str. </span><span
lang=DE-CH>1</span></p>

<p class=MsoNormal>D&#8209;79639 Grenzach&#8209;Wyhlen</p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (See Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>C. OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='font-family:Symbol'></span> <b><span
lang=EN-GB>Periodic safety update reports</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The requirements for submission of PSURs for this medicinal
product are set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates
published on the European medicines web-portal</p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=AnnexHeading><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></p>

<p class=MsoNormal style='line-height:13.0pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
style='font-family:Symbol'></span> <b><span lang=EN-GB>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The marketing authorisation holder (MAH)
shall perform the pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and
any agreed and subsequent updates of the RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>An updated
RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-21.25pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:Symbol'></span></b><b><span
lang=EN-GB> At the request of the European Medicines Agency.</span></b></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-21.25pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-family:Symbol'></span></b><b><span
lang=EN-GB> </span></b><span lang=EN-GB>Whenever the risk management system
is modified, especially as the result of new information being received that
may lead to a significant change to the benefit/risk profile or as the result
of an important (pharmacovigilance or risk minimisation) milestone being
reached</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If the <b>dates for</b> submission of a
PSUR and the update of a RMP coincide, they can be submitted at the same time.<i>
</i></span></p>

<p class=MsoNormal style='text-align:justify;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
style='font-family:Symbol'></span> <b><span lang=EN-GB>Additional risk
minimisation measures </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Non</span></u><u>-oncology indications:</u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The MAH must ensure that all physicians who
are expected to prescribe MabThera are provided with the following:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Product information<br>
Physician information<br>
Patient information<br>
Patient Alert card</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The Physician information about MabThera
should contain the following key elements:</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The need for close supervision during administration
in an environment where full resuscitation facilities are immediately available</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The need to check, prior to MabThera
treatment, for infections, for immunosuppression, for prior/current medication
affecting the immune system and recent history of, or planned, vaccination</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The need to monitor patients for
infections, especially PML, during and after MabThera treatment</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> Detailed information on the risk of PML,
the need for timely diagnosis of PML and appropriate measures to diagnose PML</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The need to advise patients on the risk
of infections and PML, including the symptoms to be aware of and the need to
contact their doctor immediately if they experience any.</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The need to provide patients with the
Patient Alert Card with each infusion</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Patient information about MabThera
should contain the following key elements:</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> Detailed information on the risk of
infections and PML</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> Information on the signs and symptoms of
infections, especially PML, and the need to contact their doctor immediately if
they experience any</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> The importance of sharing this
information with their partner or caregiver</p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> Information on the Patient Alert Card</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Patient Alert Card for MabThera in non&#8209;oncology
indications should contain the following key elements:</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB>The need to carry the
card at all times and to show the card to all treating health care
professionals</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB>Warning on the risk of
infections and PML, including the symptoms</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB>The need for patients
to contact their health care professional if symptoms occur</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Physician information, Patient
information and Patient Alert Card must be agreed with the National Competent
Authorities prior to distribution.</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Subcutaneous
formulation:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All healthcare professionals administering
MabThera subcutaneous formulation will be provided with an Educational Material
(&nbsp;step by step guide&nbsp; and  comparison card ) to minimise the risk
of off label use and administration route error.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>A. LABELLING</span></p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
  PACKAGING </span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>OUTER CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 100&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
  SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 vial contains 10&nbsp;mg/mL rituximab.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium citrate, polysorbate 80, sodium
chloride, sodium hydroxide, hydrochloric acid, water for injections. </span></p>

<p class=MsoNormal><span lang=EN-GB>Read the leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
  CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>100 mg / 10 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>2 vials of 10&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
  OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
  NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator. Keep the container
in the outer carton, in order to protect from light</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
  PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
  APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
  MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>12. MARKETING AUTHORISATION
  NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/98/067/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
  SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Justification for not including Braille
accepted</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17. UNIQUE IDENTIFIER
 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>2D barcode carrying the unique identifier included.</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18. UNIQUE IDENTIFIER &#8209;&#8209;
HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC </p>

<p class=MsoNormal>SN </p>

<p class=MsoNormal>NN </p>

<p class=MsoNormal>&nbsp;</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
  IMMEDIATE PACKAGING UNITS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>VIAL LABEL</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 100&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME
  OR BY UNIT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vial of 10&nbsp;mL (10&nbsp;mg/mL)</span></p>

<p class=MsoNormal><span lang=EN-GB>100 mg / 10 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>6. OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
  PACKAGING </span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>OUTER CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 500&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
  SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>1 vial contains 10&nbsp;mg/mL rituximab.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium citrate, polysorbate 80, sodium
chloride, sodium hydroxide, hydrochloric acid, water for injections. </span></p>

<p class=MsoNormal><span lang=EN-GB>Read the leaflet for further information. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
  CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>500 mg / 50 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>1 vial of 50&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
  ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
  OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
  NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator. Keep the container
in the outer carton, in order to protect from light</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
  PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
  APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
  MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>12. MARKETING AUTHORISATION
  NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/98/067/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
  SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Justification for not including Braille accepted</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17. UNIQUE IDENTIFIER
 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>2D barcode carrying the unique identifier included.</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18. UNIQUE IDENTIFIER &#8209;&#8209;
HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC </p>

<p class=MsoNormal>SN </p>

<p class=MsoNormal>NN </p>

<p class=MsoNormal>&nbsp;</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
  IMMEDIATE PACKAGING UNITS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>VIAL LABEL</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 500&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vial of 50&nbsp;mL (10&nbsp;mg/mL)</span></p>

<p class=MsoNormal><span lang=EN-GB>500 mg / 50 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>6. OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>PATIENT
ALERT CARD TEXT FOR NON&#8209;ONCOLOGY INDICATIONS</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:43.95pt'>
  <td width=287 valign=top style='width:215.35pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.95pt'>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>MabThera Alert Card for
  patients with non&#8209;oncology diseases</span></u></b></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'><span style='text-decoration:
   none'>&nbsp;</span></span></u></b></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>Why have I been given
  this card?</span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.5pt;margin-bottom:
  6.0pt;margin-left:21.3pt'><span lang=EN-GB style='line-height:110%'>This medicine
  may make you more likely to get infections. This card tells&nbsp;you:</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  6.0pt;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>What you need to know before having MabThera</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  6.0pt;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>What the signs of an infection are </span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  6.0pt;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>What to do if you think you might be&nbsp;getting an infection.</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.5pt;margin-bottom:
  6.0pt;margin-left:21.3pt'><span lang=EN-GB style='line-height:110%'>It also
  includes your name and doctors&nbsp;name and phone number on&nbsp;the back.</span></p>
  <p class=LUTOnormaltext align=center style='margin-top:12.0pt;margin-right:
  3.4pt;margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span
  lang=EN-GB style='line-height:110%'>What should I do with this card?</span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:31.7pt;margin-bottom:
  6.0pt;margin-left:.4in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Keep this card with you all the time&nbsp;&#8209;&nbsp;such&nbsp;as in
  your wallet or purse.</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  6.0pt;margin-left:.4in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Show this card to any doctor, nurse&nbsp;or&nbsp;dentist you see &#8209;
  not just the&nbsp;specialist who prescribes your MabThera.</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:10.6pt;margin-bottom:
  6.0pt;margin-left:14.2pt'><span lang=EN-GB style='line-height:110%'>Keep this
  card with you for 2 years after&nbsp;your last dose of MabThera.
  This&nbsp;is&nbsp;because side effects can develop&nbsp;several months after
  you have&nbsp;had treatment.</span></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'><span style='text-decoration:
   none'>&nbsp;</span></span></u></b></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>When should I not have
  MabThera?</span></b></p>
  <p class=Default style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
  margin-left:14.2pt'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Do
  not have MabThera if you have an active infection or a serious problem with
  your immune system.</span></p>
  <p class=Default style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
  margin-left:14.2pt'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tell
  your doctor or nurse if you are taking or have previously taken medicines
  which may affect your immune system this includes chemo&#8209;therapy.</span></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  color:windowtext'>What are the signs of getting an infection?</span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:21.25pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Look out for the following possible signs of
  infection:</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Fever or cough all the time </span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Weight loss</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Pain without injuring yourself</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:.5in;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'></span><b><span lang=EN-GB
  style='line-height:110%'> </span></b><span lang=EN-GB style='line-height:
  110%'>Feeling generally unwell or listless.</span></p>
  <p class=LUTOnormaltext style='margin-top:6.0pt;margin-right:3.4pt;
  margin-bottom:0in;margin-left:21.25pt'><b><span lang=EN-GB style='line-height:
  110%'>If you get any of these, tell a doctor or nurse straight away.</span></b></p>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>You should also tell
  them about your MabThera treatment.</span></b></p>
  </td>
  <td valign=top style='border:solid black 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;
  height:43.95pt'>
  <p class=Default align=center style='margin-bottom:6.0pt;text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt;color:windowtext'>What else do I need to
  know?</span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:4.8pt;margin-bottom:
  6.0pt;margin-left:21.3pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Rarely MabThera can cause a serious brain infection,
  called Progressive Multifocal Leukoencephalopathy or PML.
  This&nbsp;can&nbsp;be fatal. </span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:21.25pt;page-break-after:avoid'><span lang=EN-GB
  style='font-family:Symbol'></span><b><span lang=EN-GB style='line-height:
  110%'> </span></b><span lang=EN-GB style='line-height:110%'>Signs of PML
  include: </span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:64.1pt;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>&#8209;<b> </b>Confusion, memory loss
  or problems thinking</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:64.1pt;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>&#8209;<b> </b>Loss of balance or a
  change in the way you walk or talk</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:64.1pt;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>&#8209;<b> </b>Decreased strength or
  weakness on one side of your body</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:.05in;margin-bottom:
  0in;margin-left:64.1pt;text-indent:-.2in;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>&#8209;<b> </b>Blurred vision or loss
  of vision.</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;text-indent:45.25pt;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>&nbsp;</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>If you get any of these, tell a doctor or nurse
  straight away. You should also tell them about your MabThera treatment.</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>&nbsp;</span></p>
  <p class=LUTOnormaltext align=center style='margin-left:18.55pt;text-align:
  center;page-break-after:avoid'><b><span lang=EN-GB style='line-height:110%'>Where
  can I get more information?</span></b></p>
  <p class=LUTOnormaltext style='margin-left:18.55pt;page-break-after:avoid'><span
  lang=EN-GB style='line-height:110%'>See the MabThera package leaflet for more
  information.</span></p>
  <p class=LUTOnormaltext style='margin-left:18.55pt;page-break-after:avoid'><b><span
  lang=EN-GB style='line-height:110%'>Treatment start date and contact details </span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Date of most recent infusion: ____________</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Date of first infusion: ___________________</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Patients Name:________________________</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Doctors Name:________________________</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Doctors contact details:_________________</span></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><b><span lang=EN-GB
  style='line-height:110%'>&nbsp;</span></b></p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:-.05pt;margin-bottom:
  6.0pt;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>Make sure you have a list of all your medicines when
  you see a health care professional. </span></p>
  <p class=MsoNormal style='margin-left:18.55pt'>Please talk to your doctor or
  nurse if you have any questions about the information in this card.</p>
  <p class=LUTOnormaltext style='margin-top:0in;margin-right:3.4pt;margin-bottom:
  0in;margin-left:18.55pt;page-break-after:avoid'><span lang=EN-GB
  style='line-height:110%'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
  PACKAGING </span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>OUTER CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400&nbsp;mg solution for
subcutaneous injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
  SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=FR>1 vial contains
1400&nbsp;mg/11.7 mL rituximab.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Recombinant human hyaluronidase (rHuPH20)</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;histidine</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;histidine hydrochloride monohydrate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>,</span><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>&#8209;trehalose dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;methionine</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
  CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#BFBFBF'>Solution
for injection</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>1,400&nbsp;mg/11.7&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB>1 vial </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For subcutaneous use only </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
  OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
  NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8. EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C 
8&nbsp;C). Do not freeze.&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton, in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
  PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
  APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
  MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>12. MARKETING AUTHORISATION
  NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>EU/1/98/067/003</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
  SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Justification for not including Braille
accepted</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17. UNIQUE IDENTIFIER
 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>2D barcode carrying the unique identifier included.</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18. UNIQUE IDENTIFIER &#8209;&#8209;
HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC </p>

<p class=MsoNormal>SN </p>

<p class=MsoNormal>NN </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
  IMMEDIATE PACKAGING UNITS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>VIAL LABEL</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>MabThera
1400&nbsp;mg solution for subcutaneous injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:darkgray'>subcutaneous</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>Only for
subcutaneous use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME
  OR BY UNIT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>1,400&nbsp;mg/11.7&nbsp;mL
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>6. OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Information to appear on <u>Peel&#8209;off sticker</u></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>MabThera
1400&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1,400 mg/11.7 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC for Non-Hodgkins Lymphoma</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
  PACKAGING </span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>OUTER CARTON</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600&nbsp;mg solution for
subcutaneous injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
  SUBSTANCE(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=FR>1 vial contains 1600&nbsp;mg/13.4
mL rituximab.</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Recombinant human hyaluronidase (rHuPH20)</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;histidine</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;histidine hydrochloride monohydrate</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>,</span><span lang=EN-GB style='font-family:Symbol'>a</span><span
lang=EN-GB>&#8209;trehalose dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB>L&#8209;methionine</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
  CONTENTS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>Solution
for injection</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>1,600&nbsp;mg/13.4&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB>1 vial </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For subcutaneous use only </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
  OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
  NECESSARY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8. EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C 
8&nbsp;C). Do not freeze.&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton, in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
  lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
  PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
  APPROPRIATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING
  AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>12. MARKETING AUTHORISATION
  NUMBER(S)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>EU/1/98/067/004</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
  SUPPLY</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17. UNIQUE IDENTIFIER
 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>2D barcode carrying the unique identifier included.</p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18. UNIQUE IDENTIFIER &#8209;&#8209;
HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC </p>

<p class=MsoNormal>SN </p>

<p class=MsoNormal>NN </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:37.2pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:37.2pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
  IMMEDIATE PACKAGING UNITS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>VIAL LABEL</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT
  AND ROUTE(S) OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600&nbsp;mg solution for
subcutaneous injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:darkgray'>subcutaneous</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Only for subcutaneous use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME
  OR BY UNIT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>1,600&nbsp;mg/13.4&nbsp;mL
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>6. OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Information to appear on <u>Peel&#8209;off sticker</u></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>rituximab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1,600 mg/13.4 mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC for Chronic Lymphocytic Leukaemia</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>MabThera
100&nbsp;mg concentrate for solution for infusion </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>MabThera
500&nbsp;mg concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>rituximab
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read this leaflet carefully before you
start taking this medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
have any further questions, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-family:Symbol'></span></b><b><span lang=EN-GB> </span></b><span
lang=EN-GB>If you get any side effects talk to your doctor, pharmacist or
nurse. This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What MabThera is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you use MabThera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How to use MabThera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store MabThera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1. What MabThera is and what it is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera contains the active substance
rituximab. This is a type of protein called a monoclonal antibody. It
sticks to the surface of a type of white blood cell called B&#8209;Lymphocyte.
When rituximab sticks to the surface of this cell, the cell dies.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera may be used for the treatment of
several different conditions</span><span lang=EN-GB> in adults and children</span><span
lang=EN-GB>. Your doctor may prescribe MabThera for the treatment of:</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>a) Non&#8209;Hodgkins Lymphoma</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This is a disease of the lymph tissue (part
of the immune system) that affects a type of white blood cell called B&#8209;Lymphocytes.</span></p>

<p class=MsoNormal><span lang=EN-GB>In adults MabThera can be given alone or
with other medicines called chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>In adult patients where the treatment is
working, MabThera may be used as a maintenance treatment for 2 years after
completing the initial treatment.</span></p>

<p class=MsoNormal>In children and adolescents, MabThera is given in
combination with chemotherapy.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>b) Chronic lymphocytic leukaemia</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Chronic lymphocytic leukaemia (CLL) is the
most common form of adult leukaemia.</span><span lang=EN-GB> CLL affects a
particular lymphocyte, the B cell, which originates from the bone marrow and
develops in the lymph nodes. Patients with CLL have too many abnormal lymphocytes,
which accumulate mainly in the bone marrow and blood. </span><span lang=EN-GB>The
proliferation of these abnormal B&#8209;lymphocytes is the cause of symptoms
you may have. MabThera in combination with chemotherapy destroys these cells
which are gradually removed from the body by biological processes.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>c) Rheumatoid arthritis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is used for the treatment of
rheumatoid arthritis. Rheumatoid arthritis is a disease of the joints. B
lymphocytes are involved in the cause of some of the symptoms you have.
MabThera is used to treat rheumatoid arthritis in people who have already tried
some other medicines which have either stopped working, have not worked well
enough or have caused side effects. MabThera is usually taken together with
another medicine called methotrexate. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera slows down the damage to your
joints caused by rheumatoid arthritis and improves your ability to do normal
daily activities.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The best responses to MabThera are seen in
those who have a positive blood test to rheumatoid factor (RF) and/or anti&#8209;Cyclic
Citrullinated Peptide (anti&#8209;CCP). Both tests are commonly positive in
rheumatoid arthritis and aid in confirming the diagnosis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>d) Granulomatosis with polyangiitis
or microscopic polyangiitis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is used for the treatment of adults
and children 2 years of age and older with granulomatosis with polyangiitis
(formerly called Wegeners granulomatosis) or microscopic polyangiitis, taken
in combination with corticosteroids.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Granulomatosis with polyangiitis and
microscopic polyangiitis are two forms of inflammation of the blood vessels
which mainly affects the lungs and kidneys, but may affect other organs as
well. B lymphocytes are involved in the cause of these conditions.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>e) Pemphigus vulgaris</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera is
used for the treatment of patients with moderate to severe pemphigus vulgaris.
Pemphigus vulgaris is an autoimmune condition that causes painful blisters on
the skin and lining of the mouth, nose, throat and genitals</span>.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2. What you need to know before you use MabThera</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Do not take MabThera </span></b><b><span
lang=EN-GB>if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you are
allergic to rituximab, other proteins which are like rituximab, or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
a severe active infection at the moment </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> you have a weak immune system.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
severe heart failure or severe uncontrolled heart disease and have rheumatoid
arthritis, granulomatosis with polyangiitis, microscopic polyangiitis or
pemphigus vulgaris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not have MabThera if any of the above
apply to you. If you are not sure, talk to your doctor, pharmacist or nurse
before you are given MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before you are given
MabThera if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>you have ever had or might now have a hepatitis infection. This is
because in a few cases, MabThera could cause hepatitis B to become active
again, which can be fatal in very rare cases. Patients who have ever had
hepatitis B infection will be carefully checked by their doctor for signs of
this infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>you have ever had heart problems (such as angina, palpitations or
heart failure) or breathing problems. </span><span lang=EN-GB></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera. Your doctor may need to take special care of you during your
treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If you have rheumatoid arthritis, granulomatosis
with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell
your doctor</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
think you may have an infection, even a mild one like a cold. The cells that
are affected by MabThera help to fight infection and you should wait until the
infection has passed before you are given MabThera. Also please tell your
doctor if you had a lot of infections in the past or suffer from severe
infections. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if
you think you may need any vaccinations in the near future, including
vaccinations needed to travel to other countries. Some vaccines should not be
given at the same time as MabThera or in the months after you receive MabThera.
Your doctor will check if you should have any vaccines before you receive
MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children
and adolescents</span></b></p>

<p class=MsoNormal><i>Non-Hodgkins lymphoma</i></p>

<p class=MsoNormal>MabThera can be used for the the treatment of children and
adolescents, 6 months of age and older, with non-Hodgkins lymphoma,
specifically CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt
lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or
Burkitt-like lymphoma (BLL).</p>

<p class=MsoNormal style='page-break-after:avoid'>Talk to your doctor, pharmacist
or nurse before you are given this medicine if you, or your child, are under 18
years of age. </p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Granulomatosis
with polyangiitis or microscopic polyangiitis</span></i></p>

<p class=MsoNormal><span lang=EN-GB>MabThera can be used for treatment of
children and adolescents, </span><span lang=EN-GB>2 years of age and older,
with granulomatosis with polyangiitis (formerly called Wegeners
granulomatosis) or microscopic polyangiitis. </span><span lang=EN-GB>There is
not much information about the use of MabThera in children and adolescents with
other diseases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before you are given this medicine if you, or your child, are under 18 years of
age.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Other medicines and MabThera</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell </span><span lang=EN-GB>your doctor</span><span
lang=EN-GB>, pharmacist or nurse if you are taking, have recently taken or
might take any other medicines. This includes medicines obtained without a
prescription and herbal medicines. This is because MabThera can affect the way
some other medicines work. Also some other medicines can affect the way
MabThera works. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In particular, tell your doctor:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
are taking medicines for high blood pressure. You may be asked not to take
these other medicines 12 hours before you are given MabThera. This is because
some people have a fall in their blood pressure while they are being given
MabThera.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
have ever taken medicines which affect your immune system  such as
chemotherapy or immune&#8209;suppressive medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Pregnancy and breast&#8209;feeding </span></b></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor or nurse if you
are pregnant, think that you might be pregnant or are planning to become
pregnant. This is because MabThera can cross the placenta and may affect your
baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you can get pregnant, you and your
partner must use an effective method of contraception while using MabThera. You
must also do this for 12 months after your last treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not breast&#8209;feed while you are
being treated with MabThera. Also do not breast&#8209;feed for 12 months after
your last treatment with MabThera. This is because MabThera may pass into
breast milk.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>It is not known whether MabThera has an
effect on you being able to drive or use any tools or machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>MabThera contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains 52.6 mg sodium (</span><span
style='color:#222222;background:white'>main component of the cooking/table
salt)</span> <span lang=EN-GB>in each 10 mL vial and 263.2 mg in each 50 mL
vial. </span></p>

<p class=MsoNormal>This is equivalent to 2.6% (for 10ml vial) and 13.2% (for
50ml vial) of the recommended maximum daily dietary intake of sodium for an
adult.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. </span></b><b><span lang=EN-GB>How MabThera is given</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How it is given</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera will be given to you by a doctor
or nurse who is experienced in the use of this treatment. They will watch you
closely while you are being given this medicine. This is in case you get any
side effects. </span></p>

<p class=MsoNormal><span lang=EN-GB>You will always be given MabThera as a drip
(intra&#8209;venous infusion).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Medicines given before each MabThera
administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Before you are given MabThera, you will be
given other medicines (pre&#8209;medication) to prevent or reduce possible side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How much
and how often you will receive your treatment</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>a) If
you are being treated for non&#8209;Hodgkins Lymphoma</span></b></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> <i>If
you are having MabThera alone</i></span></p>

<p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
lang=EN-GB>MabThera will be given to you once a week for 4 weeks.</span><span
lang=EN-GB> Repeated treatment courses with MabThera are possible.</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> <i>If you
are having MabThera with chemotherapy</i></span></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>MabThera will be
given to you on the same day as your chemotherapy. This is usually given every
3 weeks up to 8 times.</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
respond well to treatment, you may be given MabThera as a maintenance treatment
every 2 or 3 months for two years. Your doctor may change this, depending on
how you respond to the medicine.</span></p>

<p class=MsoListParagraph style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span>If
you are less than 18 years of age, you will be given MabThera with
chemotherapy. You will receive MabThera up to 6 times over a 3.5  5.5 month
period.</p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>b) If
you are being treated for chronic lymphocytic leukaemia</span></b></p>

<p class=MsoNormal><span lang=EN-GB>When you are treated with MabThera in
combination with chemotherapy, you will receive MabThera infusions on day 0
cycle 1 then day 1 of each cycle for 6 cycles in total. Each cycle has a
duration of 28 days. The chemotherapy should be given after the MabThera
infusion. Your doctor will decide if you should receive concomitant supportive
therapy.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>c) If you are being treated for
rheumatoid arthritis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Each course of treatment is made up of two
separate infusions which are given 2 weeks apart. Repeated courses of treatment
with MabThera are possible. Depending on the signs and symptoms of your
disease, your doctor will decide when you should receive more MabThera. This
may be months from now.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>d) If
you are being treated for granulomatosis with polyangiitis or microscopic
polyangiitis</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with MabThera uses four separate
infusions given at weekly intervals. Corticosteroids will usually be given by
injection before the start of MabThera treatment. Corticosteroids given by
mouth may be started at any time by your doctor to treat your condition.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are 18 years of age and older and respond
well to treatment, you may be given MabThera as a maintenance treatment. This
will be administered as 2 separate infusions which are given 2 weeks apart,
followed by 1 infusion every 6 months for at least 2 years. Your doctor may decide
to treat you longer with MabThera (up to 5 years), depending on how you respond
to the medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>e) If you are being treated for
pemphigus vulgaris</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Each course of treatment is made up of two
separate infusions which are given 2 weeks apart. If you respond well to
treatment, you may be given MabThera as a maintenance treatment. This will be
administered 1 year and 18 months after the initial treatment and then every 6
months as needed or your doctor may change this, depending on how you respond
to the medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you have
any further questions on the use of this medicine, ask your doctor, pharmacist
or nurse.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Most side effects are mild to moderate but
some may be serious and require treatment. Rarely, some of these reactions have
been fatal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Infusion reactions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>During or within the first 24 hours of the
infusion you may develop fever, chills and shivering. Less frequently, some
patients may experience pain at the infusion site, blisters, itching, sickness
(nausea), tiredness, headache, breathing difficulties, blood pressure raised, wheezing,
throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting,
flushing or palpitations, heart attack or low number of platelets. If you have
heart disease or angina, these reactions might get worse. <b>Tell the person
giving you the infusion immediately</b> if you or your child develops any of
these symptoms, as the infusion may need to be slowed down or stopped. You may
require additional treatment such as an antihistamine or paracetamol. When
these symptoms go away, or improve, the infusion can be continued. These
reactions are less likely to happen after the second infusion. Your doctor may
decide to stop your MabThera treatment if these reactions are serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infections</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell your
doctor immediately </span></b><b><span lang=EN-GB>if you or your child gets
signs of an infection including:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>fever, cough, sore throat, burning pain when passing urine or
feeling weak or generally unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>memory loss, trouble thinking, difficulty walking or sight loss 
these may be due to a very rare, serious brain infection, which has been fatal
(Progressive Multifocal Leukoencephalopathy or PML).</span></p>

<p class=MsoNormal><span lang=EN-GB>You might get infections more easily </span><span
lang=EN-GB>during your treatment with MabThera</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>These are often colds, but there have been
cases of pneumonia or urinary infections. These are listed below under Other
side effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are being treated for rheumatoid
arthritis, granulomatosis with polyangiitis, microscopic polyangiitis or
pemphigus vulgaris, you will also find this information in the Patient Alert
Card you have been given by your doctor. It is important that you keep this
Alert Card and show it to your partner or caregiver.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Skin Reactions</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Very rarely,
severe blistering skin conditions that can be life&#8209;threatening may
occur. Redness, often associated with blisters, may appear on the skin or on
mucous membranes, such as inside the mouth, the genital areas or the eyelids,
and fever may be present. <b>Tell your doctor immediately if you experience
any of these symptoms.</b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
side effects include:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>a) If
you or your child are being treated for non&#8209;Hodgkins Lymphoma or chronic
lymphocytic leukaemia</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB>Very common </span><span lang=EN-GB>side effects (may affect more
than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bacterial or viral infections, bronchitis</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> low number
of white blood cells, with or without fever</span><span lang=EN-GB> or blood
cells called platelets</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bald&nbsp;spots on the scalp, chills, headache</span></p>

<p class=MsoNormal style='margin-left:36.4pt;text-indent:-16.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>lower immunity  because of lower levels of anti&#8209;bodies called
immunoglobulins (IgG) in the blood which help protect against infection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>infections of the blood (sepsis), pneumonia, shingles, cold,
bronchial tube infections, fungal infections, infections of unknown origin,
sinus inflammation, hepatitis B</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low number of red blood cells (anaemia), low number of all blood
cells</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> allergic
reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>high blood sugar level, weight loss, swelling in the face and body,
high levels of the enzyme LDH in the blood, low calcium levels in the blood</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>unusual feelings of the skin  such as numbness, tingling, pricking,
burning, a creeping skin feeling, reduced sense of touch</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> feeling
restless,</span><span lang=EN-GB> </span><span lang=EN-GB>problems</span><span
lang=EN-GB> falling asleep</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> becoming </span><span
lang=EN-GB>very </span><span lang=EN-GB>red in the face and </span><span
lang=EN-GB>other areas</span><span lang=EN-GB> of the skin as a consequence of </span><span
lang=EN-GB>dilation of the blood vessels</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling dizzy or anxious</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>producing more tears, tear duct problems, inflamed eye
(conjunctivitis)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>ringing sound in the ears</span><span lang=EN-GB>, ear pain</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>heart problems  such as heart attack, uneven or fast heart rate</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>high or low blood pressure (low blood pressure especially when
standing upright)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tightening of the muscles in the airways which causes wheezing
(bronchospasm), inflammation, irritation in the lungs, throat or sinuses, being
short of breath, runny nose</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>being sick (vomiting), diarrhoea, pain in the stomach, irritation or
ulcers in the throat and mouth, problems swallowing, constipation, indigestion</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> eating
disorders,</span><span lang=EN-GB> not eating enough, leading to weight loss</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><i><span lang=EN-GB> </span></i><span
lang=EN-GB>hives, increased sweating, night sweats</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>muscle problems  such as tight muscles, joint or muscle pain, back
and neck pain</span></p>

<p class=MsoListParagraph style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tumour pain</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> general </span><span
lang=EN-GB>discomfort or feeling uneasy or tired, shaking, signs of flu</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>multiple&#8209;organ failure.</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
side effects (may affect up to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>blood clotting problems, decrease of red blood cell production and
increase of red blood cell destruction (aplastic haemolytic anaemia), swollen
or enlarged lymph nodes</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low mood and loss of interest or enjoyment in doing things, feeling
nervous</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>taste problems  such as</span><span lang=EN-GB style='font-family:
"Calibri",sans-serif'> </span><span lang=EN-GB>changes in the way things taste</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart problems  such as reduced heart rate or chest pain (angina)</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> asthma, too
little oxygen reaching the body organs</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>swelling of the stomach.</span></p>

<p class=MsoNormal style='margin-left:39.9pt;text-indent:-20.3pt'><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very rare
side effects (may affect up to 1 in 10, 000 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>short term increase in the amount of some types of anti&#8209;bodies
in the blood (called immunoglobulins  IgM), chemical disturbances in the blood
caused by break&#8209;down of dying cancer cells</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>nerve damage in arms and legs, </span><span
lang=EN-GB>paralysed </span><span lang=EN-GB style='layout-grid-mode:line'>face</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>heart failure</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>inflammation of blood vessels
including those leading to skin symptoms</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>respiratory failure</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>damage to the intestinal wall (perforation)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>severe skin problems causing blisters that can be life&#8209;threatening</span><span
lang=EN-GB style='layout-grid-mode:line'>. Redness, often associated with
blisters, may appear on the skin or on mucous membranes, such as inside the
mouth, the genital areas or the eyelids, and fever may be present.</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>kidney failure</span><span lang=EN-GB>
</span></p>

<p class=MsoNormal style='text-indent:.25in'><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB> </span><span lang=EN-GB style='layout-grid-mode:
line'>severe vision loss </span></p>

<p class=MsoNormal style='text-indent:.25in'><span lang=EN-GB style='layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB>Not known (it is not known how often these side effects
happen):</span><span lang=EN-GB style='layout-grid-mode:line'> </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>a reduction in white blood cells which does not happen straight away</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>reduced platelets number just after the infusion  this can be
reversed, but can be fatal in rare cases</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>hearing loss, loss of other senses</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='layout-grid-mode:line'></span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;page-break-after:
avoid'><b>Children and adolescents with non-Hodgkins lymphoma:</b></p>

<p class=MsoNormal style='page-break-after:avoid'>In general, side effects in
children and adolescents with non-Hodgkins lymphoma were similar to those in
adults with non-Hodgkins lymphoma or chronic lymphocytic leukaemia. The most
common side effects seen were fever associated with low levels of a type of
white blood cell (neutrophil), inflammation or sores in the lining of the
mouth, and allergic reactions (hypersensitivity). </p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>b) If you are being treated for
rheumatoid arthritis</span></b></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB>Very common </span><span lang=EN-GB>side effects (may affect more than
1 in 10 people):</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infections
such as pneumonia (bacterial) </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Pain on
passing water (urinary tract infection)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Allergic
reactions that are most likely to occur during an infusion, but can occur up&#8209;to
24&#8209;hours after infusion</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Changes in
blood pressure, nausea, rash, fever, feeling itchy, runny or blocked nose and
sneezing, shaking, rapid heart beat, and tiredness</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Headache</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Changes in
laboratory tests carried out by your doctor. These include a decrease in the
amount of some specific proteins in the blood (immunoglobulins) which help
protect against infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common side
effects </span><span lang=EN-GB>(may affect up to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Infections
such as bronchial tube inflammation (bronchitis)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> A
feeling of fullness or a throbbing pain behind the nose, cheeks and eyes
(sinusitis), pain in the abdomen, vomiting<sup> </sup>and diarrhoea, breathing
problems</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Fungal foot
infection (athletes foot)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> High
cholesterol levels in the blood</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Abnormal
sensations of the skin, such as numbness, tingling, pricking or burning, sciatica,
migraine, dizziness</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Loss of hair</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Anxiety,
depression</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Indigestion,
diarrhoea, acid reflux, irritation and /or ulceration of the throat and the
mouth</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Pain in the
tummy, back, muscles and/or joints</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Uncommon side
effects </span><span lang=EN-GB>(may affect up to 1 in 100 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Excess fluid
retention in the face and body</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Inflammation,
irritation and / or tightness of the lungs, and throat, coughing</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Skin
reactions including hives, itching and rash</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Allergic reactions including wheezing or shortness of breath, swelling
of the face and tongue, collapse</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very rare
side effects </span><span lang=EN-GB>(may affect up to 1 in 10, 000 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>A complex of symptoms occurring within a few weeks of an infusion of
MabThera including allergic like reactions such as rash, itching, joint pain,
swollen lymph glands and fever</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>severe blistering skin conditions that
can be life&#8209;threatening. Redness, often associated with blisters, may
appear on the skin or on mucous membranes, such as inside the mouth, the
genital areas or the eyelids, and fever may be present.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other rarely&#8209;reported side&#8209;effects
due to MabThera include a </span><span lang=EN-GB>decreased number of white
cells in the blood (neutrophils) that help to fight against infection. Some
infections may be severe (please see information on <b><i>Infections </i></b>within
this section).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>c) If
you or your child are being treated for granulomatosis with polyangiitis or
microscopic polyangiitis</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common </span><span
lang=EN-GB>side effects (may affect more than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> infections,
such as </span><span lang=EN-GB>chest infections, urinary tract infections
(pain on passing water), colds and herpes infections</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> allergic reactions
that are most likely to occur during an infusion, but can occur up&#8209;to 24&#8209;hours
after infusion</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> coughing or
shortness of breath</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> nose bleeds</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> raised blood
pressure</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>painful joints or back</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>muscle twitches or shakiness</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling dizzy</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tremors (shakiness, often in the hands)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>difficulty sleeping (insomnia)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>swelling of the hands or ankles </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Common side effects </span><span
lang=EN-GB>(may affect up to 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>indigestion</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>skin rashes, including acne or spots</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>flushing or redness of the skin</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> fever</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> blocked or
runny nose</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tight or painful muscles</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>pain in the muscles or in the hands or feet</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> low number
of red blood cells (anaemia)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> low numbers
of platelets in the blood</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>an increase in the amount of potassium
in the blood</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>changes in the rhythm of the heart, or the heart beating faster than
normal</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very rare
side effects </span><span lang=EN-GB>(may affect up to 1 in 10, 000 people):</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>severe blistering skin conditions that
can be life&#8209;threatening. Redness, often associated with blisters, may
appear on the skin or on mucous membranes, such as inside the mouth, the
genital areas or the eyelids, and fever may be present.</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='layout-grid-mode:line'>recurrence of a previous Hepatitis B
infection</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Children
and adolescents with granulomatosis with polyangiitis or microscopic
polyangiitis</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>In general,
side effects in children and adolescents with granulomatosis with polyangiitis
or microscopic polyangiitis were of a similar type to those in adults with
granulomatosis with polyangiitis or microscopic polyangiitis. Most common side
effects seen were infections, allergic reactions and feeling sick (nausea). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>d) If
you are being treated for pemphigus vulgaris</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common </span><span
lang=EN-GB>side effects (may affect more than 1 in 10 people):</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> allergic
reactions that are most likely to occur during an infusion, but can occur up to
24 hours after infusion</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> <span
style='color:#222222'>headache</span></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> <span
style='color:#222222'>infections such as chest infections</span></span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>long lasting depression</span></p>

<p class=MsoListParagraph style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>loss of hair</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Common side effects </span><span
lang=EN-GB>(may affect up to 1 in 10 people):</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>infections such as common cold, herpes infections, eye
infection, oral thrush and </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>urinary tract infections (pain on passing urine)</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>mood disorders such as irritability and depression</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>skin disorders such as itching, hives, and benign lumps</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>feeling tired or dizzy</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>fever</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:black'>painful joints or back</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>pain in the tummy</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>pain in the muscles</span></p>

<p class=m2716680816725646424gmail-msolistparagraph style='margin-top:0in;
margin-right:0in;margin-bottom:0in;margin-left:35.7pt;text-indent:-17.85pt;
background:white'><span lang=EN-GB style='font-family:Symbol;color:black'></span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='font-size:
11.0pt;color:#222222'>heart beating faster than normal</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>MabThera may
also cause changes in laboratory tests carried out by your doctor. </span></p>

<p class=MsoNormal><span lang=EN-GB>If you are having MabThera with other
medicines, some of the side effects you may get may be due to the other
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of side effects</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you get
any side effects talk to your doctor, pharmacist or nurse. This includes any
side effects not listed in this leaflet. You can also report side effects
directly via </span><span lang=EN-GB style='color:black;background:#BFBFBF'>the
national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:#BFBFBF'>Appendix V</span></a><span lang=EN-GB>.</span><span
lang=EN-GB> By reporting side effects you can help provide more information on
the safety of this medicine</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5. How to store MabThera</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton after EXP. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C 
8&nbsp;C). Keep the container in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines that you no longer use. These measures will help
protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
MabThera contains</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> The
active ingredient in MabThera is called rituximab. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB> The </span><span lang=EN-GB>10 mL</span><span lang=EN-GB> vial
contains 100&nbsp;mg of rituximab (10&nbsp;mg/mL). </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB> </span><span lang=EN-GB>The 50 mL vial contains 500 mg of
rituximab (10 mg/mL).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> The
other ingredients are sodium citrate, polysorbate 80, sodium chloride, sodium
hydroxide, hydrochloric acid and water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What MabThera
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is a clear, colourless solution,
supplied as a concentrate for solution for infusion. </span></p>

<p class=MsoNormal><span lang=EN-GB>10 mL vial  Pack of 2 vials</span></p>

<p class=MsoNormal><span lang=EN-GB>50 mL vial  Pack of 1 vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Roche Registration GmbH </p>

<p class=MsoNormal style='page-break-after:avoid'>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Roche Pharma</span><span
lang=DE-CH> AG</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>Emil&#8209;Barell&#8209;Str.
1</span></p>

<p class=MsoNormal style='page-break-after:avoid'>D&#8209;79639 Grenzach&#8209;Wyhlen</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>N.V. Roche
  S.A.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>Tl/Tel: +32
  (0) 2 525 82 11</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>Lietuva</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>UAB Roche
  Lietuva</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>Tel: +370 5
  2546799</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=RU>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=RU>&#1056;&#1086;&#1096;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=RU>&#1058;&#1077;&#1083;:
  +359 2</span>&nbsp;<span lang=RU>818 44 44</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=RU>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE>(Voir/siehe
  Belgique/Belgien)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +420 &#8209; 2 20382111</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Magyarorszg</b></p>
  <p class=MsoNormal>Roche (Magyarorszg) Kft.</p>
  <p class=MsoNormal>Tel: +36 &#8209; 23 446 800</p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche a/s </span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 &#8209; 36 39 99 99</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(See Ireland)</span></p>
  <p class=MsoNormal><b><span lang=EN-GB></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche Nederland B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 348 438050</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Eesti O</span></p>
  <p class=MsoNormal><span lang=IT>Tel: + 372 &#8209; 6 177 380</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Norge AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 &#8209; 22 78 90 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche (Hellas) A.E. </span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +30 210 61 66 100</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES>Roche Farma S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 &#8209; 91 324 81 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Polska</span></b></p>
  <p class=MsoNormal><span lang=FR>Roche Polska Sp.z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +48 &#8209; 22 345 18 88</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl: +33&nbsp; (0)1 47 61 40 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Roche Farmacutica Qumica, Lda</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: +351 &#8209; 21 425 70 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 385 1 47 22 333</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Romnia S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +40 21 206 47 01</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products (Ireland) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 (0) 1 469 0700</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche farmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 &#8209; 1 360 26 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>sland </span></b></p>
  <p class=MsoNormal><span lang=PT>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Slovensk republika </span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +421 &#8209; 2 52638201</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +39 &#8209; 039 2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche Oy </span></p>
  <p class=MsoNormal><span lang=DE>Puh/Tel: +358 (0) 10 554 500</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>K</span></b><b><span lang=EN-GB>&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=EN-GB> </span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#915;</span><span lang=DE>.</span><span
  lang=EN-GB>&#913;</span><span lang=DE>.</span><span lang=EN-GB>&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;</span><span
  lang=DE> &amp; </span><span lang=EN-GB>&#931;&#953;&#945;</span><span
  lang=EN-GB> </span><span lang=EN-GB>&#923;&#964;&#948;</span><span lang=DE>.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 &#8209; 22 76 62
  76</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche</span><span lang=EN-GB> AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46 (0) 8 726 1200</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 &#8209; 6 7039831</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 1707 366000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><a href="http://www.ema.europa.eu"><span
lang=EN-GB>http://www.ema.europa.eu</span></a><span lang=EN-GB
style='color:blue'>.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>This leaflet
is available in all EU/EEA languages on the European Medicines Agency website.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>MabThera
1400&nbsp;mg solution for subcutaneous injection </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>rituximab
</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you are given this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
have any further questions, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
get any side effects, talk to your doctor, pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What MabThera is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you are given MabThera </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How MabThera is given</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store MabThera </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>1. What
MabThera is and what it is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera contains the active substance
rituximab. This is a type of protein called a monoclonal antibody. It sticks
to the surface of a type of white blood cell called B&#8209;Lymphocyte. When
rituximab sticks to the surface of this cell, the cell dies.</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is available as a medicine given
as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution
for infusion) and as a medicine for injection under your skin (called MabThera
1400 mg or MabThera 1600 mg, solution for subcutaneous injection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400 mg is used to treat </span><span
lang=EN-GB>Non&#8209;Hodgkins lymphoma in adults.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>This is a disease of the lymph tissue (part of the immune system)
that affects a type of white blood cell called B&#8209;Lymphocytes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400 mg can be given alone or with
other medicines called chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You will always be given MabThera as a drip
(intra&#8209;venous infusion) at the start of your treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After this, you will be given MabThera as
an injection under your skin. Your doctor will decide when to start MabThera
injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients where the treatment is working,
MabThera may be used as a maintenance treatment for 2 years after completing
the initial treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>2 What
you need to know before you are given MabThera</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Do not have MabThera if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you are
allergic to rituximab, other proteins which are like rituximab, or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you are
allergic to hyaluronidase (an enzyme that helps to increase the absorption of
injected  active substance) </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
a severe active infection at the moment</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
a weak immune system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not have MabThera if any of the above
apply to you. If you are not sure, talk to your doctor, pharmacist or nurse
before you are given MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before you are given
MabThera if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
ever had or might now have a hepatitis infection. This is because in a few
cases, MabThera could cause hepatitis B to become active again, which can be
fatal in very rare cases. Patients who have ever had hepatitis B infection will
be carefully checked by their doctor for signs of this infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
ever had heart problems (such as angina, palpitations or heart failure) or
breathing problems. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera. Your doctor may need to take special care of you during your
treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before you are given this medicine if you, or your child, are under 18 years of
age. This is because there is not much information about the use of MabThera in
children and adolescents.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other
medicines </span></b><b><span lang=EN-GB>and MabThera </span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell </span><span lang=EN-GB>your doctor</span><span
lang=EN-GB>, pharmacist or nurse if you are taking, have recently taken or
might take any other medicines. This includes medicines obtained without a
prescription and herbal medicines. This is because MabThera can affect the way
some other medicines work. Also some other medicines can affect the way
MabThera works. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In particular, tell your doctor:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
are taking medicines for high blood pressure. You may be asked not to take
these other medicines 12 hours before you are given MabThera. This is because
some people have a fall in their blood pressure while they are being given
MabThera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
have ever taken medicines which affect your immune system  such as
chemotherapy or immune&#8209;suppressive medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Pregnancy and breast&#8209;feeding </span></b></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor or nurse if you
are pregnant, think that you might be pregnant or are planning to become
pregnant. This is because MabThera can cross the placenta and may affect your
baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you can get pregnant, you and your
partner must use an effective method of contraception while using MabThera. You
must also do this for 12 months after your last treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not breast&#8209;feed while you are
being treated with MabThera. Also do not breast&#8209;feed for 12 months after
your last treatment with MabThera. This is because MabThera may pass into
breast milk.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>It is not known whether MabThera has an effect
on you being able to drive or use any tools or machines.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1400 mg contains less than 1 mmol sodium
(</span><span style='color:#222222;background:white'>main component of the
cooking/table salt) </span><span lang=EN-GB>per dose, i.e. it is essentially
sodium-free.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:12.0pt'>3 How MabThera is given</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How it is
given</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera will be given to you by a doctor
or nurse who is experienced in the use of this treatment. They will watch you
closely while you are being given this medicine. This is in case you get any
side effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You will always be given MabThera as a drip
(intra&#8209;venous infusion) at the start of your treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After this, you will be given MabThera as
an injection under your skin </span><span lang=EN-GB>(</span><span lang=EN-GB>subcutaneous
injection)</span><span lang=EN-GB> over approximately 5 minutes</span><span
lang=EN-GB>. </span><span lang=EN-GB>There is a peel-off sticker on the glass
vial that specifies the medication. Your doctor or nurse will place the sticker
on the syringe before injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will decide when to start
MabThera injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When injected under your skin, it is given
in the stomach area,</span><span lang=EN-GB> not in other sites of the body,
and not into areas of the stomach where the skin is red, bruised, tender, hard
or where there are moles or scars.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Medicines given before each MabThera
administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Before you are given MabThera, you will be
given other medicines (pre&#8209;medication) to prevent or reduce possible side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How much and how often you will receive
your treatment</span></b></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> MabThera
will be given to you on the same day as your chemotherapy. This is usually
given every 3 weeks up to 8 times.</span></p>

<p class=MsoNormal style='margin-left:46.2pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
respond well to treatment, you may be given MabThera as a maintenance treatment
every 2 or 3 months for two years. </span></p>

<p class=MsoNormal><span lang=EN-GB> Your doctor may change this, depending
on how you respond to the medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor, pharmacist or
nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>4 Possible
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Most side effects are mild to moderate but
some may be serious and need treatment. Rarely, some of these side effects have
been fatal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reactions where the medicine is injected</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Many patients get some local side effects
where MabThera is injected. These include: pain, swelling, bruising, bleeding,
skin redness, itching and rash. </span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor may decide to stop your
MabThera treatment if these reactions are serious.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Infections</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor immediately </span></b><b><span
lang=EN-GB>if you get signs of an infection including:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>fever, cough, sore throat, burning pain when passing urine or
feeling weak or generally unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>memory loss, trouble thinking, difficulty walking or sight loss 
these may be due to a very rare, serious brain infection, which has been fatal
(Progressive Multifocal Leukoencephalopathy or PML).</span></p>

<p class=MsoNormal><span lang=EN-GB>You might get infections more easily during
your treatment with MabThera. These are often colds, but there have been cases
of pneumonia or urinary infections. These are listed below under Other side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
side effects include:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Very common </span></b><b><span
lang=EN-GB>side effects (may affect more than 1 in 10 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bacterial or viral infections, bronchitis</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low number of white blood cells with or without fever or blood cells
called platelets</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bald&nbsp;spots on the scalp, chills, headache</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>lower immunity  because of lower levels of anti&#8209;bodies called
immunoglobulins (IgG) in the blood which help protect against infection.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Common side effects (may affect up to 1
in 10 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>infections of the blood (sepsis), pneumonia, shingles, cold,
bronchial tube infections, fungal infections, infections of unknown origin,
sinus inflammation, hepatitis B</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low number of red blood cells (anaemia), low number of all blood
cells </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>allergic reactions (hypersensitivity), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>high blood sugar level, weight loss, swelling in the face and body,
high levels of the enzyme LDH in the blood, low calcium levels in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>unusual feelings of the skin  such as numbness, tingling, pricking,
burning, a creeping skin feeling, reduced sense of touch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling restless, problems falling asleep</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>becoming very red in the face and other areas of the skin as a
consequence of dilation of the blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling dizzy or anxious</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>producing more tears, tear duct problems, inflamed eye
(conjunctivitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>ringing sound in the ears, ear pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart problems  such as heart attack, uneven or fast heart rate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>high or low blood pressure (low blood pressure especially when
standing upright)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tightening of the muscles in the airways which causes wheezing
(bronchospasm), inflammation, irritation in the lungs, throat or sinuses, being
short of breath, runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>being sick (vomiting), diarrhoea, pain in the stomach, irritation or
ulcers in the throat and mouth, problems swallowing, constipation, indigestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>eating disorders, not eating enough, leading to weight loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>hives, increased sweating, night sweats</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>muscle problems  such as tight muscles, joint or muscle pain, back
and neck pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tumour pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>general discomfort or feeling uneasy or tired, shaking, signs of flu</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>multiple&#8209;organ failure.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon side effects (may affect up to
1 in 100 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>blood clotting problems, decrease of red blood cell production and
increase of red blood cell destruction (aplastic haemolytic anaemia), swollen
or enlarged lymph nodes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low mood and loss of interest or enjoyment in doing things, feeling
nervous</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>taste problems  such as</span><span lang=EN-GB style='font-family:
"Calibri",sans-serif'> </span><span lang=EN-GB>changes in the way things taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart problems  such as reduced heart rate or chest pain (angina)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>asthma, too little oxygen reaching the body organs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>swelling of the stomach.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Very rare side effects (may affect up to
1 in 10, 000 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>short term increase in the amount of some types of anti&#8209;bodies
in the blood (called immunoglobulins  IgM), chemical disturbances in the blood
caused by break&#8209;down of dying cancer cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>nerve damage in arms and legs, paralysed face</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>inflammation of blood vessels including those leading to skin
symptoms</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>respiratory failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>damage to the intestinal wall (perforation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>severe skin problems causing blisters that can be life&#8209;threatening
</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>kidney failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Severe vision loss (sign of brain nerves damage).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Not known (it is not known how often
these side effects happen):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>a reduction in white blood cells which does not happen straight away</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>reduced platelets number just after the infusion  this can be
reversed, but can be fatal in rare cases</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>hearing loss, loss of other senses. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:TimesNewRoman'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera may
also cause changes in laboratory tests carried out by your doctor. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are having MabThera with other
medicines, some of the side effects you may get may be due to the other medicines.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via <span
style='color:black;background:#BFBFBF'>the national reporting system listed in </span></span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><a
name="_Hlt531783609"></a><span lang=EN-GB>. By reporting side effects you can
help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:12.0pt'>5 How to store MabThera</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton after EXP. The expiry date refers to the last
day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C to
8&nbsp;C). Do not freeze. Keep the container in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>6 Contents
of the pack and other information</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera </span></b><b><span
lang=EN-GB>1400&nbsp;mg solution for subcutaneous injection contains</span></b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>The active ingredient is rituximab. Each vial contains
1400&nbsp;mg/11.7 mL of rituximab.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Each mL
contains 120 mg of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>The other ingredients are recombinant human hyaluronidase (rHuPH20),
L&#8209;histidine, L&#8209;histidine hydrochloride monohydrate, </span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>,</span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>&#8209;trehalose
dihydrate, L&#8209;methionine, polysorbate 80 and water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What MabThera
</span></b><b><span lang=EN-GB>1400&nbsp;mg solution for subcutaneous injection</span></b><b><span
lang=EN-GB> looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is a ready to use, clear to
opalescent, colourless to yellowish liquid, supplied as a solution for
subcutaneous injection in a colourless glass vial </span><span lang=EN-GB>with
a butyl rubber stopper with aluminium over seal and a pink plastic flip&#8209;off
disk</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Each vial
contains 1400&nbsp;mg/11.7 mL of rituximab. Each carton contains one vial.</span><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>Roche Registration GmbH </p>

<p class=MsoNormal style='page-break-after:avoid'>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Manufacturer</b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Roche Pharma</span><span
lang=DE-CH> AG</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>Emil&#8209;Barell&#8209;Str.
1</span></p>

<p class=MsoNormal style='page-break-after:avoid'>D&#8209;79639 Grenzach&#8209;Wyhlen</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-1.7pt;background:white;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>N.V. Roche S.A.</span></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Tl/Tel: +32 (0) 2 525
  82 11</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>UAB Roche Lietuva</span></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Tel: +370 5 2546799</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=RU style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=RU style='color:black'>&#1056;&#1086;&#1096;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=RU style='color:black'>&#1058;&#1077;&#1083;:
  +359 2</span><span style='color:black'>&nbsp;</span><span lang=RU
  style='color:black'>818 44 44</span></p>
  <p class=MsoNormal><b><span lang=RU>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>(Voir/siehe
  Belgique/Belgien)</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +420 &#8209; 2
  20382111</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='color:black'>Magyarorszg</span></b></p>
  <p class=MsoNormal><span style='color:black'>Roche (Magyarorszg) Kft.</span></p>
  <p class=MsoNormal><span style='color:black'>Tel: +36 &#8209; 23 446 800</span></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche a/s </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tlf: +45 &#8209; 36
  39 99 99</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>(See Ireland)</span></p>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Nederland B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +31 (0) 348
  438050</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Eesti O</span></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Tel: + 372 &#8209; 6 177
  380</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Norge AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tlf: +47 &#8209; 22
  78 90 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche (Hellas) A.E. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  +30 210 61 66 100</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='color:black'>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES style='color:black'>Roche Farma S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +34 &#8209; 91
  324 81 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='color:black'>Polska</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Roche Polska Sp.z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +48 &#8209; 22
  345 18 88</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tl: +33&nbsp; (0)1
  47 61 40 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='color:black'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Roche Farmacutica
  Qumica, Lda</span></p>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Tel: +351 &#8209; 21
  425 70 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;background:transparent;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 385 1 47 22 333</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Romnia S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +40 21 206 47 01</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Products
  (Ireland) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +353 (0) 1 469
  0700</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche farmacevtska
  druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +386 &#8209; 1
  360 26 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT style='color:black'>sland </span></b></p>
  <p class=MsoNormal><span lang=PT style='color:black'>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT style='color:black'>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT style='color:black'>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Slovensk republika </span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +421 &#8209; 2
  52638201</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH style='color:black'>Tel: +39 &#8209; 039
  2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Oy </span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Puh/Tel: +358 (0) 10 554
  500</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>K</span></b><b><span
  lang=EN-GB style='color:black'>&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=EN-GB style='color:black'> </span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#915;</span><span
  lang=DE style='color:black'>.</span><span lang=EN-GB style='color:black'>&#913;</span><span
  lang=DE style='color:black'>.</span><span lang=EN-GB style='color:black'>&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;</span><span
  lang=DE style='color:black'> &amp; </span><span lang=EN-GB style='color:black'>&#931;&#953;&#945;</span><span
  lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>&#923;&#964;&#948;</span><span
  lang=DE style='color:black'>.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  +357 &#8209; 22 76 62 76</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche AB</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +46 (0) 8 726
  1200</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Tel: +371 &#8209; 6
  7039831</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Products Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +44 (0) 1707
  366000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
(EMEA) web site: </span><a href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a><span
lang=EN-GB style='color:blue'>.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>This leaflet
is available in all EU/EEA languages on the European Medicines Agency website.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the patient </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>MabThera
1600&nbsp;mg solution for subcutaneous injection </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>rituximab
</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you are given this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Keep this
leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
have any further questions, ask your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
get any side effects, talk to your doctor, pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What MabThera is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you are given MabThera </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How MabThera is given</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store MabThera </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>1. What
MabThera is and what it is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera contains the active substance
rituximab. This is a type of protein called a monoclonal antibody. It
sticks to the surface of a type of white blood cell called B&#8209;Lymphocyte.
When rituximab sticks to the surface of this cell, the cell dies.</span></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is available as a medicine given
as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution
for infusion) and as a medicine for injection under your skin: called MabThera
1400 mg or MabThera 1600 mg, solution for subcutaneous injection).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600 mg is used to treat chronic
lymphocytic leukaemia </span><span lang=EN-GB>&#8209;in adults.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Chronic
lymphocytic leukaemia (CLL) is the most common form of adult leukaemia.</span><span
lang=EN-GB> CLL affects a type of white blood cell called B&#8209;lymphocytes,
which originates from the bone marrow and develops in the lymph nodes. Patients
with CLL have too many abnormal lymphocytes, which accumulate mainly in the
bone marrow and blood. </span><span lang=EN-GB>The proliferation of these
abnormal B&#8209;lymphocytes is the cause of symptoms you may have.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB> MabThera in combination with chemotherapy destroys these
cells which are gradually removed from the body by biological processes</span><span
lang=EN-GB>&#8209;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You will be given MabThera 1600 mg with
other medicines called chemotherapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>You will always be given MabThera as a drip
(intra&#8209;venous infusion) at the start of your treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After this, you will be given MabThera as
an injection under your skin. Your doctor will decide when to start MabThera
injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>2 What
you need to know before you are given MabThera</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Do not have MabThera if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you are
allergic to rituximab, other proteins which are like rituximab, or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you are
allergic to hyaluronidase (an enzyme that helps to increase the absorption of
injected active substance) </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
a severe active infection at the moment</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
a weak immune system.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not have MabThera if any of the above
apply to you. If you are not sure, talk to your doctor, pharmacist or nurse
before you are given MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before you are given
MabThera if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
ever had or might now have a hepatitis infection. This is because in a few
cases, MabThera could cause hepatitis B to become active again, which can be
fatal in very rare cases. Patients who have ever had hepatitis B infection will
be carefully checked by their doctor for signs of this infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> you have
ever had heart problems (such as angina, palpitations or heart failure) or
breathing problems. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera. Your doctor may need to take special care of you during your
treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor, pharmacist or nurse
before you are given this medicine if you, or your child, are under 18 years of
age. This is because there is not much information about the use of MabThera in
children and adolescents.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other
medicines </span></b><b><span lang=EN-GB>and MabThera </span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell </span><span lang=EN-GB>your doctor</span><span
lang=EN-GB>, pharmacist or nurse if you are taking, have recently taken or
might take any other medicines. This includes medicines obtained without a
prescription and herbal medicines. This is because MabThera can affect the way
some other medicines work. Also some other medicines can affect the way
MabThera works. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In particular, tell your doctor:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
are taking medicines for high blood pressure. You may be asked not to take
these other medicines 12 hours before you are given MabThera. This is because
some people have a fall in their blood pressure while they are being given
MabThera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> if you
have ever taken medicines which affect your immune system  such as
chemotherapy or immune&#8209;suppressive medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above apply to you (or you
are not sure), talk to your doctor, pharmacist or nurse before you are given
MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Pregnancy and breast&#8209;feeding </span></b></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor or nurse if you
are pregnant, think that you might be pregnant or are planning to become
pregnant. This is because MabThera can cross the placenta and may affect your
baby.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you can get pregnant, you and your
partner must use an effective method of contraception while using MabThera. You
must also do this for 12 months after your last treatment with MabThera.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not breast&#8209;feed while you are
being treated with MabThera. Also do not breast&#8209;feed for 12 months after
your last treatment with MabThera. This is because MabThera may pass into
breast milk.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>It is not known whether MabThera has an effect
on you being able to drive or use any tools or machines.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera 1600 mg contains less than 1 mmol sodium
(</span><span style='color:#222222;background:white'>main component of the
cooking/table salt) </span><span lang=EN-GB>per dose, i.e. it is essentially
sodium-free.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:12.0pt'>3 How MabThera is given</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>How it is given</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera will be given to you by a doctor
or nurse who is experienced in the use of this treatment. They will watch you
closely while you are being given this medicine. This is in case you get any
side effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You will always be given MabThera as a drip
(intra&#8209;venous infusion) at the start of your treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After this, you will be given MabThera as
an injection under your skin </span><span lang=EN-GB>(</span><span lang=EN-GB>subcutaneous
injection)</span><span lang=EN-GB> over approximately 7 minutes</span><span
lang=EN-GB>. </span><span lang=EN-GB>There is a peel-off sticker on the glass
vial that specifies the medication. Your doctor or nurse will place the sticker
on the syringe before injection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will decide when to start
MabThera injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When injected under your skin, it is given
in the stomach area,</span><span lang=EN-GB> not in other sites of the body,
and not into areas of the stomach where the skin is red, bruised, tender, hard
or where there are moles or scars.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Medicines given before each MabThera
administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Before you are given MabThera, you will be
given other medicines (pre&#8209;medication) to prevent or reduce possible side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How much and how often you will receive
your treatment</span></b></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When you are treated with MabThera in
combination with chemotherapy, you will receive a MabThera infusion on day 0 of
cycle 1, then subcutaneous injections on day 1 of each subsequent cycle. The
total number of cycles is of 6. Each cycle has a duration of 28 days. The
chemotherapy should be given after the MabThera administration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:white'>Your doctor will decide if you should receive concomitant
supportive therapy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor, pharmacist or
nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>4 Possible
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, although not everybody gets them. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Most side effects are mild to moderate but
some may be serious and need treatment. Rarely, some of these side effects have
been fatal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reactions where the medicine is injected</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Many patients get some local side effects
where MabThera is injected. These include: pain, swelling, bruising, bleeding,
skin redness, itching and rash. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor may decide to stop your
MabThera treatment if these reactions are serious.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Infections</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor immediately </span></b><b><span
lang=EN-GB>if you get signs of an infection including:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>fever, cough, sore throat, burning pain when passing urine or
feeling weak or generally unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>memory loss, trouble thinking, difficulty walking or sight loss 
these may be due to a very rare, serious brain infection, which has been fatal
(Progressive Multifocal Leukoencephalopathy or PML).</span></p>

<p class=MsoNormal><span lang=EN-GB>You might get infections more easily during
your treatment with MabThera. These are often colds, but there have been cases
of pneumonia or urinary infections. These are listed below under Other side
effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
side effects include:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Very common </span></b><b><span
lang=EN-GB>side effects (may affect more than 1 in 10 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bacterial or viral infections, bronchitis</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low number of white blood cells with or without fever or blood cells
called platelets</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>bald&nbsp;spots on the scalp, chills, headache</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>lower immunity  because of lower levels of anti&#8209;bodies called
immunoglobulins (IgG) in the blood which help protect against infection.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Common side effects (may affect up to 1
in 10 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>infections of the blood (sepsis), pneumonia, shingles, cold, bronchial
tube infections, fungal infections, infections of unknown origin, sinus
inflammation, hepatitis B</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low number of red blood cells (anaemia), low number of all blood
cells </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>allergic reactions (hypersensitivity), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>high blood sugar level, weight loss, swelling in the face and body,
high levels of the enzyme LDH in the blood, low calcium levels in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>unusual feelings of the skin  such as numbness, tingling, pricking,
burning, a creeping skin feeling, reduced sense of touch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling restless, problems falling asleep</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>becoming very red in the face and other areas of the skin as a
consequence of dilation of the blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>feeling dizzy or anxious</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>producing more tears, tear duct problems, inflamed eye
(conjunctivitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>ringing sound in the ears, ear pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart problems  such as heart attack, uneven or fast heart rate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>high or low blood pressure (low blood pressure especially when
standing upright)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tightening of the muscles in the airways which causes wheezing (bronchospasm),
inflammation, irritation in the lungs, throat or sinuses, being short of
breath, runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>being sick (vomiting), diarrhoea, pain in the stomach, irritation or
ulcers in the throat and mouth, problems swallowing, constipation, indigestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>eating disorders, not eating enough, leading to weight loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>hives, increased sweating, night sweats</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>muscle problems  such as tight muscles, joint or muscle pain, back
and neck pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>tumour pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>general discomfort or feeling uneasy or tired, shaking, signs of flu</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>multiple&#8209;organ failure.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon side effects (may affect up to
1 in 100 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>blood clotting problems, decrease of red blood cell production and
increase of red blood cell destruction (aplastic haemolytic anaemia), swollen
or enlarged lymph nodes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>low mood and loss of interest or enjoyment in doing things, feeling
nervous</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>taste problems  such as</span><span lang=EN-GB style='font-family:
"Calibri",sans-serif'> </span><span lang=EN-GB>changes in the way things taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart problems  such as reduced heart rate or chest pain (angina)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>asthma, too little oxygen reaching the body organs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>swelling of the stomach.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Very rare side effects (may affect up to
1 in 10, 000 people):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>short term increase in the amount of some types of anti&#8209;bodies
in the blood (called immunoglobulins  IgM), chemical disturbances in the blood
caused by break&#8209;down of dying cancer cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>nerve damage in arms and legs, paralysed face</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>heart failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>inflammation of blood vessels including those leading to skin
symptoms</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>respiratory failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>damage to the intestinal wall (perforation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>severe skin problems causing blisters that can be life&#8209;threatening
</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>kidney failure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Severe vision loss (sign of brain nerves damage).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Not known (it is not known how often
these side effects happen):</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>a reduction in white blood cells which does not happen straight away</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>reduced platelets number just after the infusion  this can be
reversed, but can be fatal in rare cases</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>hearing loss, loss of other senses. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:TimesNewRoman'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MabThera may
also cause changes in laboratory tests carried out by your doctor. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are having MabThera with other
medicines, some of the side effects you may get may be due to the other
medicines.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of side effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly <span
style='color:black;background:#D9D9D9'>via the national reporting system listed
in </span></span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:12.0pt'>5 How to store MabThera</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton after EXP. The expiry date refers to the last
day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;C to
8&nbsp;C). Do not freeze. Keep the container in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:12.0pt'>6 Contents
of the pack and other information</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What MabThera </span></b><b><span
lang=EN-GB style='color:black;background:white'>1600</span></b><b><span
lang=EN-GB>&nbsp;mg solution for subcutaneous injection contains</span></b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>The active ingredient is rituximab. Each vial contains </span><b><span
lang=EN-GB style='color:black;background:white'>1600</span></b><b><span
lang=EN-GB>&nbsp;</span></b><span lang=EN-GB>&nbsp;mg/<span style='color:black;
background:white'>13.4</span> mL of rituximab.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Each mL
contains 120 mg of rituximab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>The other ingredients are recombinant human hyaluronidase (rHuPH20),
L&#8209;histidine, L&#8209;histidine hydrochloride monohydrate, </span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>,</span><span
lang=EN-GB style='font-family:Symbol'>a</span><span lang=EN-GB>&#8209;trehalose
dihydrate, L&#8209;methionine, polysorbate 80 and water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What MabThera
</span></b><b><span lang=EN-GB style='color:black;background:white'>1600</span></b><b><span
lang=EN-GB>&nbsp;&nbsp;mg solution for subcutaneous injection</span></b><b><span
lang=EN-GB> looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>MabThera is a ready to use, clear to
opalescent, colourless to yellowish liquid, supplied as a solution for
subcutaneous injection in a colourless glass vial </span><span lang=EN-GB>with
a butyl rubber stopper with aluminium over seal and a <span style='color:black;
background:white'>blue</span> plastic flip&#8209;off disk</span><span
lang=EN-GB>. </span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Each vial
contains <span style='color:black;background:white'>1600 </span>mg/<span
style='color:black;background:white'>13.4</span> mL of rituximab. Each carton
contains one vial.</span><b><span lang=EN-GB> </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>Roche Registration GmbH </p>

<p class=MsoNormal style='page-break-after:avoid'>Emil-Barell-Strasse 1</p>

<p class=MsoNormal style='page-break-after:avoid'>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Manufacturer</b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Roche Pharma</span><span
lang=DE-CH> AG</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>Emil&#8209;Barell&#8209;Str.
1</span></p>

<p class=MsoNormal style='page-break-after:avoid'>D&#8209;79639 Grenzach&#8209;Wyhlen</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-1.7pt;background:white;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>N.V. Roche S.A.</span></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Tl/Tel: +32 (0) 2 525
  82 11</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>UAB Roche Lietuva</span></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Tel: +370 5 2546799</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=RU style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=RU style='color:black'>&#1056;&#1086;&#1096;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=RU style='color:black'>&#1058;&#1077;&#1083;:
  +359 2</span><span style='color:black'>&nbsp;</span><span lang=RU
  style='color:black'>818 44 44</span></p>
  <p class=MsoNormal><b><span lang=RU>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>(Voir/siehe
  Belgique/Belgien)</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +420 &#8209; 2
  20382111</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='color:black'>Magyarorszg</span></b></p>
  <p class=MsoNormal><span style='color:black'>Roche (Magyarorszg) Kft.</span></p>
  <p class=MsoNormal><span style='color:black'>Tel: +36 &#8209; 23 446 800</span></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche a/s </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tlf: +45 &#8209; 36
  39 99 99</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>(See Ireland)</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Nederland B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +31 (0) 348
  438050</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Eesti O</span></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Tel: + 372 &#8209; 6 177
  380</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Norge AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tlf: +47 &#8209; 22
  78 90 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche (Hellas) A.E. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  +30 210 61 66 100</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='color:black'>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES style='color:black'>Roche Farma S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +34 &#8209; 91
  324 81 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR style='color:black'>Polska</span></b></p>
  <p class=MsoNormal><span lang=FR style='color:black'>Roche Polska Sp.z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +48 &#8209; 22
  345 18 88</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tl: +33&nbsp; (0)1
  47 61 40 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='color:black'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Roche Farmacutica
  Qumica, Lda</span></p>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Tel: +351 &#8209; 21
  425 70 00</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;background:transparent;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 385 1 47 22 333</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Romnia S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +40 21 206 47 01</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Products
  (Ireland) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +353 (0) 1 469
  0700</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche farmacevtska
  druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +386 &#8209; 1
  360 26 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT style='color:black'>sland </span></b></p>
  <p class=MsoNormal><span lang=PT style='color:black'>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT style='color:black'>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT style='color:black'>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Slovensk republika </span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +421 &#8209; 2
  52638201</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH style='color:black'>Tel: +39 &#8209; 039
  2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Roche Oy </span></p>
  <p class=MsoNormal><span lang=DE style='color:black'>Puh/Tel: +358 (0) 10 554
  500</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH style='color:black'>K</span></b><b><span
  lang=EN-GB style='color:black'>&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=EN-GB style='color:black'> </span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#915;</span><span
  lang=DE-CH style='color:black'>.</span><span lang=EN-GB style='color:black'>&#913;</span><span
  lang=DE-CH style='color:black'>.</span><span lang=EN-GB style='color:black'>&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;</span><span
  lang=DE-CH style='color:black'> &amp; </span><span lang=EN-GB
  style='color:black'>&#931;&#953;&#945;</span><span lang=EN-GB
  style='color:black'> </span><span lang=EN-GB style='color:black'>&#923;&#964;&#948;</span><span
  lang=DE-CH style='color:black'>.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  +357 &#8209; 22 76 62 76</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche AB</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +46 (0) 8 726
  1200</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=308 valign=top style='width:231.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT style='color:black'>Tel: +371 &#8209; 6
  7039831</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Roche Products Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Tel: +44 (0) 1707
  366000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
(EMEA) web site: </span><a href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a><span
lang=EN-GB style='color:blue'>.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>This leaflet is available in all EU/EEA languages
on the European Medicines Agency website.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
